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Abstract  
The aim of this thesis was to use large linked electronic health datasets from primary 
and secondary care to better estimate the burden of community-acquired pneumonia 
(CAP) in older adults in the UK, and to identify the determinants of severe outcomes of 
these common infections.  Hospitalisation for CAP is increasingly common in this older 
age group, and these patients remain at an elevated mortality risk for over a year after 
hospital discharge, making this an important area of study. 
CAP incidence was estimated at 7.99 episodes/1000 person-years (IQR:7.92-8.07/1000); 
rates were higher in men than women and rose strikingly with age.  CAP incidence 
generally increased between 1997 and 2011, but this growth was attenuated when the 
rates were age-standardised. 
To separate trends in incidence from trends in treatment location, CAP episodes 
admitted to hospital within 28 days of diagnosis were compared to CAP episodes that 
were not hospitalised.  A wide range of factors potentially associated with hospital 
admission were investigated, and 14 co-morbidities, five frailty factors, and four 
medications/vaccinations were identified.  Despite adjusting for these factors, the 
average predicted probability of hospitalisation after CAP rose from 57% (1998-2000) to 
86% (2009-2010), while duration of hospitalisation and 28-day mortality decreased.   
Finally, prognostic models were developed with the aim of assisting GPs in identifying 
CAP patients with an unexpectedly high mortality risk in the year after hospital 
discharge.  Among 17 factors identified, increasing age, dementia, congestive heart 
failure, low weight, residential care and leukaemia/lymphoma were the strongest 
positive predictors of mortality, while being female, an ex-smoker and pneumococcal 
vaccination received more than a year ago had the strongest negative effects.  The 
model showed a reasonable ability to distinguish between patients who died and 
survived. 
The linked data used in this study allowed greater capture of incident CAP episodes and 
thus better estimates of the burden of disease.  They also provided enriched patient 
medical histories, enabling detailed examination of the determinants of hospitalisation 
or death after CAP.  The results presented will be of use to both clinicians and health 
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planners as the UK’s population ages, and burden of CAP increases.  Further work is 
needed to fully understand the increasing hospitalisation trend seen, and to externally 
validate the prognostic models developed.  
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Chapter 1 Background 
This thesis uses linked electronic health records from primary and secondary care to 
obtain better estimates of the burden of community-acquired pneumonia (CAP) and 
lower respiratory tract infections (LRTI) among the UK’s older adults, and to examine 
factors associated with serious outcomes after CAP.  In the process of exploring these 
themes, methodological aspects of the use of routinely collected data are also 
considered.   
This background chapter provides an overview of pneumonia; its characteristics, 
treatment and outcomes, and why, among the older population, infections such as this 
are increasingly important.  I then summarise the objectives of this thesis, and provide 
an outline of each of the chapters. 
1.1 Pneumonia  
Pneumonia is a severe infection of the lower respiratory tract which particularly affects 
the very young (aged <5 years), older adults (≥65 years), those with underlying health 
conditions and the immunosuppressed.  Morbidity and mortality due to pneumonia are 
high; between 22% and 44% of patients with CAP require hospitalisation,[1] and 
pneumonia is the leading cause of death due to infection in both Europe and the US.[2] 
The defining feature of pneumonia is inflammatory exudate of the lung parenchyma, 
which results in patients typically presenting with symptoms of cough, fever, 
breathlessness or rapid breathing and chest or pleuritic pain.[1]       
1.1.1 The microbial ecology of the lung 
Until recently it was thought that the lungs were a sterile environment,[3] and that 
pneumonia occurred when this sterile environment was compromised.  However, an 
increasingly accepted theory is that the lungs have their own microbiome.  The 
respiratory tract is an oxygen-rich environment, with a temperature that varies from 
that of the air outside (at the mouth) to the core temperature of the body at the alveoli, 
making the lung itself a warm, moist environment where, if unchecked, bacteria can 
thrive.[4]  Microbes move into the lung via several sources; inhaled air, which contains 
104-106 bacteria/mm3, micro-aspiration of the contents of the upper respiratory tract, 
and dissemination of microbes along the mucosa.  The microbiome of the lung is more 
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similar to that of the oropharynx than that of inhaled air, the nasopharynx or the lower 
GI tract.  This is due to microaspiration of pharyngeal secretions, much of which may 
occur during sleep when people are lying down and the reflexes of the larynx and cough 
(which usually occurs once every two hours awake) are suppressed.[5]  In healthy lungs, 
the most common phyla of bacteria are Bacteroidetes and Firmicutes, and genera are 
Prevotella, Veillonella and Streptococcus.[5]  The composition of the microbiome is 
thought to be relatively uniform within a healthy respiratory tract, although its diversity 
decreases with increasing distance from the oropharyrnx.  Compared to the digestive 
system, the bacterial density in the respiratory system is quite low.[4]   
1.1.2 Defence mechanisms of the respiratory system 
The configuration of the lung microbiome depends not just on the migration of microbes 
into the airways, but also on their rate of reproduction within the lung and their removal 
by the defences of the respiratory system.  Prevention of microbial entry starts in the 
upper airways where the nasal passages are lined with hairs to trap large particles.  
Smaller particles that pass through these hairs and settle on the mucosa are cleared by 
columnar ciliated epithelium towards the oropharynx.  The larynx plays an important 
role in protecting the airway as the epiglottis, a cartilaginous flap, closes over the 
trachea during swallowing and vomiting and so prevents aspiration.  Microbes that pass 
through the larynx and trachea reach the bronchi and then the bronchioles.  The bronchi 
contain submucosal mucus-secreting glands and are lined by an epithelium with cilia and 
goblet cells.  The bronchioles also contain a single layer of ciliated cells, but have very 
few goblet cells.[6]  The mucus-secreting glands and goblet cells both play an important 
role in defence, as they secrete globules of mucus which are fairly impermeable to 
water.  The globules form an almost complete covering of mucus which sits on a layer 
of liquid found around the cilia of the epithelial cells.  The tips of the cilia engage with 
the bottom of the mucus layer and the cilia move in a coordinated manner to push the 
mucus upwards toward the pharynx, leading to its expulsion from the airways by either 
coughing or swallowing.  This is called the mucociliary escalator. Clearance of mucus 
from the large bronchi is relatively fast, taking only 30-60 minutes, however it can take 
several days for mucus to be cleared from the lower bronchioles.[6]   
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In addition to mucin, the mucus also contains other secretions from the cells in the 
airways, such as antimicrobial molecules (defensins, lysozymes), specific antibodies (IgA) 
and cytokines.  These aid the immune system in identifying and killing the bacteria.  
Microbes and other particles thus get trapped in the layer of mucus, and are either 
inactivated or expelled from the airways before they cause any harm.[6]   
Pathogens which manage to breach the physical barriers of the lungs are met by a 
coordinated defence provided by several cell types.  Macrophages modify and control 
acute and inflammatory responses by secreting chemokines and other cytokines which 
promote or suppress the immune response.  They can also work with dendritic cells to 
phagocytose infective material.  Epithelial cells assist macrophages in producing 
chemokines and cytokines which leads to neutrophil accumulation and local 
inflammation.  Cytokines perform many roles, including preventing microbes from 
adhering to the epithelial surface, inhibiting viral infections by disrupting their assembly 
processes, and triggering pro-inflammatory meditators which increase vascular 
permeability, bronchoconstriction and inflammatory cell infiltration.[7]   
Neutrophil numbers in the airway are low, however a pool of these cells exists in the 
pulmonary circulation, and they can be recruited quickly to any site of infection.  
Neutrophils can travel out of pulmonary capillaries into the air spaces, where they 
phagocytose and kill microbes.  They also produce mediators which activate B cells and 
dendritic cells.  The latter facilitate antigen presentation to T and B lymphocytes, 
resulting in a more specific response to the pathogen and development of 
immunological memory.[7]   
The mechanical and immunological defence systems of healthy lungs result in an 
environment that is not conducive to extensive bacterial growth, and thus levels of 
bacterial reproduction are relatively low.  In healthy lungs the composition of the lung 
microbiome is therefore mainly determined by the balance of immigration and 
removal.[4]  The pathogens known to cause pneumonia (further discussed in the section 
below) have been found in the lungs of healthy, pneumonia-free subjects.[5]  This 
suggests the disease occurs due to the preferential reproduction of a single type of 
pathogen above all others in the microbiome.  While research into this area is ongoing, 
there is in vitro evidence that features of the host inflammatory defences promote the 
25 
 
growth of certain potential pathogens via a positive feedback loop, leading to their 
domination of the lung microbiota.[5]    
1.1.3 Classification and aetiology of pneumonia 
Pneumonia can be classified into two main groups that reflect the setting in which 
infection was thought to be acquired: community-acquired or hospital-acquired 
pneumonia (HAP).  This grouping is significant as CAP and HAP have different risk factors, 
mortality rates and treatment regimens, due in part to differing aetiologies.     
CAP is caused by a variety of pathogens with bacteria the predominant cause; a recent 
review of 25 studies of the aetiology of CAP in European adults found that the most 
commonly isolated causative agent was S. pneumoniae (identified in 12-85% of patients 
in 19 studies).[8]  Six of the studies stratified by age, and from these S. pneumoniae, H. 
influenzae and respiratory viruses were more frequently isolated among those aged ≥65 
years, while M. pneumoniae was more frequently isolated from those aged <65.[8]  The 
bacterial causes of CAP are typically sensitive to first-line antibiotics.[1]  In practice, 
microbiological confirmation of the infectious aetiology of CAP is often not performed.  
In the primary care setting, microbiological investigations are not currently routinely 
recommended for patients with CAP, as knowledge of the causative organism typically 
does not alter the treatment plan.[1, 9]  While this testing does occur in hospital, it can 
be difficult to identify the causative pathogen of CAP when antibiotic treatment has 
been initiated before sample acquisition.  Some patients struggle to provide a sputum 
sample for culture, this is a particular problem among older adults.  As a result, the 
majority of CAP cases have no information on aetiology recorded in their primary or 
secondary care records. 
In contrast to CAP, HAP is more likely to be due to Staphylococcus aureus (including 
methicillin-resistant strains), or other bacteria which require broad-spectrum antibiotic 
treatment.[10]  Consequently, CAP and HAP are considered separately to one another 
in both clinical and research settings.  This thesis focuses on CAP, due to its higher 
incidence and the potential for it to affect a larger population than HAP.  Episodes of 
HAP are excluded from all analyses, due to their differing aetiology, treatment and 
prognosis.   
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In 2005, the US introduced an additional category, health care-associated pneumonia 
(HCAP), which is used to describe pneumonia in patients who receive home wound care 
or infusion therapy, chronic dialysis, reside in a nursing home or care facility or have 
been hospitalised for ≥2 days in the past three months.[11]  Early research in the US 
suggested that HCAP patients were more similar to HAP than CAP patients, with 
comparatively high levels of multidrug resistant (MDR) pathogens and mortality, leading 
to the recommendation of broad-spectrum antibiotic treatment for this group.[11, 12]  
However, the concept of HCAP remains controversial; a recent systematic review 
showed that across multiple international studies, HCAP classification was poorly 
predictive of MDR pathogens.  Furthermore,  HCAP and CAP mortality rates were 
comparable when age and co-morbidity were taken into account.[13]  The inclusion or 
exclusion of HCAP as a separate entity is particularly important among older 
populations, who have a higher risk of developing pneumonia and who comprise 83% of 
those in residential care.[14]  At present, evidence from Europe does not suggest that 
HCAP is microbiologically distinct from CAP, or that separate treatment guidelines or 
categorisation is warranted, and as such the term has not been widely adopted in 
European treatment guidelines.[13, 15, 16]  Throughout this work, I use the current UK 
and European definition of CAP which includes those in residential or nursing facilities, 
and those who receive home care.   
1.1.4 Diagnosis of CAP 
Patients who have CAP can be diagnosed in primary care or in hospital, and the 
diagnostic criteria for CAP differ in these settings.   The gold standard for diagnosing 
pneumonia is a chest radiograph, which typically shows new shadowing which cannot 
be otherwise explained (caused by the inflammatory exudate).   
In contrast, in a community setting (such as in UK primary care) it is not common practice 
for a chest radiograph to be performed to diagnose pneumonia.  In the absence of a 
chest radiograph, the British Thoracic Society (BTS) guidelines define ‘suspected CAP’ as 
including the following four features: 
“Symptoms of an acute lower respiratory tract illness (cough and at least 
one other lower respiratory tract symptom). 
New focal chest signs on examination. 
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At least one systemic feature (either a symptom complex of sweating, 
fevers, shivers, aches and pains and/or temperature ≥38°C). 
No other explanation for the illness.”[1]   
Diagnosis of ‘definite CAP’ uses the same criteria as suspected CAP, with the addition of 
a chest radiograph showing lung shadowing that is thought to be new.   
The combination of non-specific signs and symptoms used to diagnose pneumonia 
clinically can make it difficult to differentiate from other illnesses.  For example, focal 
chest signs such as ‘crackles’ can also be present due to other conditions which cause 
lung stiffening.[17]  More generally, there are a range of diseases other than pneumonia 
which can present with breathlessness, fatigue and/or cough, for instance less severe 
lower respiratory tract infections (LRTI, described in section 1.1.5), chronic obstructive 
pulmonary disease (COPD) or heart failure.  This results in the diagnosis of pneumonia 
being subject to a degree of diagnostic inaccuracy.   
Of particular relevance to the work in this thesis is that the difficulty in diagnosing 
pneumonia is magnified among older adults.  Older patients have been shown to 
present with fewer symptoms than younger patients,[18] and their symptoms are more 
commonly non-specific, such as confusion, tiredness or loss of appetite without chest 
signs.[18, 19]  Additionally, older patients have more complex underlying health issues, 
and the BTS highlights that CAP is particularly difficult to diagnose among older patients 
with COPD, other respiratory disease or left ventricular failure.  To reflect the potentially 
challenging nature of diagnosing CAP in the older population, the BTS diagnostic criteria 
for this age group are slightly less specific:   
“the presence of chest radiograph shadowing accompanied by acute 
clinical illness (unspecified) without other obvious cause.”[1] 
The accuracy of a clinical CAP diagnosis made in general practice has been assessed in a 
number of countries.  For example, a large multi-country European study (including 
England and Wales) was carried out between 2007-2010, comprising 2810 adult patients 
(mean age 50 years ± 17 years) presenting to primary care with acute cough; the GP 
diagnoses for these patients were compared with the results of subsequent chest 
radiographs, carried out in the week following diagnosis.[20]  Overall, 5% of patients had 
radiological evidence of pneumonia. Despite the potential for misdiagnosis of other 
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conditions as CAP (as highlighted above), the study found that GP diagnoses of 
pneumonia had a high specificity (99%).  However, clinical diagnoses had low sensitivity 
(29%, i.e. the GPs were only identifying 29% of radiologically-confirmed pneumonias). 
Patients who had radiological pneumonia without a GP clinical diagnosis had less severe 
symptoms and signs compared to those who were diagnosed clinically.   
In hospital settings where chest radiographs are readily available, patients are also 
diagnosed as having CAP when a chest radiograph does not confirm the diagnosis.  For 
example, a Canadian study comparing A&E discharge diagnoses of pneumonia to 
radiology reports found that of 671 A&E clinical pneumonia diagnoses, 45% of cases 
were confirmed by the radiology reports, while 43% were classified as ‘normal’ or ‘non-
pneumonia’.[21]  In a second Canadian study, of 2706 patients who were thought on 
clinical examination to have pneumonia, 911 (34%) were not confirmed with chest 
radiographs.[22]  Other studies have also reported low to moderate agreement of 
pneumonia diagnoses between hospital clinicians and radiologists.[23, 24]  
However, the interpretation of chest radiographs is also subjective and there have been 
numerous reports of inter-observer variability in detecting infiltrates due to pneumonia 
on chest radiographs. In the large multi-country European study, appreciable inter-
observer variation between radiologists was noted, with a kappa statistic of 0.45.[20] 
Similarly,  moderate agreement between radiologists, or between radiologists and other 
hospital physicians, in the diagnosis of pneumonia from chest radiographs has been 
reported in studies from the UK, from elsewhere in Europe and from the USA .[24-26]  
Interpretation of chest radiographs may be more complicated still among older adults, 
due to a higher prevalence of abnormal radiographic findings from pre-existing illnesses 
such as COPD, heart failure or previous episodes of severe LRTI.  As a result, it is possible 
that the levels of discrepancy in interpretation of chest radiographs may be higher 
among older populations than in the studies reported above.  In the second of the 
Canadian studies, patients with unconfirmed pneumonia were older and had more 
severe illness (defined using the pneumonia severity index (PSI), described in section 
1.3.2.2) than those with chest radiograph confirmation, and the two groups had similar 
adjusted in-hospital mortality rates.[22]  There were also differences in the underlying 
aetiology, identified by blood culture; patients with confirmed pneumonia were more 
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commonly infected with S.pneumoniae (64% v 14%), while gram-negative bacteria were 
more common in the unconfirmed pneumonia group (14% vs 40%).[22]  Thus, while 
consolidation on a chest radiograph is important to diagnose pneumonia, patients can 
experience severe disease and poor outcomes when they have a clinical diagnosis of 
pneumonia without evidence of an infiltrate. 
1.1.5 Other lower respiratory tract infections 
Pneumonia is a severe subset of a broader group of acute infections of the airways 
and/or lungs (the trachea and below) known as lower respiratory tract infections (LRTIs).  
The majority of LRTI are milder than pneumonia and are self-limiting, requiring 
treatment with antibiotics at most.[27]  However, less severe LRTI can deteriorate and 
become CAP.  When examined among primary care patients, the risk of progression 
from chest infection to pneumonia was particularly high in older adults.[28]   
The aetiology of community-acquired LRTI in the UK has been investigated by two 
studies which showed that, among individuals of all ages, causes included (as percent of 
the total study population) influenza viruses (9%, 24%), S. pneumoniae (17%, 19%), H. 
influenzae (10%, 6%), rhinoviruses (4%, 33%) and multiple organisms (13%, 23%).[13, 
14]  However, as for CAP, microbiological confirmation of the cause of LRTI is rarely 
performed as it does not alter the treatment plan.[9]    
Generally, community-acquired LRTI short of CAP is diagnosed clinically, following the 
ERS definition: 
“cough as the main symptom, with at least one other lower respiratory 
tract symptom (sputum production, dyspnoea, wheeze or chest 
discomfort/pain) and no alternative explanation (e.g. sinusitis or 
asthma)”.[9] 
1.1.6 Burden of CAP  
A 2012 review of studies of CAP incidence among adults in Europe has demonstrated 
wide ranging incidence estimates for CAP, with a sharp increase in rates with increasing 
age, variation between countries and a generally higher burden in men than women.[29]  
The older population had considerably higher CAP rates than younger adults.  Incidence 
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among older adults treated as outpatients ranged from 1.9/1000 population (among 
Spanish females ≥65 years) to 33.0/1000 (among Finnish adults ≥60 years), while for 
hospitalised older adults the range was 4.8/1000 population to 10.5/1000 person-
years.[29]  Incidence has been shown to be particularly high among those with specific 
co-morbidities such as chronic lung disease, cerebrovascular disease, dementia, liver or 
renal disease, cancer or immunosuppressive conditions.[30, 31]  Rates are also 
increased among those taking immunosuppressive medications,[32, 33] among smokers 
and ex-smokers,[30] those who are underweight and individuals with a history of alcohol 
abuse.[31]   
As for CAP, LRTI as a whole are more common with increasing age; UK studies have 
provided LRTI incidence estimates varying from 45/1000 population (men aged ≥60) to 
121/1000 (adults aged 70-79).[34, 35]   
The results of a detailed literature review of CAP and LRTI incidence studies in Europe 
are presented in Chapter 4. 
1.1.7 The importance of CAP in an ageing population 
Infections such as pneumonia are a particular burden among older adults, where they 
are a major cause of morbidity, mortality and healthcare usage.  The older population 
have both an increased risk of acquiring these illnesses, and subsequently suffering from 
more severe manifestations of disease.  This increased susceptibility to CAP (and more 
broadly LRTI) is due in part to age related loss of functional reserves, and general 
deterioration of the immune system known as immunosenescence.[36]  Ageing also has 
an effect on many of the mechanical defence systems of the lungs that are outlined in 
section 1.1.2, including reduction in the elasticity of the lungs, in cough function and in 
the ciliary mechanism, leading to less efficient clearing of mucus from the lungs.[3]  In 
addition, improved treatment and management of major clinical events such as 
myocardial infarction (MI) or stroke, and chronic conditions such as diabetes or COPD 
have enabled patients increasingly to survive and live with diseases which affect their 
general health.  The majority of the UK’s older population are thought to be living with 
one or more long-term condition; the 2011 General Lifestyle Survey found that 58% of 
65-74 year olds and 68% of those aged ≥75 years reported having a long standing 
illness.[37]  In many cases, two or more illnesses (known as multi-morbidity) are present; 
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estimates from Scotland found multi-morbidity existed in 65% of 65-84 year olds and 
82% of those aged  ≥85 years.[38]   
1.1.7.1 Frailty 
In addition to the comparatively high prevalence of co-morbidities, older adults are also 
susceptible to a more general vulnerability in underlying health which is less easy to 
define.  Frailty is typically characterised by declines in functional reserves across a range 
of physiological systems related to ageing.[39]  These cumulative declines result in frail 
older adults having less resistance to stressors (such as infections), and being more 
vulnerable to many adverse outcomes ranging from dependency or falls to 
hospitalisation or death.[39]  Frailty is made more complex by it being a dynamic state 
that can be reversible, although decline is more common than improvement.[40, 41]  
The ongoing discussion around the definition of frailty has resulted in a number of 
approaches to measuring it, the two most prominent of which are outlined in section 
1.2.1.1.  A 2012 systematic review of the prevalence of frailty among community-
dwelling older adults worldwide reported an overall weighted prevalence of frailty of 
10.7%.  The results from individual studies ranged from 4.0% to 59.1%,[42] with much 
of this variation attributed to differences in the frailty measures used. 
1.1.7.2 The changing demography of the UK 
The high burden of CAP among the older population is of particular importance as life 
expectancy in the UK is generally increasing, and is expected to continue to do so.[43]  
Recent estimates from the Office for National Statistics (ONS) suggest that the 
percentage of the UK population aged ≥65 years will increase from 17% in 2010 to 23% 
in 2035, with the proportion aged ≥85 years rising from 2% to 5% of the population over 
the same period.[44]  This represents almost 7 million additional older adults in 20 years 
time, including more than two million aged ≥85 years.[45]  Similar trends are being seen 
across Europe,[44] and these demographic changes will have wide-ranging 
consequences for future healthcare provision and usage.    
1.1.7.3 Limitations of current UK CAP incidence studies 
In order to adequately plan future resource use, it is imperative that we have accurate 
estimates of the burden of CAP among the older population, given its increasing size.  As 
shown in detail in the literature review in Chapter 4, current UK incidence estimates of 
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CAP (and LRTI more generally) are from studies that were restricted to stand-alone data 
from either primary or secondary care settings, preventing the total burden of these 
infections among older adults from being calculated.  Use of stand-alone GP records may 
not completely capture hospitalised cases, and use of hospital admissions data excludes 
patients well enough to receive treatment at home.   Additionally, despite the majority 
of CAP cases occurring in older adults and the risk of infection increasing with age, 
studies rarely further stratify older populations by age to better understand trends in 
disease burden within this diverse and growing group.        
1.1.8 Vaccination to prevent CAP among older adults 
The most effective way to tackle CAP among an expanding older population is to prevent 
the illness from occurring.  Prevention strategies for those aged 65 and over centre on 
routine vaccination against two pathogens which may be responsible for 50% of CAP in 
this population;[46] S. pneumoniae, and influenza virus.   
Pneumococcal polysaccharide vaccine (PPV23) contains purified capsular 
polysaccharide from the 23 types of pneumococcus which account for around 96% of 
isolates that cause serious infection in the UK.[47]   The introduction of PPV23 
vaccination for older adults was staged between 2003 and 2005, and it has been offered 
to all those aged ≥65 since that time.  Vaccination is only recommended once except for 
those with no spleen, splenic dysfunction or chronic renal disease, for whom vaccination 
is recommended every five years.[48]  Cumulative vaccine coverage among older adults 
has risen from 29% in 2003/4 to 70.5% by the end of March 2011.[49, 50]  However, 
research has shown a relative lack of long-term protection of PPV23.  In England, vaccine 
effectiveness (VE) was found to wane over time from 48% (95% CI: 32%-60%) within two 
years of vaccination to 15% (95% CI: -3%-30%) after five or more years.[51]  A 2008 
Cochrane systematic review additionally highlighted the low VE among adults with 
underlying health conditions.[52]  
Since 2000, influenza vaccine has been offered from September/October each year to 
all patients aged ≥65 years, as well as younger patients with underlying health 
conditions.  Among older adults, uptake has remained around 73% since 2005/6, which 
is just below the European Union target of 75%.[53]  The vaccine needs to be given each 
year as the circulating strains of influenza vary, thus the vaccine is tailored to the strains 
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predicted to be important each season.  The changing composition of the vaccine leads 
to varying levels of VE which is lower in years when there is a mismatch between the 
vaccine and circulating strains.  Regrettably VE has been found to be generally lower in 
those aged 65 years and older compared to those aged <65.[54]  The effectiveness of 
influenza vaccine at protecting against pneumonia has ranged from 46% (30-58%) 
effective in well matched years, to having no effect in mismatched years.[55]    
1.1.9 Treatment of CAP 
As with diagnosis, management of CAP can occur in primary care, or in hospital (where 
patients may present directly via A&E or via a referral from their GP).       
1.1.9.1 Treatment of CAP in primary care 
Clinical scores can be used to assess severity of CAP, and thus guide treatment 
management.  One such score is the CRB-65 score, which has been adapted from the 
CURB-65 score to enable its use in primary care (CURB-65 and CRB-65 are further 
described in section 1.3.2).  For those who have a mild form of CAP and are able to be 
managed in the community, the BTS recommended treatment is amoxicillin 500mg 
three times daily for seven days, with doxycycline or clarithromycin as alternatives for 
patients sensitive to penicillins.[1]  Among patients who have signs of a moderate to 
severe infection, urgent hospital admission should be considered.   
For CAP patients treated in the community, the BTS recommend that patients are 
reviewed after 48 hours (or before if clinically indicated) to reassess disease severity 
after initiation of treatment.  Patients who have not improved may require 
hospitalisation.[1] 
1.1.9.2 Treatment in secondary care: hospitalisation 
Patients can be hospitalised for a variety of reasons following onset of CAP, from clinical 
severity of disease (for moderate/severe CAP) or complications posed by co-existing 
illnesses, to social factors such as living alone and being unable to care for themselves 
when ill.     
As in primary care, treatment of CAP in hospital depends on the level of severity of 
disease, again commonly assessed using the CURB-65 score.  Antibiotics should be 
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commenced as soon as possible after diagnosis, and within four hours of presentation 
to hospital among those admitted.[56]  Hospitalised patients may also require additional 
oxygen therapy or intravenous fluids.[1] 
1.1.10 Treatment of other LRTI  
In view of the potential for CAP to have evolved from a less severe LRTI, and the 
increased risk of this occurring among older adults, it is important to also consider LRTI 
as a broader group when thinking about CAP among those aged ≥65 years.   
Current National Institute for Health and Clinical Excellence (NICE) guidelines for 
antibiotic prescribing in primary care for respiratory tract infections only recommend 
immediate antibiotic treatment for LRTI (short of CAP) among older patients considered 
high risk.  Patients aged 65 to 79 years must have two of the following conditions to be 
considered in this group, while those aged 80 years and over must have at least one of; 
diabetes, a history of congestive heart failure, current steroid use, or hospitalisation in 
the previous year.[27]  A delayed antibiotic prescribing strategy with advice can be 
considered for less severe cases.      
Re-consultation in primary care for LRTI is common, with between 25% and 33% of 
patients presenting back to their GP within 28 days of their initial appointment.[35, 57-
60]  Re-consultation may be initiated by the GP or more commonly by the patient.[58]   
1.2 Severe outcomes of CAP 
In severe cases of CAP, patients may require hospitalisation and/or may die.  As with 
incidence, the risk of severe outcomes following CAP also increases with age, with case 
fatality rates among older European adults ranging from 13-30%.[29]   
1.2.1 Hospitalisation  
Previous UK studies have found that between 22% and 44% of adults with CAP are 
hospitalised.[1]  However, these estimates are over 15 years old and do not take into 
account the probable variability in treatment location by age.  In recent years, 
hospitalisations for pneumonia among older adults have been examined in both the UK 
and other European countries, and several studies using large hospital admissions 
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databases to analyse trends in pneumonia hospitalisations over time have been 
published. 
In England, increasing hospitalisations for CAP were initially reported by Trotter et al, 
who used hospital admissions data for the whole country (provided by Hospital Episode 
Statistics (HES)) to investigate the rate of first admissions for pneumonia each year 
between April 1997 and March 2005.[61]  Over the study period the hospitalisation rate 
increased among all age groups, but in particular among older adults.  Admissions 
increased 35% among 65-74 year olds, 28% among those aged 75-84 and 39% among 
those aged ≥85 years compared to 20% among the under 65’s (from 2.63/1000 
population, 6.84/1000, 15.99/1000 and 0.7/1000 respectively).  The level of co-
morbidity recording, measured using a summary co-morbidity score (the Charlson index, 
described in section 1.2.1.1) increased over the study period, but neither changes in co-
morbidity score nor increasing age fully explained the rising number of hospital 
admissions.   
More recently, Bardsley et al explored whether the number of hospitalisations in 
England for ambulatory care sensitive conditions (ACSC) had changed over time.[62]  
Again, stand-alone English HES records were used to investigate whether admissions for 
a range of conditions including pneumonia increased between April 2001 and March 
2011.[62]  The analysis provided more up to date admission rates for pneumonia, but 
lacked the level of detail provided by Trotter et al due to the broader scope of the 
research.  Rates were not presented stratified by age, but were instead standardised to 
the European Standard Population.  A 118% increase in the standardised pneumonia 
admission rate was found over the study period, which was among the highest relative 
increases for any condition in the study, along with influenza.  In addition to the changes 
in hospitalisations over time, a separate report (also using HES data) highlighted that 
emergency admissions in England in 2012/13 disproportionately affected older adults, 
and that this varied by condition; 40% of emergency admissions were for older adults, 
but among emergency admissions for pneumonia, this rose to 70%.[63]   
An increase in pneumonia hospitalisations over time has also been noted in several 
other European countries.  Studies from Denmark,[64, 65] the Netherlands,[66] and 
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Portugal,[67] have all used routinely collected data to demonstrate rising admissions for 
pneumonia over the last 10 to 20 years.     
1.2.1.1 Factors that may influence trends in CAP hospitalisation  
Increasing hospitalisation levels for CAP have been well described, but what is driving 
these increases is less well understood.  The results of a detailed literature review of risk 
factors for hospitalisation after a CAP episode are presented in Chapter 6.  An overview 
of possible reasons for the increasing trends seen is provided below. 
Increasing incidence 
It is important to contextualise any trends in hospitalisation against the underlying 
trends in pneumonia incidence.  For example, if CAP incidence increases over a period 
and the proportion of CAP patients hospitalised remains stable, the number of 
hospitalisations would also increase.  Thus, increasing hospitalisations may simply 
reflect (at least in part) rising CAP rates.  Use of stand-alone hospital admission data such 
as HES (used in the English hospitalisation studies) does not enable the distinction 
between increases in underlying incidence of a disease, and increases in hospital 
admissions over and above any increase in incidence.   
Increasing prevalence of co-morbidities 
Increasing levels of co-morbidity among the older population may also have played a 
key role in rising CAP admissions, as co-morbidities may affect both patients’ 
susceptibility to CAP, and the severity of their illness.  A commonly used method to 
summarise the extent of a patient’s co-morbidities is to calculate their Charlson index 
score. 
The Charlson Index 
The Charlson index was originally published in 1987 as a new method to classify 
prognostic co-morbidity in longitudinal studies.  The index was developed using the 
medical information of 604 patients admitted to the medical service at a New York 
hospital over a one-month period in 1984.  The vital status of these patients was 
established at one year, including deaths during the initial hospitalisation and post-
discharge.  Cox regression was used to quantify the association between a range of 
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diseases and mortality at one year, and the resulting hazard ratios (HRs) were rounded 
and used to create the score that is still in use today.  Conditions with HRs of 1.2 or less 
were not included in the final model, HRs ≥1.2 and < 1.5 were assigned a weight of 1; 
conditions with a HR ≥1.5 and < 2.5 a weight of 2; conditions with a HR of ≥2.5 to < 3.5 
a weight of 3; and two conditions with weights of 6 or more were assigned a weight of 
6.   
Seventeen co-morbidities were included in the final score, two of which had scores 
which increased with increasing severity of disease (liver disease and diabetes), resulting 
in 19 factors to be considered.  These co-morbidities and their associated scores are 
presented in Table 1-1.   
Table 1-1  Scores assigned to co-morbidities when using the Charlson index 
Score Co-morbidity 
1 Myocardial infarction  
Congestive heart failure  
Peripheral vascular disease  
Cerebrovascular disease   
Dementia  
Chronic lung disease  
Connective tissue disease  
Peptic ulcer disease  
Mild liver disease  
Diabetes 
2 Hemiplegia   
Severe renal disease  
Diabetes with complications  
Solid cancer  
Leukaemia  
Lymphoma 
3 Moderate/severe liver disease 
6 Metastatic cancer  
AIDS 
 
The total score was calculated for each patient by summing the scores for each co-
morbid condition that they had, and their final co-morbidity score was then categorised 
as none (0), mild (1-2), moderate (3-4), or severe (≥5).[68]  External validation of the 
score was performed in a cohort of 685 women first treated for breast cancer between 
1962 and 1969 at Yale hospital.[68]  In this cohort, 10-year mortality was the outcome 
of interest (although as the cohort were all breast cancer patients those who died of 
breast cancer were categorised as having left the study rather than having died).  Formal 
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assessment of the model’s performance (using methods outlined in section 7.3) was only 
assessed graphically in the original paper. 
As mentioned previously, the majority of the UK’s older population are now thought to 
be living with at least one long-term condition.[37]  Of the European papers reporting 
increasing CAP hospitalisations above, only two studies investigated the possible 
contribution of rising co-morbidity levels through use of the Charlson index.[61, 64]  
When assessing the suitability of the Charlson index to adjust for co-morbidity status, it 
is important to consider its development and intended application as a score to predict 
mortality.  While hospitalisation and death are both considered severe outcomes of 
disease, risk factors for these two events may differ, and therefore a score developed to 
predict mortality may not be the best tool to explain hospitalisation trends.  The use of 
a score to adjust for co-morbidities also precludes identification of the risk of 
hospitalisation associated with individual co-morbidities.  Among the growing older 
population it would be useful to better understand the role individual conditions such 
as dementia and chronic respiratory disease play in CAP hospitalisation trends, in order 
to inform clinicians and plan future resource allocation.  Furthermore, stand-alone 
hospitalisation data (as used in the two English studies) have suboptimal recording of 
patients’ co-morbidities, including only those pertinent to patients’ care.   
Medications and vaccinations 
A consequence of the rising prevalence of co-morbidities is increasing prescription 
medication use.  Some of these drugs, such as immunosuppressive medications used to 
treat conditions such as rheumatoid arthritis and chronic lung disease, increase patients’ 
risk of CAP.[30]  Conversely, some medicines such as statins may offer some protective 
effect,[32] as does prompt treatment of LRTI with antibiotics.[28]  Interestingly, 
hospitalisations for CAP have risen despite the introduction of vaccinations for influenza 
and pneumococcal disease for older or at risk groups.[53, 48]  There is evidence that 
influenza vaccine protects older individuals against hospitalisation after pneumonia,[69-
71] however, PPV23 has not been shown to have such an effect.[72]  The effect of 
medications or vaccinations on the rising hospitalisation levels has been relatively little 
studied.  Vaccination and medication use are simply not recorded in HES, and as a result 
their effect on CAP hospitalisation levels in England has not been quantified.     
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Increasing prevalence of frailty  
As highlighted in section 1.1.7, older adults are more prone to a general vulnerability in 
underlying health, called frailty.  Frail patients are identified using a number of factors 
(due to the multiple systems involved), and many studies have developed models to this 
end.  The inclusion of a range of factors, rather than simply summing the number of co-
morbidities an older adult has, enables identification of frail older adults who do not 
have life threatening diseases but who have experienced physiological changes which 
make them more susceptible to adverse events.  Two frequently discussed measures of 
frailty are the frailty phenotype and the frailty index.[73, 74]  The ‘phenotype’ 
hypothesises that frailty can be recognised from a set of five deficits: measured slow 
walking speed, measured impaired grip strength, self-reports of declining activity levels, 
exhaustion and unintended weight loss.  Patients with a score of three or more deficits 
are categorised as frail, and those with one or two deficits are pre-frail.[73]  While the 
phenotype method is simple to use and extensively validated, the factors it contains are 
not routinely collected in primary or secondary care, limiting its usefulness in either 
setting.[39] 
An alternative methodology is the ‘index’ (or cumulative deficit approach) whereby 
information on a large number of deficits is collected across co-morbidities, clinical signs 
and symptoms, disabilities or abnormal test findings.  To be considered for inclusion, 
deficits must accumulate with age, be biologically plausible, and not saturate too early 
(i.e. the deficit cannot have a prevalence of 100% before older age).[74]  Several indexes 
have been developed, and their ability to predict adverse outcomes found to be high as 
long as more than 30 deficits are included.[74]  Patients’ scores are calculated as the 
proportion of deficits they have, with higher proportions correlated with increasing 
susceptibility to adverse outcomes.  Across these models, deficits have been found to 
accumulate within patients at on average 0.03/year.[74]  The proportion of deficits 
tolerated by patients seems to be limited at around 0.67, after which no further 
accumulation is sustainable and death becomes likely.[75] 
Despite the abundance of frailty measures available, frailty is not commonly included in 
studies assessing severe outcomes following CAP among older adults.  However, it 
certainly plays a large role in clinicians’ treatment location decisions for some patients.   
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1.2.2 Mortality 
1.2.2.1 Short-term CAP mortality 
CAP is the most common cause of death from infection in Europe and the US.[2, 76]  In 
2013 influenza/pneumonia was the fourth leading cause of death among women in 
England and Wales, and the sixth among men, accounting for 5.9% and 4.7% of deaths 
respectively.[77]  Age specific pneumonia mortality rates from the ONS in men ranged 
from 3.99/1000 among 65-74 year olds to 258.99/1000 in those aged ≥90 and in women 
from 2.86/1000 among 65-74  year olds  to 207.79/1000 in those aged ≥90.   
However, these rates underestimate the total contribution of pneumonia to mortality 
in England and Wales.  In 2001, the coding system used changed from the Ninth to the 
Tenth Revision of the International Classification of Diseases (ICD-10), and the rules for 
assigning cause of death were modified.[78]  In brief, following changes to Selection Rule 
3, the condition that led directly to the death was no longer assigned as the underlying 
cause when the disease thought to have started the fatal sequence was also recorded 
on the death certificate.[79]  For example, a patient with dementia who died directly 
from pneumonia would, from 2001 onwards, have dementia coded as their underlying 
cause (rather than pneumonia pre-2001).  Subsequent analysis showed that of deaths 
coded as due to pneumonia in 1999 using ICD-9, only 60% would have also been coded 
so using ICD-10; 13.7% changed coding to circulatory diseases, 10.1% dementia or 
Alzheimer’s and 5.5% neoplasms.[78]  Pneumonia is still recorded as a contributory 
cause; thus it is important to examine both underlying and contributory causes of death 
when investigating pneumonia mortality. 
1.3 Severity assessment of CAP 
To aid clinicians in deciding which patients are at increased risk of mortality, a severity 
assessment is usually undertaken.  Severity assessment is one of the cornerstones of 
pneumonia management – as such several tools have been developed in order to inform 
this process (outlined in sections 1.3.2.1 to 1.3.2.3).  Before discussing these tools I 
provide a brief introduction into the methods used to develop them. 
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1.3.1 Overview of prognostic modelling  
Prognostic models (also known as risk scores) are used in many areas of medicine in 
order to aid clinical decision making.  Patients’ clinical and/or non-clinical characteristics 
are used to estimate the probability of experiencing a specified outcome, given the set 
of characteristics provided.    
An advantage of prognostic models is that they incorporate several different factors 
which may influence the likelihood of an event, and so the prediction of risk does not 
simply depend on one factor.  The models are developed using multivariable modelling.  
Commonly, the factors included in the model are weighted using the models’ regression 
coefficients, which represent their importance as risk predictors.  The sum of the weights 
for the factors present in a patient provides their total score.  The score is then used to 
estimate the predicted absolute risk that the patient will experience the outcome.     
1.3.2 Use of prognostic models to identify CAP patients at increased risk of 
mortality 
There have been a large number of studies undertaken to enable identification of 
patients at short-term (usually 30 day) increased risk of mortality from CAP, most of 
which were designed to be used at the point of diagnosis.  Two of the most commonly 
used and cited scores, CURB-65 and the Pneumonia Severity Index (PSI) are outlined 
below.[80, 81]   
1.3.2.1 CURB-65 and associated scores 
The CURB-65 and CRB-65 prognostic scores were developed by Lim et al in 2003.[80]  
They were based upon the modified British Thoracic Society (mBTS) rule, a score 
developed to identify patients with severe CAP and at high risk of mortality, which was 
modified from the existing BTS rules for assessing severity of CAP at point of hospital 
admission.  The mBTS included confusion, urea >7 mmol/l, respiratory rate > 30/min and 
diastolic blood pressure < 60 mm Hg.[82]  Lim et al expanded the mBTS score to create 
a more general rule with several categories which could separate patients into groups 
according to mortality risk, and suggest appropriate management strategies.  The 
expanded score was developed and validated using prospectively collected CAP hospital 
admission data from 1068 patients in the UK, New Zealand and the Netherlands.[80]  
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New factors identified as independent prognostic indicators were only included in the 
final model if they were routinely available at the point of admission to hospital (serum 
albumin was excluded from the final model for this reason).  Additionally, the final CURB-
65 model was further adapted to include only clinical features and exclude laboratory 
results (CRB-65).  The final CURB-65 and CRB-65 scores are outlined in Table 1-2.   
Table 1-2 Factors included in CURB-65, CRB-65 and their scores 
 Points assigned 
Factor CURB-65 CRB-65 
Confusion 1 1 
Urea >7 mmol/l 1 N/A 
Respiratory rate ≥30/min 1 1 
Low Blood pressure (systolic <90 mm Hg or diastolic ≤60 mm Hg) 1 1 
Age ≥65 years 1 1 
Risk category & recommended treatment Score  (Mortality risk, %) 
Mortality low, likely suitable for home treatment 0 or 1  (1.5%) 
0 
(1.2%) 
Mortality intermediate, consider/likely to need  
hospital referral/assessment/treatment 
2  
(9.2%) 
1 or 2 
(8.15%) 
Mortality high, manage in hospital as severe pneumonia ≥3  (22%) 
3 or 4 
(31%) 
 
The removal of test results (the urea measurement) enabled CRB-65 to be used in 
primary care.  However, the score was developed using hospitalised CAP patients, and a 
systematic review of studies using CRB-65 found that while the score performed well in 
hospitalised patients, it consistently over-predicted the probability of 30-day mortality 
in community-based patients.[83]  One of the validation studies included in the 
systematic review included only primary care patients aged ≥65 years in their validation 
of CRB-65.[84]  Due to their age, none of these patients were categorised as ‘low risk’ 
(score=0), and the authors suggested that among the older primary care population, 
changing the cut-off for ‘high risk’ from ≥3 to ≥2 may be more appropriate.  It should be 
noted that neither the original CRB-65 derivation study, nor the validation of the score 
in older primary care patients included patients residing in nursing homes in their study 
populations, potentially limiting the accuracy of predictions of the scores in older, more 
frail populations.   
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1.3.2.2 The Pneumonia Severity Index (PSI) 
The PSI was developed in the USA in 1997 to identify patients at low-risk of dying within 
30 days of a pneumonia diagnosis, who may be suitable for ambulatory treatment.[81]  
The index was derived using a cohort of >14,000 hospitalised cases of pneumonia in the 
USA in 1989, and used in-hospital mortality within 30 days of diagnosis as the outcome.  
Of the three demographic factors, six co-morbidities, five abnormal physical findings and 
seven abnormal laboratory findings considered, 20 were included in the final index and 
each assigned a score (Table 1-3).  Patients’ total scores were then spilt into five risk 
groups, and the index externally validated in two separate cohorts. 
Table 1-3 Factors included in the Pneumonia Severity Index and their scores 
Type of factor Factor Points assigned 
Demographic Men Age (years) 
Women Age (years) – 10 
Nursing home resident + 10 
Co-
morbidities 
Cancer + 30 
Liver disease + 20 
Congestive heart failure + 10 
Cerebrovascular disease + 10 
Renal disease + 10 
Physical 
examination 
findings 
Altered mental status + 20 
Respiratory rate ≥30/min + 20 
Systolic blood pressure  <90mm Hg + 20 
Temperature <35°C or ≥40°C + 15 
Pulse ≥125/min + 10 
Laboratory 
and 
radiographic 
findings 
Arterial pH <7.35 + 30 
Blood urea nitrogen ≥30mg/dl (11 mm/l) + 20 
Sodium <130mm/litre + 10 
Glucose ≥250mg/dl + 10 
Hematocrit <30% + 10 
Partial pressure of arterial oxygen <60 mm Hg + 10 
Pleural effusion + 10 
Risk category Total score Risk of death (%) 
I ≤50 (age ≤50, no co-morbidity, no abnormal physical findings) 0.1 
II ≤70 0.6 – 0.9 
III 71-90 0.9 – 2.8 
IV 91-130 8.2 – 9.3 
V >130 27.0 – 29.2 
 
Due to its more complex nature, the PSI is not routinely used in UK settings and the BTS 
recommends the use of the more simple CURB-65/CRB-65 to assess pneumonia 
severity.[1] 
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1.3.2.3 Other models 
Prognostic models to predict mortality risk after CAP developed in and designed 
specifically for use in primary care are considerably less common than those for 
hospitalised CAP patients.  Models tailored specifically to the higher-risk, older 
population with their high co-morbidity burden would be of particular use in this setting.  
Bont et al developed a model for use in primary care to predict older adults’ risk of 
hospitalisation or death in within 30 days of an LRTI, including CAP.[85]  The model was 
developed using data from the database of the Utrecht GP research network, and 
validated using data from the Second Dutch National Survey of General Practice.  It 
included factors that should be included in a patient’s medical notes, so no additional 
tests were required for its use.  The final model included the type of LRTI diagnosis 
(bronchitis, COPD exacerbation, or pneumonia), age (65-79, ≥80 years,) congestive heart 
failure, diabetes, steroid use, hospitalisations in the last year (0, 1, ≥2) and use of 
antibiotics in the previous month.  A further model was subsequently derived using the 
same development cohort, but for use specifically in patients aged ≥80 years.[86]  The 
model was built with the same outcomes and aims, and included the same factors as 
the Bont et al model, with the exception of congestive heart failure.   
A prediction rule specifically for use in older adults during the influenza season was 
developed by Hak et al,[87] in order to predict a combined outcome of hospitalisation 
for pneumonia or influenza, or death (all causes) during the influenza season.  The model 
was limited to the influenza season as the authors’ aim was to encourage influenza 
vaccination among the older population.  Data from three health plans in the US were 
used to form large cohorts of older adults; patient records from one plan were used to 
develop the model, and the rest of the data used for its validation.  Fifteen clinical 
characteristics were considered as potential predictors.  The final model consisted of 
age (<70, 70-74, 75-79, 80-89, ≥90), sex, outpatient visits in the previous year (0, 1-6, 7-
12, ≥13), previous hospitalisation due to pneumonia/influenza, pulmonary disease, 
heart disease, renal disease/transplant, dementia/stroke and non-
haematological/haematological cancer.   
While these studies highlighted the important role of individual co-morbidities in post-
LRTI mortality risk in older adults, none of the studies focussed solely on CAP and all 
used combined outcomes of hospitalisation or death.  Risk factors for hospitalisation 
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may differ to those for death, and the use of a combined outcome does not allow these 
effects to be teased apart.  Additionally, important predictors such as vaccination status 
and frailty were not considered for inclusion in the models.     
1.3.2.4 Longer-term increased mortality post-CAP hospitalisation 
Interestingly, it has also been shown that there is a longer-term effect of CAP on 
patients’ risk of mortality, for a year or more after CAP diagnosis.[88]  The first large 
study to demonstrate this was by Kaplan et al, who used US hospital discharge data from 
Medicare (a large database of American older adults’ health insurance administrative 
claims) to compare mortality rates between older CAP patients (n>15,000) and age- sex- 
and race-matched controls (patients hospitalised for other conditions, n>75,000).[88]  
In-hospital mortality was higher in the CAP group compared to the hospitalised control 
group (11% vs 5.5%).  Importantly, among the patients who survived the hospitalisation, 
one-year post-discharge mortality rates (adjusted for co-morbidity) remained higher 
among CAP patients compared to the controls (33.6% vs. 24.9%). The monthly risk of 
death in both groups decreased over the year-long period, but remained higher in the 
CAP group up to and including the twelfth month of follow-up (1.92% vs. 1.37%).   When 
these results were standardised to the general US population, the mortality risk among 
the CAP cohort was considerably higher than that of the population in general.  
Increased long-term mortality post-CAP has since been shown in several additional 
studies among older adults, using mortality periods ranging from 90 days to several 
years.[89-92]      
The exact mechanism behind the increased mortality risk after a CAP hospital discharge 
is not known – it could be that the CAP episode leads to increased mortality, or that the 
CAP is due to patients being less well generally, and thus it is a marker for underlying ill-
health.  Many studies have looked at physical markers during hospitalisation, but there 
is no universal agreement on what lies behind this excess mortality.[93]   
Certainly, some effects of CAP remain after the infection clears.   As described in section 
1.1.2, infection with CAP triggers a rapid increase in pro-inflammatory cytokines, which 
can lead to worsening of disease and in severe cases lung damage.  Inflammatory 
exudate enters the alveoli and can prevent the amount of air reaching the alveoli from 
equalling the amount of blood reaching the alveoli.  Thus, a lower level of oxygen is 
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transferred to the blood (hypoxia), while removal of carbon dioxide remains stable.  This 
ventilation/perfusion (V/Q) mismatch leads to type 1 respiratory failure.  However, sub-
clinical inflammation has been shown to continue even after clinical recovery.[94, 95]  
This has a range of effects on the body.   
Many of these effects increase the short-term risk of acute cardiovascular events. 
Among patients with atherosclerosis, increased inflammatory activity within coronary 
atherosclerotic plaques can make them unstable and increases the possibility of their 
rupturing.[96]  In addition, systemic inflammation temporarily disturbs endothelial 
function, which results in decreased vasodilation, and an increase in the procoagulant 
properties of the blood by promoting platelet activation and adhesion of leukocytes.[96, 
95]  Platelets can also be activated by bacterial products such as lipopolysaccharide, 
which induces mechanical stress.[95]  Aggregation of platelets on the surface of a 
ruptured atherosclerotic plaque causes thrombus formation, increasing the risk of an 
acute ischaemic event in the coronary or cerebral vessels.[95] 
Myocardial injury may result not only from the cytokines arising from the 
inflammatory response, but also via endotoxins, or infection of the cardiomyocytes 
with the pathogen which caused the pneumonia.[96]  Additionally, demand ischaemia 
can occur as a result of the decreased ratio of metabolic supply to demand.  This is 
caused by the combined effects of V/Q mismatch, and the increased heart rate which 
is a consequence of the systemic response to CAP.[96]   
Furthermore, the systemic inflammatory response can result in acute kidney injury, 
and impaired sodium and water metabolism, which leads to volume 
overload.  Medications with a high sodium content, such as some antibiotics, can 
exacerbate this effect.[96]    
The results of a literature review of studies that investigated factors associated with 
long-term mortality after a CAP hospitalisation are presented in Chapter 7. 
1.3.2.5 Longer-term risk predictions 
CURB/CRB-65, PSI and the other models described previously are useful for short-term 
assessment of mortality and treatment decisions.  However, they do not assist clinicians 
concerned about their patients’ health after discharge from hospital for CAP, or their 
heightened long-term mortality risk.  Increasing levels of CAP hospitalisation among a 
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growing older population, who may have a raised mortality risk post-hospital discharge, 
will result in a large burden on primary care.  A risk-stratification tool to aid GPs in 
recognising their patients’ longer-term mortality risk post CAP hospital-discharge would 
help decision making around resource allocation, and which patients are in need of extra 
care or additional check-ups. 
1.4 The benefits of using linked data to investigate the burden and outcomes of 
CAP 
Use of linked primary and secondary care data (described in detail in Chapter 2) can 
overcome many of the limitations of existing studies.  The burden of CAP is more fully 
captured by the inclusion of both cases treated in the community, and those that 
required treatment in hospital.   
Utilising linked data enables any increase in CAP hospitalisation to be investigated 
separately to any increase in CAP incidence, which has not been possible in existing 
studies (described in more detail in Chapter 6).  The rich patient histories provided in 
combined primary and secondary care records allow extensive investigation of the 
effects of co-morbidities, medications, vaccinations, lifestyle and frailty factors on 
treatment setting over time, that would not be possible using stand-alone data sources.  
Additionally, the pathways of care for patients with CAP, from initial diagnosis and 
treatment in general practice to hospital admission and death can be reviewed.  Without 
being able to separate increasing incidence from increasing hospitalisations, it is difficult 
to know where to direct healthcare resources – into slowing CAP incidence, or targeting 
use of appropriate treatment settings.  Likewise, it would be of considerable use to 
better understand how patients hospitalised for CAP differ from those treated in an 
ambulatory setting.  The use of linked data enables these questions to be explored. 
Finally, these data facilitate the development of risk scores to be used in primary care 
to assess patients’ longer-term mortality risk post CAP hospital-discharge.  Hospital 
admission records provide diagnostic codes for the main and secondary conditions 
treated in each period of care, as well as dates of discharge (used to define cases), 
primary care records contain patients’ co-morbidity status and general health profile 
(used to define potential predictors of mortality), and mortality records supply accurate 
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dates of death (used to define the outcome) as well as underlying and contributory 
causes of death (used to investigate the cause). 
1.5 Rationale 
In summary, this chapter has highlighted the particular importance of CAP among older 
populations.  Existing studies of CAP and other LRTI in the UK have not focussed on this 
high risk, high burden population, and are limited by their use of stand-alone primary or 
secondary care data.  By linking these data sources, it is possible to estimate more 
completely the incidence of these infections, and to differentiate between community- 
and hospital-acquired cases.  Trends in hospitalisation can be separated from those for 
incidence, and risk factors that may also explain increasing hospitalisations be 
thoroughly investigated.  In addition, factors that may predict longer-term mortality risk 
post-CAP can be assessed and combined to develop a prognostic score to aid clinical 
decision making.     
1.6 Research objectives 
In this thesis I have two main research aims, each with more than one objective. 
1.6.1 Aim 1: To develop methods using linked electronic health records to better 
understand the burden of CAP and LRTI among older adults in the UK  
Objective 1 – To use linked primary and secondary care records to better quantify the 
incidence of LRTI and CAP among older adults in the UK over time. 
This is informed and supported by two supplementary objectives: 
Objective 1a – To define an appropriate exclusion period for new patients’ records at 
the start of follow-up, in order to ensure reports of historical episodes of disease are not 
included in incidence analyses. 
Objective 1b – To compare CAP incidence estimates using stand-alone GP records to 
those from GP records linked to hospital admissions, to better understand the added 
value of using the linked data. 
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1.6.2 Aim 2: To identify risk factors for severe outcomes after CAP in the older 
population.   
Objective 2 – Among older patients with CAP, to identify the risk factors for 
hospitalisation after a CAP episode, and to assess to what extent these factors 
contribute to the increasing hospitalisation trend over time in England. 
Objective 3 - To estimate the risk of mortality in the week, month and year after 
discharge from hospital for CAP by developing prognostic models for each period, to 
attempt to aid GPs when making decisions about post-discharge care for these patients. 
1.6.3 Outline of Chapters 
In Chapter 2 I provide detail on the data sources utilised for these analyses, and the 
methods used to collate the multiple data sources into a single resource.  The statistical 
methods used in each chapter are briefly outlined. 
In Chapter 3 I investigate the appropriate point at which to start including new patients’ 
records in analyses, in order to include incident rather than historical reports of CAP 
(Objective 1a).  The findings of this chapter are used in all subsequent work. 
In Chapter 4 I begin by providing the results of a review of the literature on the incidence 
of CAP and LRTI in older adults in Europe.  This is followed by my own analysis of the 
incidence of LRTI and CAP among the UK’s older population between 1997 and 2011 
using linked data (Objective 1), which is presented as a paper published in PlosOne.[97] 
The difference between CAP incidence estimates using stand-alone GP records and 
linked GP hospital admissions records (Objective 1b) is the focus of Chapter 5.  Estimates 
from the same cohort of individuals are compared to better understand the potential 
added value of using the linked data. 
The final two analyses focus on CAP, looking at factors associated with severe outcomes 
following a CAP diagnosis. 
Firstly, in Chapter 6 I start by reviewing the literature on risk factors for hospitalisation 
after CAP.  I then compare CAP patients treated in the community to those hospitalised 
within 28 days of diagnosis, in order to identify risk factors for hospital admission 
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(Objective 2).  A range of co-morbidities, frailty and other factors are investigated, as is 
their contribution to the increasing level of hospitalisation after CAP between 1998 and 
2011.  In addition to the main analysis, presented as a paper published in BMJ Open, 
supplementary methods and an exploratory analysis are provided. 
In Chapter 7 the focus is on patients who are discharged from hospital having been 
admitted for CAP, and their increased mortality risk in the year post-discharge.  I first 
review the literature on factors associated with long-term mortality after a CAP 
hospitalisation.  In an attempt to aid GPs when making decisions regarding these 
patients, I then develop a series of prognostic models to predict patients’ risk of death 
in the first week, eight to thirty days and 31 to 365 days post-discharge (Objective 3).  
The models use information routinely collected in GP records, so that they could be 
incorporated into GP medical record software in the future for automatic risk 
calculation. 
Finally, in Chapter 8 I discuss the findings of this thesis.  The strengths and limitations of 
both the work I present, and more generally the use of linked electronic health records 
are considered.  Further areas for research are outlined and the clinical implications of 
the work are discussed.   
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Chapter 2 Research methods 
This chapter describes the data sources used in this thesis.  The identification of the 
initial cohort of individuals included in the analyses is described, followed by the 
methods used to find CAP and other LRTI records and their subsequent management 
into episodes of illness (used to estimate incidence for objective 1).  Nested subsets of 
these episodes then provided the data for the analysis of risk factors for hospitalisation 
post-CAP (objective 2) and the prognostic score for mortality risk after CAP 
hospitalisation (objective 3), as outlined in section 2.1.6.   
2.1 Data sources 
I mainly utilised anonymised data from three sources; primary care, secondary care and 
mortality records.  For incidence analyses (presented in Chapter 5), linked data on Index 
of Multiple Deprivation (IMD) were also used.   
2.1.1 Primary care data from CPRD GOLD 
The Clinical Practice Research Datalink (CPRD, formerly known as the GPRD – General 
Practice Research Database) was started in 1987, and is now one of the world’s largest 
databases of primary care electronic medical records.  At the time of this study it 
contained anonymised information for >14 million patients who were broadly 
representative of the UK population with respect to age, sex and region.[98, 99]  
Patients’ inclusion in CPRD is optional, and individual patients may opt out of being 
included in the database at any point.  Opt-out rates are extremely low, and in 2013 
were reported at only 1,000 out of 12 million patients.[100] 
General practitioners (GPs) who contribute to CPRD record diagnoses, signs and 
symptoms as standard in clinical practice.  Diagnoses are coded using Read codes, with 
additional fields and coding systems used where needed.  Other relevant data including 
referrals, test results and prescription information are also provided. 
2.1.1.1 Data quality 
To ensure that the data remain of an appropriate quality, CPRD carry out internal checks 
on each collection of data submitted by every practice.  Two assessments are 
undertaken; that there is continuity in data recording for a number of different aspects 
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of the patient’s record, and that the number of deaths recorded over time is broadly 
within an expected range.  If a meaningful gap in continuity or death recording is found, 
the date at which the gap ends is identified.  The practice is assigned an ‘up to standard’ 
(UTS) date at the latest of these dates and the data deemed to be research quality from 
this point onwards. The generalisability and validity of both CPRD and HES data are 
discussed in section 2.1.5. 
2.1.1.2 Data supplied by CPRD 
CPRD provide data to researchers in several file types which include different categories 
of information.  Patients are assigned a unique identifier which enables their records to 
be linked across the files, and a consultation identifier allows events from the same 
consultation to be connected.  The file types utilised in this work are outlined below: 
Patient file 
Demographic details such as patients’ sex and year of birth are provided in the Patient 
file, which also includes important dates such as the most recent date the patient joined 
the practice, and (when relevant) the date they transferred out of the practice.   
Practice file 
The Practice file gives information on the region where the practice is based, the date 
from when data from the practice were deemed to be of research quality (UTS date), 
and the date of the last data collection from the practice. 
Consultation file 
This file details the type of consultation, for example if it was a visit to the practice, a 
telephone call, night visit, discharge summary or hospital letter and so on. 
Clinical file and Additional Clinical Details file 
The Clinical file contains patients’ medical history data including diagnoses, signs and 
symptoms, coded using Read codes.  Diagnoses made during any admissions to hospital, 
provided via hospital letters or discharge summaries are also able to be recorded in this 
file.  The clinical file can be linked to an ‘Additional Clinical Details’ file which is a 
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structured area for the GP to enter information on a wide range of specific topics, such 
as smoking status, alcohol consumption, weight, or problems with mobility or self-care. 
Referral file 
Patient referrals to external care centres are provided in this file.  Diagnoses – the reason 
for the referral - are included, as is the referral speciality and type, such as day case, 
inpatient etc. and the level of urgency. 
Test file 
Tests ordered are entered as well as the results, and a Read code for the diagnosis or 
signs and symptoms. 
Therapy file 
Therapy data are entered from a Multilex Drug Dictionary.  All prescriptions issued by 
the GP are recorded with the date of issue, and the British National Formulary (BNF) 
chapter and product code.  Additionally, the number of tablets, numeric daily dose, 
number of days the medicine is to be taken, and whether the prescription is a repeat 
may be recorded.     
Immunisation file 
Vaccinations offered to the patient are detailed, along with whether they accept.  
Vaccines given are documented with the date, and whether the immunisation is routine. 
2.1.2 Secondary care data from HES 
HES data comprise anonymised data on admissions to NHS hospitals in England.  
Hospitalisations in HES have admission and discharge dates provided and this period of 
time is known as a ‘spell’.  Each spell may contain more than one episode (which denotes 
a period of consultant care) and each episode can contain up to 20 diagnoses.  The 
primary diagnosis of each episode is defined in the NHS data dictionary as:  
“the main condition treated or investigated during the relevant episode of 
healthcare“.[101]   
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Within the first episode of patient care, I took the primary diagnosis to represent the 
reason for the patient’s admission.  Demographic information such as year of birth and 
sex is also provided, as is supplementary information such as the method by which the 
patient was admitted to hospital (for example via A&E) and whether they were 
discharged to their usual home, to another facility, e.g. residential care, or if they died 
in hospital.  
Unlike the diagnoses contained in CPRD, which are largely entered by the GP during a 
patient’s consultation, diagnoses in HES data are entered by a team of clinical coders 
after a patient has been discharged from hospital.  The clinical coders translate the 
diagnoses in a patient’s medical notes into a series of diagnostic codes using the ICD-10 
coding system.    
2.1.3 ONS mortality data and IMD 
Mortality data for individuals in England are available via the Office for National 
Statistics (ONS).  Anonymised death certificate data are provided which include the 
patient’s date of death, the underlying cause of death and up to 15 contributory causes 
coded using ICD-10. 
Socioeconomic data are available via IMD quintile, a deprivation score calculated by 
combining a number of factors across seven domains (income, employment, health 
deprivation and disability, education, skills and training, barriers to housing and services, 
crime and living environment).[102]  IMD quintiles are provided at individual patient 
level for patients in practices that have consented to linkage.  Quintiles are calculated 
over Lower Super Output Areas (LSOA), small-level geographic regions defined by ONS 
which contain between 1000 and 3000 people.[103] 
2.1.4 Data linkage 
English CPRD practices can consent to having their patients’ data linked to a number of 
supplementary data sources such as HES, ONS mortality statistics and IMD quintile.  Data 
linkages are undertaken by a trusted third party to ensure patient anonymity.  For HES 
data, deterministic linkage is undertaken using a patient's NHS Number, date of birth, 
sex and postcode which are run through a stepwise algorithm.[104]   
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Individual ONS mortality records are initially linked via HES, and subsequently via CPRD 
if no link via HES is established.  Each record linkage is ranked according to the quality 
of the match (on NHS number, sex, date of birth, and postcode) between the data 
sources.  The quality of ONS-HES links range from 1 (high quality) to 8 (low quality), but 
only records assigned a value of 4 or less are deemed to be of sufficient quality to be 
provided for research use.  All records which cannot be linked via HES, but can be linked 
via CPRD practice information are assigned a score of 0 and are also provided to 
researchers.  The matching scoring criteria for records made available for research use 
are shown in Table 2-1. 
Table 2-1 ONS-HES, and ONS-CPRD record match quality values 
Match quality Matches on HES information 
1  NHS number, sex, date of birth, and postcode 
2  NHS number, sex, and date of birth 
3  NHS number, sex, date of birth (partial match), and postcode 
4  NHS number, sex, and date of birth (partial match) 
 
Matches on CPRD practice information (where no match to HES was 
established) 
0  NHS number, sex, date of birth, and postcode 
 
Patients are linked to IMD scores via their postcode.  The scores are then divided into 
quintiles, and the quintiles provided to researchers. 
Linked CPRD, HES and ONS data were available for >50% of English CPRD practices at the 
time the work on this thesis commenced.[104]  Data linkages are not available for CPRD 
practices in Scotland, Wales or Northern Ireland due to the different versions of HES 
collected in these countries.  HES data are available for linked English CPRD practices 
from 1st April 1997.  For the work in this thesis I used records from ONS linkage for 
patients whose deaths were recorded from 2001 (the start of death coding using ICD-
10), and IMD quintile data from 2007.   
2.1.5 Generalisability and validity of the data  
Both CPRD and the subset linked to HES have been shown to contain patients and 
practices that are broadly representative of the UK population with respect to age, sex 
and geographic region.[99, 105]  CPRD has been used extensively for epidemiological 
56 
 
research across a range of conditions.  A systematic review of 212 papers researching 
the validation and validity of 183 different diagnoses recorded within the data found 
that validity was high; respiratory diagnoses were confirmed in a median of 88% of 
diagnoses when validated internally (by checking against freetext or signs or symptoms 
also recorded in CPRD) or externally (by requesting additional anonymised information 
on the illness from the GP, for example hospital discharge letters).  Overall a median of 
89% of all diagnoses across a range of disease groups were found to have been 
confirmed by internal or external validation.[106]  
It is important when using clinical data for research to consider the potential impact of 
external influences on trends in recording practices.  One such influence is the 
introduction of the Quality and Outcomes Framework (QOF) in 2004.  QOF is a voluntary 
annual programme for English general practices, in which they are scored against a 
series of indicators, and financially rewarded when they meet set targets.[107]  Indictors 
are broadly categorised as clinical (measures pertaining to specific diseases such as 
COPD, or diabetes) and public health (measures such as the percentage of patients aged 
>15 who have a recorded smoking status in the previous 15 months).  The number of 
clinical indictors varies per condition, and several indictors include the regularity of 
recording of important clinical measures such as lung function in COPD patients, or 
blood pressure measurements among diabetics.[108]  These indicators have resulted in 
increased levels of recording among patients with QOF conditions (in order for indicator 
targets to be met).  However, there is also some evidence that QOF has had a slightly 
detrimental effect on recording of some non-incentivised activities.[109]   
The introduction of QOF has resulted in appreciable improvement in recording of some 
lifestyle factors.  In particular, the recording of smoking status in CPRD has improved 
considerably over this period.  In 1996, current and former smoking status were 
recorded at 79% and 29% of their respective rates when compared to the British 
National Household Survey.[110]  By 2007-2011, CPRD prevalence of current smokers 
was within 1% of that from the Health Survey for England, although prevalence of 
former smoking was still up to 7% lower.[111]  To a lesser extent, increasing recording 
in the last three years has also been reported for alcohol consumption and BMI (up to 
approximately 60% and 50% respectively by 2011).[99] 
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HES is less extensively validated than CPRD, as contact with care providers to check 
patient records and diagnoses is less easily achievable.  The Audit Commission has been 
auditing clinical coding within hospitals since 2007/08, and has found that the accuracy 
of clinical coding is improving.[112]  They found that the average clinical diagnosis error 
rate decreased from 17% in 2007/08 to 13% in 2009/10.[112]  Information on the 
accuracy of specific diagnoses over this period was not provided.   
2.1.6 Overview of the data used for each study objective  
Figure 2-1 represents the populations used for each study objective.   
In order to estimate the incidence of CAP (and LRTI as a whole, objective 1) I utilised 
both unlinked and linked CPRD data, including HES records when patients were eligible 
for linkage (all records included within the white box and those nested within it in Figure 
2-1).  Using these data, I identified records pertaining to LRTI, to pneumonia or to 
hospitalisation and created LRTI and pneumonia illness episodes which were 
subsequently categorised as community or hospital-acquired infections (described in 
detail in sections 2.4.1 and 2.4.2).   
Patients in the initial cohort who were eligible for linked-HES data and who had a CAP 
episode were included in the analysis of objective 2, identification of risk factors for 
hospitalisation after CAP.  (All records within the medium and dark purple boxes in 
Figure 2-1). 
Patients from the hospitalisation cohort who were hospitalised with CAP and survived 
until at least the day after discharge were included in the analysis of objective 3, 
development of prognostic models to predict mortality after CAP hospitalisation.  (All 
records in the dark purple box in Figure 2-1). 
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Figure 2-1 Hierarchy of study populations for study objectives 1, 2 and 3. 
 
2.2 Initial cohort: eligibility criteria and study period  
Patients records were processed through a series of steps as outlined in Figure 2-2 and 
described in detail below.  
Figure 2-2 Process of defining the initial cohort 
 
All patients aged ≥65 years who were registered with an up to standard CPRD practice 
for ≥1 day between 1st April 1997 and 31st March 2011 were included in the initial cohort.  
Within this group, patients eligible for linkage to HES, ONS or IMD records were 
identified (via CPRD), and their linked data retrieved.   
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2.2.1 Data extraction 
Detailed CPRD records were obtained for all patients who had one or more pneumonia 
or other LRTI consultation in CPRD or any LRTI hospitalisation in HES (as defined in 
section 2.3.2) within the study period.  Patients who met the inclusion criteria but had 
no LRTI records during the study period were included as the denominator in incidence 
analyses (Chapters 3, 4 and 5).  Limited data such as demographic details were provided 
for these patients in the CPRD denominator files.   
2.2.2 Period of time patients’ records were used for pneumonia and LRTI diagnoses 
When establishing the initial dataset of pneumonia and LRTI illness episodes, patients’ 
records were included from the latest date of their 65th birthday, their current 
registration date (CRD) (plus the time established in the analysis in Chapter 3), 1st April 
1997 and the practice’s up-to-standard (UTS) date. 
Records were included until the earliest of a patient’s transfer out date (if they moved 
GP surgery), death date (defined using CPRD or the death date from linked-ONS records, 
described in section 2.6), their 116th birthday (to limit patients with spurious year of 
birth, as there are no records of a person living to this age in the UK) and the practice’s 
last data collection date. 
Once the dataset of illness episodes was established, specific start and end dates within 
these broad limits were used in each study.  These varied between studies and are 
specified in each chapter of the thesis. 
2.3 Defining LRTI, CAP and hospitalisations  
The focus of this thesis is on CAP.  However, as described previously, less severe LRTI 
can progress to CAP, and thus it is important to also consider LRTIs as a whole.  In order 
to prevent multiple consultations for the same illness being included as separate 
incident events, within each patient’s data, records for LRTI in general and pneumonia 
specifically were identified and consolidated into illness episodes.  Due to pneumonia 
being a subset of LRTI, I initially defined LRTI illness episodes, and then defined 
pneumonia episodes within these LRTI illnesses.  For this reason, I describe the methods 
in the rest of this chapter first for LRTI, and then for pneumonia.  These illness episodes 
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were subsequently assigned as community- or hospital-acquired, depending on their 
proximity to any prior hospital admission.  The section below explains this process in 
detail. 
2.3.1 LRTI and CAP illness-episode definitions  
A community-acquired LRTI of any type was defined as the presence of a diagnosis of 
LRTI in CPRD, or as the primary diagnostic code in the first episode of a hospitalisation 
(which I assumed to represent the reason for admission) in HES, with no LRTI code in 
CPRD/HES in the previous 28 days or record of hospitalisation in the previous 14 days.  
Hospitalisation was defined differently in HES-linked and unlinked data, as outlined in 
section 2.3.3.   
CAP was defined as for LRTI, but using a restricted subset of codes specifically for 
pneumonia. 
2.3.2 LRTI and pneumonia records 
The LRTI code list was developed by three clinical epidemiologists, who searched the 
CPRD Medical Browser for any relevant Read codes (Appendix A).  Codes denoting an 
acute infection of the trachea and the airways below were included, such as those (with 
or without a specific aetiology) for tracheitis, bronchitis, lower respiratory tract 
infection, chest infection and pneumonia.  As outlined in section 1.1.3, the causative 
pathogen of LRTI is rarely investigated in general practice and so a broad code list was 
used.  COPD exacerbations which mentioned infection were also included.  Codes for 
potentially non-acute conditions such as chronic bronchitis, tuberculosis and abscesses 
of the lung and trachea were excluded.  Codes for aspiration pneumonitis were also 
excluded in line with previous studies of CAP.[1] 
Within the LRTI code list, codes which stipulated or otherwise indicated pneumonia, 
(e.g. ‘lung consolidation’) were identified so that pneumonia could additionally be 
analysed separately.  Codes that stipulated a post-operative infection were flagged so 
that they could be identified as hospital-acquired, and ‘history of pneumonia’ codes 
were also labelled.  This process was repeated using the ICD-10 code list for use in the 
HES data (Appendix A).   
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2.3.3 Identifying hospitalisations 
The focus of this thesis was community-acquired pneumonia, thus hospital-acquired 
infections were excluded.  To do this I needed to identify hospitalisations both in the 
HES-linked and CPRD stand-alone data.  The different recording systems used 
necessitated different approaches which are described below.  
2.3.3.1 Hospitalisation recorded in HES (for HES-linked patients) 
HES data were provided from 1st April 1997 to 31st October 2011.  Among patients 
eligible for HES linkage, hospital admission was defined using the HES admission and 
discharge dates.  Occasionally HES spells are not clearly delineated, and in these cases 
the spells were summarised and the last of the discharge dates used in analyses.  These 
‘multiple spells’ took three forms: 
 Sequential spells: the patient was admitted and discharged on the same date, 
and then subsequently readmitted for more than one day. 
 Nested spells: a second spell started and ended within a patient’s earlier spell. 
 Overlapping spells: a second spell started during a patient’s first spell, but ended 
later than the first spell.   
The three scenarios are represented in Figure 2-3.   
 
Figure 2-3 Methods of summarising multiple HES hospitalisations that were not clearly 
delineated  
TYPE OF MULTIPLE SPELL 
Overlapping 
Nested 
Sequential 
SUMMARY RECORD USED 
Summary 
discharge 
date 
Admission 
date 
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When more than one of these situations arose in parallel, the summary discharge date 
took the value of the latest discharge date in the sequence.  The primary code of the 
first episode in the sequence was used as the admitting condition – if there were two 
admissions in a day (as in scenario one, above) the spell with admission and discharge 
on the same day was deemed the first hospitalisation on that date, and so the primary 
code of the first episode in that spell used as the admission reason for that cluster of 
hospitalisations. 
For patients who were eligible for HES but who had no hospitalisation records, it was 
assumed they had not been admitted to hospital within the study period.   
2.3.3.2 Hospitalisation records in CPRD (for non HES-linked patients) 
There is no single recording system for patients’ hospitalisations within CPRD, resulting 
in hospital admissions, discharges and referrals being recorded in several file types: the 
clinical, referral, test and consultation files.  Within these files a range of codes and 
coding systems are used, which range from specific information such as ‘inpatient’ for 
hospital admission, to more general categories such as ‘discharge notice received’ which 
may apply to a discharge from a hospital admission or outpatient department.   
Read codes pertaining to hospitalisation in general (rather than specific reasons for 
hospitalisation, such as hip replacement) were identified in the medical browser by Sara 
Thomas.  Records relating to hospitalisation in the additional coding systems were also 
identified in the consultation, referral and clinical files by Sara Thomas and myself. 
Due to the complexity of the data, records were categorised (by Sara Thomas and 
myself) into eight levels of hospitalisation; hospitalised as an inpatient, history of 
hospitalisation, referral for possible hospital admission, A&E record, hospital day-case, 
non-urgent hospitalisation, hospice referral/admission and ‘possibly hospitalised’ (for 
less definitive codes).  Records with stronger evidence of inpatient care were prioritised 
over other categories of hospitalisation recorded on the same day.  These fine levels of 
categorisation enabled different combinations of hospitalisation categories to be used 
for different scenarios as laid out in sections 2.4.2 and 2.5.1.   
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2.4 Creation of LRTI and CAP illness episodes 
2.4.1 LRTI episode structure  
In CPRD, all records for LRTI during the study period were extracted from the clinical, 
referral and test files.  Within these records, pneumonia codes were flagged and 
multiple LRTI records on one date combined into a single record.  In HES all LRTI and 
pneumonia codes were flagged, along with their position within a hospital episode and 
spell.   
All CPRD LRTI codes and the HES records which had an LRTI code in the primary code of 
the first episode of a spell were then used to derive the incident date of an episode of 
illness.  Patients may consult multiple times for an ongoing LRTI, and so LRTI records 
within 28 days of a prior LRTI consultation were considered a continuation of the 
previous episode.  The 28 day re-consultation period was used in line with previous 
research.[35, 57-60]  Thus one LRTI episode could contain several consultations, and a 
new illness was only recorded when there were more than 28 days between two LRTI 
consultations (Figure 2-4).  For example if a patient had consultations for LRTI on 1st 
January, 3rd January, 17th January, 8th March, and 7th April then three episodes of LRTI 
were defined with incident dates of 1st January , 8th March, and 7th April.   
 
 
Pneumonia episodes could start on the LRTI incident date (i.e. the patient presented 
with pneumonia) or later within an LRTI episode as long as there was no hospitalisation 
record between the LRTI and pneumonia codes (as the pneumonia may then have been 
hospital-acquired, discussed further in section 2.4.2).  As for LRTI as a whole, pneumonia 
Days between consultations 
2 14 50 30 
KEY 
LRTI 
consultation 
 
Incident LRTI 
consultation 
Figure 2-4 Defining incident LRTI consultations 
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codes within 28 days of each other were considered part of the same episode (Figure 
2-5). 
 
2.4.2 Defining community-acquired episodes 
In order to minimise the number of hospital-acquired cases included in the analysis, LRTI 
cases that occurred ≤14 days after a patient was discharged from hospital were 
considered potentially hospital-acquired (Figure 2-6).  This period was extended to 28 
days if the previous hospitalisation included an LRTI or pneumonia code (in keeping with 
the LRTI episode structure above).  Records denoting hospital discharge were by 
necessity defined differently in CPRD-only and HES-linked data.  In CPRD-only data 
hospitalisation records suggesting the patient had been in hospital for at least one day 
were used (hospitalisation categories; ‘inpatient’, ‘day-case’, ‘non-urgent’ or ‘hospice’), 
whereas in HES-linked data the date of hospital discharge was used.   
When LRTI episodes included a hospitalisation which was followed within 14 days by a 
pneumonia code, the LRTI was included but the pneumonia was considered hospital-
acquired.  This was due to an inability to ascertain whether the pneumonia infection was 
a worsening of the LRTI, or a hospital-acquired infection. 
 
Figure 2-5 Defining incident pneumonia consultations 
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2.4.3 Discrepant recordings for pneumonia and other LRTI in the linked data 
A hierarchy was developed to manage CPRD and HES records with the same event date, 
but conflicting pneumonia or other LRTI codes in the two data sources.  CPRD records 
for pneumonia or other LRTI occurring on the same day as a HES admission with no HES 
pneumonia or other LRTI code at any point in the hospitalisation were not included as 
illness episodes as it was reasoned that they may have been misdiagnosed by the GP.  
Records as above that did have a pneumonia or other LRTI code at some point during 
the HES spell were included as the patient may have been admitted with a more serious 
condition (e.g. a stroke) and the co-existing infection not coded until later.  When the 
primary code in a HES record was LRTI and the CPRD code was for pneumonia (and vice 
versa) the HES diagnosis was used, as diagnostic tools such as radiography are widely 
available in hospital settings and therefore more likely to have been used in hospital 
diagnoses. 
2.5 Further management of the data to identify hospitalisation post-LRTI, and 
define person-time at risk of community-acquired infection 
2.5.1 Hospitalisation after an LRTI episode 
Patients were considered to have been hospitalised in the 28 days after an incident CAP 
record if they had a HES admission date in that time (linked data, objectives 1, 2 & 3).  In 
the unlinked data, a CPRD hospitalisation record for a non-routine admission (i.e. 
‘inpatient’ or ‘hospice’) after a CAP episode and more widely for any LRTI was examined 
briefly in descriptive analyses of patients with incident infections in Chapter 4 (Figure 
2-7).   
Figure 2-6 Defining potentially hospital-acquired LRTI 
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Figure 2-7 Hospitalisation within 28 days of an LRTI episode 
 
2.5.2 Defining person-time at risk in incidence analyses (Chapters 3, 4 & 5) 
2.5.2.1 Time not at risk of community-acquired LRTI 
For incidence analyses, patients were deemed not at risk of an incident LRTI during an 
episode of LRTI (whether community or hospital-acquired) and for 28 days after the last 
LRTI consultation in the episode (Figure 2-8) (due to the 28 day re-consultation period 
explained above).  Hospital inpatients were not considered at risk of community-
acquired infections, and so person-time was excluded from the denominator during all 
HES-recorded hospitalisations and for the 14 days after discharge.  If there was a 
hospitalisation within an LRTI episode, time at risk of a new LRTI began at the latter of 
these two times (Figure 2-9, Figure 2-10).   
 
 
This patient was not at risk over the three LRTI consultations in the episode or for 28 
days after their last LRTI record.   
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Figure 2-8 Defining person-time not at risk due to an LRTI episode 
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This patient was not at risk over the three LRTI consultations in the episode, the 
hospitalisation that occurred within the 28 day ‘wash out’ period or for 14 days after 
discharge from hospital. 
 
 
This patient was not at risk during their initial hospitalisation, the subsequent potentially 
hospital-acquired LRTI episode, the hospitalisation that followed or for 14 days after 
discharge from hospital. 
Time was not excluded for the duration of hospitalisations in the stand-alone CPRD 
patients’ data as no admission or discharge dates were recorded in CPRD.  There has 
been no validation of CPRD hospitalisation codes, nor the timing of recording of these 
codes (for example these could be recorded on the patient’s date of admission, date of 
discharge or the date the practice received the discharge summary), and so the 14 day 
post-discharge period was not excluded either when using the stand-alone CPRD data.  
Further details of how person-time was handled in the stand-alone data, the reasoning 
behind this decision, and possible implications on estimates from stand-alone data are 
discussed in section 4.5. 
Figure 2-9 Defining person-time not at risk due to an LRTI episode or hospital admission 
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Figure 2-10 Defining person-time not at risk due to a hospital-acquired LRTI 
episode 
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2.5.2.2 Adaptations for time not at risk of CAP 
Cases of less severe LRTI remained at risk of pneumonia until they had a pneumonia-
coded record or were hospitalised.  Cases that developed pneumonia within an LRTI 
episode (prior to any hospitalisations) had person-time excluded from the denominator 
from the date of the pneumonia code, until 28 days after the last consultation within 
that episode (Figure 2-11).  LRTI episodes that contained a hospitalisation had person-
time excluded from the date of hospitalisation to the latter of 14 days after discharge or 
28 days after the end of the episode (Figure 2-12). 
 
This patient was at risk of pneumonia through their incident LRTI record until the 
pneumonia code. 
 
 
 
 
 
 
 
This patient was at risk of pneumonia during the first 5 days of their LRTI, until they were 
hospitalised.  The hospitalisation then made them ineligible for being at risk of 
community-acquired infection, including pneumonia. 
Figure 2-11 Defining person-time not at risk of pneumonia 
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Figure 2-12 Defining person-time not at risk of CAP due to hospitalisation 
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2.6 Defining date of death  
Patients’ date of death (as described below) was utilised when deriving the date of end 
of follow-up in all analyses.  ONS-provided date of death was further used as an outcome 
in the analyses of hospitalisation after CAP and prognostic models (Chapter 6 and 
Chapter 7). 
2.6.1 Date of death in ONS unlinked patients 
For patients ineligible for linked data, I used the date of death field contained within 
CPRD.  CPRD derived this date from an algorithm they developed which took the earliest 
of; the transfer out date if reason of transfer was death, the event date of a statement 
of death Read code, and the event date recorded in the ‘death administration’ 
structured data area.  If no date of death was recorded the patient was assumed to have 
survived until the end of their follow-up. 
2.6.2  Date of death in ONS linked patients (objectives 2 and 3) 
Date of death from linked death certificate data was available for all patients with linked 
data.  In an extremely small number of patients (n=87), more than one death record for 
a patient was identified by the linkage process.  In 40 of the 87 patients the multiple 
records had the same match quality value (described in section 2.1.4), and so a different 
mechanism to establish which record to include was required.  For reference, I 
compared the CPRD and ONS dates of death for patients who only had one ONS-linked 
date of death, and almost all (98%) of these dates were found to be within 28 days of 
each other.  Given the similarities between the criteria used for the match quality scores 
(see Table 2-1, above) I decided to use the ONS death date that was closest to the CPRD 
date (when patients had both dates recorded) rather than use the match quality when 
patients had multiple ONS death record matches.  When patients had multiple ONS 
death records but no CPRD date of death, I used the best quality ONS match.   
2.7 Covariates  
Several key variables were used in incidence analyses, and a wide range of variables 
were used in subsequent analyses on hospitalisation (objective 2) and prognostic 
modelling (objective 3), and these are outlined below.   
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2.7.1 Year of illness 
Time was categorised using the financial year structure of 1st April to 31st March the 
following calendar year.  CAP and other LRTI are caused by pathogens which 
predominantly circulate in the autumn and winter, and this categorisation ensured that 
winter peaks of illness were not split across two time periods.   
2.7.2 Age 
In order to preserve patient anonymity CPRD only supply researchers with patients’ year 
of birth.  All patients were given an estimated date of birth of 1st July in their birth year, 
resulting in a maximum margin of error of six months.  Age was categorised into five-
year groups from 65 to 89 and then ≥90 years. 
2.7.3 Sex 
Patients were included in the analyses if their sex was coded as male or female.  A small 
number of patients with an indeterminate gender were excluded from the studies, as 
there were too few of them to be included in multivariable analyses. 
2.7.4 Region 
Regions in England were defined using the ten Strategic Health Authorities (SHAs) in 
place at the start of this study, and additionally Wales, Scotland and Northern Ireland.  
Smaller level geographical groupings are not available within CPRD in order to preserve 
patient anonymity. 
2.7.5 Additional co-variables used in objectives 2 and 3 
The analyses involved in objective 2 and 3 required the definition of a range of additional 
co-variables that were thought to be potentially associated with either hospitalisation 
or death after a CAP episode.  These co-morbidities, medications, vaccinations, and 
lifestyle and frailty factors are defined in detail in section 6.4 but are summarised briefly 
here. 
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2.7.5.1 Co-morbidities 
Twenty two co-morbidities of interest were defined.  All the constituent co-morbidities 
in the Charlson co-morbidity index were included.[68]  In addition I considered 
additional cardiac, neurological, and immune disorders that could increase the risk of 
severe CAP or mortality from non-respiratory causes after CAP.   
Among the Charlson co-morbidities, lung disease is an important risk factor for severe 
CAP, as it results in injury to the respiratory tract, reducing the effectiveness and 
efficiency of the mucociliary escalator and creating pockets of environment which are 
more accommodating of some species of bacteria.[4]  Several of the Charlson co-
morbidities also result in patients having an increased risk of severe infection due to a 
weakened immune response (the importance of which as a defence against CAP was 
outlined in section 1.1.2).  I added to the Charlson co-morbidities additional disorders of 
the immune mechanism, such as aplastic anaemia; the full list is given in section 6.4.1.3.  
Similarly, I considered neurological co-morbidities such as Parkinson’s disease and 
multiple sclerosis, which can result in damage to the mechanical barriers to infection, 
such as a reduced cough reflex or ability to swallow.  As highlighted in section 1.3.2.4, 
systemic infection can increase the short-term risk of acute cardiovascular events, 
particularly among individuals with existing cardiovascular disease.  The Charlson co-
morbidities include cardiovascular conditions such as myocardial infarction and 
cerebrovascular disease; I added ischaemic heart disease to this list.    
2.7.5.2 Frailty factors 
A range of frailty factors were defined, based on those in the frailty index described in 
section 1.2.1.1.  These were the presence of; mobility issues, a patient’s inability to care 
for themselves (self-care), a bedsore or ulcer, tiredness, anxiety or depression, low 
weight or poor nutrition, incontinence or catheterisation, a history of falling, visual 
impairment and recent need of a carer.  Additionally their living arrangements (such as 
living alone, in sheltered accommodation or residential care) were recorded. 
2.7.5.3 Medications and vaccinations 
Medications used to treat CAP/other LRTI (antibiotics) as well as those that may increase 
the risk of severe outcomes after CAP such as inhaled corticosteroids, oral steroids, 
immunosuppressants other than steroids, and those that may be protective such as 
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statins were investigated.  Influenza and pneumococcal vaccination status were also 
included to examine their effect on the severity of infection. 
2.7.5.4 Lifestyle factors 
Patients’ smoking status (current, ex- or never smoker) and if they had a history of excess 
alcohol consumption were explored as these factors can also increase a patient’s risk of 
CAP.  A major long-term effect of cigarette smoking is a reduction in mucociliary 
transport, resulting in an increased susceptibility to respiratory tract infections.[6]  
Alcohol has immunosuppressive effects that can last for several months, and drinking 
can also increase the risk of aspiration pneumonia. 
2.8 Statistical methods 
The statistical methods used in each analysis are described in detail in individual 
chapters.  Common statistical methodology, and the analyses themselves are outlined 
below. 
2.8.1 Clustering of illness episodes 
Due to the high incidence of CAP and other LRTI within the older population under study, 
some patients experienced more than one episode of illness in a year.  These episodes 
are said to be clustered or correlated within a patient.  Standard model fitting methods 
assume that all observations (in this case CAP episodes) are independent of one another 
with respect to exposure status.  In clustered data this assumption may not be true, and 
a correction needs to be made for any within-subject correlations.  Ignoring the violation 
of the independence assumption leads to standard errors (SEs) which are too small, 
confidence intervals around exposure effect estimates which are too narrow and p-
values which are too small.[113]  This increases the risk of Type 1 error, in which an 
association between an outcome and exposure is reported but is actually due to chance.  
The different methods used in this thesis for adapting models to the clustered data and 
taking the clustering into account, resulting in valid standard errors and p-values, are 
outlined below. 
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2.8.1.1 Robust standard errors 
When parameters such as rate ratios or odds ratios are estimated using the likelihood 
approach, their SEs are estimated using the variability assumed by the underlying 
statistical model.  When data are clustered, the precise probability model underlying the 
likelihood may not be correct due to the violation of the independence assumption.  
Robust standard errors take a different approach and are estimated using the variability 
in the data itself, which is measured by the residuals (the difference between each 
outcome and the predicted value of the outcome from the regression model).[113]  Only 
the SEs are affected and the parameter estimates (odds ratios (ORs), rate ratios (RRs) or 
hazard ratios (HR)) do not differ from those computed without robust SEs.  One 
adaptation needed when using this method is the use of Wald tests rather than 
likelihood ratio tests (LRTs) for hypothesis testing, as likelihood is not affected by robust 
SEs and so LRTs do not take account of the clustering.[113]   
I used this simplest approach to clustering in Chapter 7, where Cox regression with 
robust SEs was used to develop a series of prognostic models to predict mortality risk 
after CAP hospital discharge.  
2.8.1.2 Generalised estimating equations, or population averaged approach 
Generalised estimating equations (GEE) extend the approach of robust SEs while also 
taking account of the correlations when calculating the effect estimates.  The assumed 
correlations of the residuals are known as the working correlation matrix, and the 
appropriate matrix is specified when analysing the data.  The most commonly used is 
the ‘exchangeable’ correlation matrix which assumes that any two observations within 
a cluster are equally correlated.[114]  The working correlation matrix is then used to 
adjust the model parameter estimates and SEs for the correlation in the data (in effect 
by giving relatively more weight to smaller clusters). The regression coefficient produced 
is the average of the individual regression lines for each cluster and is interpreted as the 
mean effect across the population, which is why GEE is also known as a population 
averaged approach.[114]  As when using the robust standard errors approach, likelihood 
ratio tests cannot be performed, and Wald tests should be used instead. 
In Chapter 6 I used population averaged logistic regression to estimate the percentage 
of patients with CAP who were hospitalised within 28 days, between 1998 and 2011.   
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2.8.1.3 Random effects and multilevel models, or subject-specific approach 
Random effects models take a different approach to the issue of clustered data.  Rather 
than treating the correlation between outcomes as a nuisance which can be adjusted 
for (as in GEE), random effects models explicitly include the clustering in the model.  
Each cluster is assumed to have been randomly drawn from the population, and 
individual clusters are allowed to vary from the regression model, producing cluster level 
residuals (the difference between the predicted value of the outcome from the cluster-
specific regression and the predicted value of the outcome from the overall regression 
model).  These residuals are treated as a random unobserved variable distributed with 
a mean of zero, and so only the standard deviation of the distribution (the group-effect) 
needs to be estimated.[114]      
The inclusion of the cluster level group-effect in the model results in changes to both 
the log effect estimate and the SEs produced by the model – although the change to the 
log effect estimate is smaller than that of the SEs.  Comparison of the log-likelihood of a 
random effects model with a standard regression model can be undertaken using a LRT 
to assess whether the addition of the random effects term provides a better fit for the 
data.  Estimates produced from a random effects model are interpreted differently to 
those from population averaged models above; instead of representing the mean effect 
of the variable of interest across the population, they represent the effect of the variable 
on the mean subject or cluster.  Thus the effect estimates produced by multilevel models 
are said to be subject- or cluster-specific. 
Poisson regression with random effects was used to calculate the incidence of CAP in 
two chapters.  In Chapter 4, I estimated the burden of CAP (and LRTI more broadly) 
among older adults in the UK between 1997 and 2011.  Subsequently, in Chapter 5 I 
compared the incidence estimates of CAP derived from stand-alone CPRD data to those 
from linked CPRD-HES in order to assess the added value of using linked-data when 
estimating CAP incidence.   
Multilevel models can be extended to have as many levels as appropriate.  Each 
additional level of clustering added to the model results in a new cluster-specific group 
effect being added.   The model testing process above can be extended to test three 
levels of clustering against two, and so on to check that the appropriate number of levels 
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of clustering are being included.  In Chapter 6 I used multilevel logistic regression, and 
investigated whether in addition to CAP episodes being clustered within patients, 
treatment decisions were clustered within general practices, which is an example of a 
three-level model.  The multilevel model was then used to investigate risk factors for 
hospitalisation in the 28 days after a CAP diagnosis. 
2.8.1.4 Comparison of results using the population-averaged and multilevel 
approaches 
Coefficients produced by models using a subject-specific approach are usually larger 
than those produced using a population-averaged approach.  However, the ratio of the 
parameter estimate to its standard error is generally similar for the two models, 
resulting in equivalent results from significance tests.[114]  Both approaches are equally 
valid, and the most appropriate method to answer the research question should be 
chosen.   
I have mainly used subject-specific approaches (random effects and multilevel models) 
for the work in this thesis, as these are considered the most satisfactory (due to their 
being based on a full probability model for the data),[113] and I was generally interested 
in establishing effects at the individual CAP episode level.   
In order to investigate the trend in hospitalisation following CAP over time (Chapter 6), 
a population-averaged approach was more appropriate as I wanted to examine this 
trend over the population.  I therefore converted the results from the multilevel risk 
factor model into population-averaged results for this part of the analysis.   
2.8.2 Predictive and causal model building 
It is important to choose the appropriate modelling strategy for the type of analysis 
being performed.  In general, strategies can be categorised as predictive or causal and 
these are used to answer different types of question, as outlined below.   
2.8.2.1 Predictive modelling 
Predictive modelling is used when trying to predict an outcome in a given set of 
circumstances.  The aim is to use the minimum number of variables to explain most of 
the variation in the outcome.[115]  The number of variables in the model is particularly 
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important in prognostic scores, as a balance must be struck between including enough 
variables to predict the outcome of interest as accurately as possible but not including 
so many as to make the score unwieldly or underpowered, thus limiting its real-world 
use.  Commonly, variables are ‘selected’ into a regression model using a stepwise 
process; variables are either added to a model (forwards stepwise selection) or removed 
from a model initially containing all variables of interest (backwards stepwise selection).  
Decisions on whether the change should be retained are made by comparing the models 
with and without the variable of interest (using a predefined cut-off of the p-value from 
either a LRT or Wald test as appropriate) to assess the fit of the new model compared 
to the old.  The model with the better fit is then used as the comparison model, and a 
new variable added (forward) or removed (backward) until all variables of interest have 
been considered.  The end result is a parsimonious model.  A predictive modelling 
approach was used in Chapter 7 to develop the prognostic models to predict mortality 
risk after CAP hospital discharge. 
2.8.2.2  Causal modelling 
An alternative method is causal (or explanatory) modelling, which aims to estimate the 
effect of the risk factors of interest, while also controlling for any potential confounders.  
The model is in effect being used to test a causal explanation, and any variable which 
may be a risk factor or confounder should be included.[116]  If the study population is 
large enough, all potential risk factors and confounders can be included in the model as 
there is no need to aim for parsimony.  However, if there are a large number of variables 
of interest, this may result in unstable or exaggerated estimates due to sparsity of data 
or multicollinearity.  In such cases restricting the number of variables included in the 
model should be considered.  A further important consideration is the hierarchical 
relationship between the factors of interest and whether the effects of a factor (or group 
of factors) are direct, or mediated through other factors.  If it is possible that some 
factors are mediators, models should be built sequentially in order to be able to assess 
the effects of distal variables without adjusting for the more proximate mediators.  The 
mediators are then added to the model in order of increasing proximity to the 
outcome.[116]  The estimates produced for the mediators show their effect on the 
outcome, adjusted for the effects of the more distal variables, and the effects of the 
distal variables in this model represent those not mediated through the new group of 
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variables.  A hierarchical framework of how potential risk factors are related should be 
considered before analysis.   
A causal modelling approach was used for the analyses of risk factors for hospitalisation 
after CAP (presented in Chapter 6).  Mediation analysis was used to investigate the effect 
of distal and proximate risk factors on hospitalisation, as well as the extent which trends 
in hospitalisation after CAP over time were explained by these factors.   
2.9 Power calculations 
A major advantage of the use of CPRD and linked HES is the very large size of the 
datasets.  This enables precise estimation of incidence, and exploration of a wide range 
of potential risk factors for hospitalisation and death following CAP.  Due to the large 
size, formal power calculations were not performed for the majority of analyses.  The 
sample size requirements when developing prognostic scores are discussed in Chapter 
7. 
2.10 Ethics approval 
Ethics approval for the study was provided by the London School of Hygiene and Tropical 
Medicine ethics committee (6116), and the Independent Scientific Advisory Committee 
(11_033).   
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Chapter 3 Determining start of follow-up for analyses using incident 
episodes of community-acquired LRTI and pneumonia in older 
individuals. 
In the previous chapter I described the internal data quality checks that CPRD undertake 
to ensure that records from each practice are fit for research use (section 2.1.1.1).  The 
date at which the records meet this standard is known as the ‘up to standard’ date (UTS).  
While the checks performed by CPRD protect against large-scale errors, individual 
patient-level data quality issues also need to be considered when assigning patients’ 
start of follow-up.  In this chapter I outline these issues, and report an analysis 
undertaken to minimise these problems. 
3.1 Background 
3.1.1 Incorrect date recording for historical illnesses in general practice  
There can be inconsistencies in the recording of illness in the first few months after 
patient registration, for example when recording patients’ medical histories.  Upon 
registering with a new GP, patients provide their medical history and report any previous 
instances of severe or chronic illness.  This information is commonly obtained during a 
new-patient health check (which may not occur immediately after patient registration) 
or during a consultation with a GP.  GPs are able to record historical diagnoses on the 
date the diagnosis was originally made (or a close approximation to this date), but these 
diagnoses are also sometimes recorded on the date of the current consultation.  
Reasons for this include patients not remembering the date of onset of a previous 
illness, GPs noting elsewhere that diagnoses are historical (for example in the freetext 
field, which is not routinely provided with CPRD data), or due to time pressures in a short 
consultation preventing information from being entered on a number of dates.  
Historical diagnoses coded using the current appointment date incorrectly appear to 
researchers to be a new illness, and if included in analyses lead to overestimation of the 
incidence of disease.   
However, this over-reporting only affects a subgroup of the CPRD population.  Patients 
who registered before the practice became ‘up to standard’ do not begin follow-up in 
research studies until on or after the UTS date, and thus any historical illnesses reported 
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when the patient first registers with the practice will be automatically excluded from 
incidence analyses (Figure 3-1).  Conversely, patients who registered after their practice 
became UTS do not have this exclusion period if the UTS date is taken as the start of 
follow-up, and so pose a problem for researchers – are illnesses recorded early in a new 
patient’s follow-up incident events or prevalent/historical episodes that have been 
recorded retrospectively and which need to be excluded from incidence analyses?   
 
 
 
 
 
 
 
 
 
 
3.1.2 Assessment of the length of the over-recording period 
The relationship between time since registration and measured incidence rates in CPRD 
data has previously been examined for several chronic and acute conditions (including 
pneumonia) by Lewis et al.[117]  Patients were stratified by whether they had registered 
with the practice pre- or post- the practice’s UTS date.  Within these groups incidence 
rates were calculated for each condition over the first three years of follow-up.  To 
quantify when the period of over-reporting ended, incidence rates in three-month 
periods for the first year were each compared to the rate in months 13-36 and incidence 
rate ratios (IRR) produced.   The rate in months 13-36 was considered the baseline, as 
by this point it was assumed any over-reporting would have ended.  IRRs greater than 
1.2 were considered to be overestimations.  It was shown that rates were uniformly 
Patient registers 
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Figure 3-1 Inclusion of past medical history records in analysis, by whether a patient 
registers with a GP pre-UTS or post-UTS  
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higher at the start of follow-up in the group of patients who registered with a practice 
post-UTS.  The length of this overestimation varied both by disease type (acute or 
chronic) and to a lesser extent by different diseases of the same type.  Chronic relapsing 
diseases appeared to have incidence rates which were overestimated for 12 months or 
longer at the start of follow-up, while neoplastic disease incidence was overestimated 
in the first 6 months.   Acute conditions varied from over-reporting in the first three 
months (myocardial infarction, wrist fracture, deep vein thrombosis/pulmonary 
embolism), to six months (urinary tract infections) and nine months (pneumonia).   
3.1.3 Tailoring of these analyses to specific populations 
The Lewis analysis provided an important and interesting overview of the problem of 
over-reporting in the first months after registration within CPRD data.  In order to make 
as accurate choice of exclusion period as possible, the authors suggested that similar 
analyses were undertaken by researchers on their diagnoses of interest, to further refine 
the methodology Lewis developed.  However, in addition to varying by disease type, the 
period of over-reporting may vary by other factors such as age, sex or year of 
registration.  A better understanding of the heterogeneity of over-reporting by these 
factors would enable further refinement of the follow-up exclusion period needed.  
These additional factors are discussed in more detail below.   
3.1.3.1 Additional factors which may influence the period of over-reporting 
Age 
Lewis’ investigation included patients of all ages, which is a heterogeneous population.  
The post-UTS group is made up of patients who have recently changed GP, and the 
reasons behind this may differ between younger and older adults.  If different age 
groups also report their medical history to their GPs at different times, this would affect 
the exclusion period required.  For example, declining health or an inability to live 
independently may lead to older patients to move into supported or residential 
accommodation, and consequently also to change GP.  Patient behaviour upon 
registration may also differ with age; underlying illness and the need for repeat 
prescriptions may motivate older patients to provide their medical history to a new GP 
in a timelier manner than younger, healthier patients (and thus require a smaller 
exclusion period).  Finally, older patients may visit the GP more frequently than the 
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general population which may affect the timeframe of any over-reporting of previous 
illness. 
Sex 
Men have been shown to consult their GP slightly less than women.[118]  If this extends 
to taking longer to make initial contact with their GP, it could result in different lengths 
of over-reporting periods between the sexes.  
Year of start of follow-up 
The analysis by Lewis included records from 1987 to 2003.  Health service provision and 
strategy has changed since the first practices became up to standard in 1987, and 
electronic health record use has proliferated from being rare to the norm over this 
period.  More recently the introduction of QOF in 2004 has led to an increase in 
recording of QOF-incentivised conditions and a more complete reporting of their 
detail.[109]  While CAP is not included in the QOF scheme, other common co-morbidities 
in older adults which are risk factors for CAP (such as diabetes and COPD) are.[107]  The 
proliferation of electronic health records over time and introduction of QOF may have 
had an effect on recording of medical histories, and for investigators using a restricted 
time-period of records it may be possible to further improve the exclusion window 
needed post-UTS.   
Health checks 
New-patient health checks can be noted in patients’ records using a variety of Read 
codes, as can additional health checks which are offered to patients at certain ages, for 
example the over-75 health check.  Excluding pneumonia records on the same date as 
these checks could further refine the window of record exclusion, resulting in the 
incidence rate returning to the baseline more quickly. 
Person-time at risk 
Lewis calculated incidence over three month windows, excluding participants from 
contributing person-time from the date of the illness and, for acute conditions, 
restarting contributions in the second three-month period following the event date.  
Defining episodes of illness using start and end dates, and excluding person-time at risk 
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during this period is a more exact way of determining who should be contributing to the 
analysis at any one time.   
Width of incidence windows 
Dividing follow-up into smaller incidence windows of four weeks (rather than three 
months) enables more accurate evaluation of when the incidence reaches baseline, and 
thus allows a more precise period of time to be removed from start of follow-up.   
Repeat episodes 
Lewis included a maximum of one acute illness per six months.  Inclusion of more 
frequent repeat episodes of infections is possible when using a smaller incidence 
window, and is particularly important for common seasonal diseases.    
3.1.4 Aims 
This analysis aimed to refine the exclusion period required at the beginning of patient 
records when examining CAP episodes in patients who registered with a GP after the 
UTS date.  I utilised the episode structure for CAP events outlined in section 2.4 to enable 
accurate inclusion of repeat events.  Incidence was calculated over 28 day windows 
(rather than Lewis’ original 3-month window) to increase the precision of the estimate 
of period of exclusion.  I investigated the length of time it took for the incidence of CAP 
to return to baseline in older patients who registered pre- and post-UTS, further 
stratified by age, sex, and year of start of follow-up.  Additionally, records for CAP on the 
date of health checks were excluded to examine their contribution to over-reporting.   
3.2 Methods 
3.2.1 Study population and follow-up period 
As this analysis was concerned with over-reporting in GP records, the data used were 
limited to CPRD stand-alone data.  In order to investigate whether over-reporting had 
changed over time, records from the beginning of CPRD in 1987 were eligible for 
inclusion in the study.   
Patients were classified into two groups – those who registered before the practice’s 
UTS date (the ‘pre-UTS’ group), and those who registered after or on the practice’s UTS 
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date (‘post-UTS’).  Patient follow-up began at the later of the registration and UTS dates.  
Patients who were younger than 65 years of age when they started follow-up were 
excluded, as it was specifically the level of over-reporting within the older population 
that was of interest.  (In the pre-UTS group, patients aged <65 when they registered with 
their GP were excluded; in the post-UTS group patients aged <65 when the practice 
became UTS were excluded).  Patients aged ≥65 years who did not have a three year 
period between registering and UTS (i.e. those who registered with their GP less than 
three years before the practice became UTS) were not included in this analysis, as they 
did not clearly belong in either group (those registered pre- or post-UTS, Figure 3-2).  
Follow-up ended at the earliest of the patient’s date of death, the date they transferred 
out of the GP practice, three years after the start of follow-up and the date of last data 
collection from the practice.   
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3.2.2 Data management and structure 
Within the maximum three years of follow-up for this analysis, all pneumonia (or wider 
LRTI) codes were ordered into illness episodes as defined for stand-alone CPRD data in 
section 2.4.1.  These episodes were then deemed community- or hospital-acquired 
depending on whether there was a CPRD code for hospitalisation in the 14 days prior to 
the incident date (section 2.4.2).  Hospital-acquired episodes were not included in 
subsequent analyses. 
Time was divided into 28 day intervals from the start of follow-up.  Due to the illness-
episode structure used (with episodes at least 29 days apart), it was only possible for 
patients to have a maximum of one event per 28 day period.   
Figure 3-2 Patients aged ≥65 years included and excluded from these analyses 
 
Included: Pre-UTS group 
Patient 
registers 
Practice 
UTS 
≥3 years 
Included: Post-UTS group 
Any time 
period Patient 
registers 
Practice 
UTS 
 
Excluded from these analyses 
Patient 
registers 
Practice 
UTS 
 
<3 years 
Key: 
Records excluded from analyses 
Records included in analyses 
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3.2.3 Covariates of interest 
Analyses within the pre and post-UTS groups were further stratified by several factors. 
3.2.3.1 Age and sex 
Age was categorised into 5-year groups from 65 to 84 and ≥85 years.  Sex was classified 
as male or female. 
3.2.3.2 Year of start of follow-up 
To investigate whether over-reporting had changed over time, patients were divided 
into three groups depending on their start of follow-up: 9th September 1987 to 31st 
March 1997, 1st April 1997 to 31st March 2004, 1st April 2004 to 26th August 2011 (the 
end of data collection).  Cut points were chosen based on dates useful to researchers 
who use CPRD: the start of HES-CPRD linkage (1st April 1997) and the introduction of 
QOF (1st April 2004).  
Additionally, the month of start of follow-up was examined for patients in both the pre- 
and post-UTS groups, to see if any seasonal trends were evident. 
3.2.3.3 Health checks 
A Read code list for health checks was devised to explore whether CAP records coded 
on the day of a health check or medical screen could be identified and excluded.  Health 
checks were divided into two sets of codes; a ‘strict’ list, which included items offered 
to newly registered patients, such as new-patient checks, screens and histories, and a 
‘general’ list which also included other routine screens and checks such as geriatric 
screening, retirement and insurance medical exams.   
All records containing a strict or general health check code within the first year of follow-
up were flagged.  If a health check was on the same date as the incident code of a CAP 
episode, that episode was assumed to be historic and was excluded from the analysis.   
3.2.4 Statistical analyses 
The baseline characteristics of the pre- and post-UTS groups were examined, including 
age at start of follow-up, sex, year-group and month of start of follow-up. 
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Yearly rates of CAP were calculated for each 28-day period of the three years of follow-
up, stratified by pre/post-UTS groups using Equation 3-1.  Patients could not contribute 
person-time at risk to the analyses during any CAP episode, whether community or 
hospital-acquired.  Person-time was excluded from the date the episode started until 29 
days after the last CAP code within an episode (as outlined in section 2.5.2).   
Equation 3-1 Yearly incidence rate for CAP 
Yearly rate for 28 day period = Number of incident CAP diagnoses
Person time at risk (days)
  x 365.25   
 
Rates were further stratified by age, sex, year group and health checks, and the pre- and 
post-UTS rates compared graphically. 
Incidence rate ratios (IRRs) were calculated using Poisson regression, comparing rates in 
each of the 13-four week periods of the first year of follow-up to those of weeks 53-156 
combined.  This latter period was used to estimate the baseline incidence rate and (as 
in Lewis,[117]) the IRRs were deemed to be ‘at baseline’ when they were within 20% of 
the baseline rate (IRR<1.2).  As patients could not have more than one CAP per 28-day 
incidence window, it was not necessary to take clustering of illness-episodes within 
patients into account in this analysis.   
3.2.5 All LRTI 
The primary analyses of interest were on the effect of over-reporting on CAP estimates.  
However, I also repeated the analyses for all LRTI (using the methods described above) 
in order to better understand the exclusion period required for a generally less severe 
group of infections.  As CAP was the primary analysis which informed future work, 
results for LRTI are presented briefly with supplementary results provided in Appendix 
B. 
3.3 Results 
Within CPRD there were 1,149,386 patients aged ≥65 when they joined their practice or 
on the date when their practice was deemed UTS.  Of these, 9.7% (111,103) were 
excluded from the analysis due to not having three years of follow-up before the 
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practice became UTS.  The remaining 1,038,283 patients were included in the analysis, 
55.5% of which were in the pre-UTS group and 44.5% in the post-UTS group (Table 3-1). 
Table 3-1 Baseline characteristics of the study population 
 Registered pre-UTS Registered post-UTS 
 n (%) n (%) 
Number of patients 576175 (55.5) 462108 (44.5) 
Sex   
Male 240144 (41.7) 178607 (38.7) 
Female 336031 (58.3) 283501 (61.3) 
Age at start of follow-up   
Median (IQR) 74 (69-80) 76 (70-84) 
65-69 162078 (28.1) 107157 (23.2) 
70-74 144976 (25.2) 91503 (19.8) 
75-79 121739 (21.1) 82963 (18.0) 
80-84 80629 (14.0) 76449 (16.5) 
85+ 66753 (11.6) 104036 (22.5) 
Year follow-up started   
1987 - 1996 253658 (44.0) 116197 (25.1) 
1997 - 2003 280766 (48.7) 157026 (34.0) 
2004 - 2011 41751 ( 7.2) 188885 (40.9) 
Month follow-up started   
January 83071 (14.4) 39224 ( 8.5) 
February 23670 ( 4.1) 33601 ( 7.3) 
March 51116 ( 8.9) 36246 ( 7.8) 
April 40472 ( 7.0) 39431 ( 8.5) 
May 35099 ( 6.1) 36313 ( 7.9) 
June 42406 ( 7.4) 38316 ( 8.3) 
July 40130 ( 7.0) 45431 ( 9.8) 
August 29332 ( 5.1) 37826 ( 8.2) 
September 84418 (14.7) 42573 ( 9.2) 
October 56957 ( 9.9) 43936 ( 9.5) 
November 52354 ( 9.1) 36499 ( 7.9) 
December 37150 ( 6.4) 32712 ( 7.1) 
 
The patients who registered post-UTS were slightly older than those registered pre-UTS 
(median ages 76 (IQR: 70-84) and 74 (IQR: 69-80) respectively).  The largest age category 
in both pre- and post-UTS groups was 65-69 year olds (28.1% and 23.2% respectively).  
Within the pre-UTS group, the proportion of patients decreased as age increased; this 
trend was also seen in the post-UTS group until the ≥85 year category which accounted 
for 22.5% of post-UTS patients.  Over 90% of those who registered pre-UTS did so before 
2004, while 40% of patients who registered post-UTS did so after 2004.  
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The month of start of follow-up for patients in the post-UTS group (for whom follow-up 
started at their registration date) was relatively evenly distributed, while in the pre-UTS 
group (who started follow-up on the UTS date) there were peaks in January (14.4%) and 
September (14.7%) representing times when large numbers of practices join the CPRD.   
3.3.1 Period of over-reporting of CAP incidence and unstratified IRRs 
Before any stratification, CAP incidence was higher in those registered post-UTS 
compared to those registered pre-UTS throughout the three years of follow-up.   
Incidence of CAP in the pre-UTS group was relatively stable over follow-up.  The 
incidence of CAP among post-UTS patients reached a plateau at around window 8 
(weeks 29-32, Figure 3-3) and the IRRs were within 20% of the baseline (weeks 53-156 
combined) in all age groups and year groupings by week 29 (Table 3-2).   
Figure 3-3 Comparison of CAP incidence in those who registered pre and post-UTS over 
the first three years of follow-up 
 
(The unlabelled markers on the x-axis represent each 28 day period, time is days is also 
provided for ease of interpretation).
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Table 3-2 Incidence rate ratios (IRRs) comparing incidence of CAP in four weekly periods of the first year with the incidence in the second and third 
years of follow-up, for patients who registered post-UTS, stratified by age, sex and year of start of follow-up  
Time 
(weeks) 
Unstratified 
IRR (95%CI) 
Age at start of follow-up IRR (95%CI) Sex IRR (95%CI) Year of start of follow-up IRR (95%CI) 
65-69 70-74 75-79 80-84 85+ Male Female 1987 - 1996 1997 - 2003 2004 - 2011 
1-4 3  (2.44-3.68) 
3.01  
(1.45-6.28) 
3.02  
(1.62-5.63) 
2.17  
(1.43-3.29) 
2.51  
(1.73-3.63) 
2.47 
(1.93-3.17) 
3.58  
(2.49-5.16) 
2.62  
(2.06-3.35) 
0.76  
(0.59-0.98) 
3.29  
(2.37-4.58) 
3.27  
(2.36-4.54) 
5-8 2.03  (1.71-2.4) 
1.48  
(0.9-2.45) 
1.54  
(1-2.38) 
1.62  
(1.13-2.32) 
1.83  
(1.33-2.51) 
1.79  
(1.45-2.22) 
2.1  
(1.6-2.76) 
1.98  
(1.6-2.45) 
0.7  
(0.55-0.89) 
2.08  
(1.6-2.69) 
2.31  
(1.76-3.04) 
9-12 1.63  (1.4-1.9) 
1.13  
(0.73-1.75) 
1.39  
(0.92-2.11) 
1.39  
(1-1.95) 
1.69  
(1.24-2.31) 
1.33  
(1.11-1.6) 
1.75  
(1.36-2.26) 
1.55  
(1.28-1.87) 
0.53  
(0.43-0.66) 
1.82  
(1.43-2.33) 
1.74  
(1.37-2.2) 
13-16 1.5  (1.3-1.74) 
1.32  
(0.82-2.13) 
1.11  
(0.77-1.62) 
1.29  
(0.93-1.79) 
1.38  
(1.04-1.84) 
1.32  
(1.09-1.6) 
1.68  
(1.31-2.15) 
1.39  
(1.16-1.66) 
0.61  
(0.48-0.78) 
1.71  
(1.34-2.17) 
1.53  
(1.22-1.92) 
17-20 1.38  (1.2-1.59) 
0.87  
(0.59-1.28) 
1.23  
(0.83-1.83) 
1.16  
(0.85-1.59) 
1.09  
(0.85-1.4) 
1.35  
(1.11-1.64) 
1.5  
(1.18-1.9) 
1.3  
(1.09-1.56) 
0.46  
(0.38-0.57) 
1.51  
(1.2-1.89) 
1.52  
(1.21-1.9) 
21-24 1.35  (1.17-1.55) 
0.88  
(0.59-1.3) 
0.9  
(0.64-1.26) 
1.08  
(0.8-1.47) 
1.29  
(0.97-1.7) 
1.31  
(1.08-1.6) 
1.33  
(1.06-1.67) 
1.36  
(1.13-1.63) 
0.7  
(0.55-0.91) 
1.31  
(1.06-1.62) 
1.55  
(1.23-1.96) 
25-28 1.27  (1.11-1.46) 
0.93  
(0.62-1.41) 
0.98  
(0.68-1.4) 
0.82  
(0.63-1.07) 
1.35  
(1.01-1.81) 
1.22  
(1-1.48) 
1.32  
(1.05-1.66) 
1.24  
(1.04-1.48) 
0.71  
(0.55-0.93) 
1.54  
(1.22-1.95) 
1.15  
(0.94-1.41) 
29-32 1.05  (0.92-1.19) 
0.81  
(0.55-1.19) 
0.66  
(0.49-0.89) 
0.97  
(0.72-1.3) 
0.98  
(0.77-1.26) 
1.01 
(0.85-1.21) 
1.1  
(0.89-1.35) 
1.02  
(0.87-1.19) 
0.48  
(0.39-0.6) 
1.18  
(0.97-1.45) 
1.08  
(0.89-1.32) 
33-36 1.09  (0.95-1.24) 
0.68  
(0.48-0.97) 
0.94  
(0.66-1.34) 
1.23  
(0.88-1.73) 
0.96  
(0.75-1.23) 
0.98  
(0.82-1.17) 
1.09  
(0.89-1.35) 
1.08  
(0.92-1.28) 
0.51  
(0.41-0.64) 
1.22  
(0.99-1.51) 
1.12  
(0.91-1.37) 
37-40 1  (0.89-1.14) 
0.79  
(0.54-1.15) 
0.61  
(0.46-0.81) 
0.68  
(0.53-0.88) 
1.11  
(0.85-1.46) 
1  
(0.84-1.21) 
0.98  
(0.81-1.2) 
1.02  
(0.87-1.2) 
0.69  
(0.53-0.9) 
1.12  
(0.91-1.36) 
0.97  
(0.8-1.18) 
41-44 1.12  (0.98-1.28) 
0.61  
(0.43-0.85) 
0.79  
(0.57-1.1) 
0.84  
(0.63-1.1) 
1.35  
(1-1.84) 
1.07  
(0.89-1.3) 
1.1  
(0.89-1.37) 
1.13  
(0.95-1.35) 
0.92  
(0.68-1.25) 
1.07  
(0.88-1.3) 
1.22  
(0.98-1.51) 
45-48 1.08  (0.94-1.23) 
0.9  
(0.6-1.36) 
0.87  
(0.61-1.23) 
0.8  
(0.61-1.06) 
0.89  
(0.69-1.14) 
1.17  
(0.95-1.44) 
1.16  
(0.93-1.44) 
1.02  
(0.87-1.21) 
0.83  
(0.62-1.11) 
0.92  
(0.76-1.1) 
1.31  
(1.04-1.65) 
49-52 1.07  (0.93-1.22) 
1.1  
(0.69-1.75) 
0.92  
(0.64-1.31) 
1.01  
(0.74-1.38) 
0.98  
(0.75-1.28) 
1  
(0.82-1.21) 
1.25  
(0.99-1.58) 
0.95  
(0.81-1.11) 
0.82  
(0.61-1.09) 
1.13 
(0.92-1.39) 
1.07  
(0.87-1.32) 
(IRR in bold represent the first time the IRR fell to below the threshold of 1.2) 
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3.3.1.1 Results stratified by age  
Pre-UTS patients had lower incidence of CAP than patients in the same age group who 
registered post-UTS, and this discrepancy increased with increasing age (Figure 3-4 and 
Table 3-2).  The period of over-reporting also increased with increasing age group, 
ranging from 8 weeks among those aged 65-69, to 28 weeks for those aged ≥85 years.  
In all age groups the IRRs oscillated after their initial decrease below the threshold, with 
most returning to an IRR>1.2 once after their initial decrease (Table 3-2).   
 
Figure 3-4 Comparison of age-stratified CAP incidence in those who registered pre and 
post-UTS over the first three years of follow-up 
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3.3.1.2 Results stratified by sex 
There was no clear difference in length of over-reporting of CAP incidence by sex (the 
IRRs for were within 20% of the baseline at weeks 29-32 weeks for both men and 
women), although men had slightly higher incidence of CAP in the initial periods of 
investigation (Table 3-2, Figure 3-5). 
 
Figure 3-5 Comparison of CAP incidence stratified by sex in those who registered pre 
and post-UTS over the first three years of follow-up 
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3.3.1.3 Results stratified by time period of registration 
Over-reporting was difficult to ascertain in the 1987-1996 period.  The CAP trend over 
time among the post-UTS group was strikingly different to that in the other two periods 
under study.  Both pre- and post-UTS groups were lower than those in other time 
periods and showed a gradual general increase in incidence over time, although the IRRs 
were consistently less than one throughout the first year of follow-up (Table 3-2, Figure 
3-6). 
The two later time periods showed similar patterns to one another, with a high initial 
peak of over-reporting.  The 1997-2003 post-UTS group took four weeks longer to reach 
the 20% threshold than the 2004-2011 post UTS-group (29-32 weeks and 25-28 weeks 
respectively). 
 
Figure 3-6 Comparison of CAP incidence stratified by year of start of follow-up in those 
who registered pre and post-UTS over the first three years of follow-up 
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3.3.1.4 Results stratified by health check status 
Excluding CAP episodes which started on the same day as a record for a health check did 
not reduce the period of over-reporting, irrespective of whether the general or strict 
health check code list was used.  There was a very slight decrease in incidence over the 
first two four-week periods, but exclusion of neither strict nor general health check 
codes reduced the exclusion period required from follow-up (Figure 3-7). 
 
Figure 3-7 Comparison of CAP incidence over the first year of follow-up in the post-
UTS group stratified by health check exclusion 
 
 
3.3.2 Period of over-reporting for LRTI as a whole 
The period of over-reporting of LRTI incidence as a whole was considerably lower than 
that of CAP, overall and across all stratifications undertaken.  In all but three groups, 
LRTI incidence had returned to baseline by the second risk period (4-8 weeks), with the 
exceptions of those aged ≥85 and the year group 2004-2011 which both returned to 
baseline at 9-12 weeks, and the 1987-1996 period which (as for CAP) was consistently 
lower than the baseline period (Table 3-3 and Appendix B).    
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Table 3-3 Incidence rate ratios (IRRs) comparing incidence of any LRTI in four weekly periods of the first year with the incidence in the second 
and third years of follow-up for patients who registered post-UTS, stratified by age, sex and year of start of follow-up  
Time 
(weeks) 
Unstratified 
IRR (95%CI) 
Age at start of follow-up IRR (95%CI) Sex IRR (95%CI) Year of start of follow-up IRR (95%CI) 
65-69 70-74 75-79 80-84 85+ Male Female 1987 - 1996 1997 - 2003 2004 - 2011 
1-4 1.57 (1.51-1.64) 
1.34 
(1.23-1.46) 
1.36 
(1.24-1.49) 
1.31 
(1.2-1.43) 
1.52 
(1.39-1.66) 
1.65 
(1.53-1.77) 
1.69 
(1.58-1.8) 
1.5 
(1.43-1.58) 
0.8 
(0.74-0.85) 
1.55 
(1.46-1.65) 
1.73 
(1.63-1.84) 
5-8 1.15 (1.11-1.19) 
0.93 
(0.86-1) 
0.94 
(0.88-1.02) 
1.06 
(0.98-1.14) 
1.15 
(1.07-1.25) 
1.21 
(1.14-1.29) 
1.2 
(1.13-1.27) 
1.12 
(1.07-1.17) 
0.66 
(0.62-0.7) 
1.15 
(1.09-1.22) 
1.24 
(1.18-1.31) 
9-12 1.11 (1.07-1.15) 
0.96 
(0.89-1.03) 
0.95 
(0.88-1.03) 
1.05 
(0.97-1.13) 
1.13 
(1.04-1.22) 
1.1 
(1.04-1.17) 
1.15 
(1.09-1.22) 
1.08 
(1.04-1.13) 
0.65 
(0.61-0.69) 
1.14 
(1.08-1.2) 
1.17 
(1.11-1.24) 
13-16 1.07 (1.04-1.11) 
1 
(0.92-1.07) 
0.93 
(0.86-1) 
1.01 
(0.94-1.09) 
0.98 
(0.91-1.05) 
1.11 
(1.04-1.18) 
1.11 
(1.05-1.17) 
1.05 
(1-1.09) 
0.71 
(0.67-0.76) 
1.09 
(1.03-1.15) 
1.12 
(1.06-1.18) 
17-20 1.06 (1.03-1.1) 
0.96 
(0.89-1.03) 
0.95 
(0.88-1.02) 
1 
(0.93-1.09) 
1.05 
(0.97-1.13) 
1.07 
(1-1.13) 
1.07 
(1.01-1.13) 
1.06 
(1.01-1.1) 
0.69 
(0.64-0.74) 
1.05 
(1-1.11) 
1.14 
(1.08-1.2) 
21-24 1.04 (1.01-1.08) 
0.98 
(0.91-1.06) 
0.82 
(0.76-0.88) 
0.94 
(0.87-1.02) 
1.07 
(0.98-1.15) 
1.1 
(1.03-1.17) 
1.07 
(1.01-1.13) 
1.02 
(0.98-1.07) 
0.72 
(0.67-0.77) 
1.03 
(0.98-1.09) 
1.11 
(1.05-1.17) 
25-28 1.03 (0.99-1.06) 
0.91 
(0.85-0.98) 
0.99 
(0.91-1.07) 
1 
(0.93-1.08) 
0.97 
(0.9-1.05) 
1.03 
(0.97-1.1) 
1.02 
(0.97-1.08) 
1.03 
(0.99-1.08) 
0.75 
(0.7-0.81) 
1.03 
(0.98-1.09) 
1.07 
(1.02-1.13) 
29-32 1 (0.97-1.04) 
0.9 
(0.83-0.96) 
0.94 
(0.87-1.02) 
1 
(0.92-1.08) 
0.98 
(0.91-1.06) 
1 
(0.94-1.07) 
1.05 
(0.99-1.12) 
0.97 
(0.93-1.02) 
0.76 
(0.71-0.82) 
0.96 
(0.91-1.01) 
1.08 
(1.03-1.14) 
33-36 1.02 (0.98-1.05) 
0.95 
(0.88-1.03) 
0.91 
(0.84-0.98) 
1.01 
(0.93-1.09) 
0.98 
(0.91-1.06) 
1.03 
(0.97-1.1) 
1.02 
(0.97-1.08) 
1.01 
(0.97-1.06) 
0.81 
(0.75-0.87) 
0.98 
(0.92-1.03) 
1.09 
(1.03-1.15) 
37-40 1.01 (0.97-1.04) 
0.95 
(0.88-1.03) 
0.96 
(0.88-1.04) 
0.97 
(0.9-1.05) 
1.02 
(0.94-1.11) 
0.96 
(0.9-1.03) 
1.05 
(0.99-1.12) 
0.98 
(0.93-1.02) 
0.82 
(0.76-0.88) 
0.96 
(0.91-1.01) 
1.07 
(1.02-1.13) 
41-44 1 (0.96-1.03) 
0.91 
(0.84-0.98) 
0.92 
(0.85-0.99) 
0.89 
(0.83-0.97) 
1.06 
(0.97-1.15) 
1.03 
(0.96-1.1) 
0.99 
(0.94-1.05) 
1 
(0.96-1.05) 
0.87 
(0.8-0.94) 
0.98 
(0.92-1.03) 
1.03 
(0.97-1.09) 
45-48 1.04 (1-1.08) 
0.99 
(0.92-1.07) 
0.98 
(0.91-1.07) 
0.97 
(0.89-1.05) 
1.01 
(0.92-1.09) 
1.07 
(0.99-1.14) 
1.05 
(0.99-1.11) 
1.03 
(0.98-1.08) 
0.9 
(0.83-0.98) 
1.01 
(0.96-1.07) 
1.07 
(1.01-1.13) 
49-52 1.01 (0.98-1.05) 
1.01 
(0.93-1.09) 
0.98 
(0.9-1.06) 
0.91 
(0.84-0.99) 
0.99 
(0.91-1.08) 
1.02 
(0.95-1.09) 
1 
(0.95-1.06) 
1.02 
(0.97-1.07) 
0.89 
(0.82-0.96) 
1.04 
(0.98-1.1) 
1 
(0.95-1.05) 
IRR in bold represent the first time the IRR fell to below the threshold of 1.2 
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3.4 Discussion 
The overall period of over-reporting of CAP incidence among older adults who registered 
with their GP post-UTS was 28 weeks.  The duration of increased incidence in the first 
few months after patient registration varied by age and year of start of follow-up, but 
not by sex.   
The narrow (28 day) incidence windows used in this analysis, coupled with the use of 
episodes of illness (including start and end dates) permitted a more precise approach to 
the problem of over-reporting of historical illness than that used by Lewis et al.  They 
used three month incidence windows, and recommended a nine month period of 
exclusion at the start of follow-up for post-UTS patients when examining pneumonia 
incidence.  The data I have presented demonstrate that for studies of CAP among older 
adults this period can be reduced to 28 weeks (around 6.5 months), or even less in 
patients aged less than 85 years.   
The longer over-reporting among the oldest old after joining a practice may be due to a 
proportion of these patients moving into residential or nursing care, necessitating a 
change of GP.  These frail patients are more likely to have had a previous episode of CAP, 
as well as being at higher risk of CAP in the future than the younger-old.  The additional 
2.5 months of follow-up gained from using a 28 week rather than nine month period of 
exclusion is particularly valuable among these patients with high CAP incidence and 
probable shorter survival than their younger counterparts.  Starting follow-up slightly 
earlier after registration should enable more of these vulnerable and high-risk patients 
to be included in analyses. 
Results prior to 1997 were surprising – unlike in other time-periods, the incidence 
increased over time and was lower in the first year of follow-up than the second and 
third combined.  While this was an interesting finding, it does not impact on any of the 
later work in this thesis, which only included records from 1997 onwards, (the point from 
which HES-linked data are available).  Incidence of CAP reached within 20% of baseline 
four weeks faster in 2004-2011 (post-QOF) than in 1997-2003, although there is no 
evidence that this is attributable to QOF itself (pneumonia has never been included as a 
QOF indicator).  This may simply reflect improved timeliness of GP recording of historical 
events among the older population over time.   
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Exclusion of episodes of illness recorded on the same day as a health check did not 
enable any further refinement of the exclusion period.  For a record to be recognised as 
a health check a relevant code must be used by the GP.  It is possible that GPs who record 
health check codes are the same GPs who record historical events with historical dates.   
Alternatively, historical illnesses recorded during these health checks could be being 
entered as ‘freetext’ by some GPs, and thus not coded using Read codes or captured in 
this analysis.   
Those who registered when the practice was already contributing data to CPRD (the 
post-UTS group) consistently had higher incidence of CAP than the pre-UTS group.  The 
post-UTS group was generally older than the pre-UTS group, and this difference was 
most notable among those aged ≥85 who comprised >22% of the post-UTS group but 
<12% of the pre-UTS group.  Additionally, a higher proportion of the data contributed 
by the post-UTS group was in the latter years of the study, whereas the pre-UTS group 
contributed the vast majority before 2004 (post-UTS: 40.9% patients entered the study 
in or after 2004; pre-UTS: 92.7% entered before 2004).  The combination of increasing 
incidence of CAP with age, ad improved use of electronic health records over time are 
likely the underlying reasons for the higher overall rate in the post-UTS group than the 
pre-UTS group. 
LRTI as a broad group was less susceptible to over-reporting than CAP, and had both a 
smaller and shorter period of raised incidence.  Patients visiting a new GP almost 
certainly report historic episodes of severe, less common illness such as pneumonia 
more than illnesses they contract yearly such as other LRTI.  Those who are not 
registered with a GP may be prompted to do so if they become ill and require medical 
attention, and thus the small, short increase in LRTI may in part be documenting incident 
events.     
As highlighted above, this refinement of Lewis’ methods has many advantages, such as 
the use of shorter incidence windows, analysis of a specific sub-population, and 
additional stratification of results by age and study period.  However, there are some 
potential limitations which should be considered.  It is probable that in addition to 
historical illnesses, some of the CAP events recorded early in follow-up represent truly 
incident illnesses.  As for LRTI as a whole, they may have represented patients’ who 
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registered once ill with CAP, or alternatively they could denote expected end of life 
events in patients who have moved to palliative or enhanced nursing care.  It is 
impossible to distinguish between the historical and incident events in these data (hence 
the need for this analysis).  Given this, the exclusion of both the events and the person-
time contributed by post-UTS registered patients in the first few months of follow-up 
avoids overestimation of incidence and provides conservative but more robust 
estimates.   
Patients who registered with their GP less than three years before the practice became 
UTS were not included in these analyses, as they did not clearly fit into either of the pre- 
or post-UTS groups.  There is no obvious reason to expect that these 9% of the study 
population would have a different level of over-reporting of CAP to those who were 
included in the analyses, and so generalising these results to the entire pre-UTS group 
(including the 9% excluded here) should be acceptable. 
3.5 Implications of this work 
This work informs all subsequent analyses in this thesis, the majority of which concern 
CAP.  Those analyses concerning LRTI also include pneumonia diagnoses within the 
broader LRTI umbrella.  For consistency, I have used a 28 week period of exclusion (that 
of CAP among those aged ≥85 years) in all ensuing analyses to safeguard against 
probable over-reporting of any type of LRTI in any age group.  Rather than adding this 
period solely to those who registered post-UTS, I added 28 weeks (196 days) to the 
current registration date of patients who registered either after or less than 28 weeks 
before their practice became UTS (thus also capturing the group of patients excluded 
from these analyses).  Any historical illnesses in the early period of these patients’ 
follow-up that were recorded shortly after the start of UTS were thus also excluded. This 
should have ensured that historical reports of CAP and other LRTI were not included in 
my analyses.   
The reduction of the period of exclusion from nine months to 28 weeks also permitted 
the inclusion of 74 additional days of follow-up per patient registered post-UTS.  More 
than 340,000 such patients were in CPRD from 1997 onwards (when HES-linked data 
became available), enabling over 70,000 person-years to additionally be utilised in the 
incidence analyses of CAP and LRTI, which are outlined in the next Chapter.   
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Chapter 4 Incidence of community-acquired pneumonia and of lower 
respiratory tract infections in general among older adults in the 
United Kingdom 
In this Chapter I first describe the existing literature around the burden of CAP and LRTI 
in general among older adults within the UK and the rest of Europe.  I then detail a 
descriptive analysis of the incidence of community-acquired LRTI and specifically CAP 
among older adults in the UK (objective 1).  The main analyses in this Chapter are 
presented as a paper published in PlosOne in 2013.   
4.1 Literature review 
4.1.1 Aim of review  
The aim of the literature review was to summarise existing evidence for the burden of 
CAP, and of all LRTI, among older adults in Europe.  A broad review of the clinical and 
economic burden of CAP in Europe was published in 2012.[29]  This paper included 
information on several aspects of CAP, including aetiology, antibiotic resistance, 
morbidity and mortality, economic costs, treatment and prevention in addition to 
incidence.  By necessity, the incidence aspect of the review was short and the strengths 
and limitations of each paper not thoroughly discussed.  The CAP incidence section of 
this review extends that work, focusing specifically on CAP incidence estimates in the 
older population.  To the best of my knowledge, the incidence of LRTI more generally 
(not restricted to CAP) has not previously been summarised within the European older 
population.  
The primary focus of this review was on studies from the UK, in order to summarise 
existing knowledge about burden of disease among the UK’s expanding older population 
(and to highlight the methodological limitations of existing research).  Studies from 
Europe were included for context, but those from the US were not included due to their 
differing categorisation of pneumonia types (as described in section 1.1.3).   
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4.1.2 Methods 
4.1.2.1 Search strategy 
Records in Medline were searched from 1980 to the present day.  A list of Medical 
Subject Headings (MeSH) and free text words was developed to look for articles which 
explored the incidence of community-acquired pneumonia or LRTI in Europe among 
older adults (either as a focus or a subgroup).  Terms for pneumonia, LRTI, incidence, 
older adults and European countries were combined; the search strategy is provided in 
Appendix C.  The term ‘community-acquired’ was not included in the search strategy as 
LRTI is less commonly categorised as such than pneumonia.  Instead, whether the study 
was regarding community-acquired pneumonia was assessed during the screening 
process. 
I also examined annual reports from the Royal College of General Practitioners (RCGP), 
a large network of GPs across England and Wales who report new episodes of selected 
illness including pneumonia and LRTI as a whole via a weekly returns service.[119] 
4.1.2.2 Inclusion criteria 
I searched for articles published between 1980 to March 2015 (the date of the final 
search).  Studies which presented original data for patients aged ≥50 years on the 
incidence of CAP/LRTI, or which included information from which the incidence in older 
age groups could be calculated, were included.  In order to include as many studies as 
possible, a minimum age of 50 rather than 65 years was used due to the considerable 
variability in age categorisation between studies.  Case series, case reports, articles 
which were not available in English and review articles which did not present original 
research were excluded.  In order to investigate the complete burden of CAP (and of all 
LRTI), two further restrictions were placed on results. 
a) Studies which presented only pathogen-specific (e.g. Streptococcus pneumoniae) 
or LRTI subset-specific (such as bronchitis or influenza) rates were not included, 
as it is difficult to estimate how much these subsets contribute to the total 
burden of disease. 
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b) CAP and other LRTI are treated in primary and/or secondary care settings.  
Studies which are set only in a secondary care setting, whether they include both 
inpatients and/or outpatients will not capture patients who present to primary 
care, and thus are not a good measure of the total burden of these infections.  
For this reason, studies set solely in hospital settings were not included in this 
review.  In contrast, studies set in primary care may include both GP 
consultations with patients with pneumonia, and retrospectively recorded 
hospitalised pneumonia episodes.  This is possible, because (as highlighted in 
section 2.1.1.2), GPs are provided discharge summaries of their patients’ hospital 
admissions, which can be added to their general practice records (although the 
completeness of this recording has not been examined).  Thus studies based on 
GP data were considered eligible for this review.   
I screened all articles based on the title and abstract.  The full text was obtained for 
articles which potentially met the inclusion criteria, for further assessment of eligibility.  
When I was uncertain about the eligibility of a paper, I discussed it with my supervisor 
and we came to a decision together.  The reference lists of included studies were 
scanned for further papers which met the search criteria but were not included in the 
Medline results. 
4.1.2.3 Data extraction 
I extracted the data from each paper using a standardised data extraction form in Excel.  
Study characteristics of interest included the location, year and duration of the study, 
the data sources utilised, number of cases, age categorisation used, study design, case 
ascertainment, case definitions and methods of calculating incidence.  For ease of 
comparison, rates/risks were converted to per 1000 population/person-years where 
necessary.   
Key features of each study were summarised narratively, and are described below.  I 
assessed the quality of the studies in terms of the case definitions used, case 
ascertainment, and how multiple events and person-time at risk were handled.  No 
formal quality assessment was performed.   
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4.1.3 Results 
After de-duplication the Medline search generated 1412 citations.  A flow diagram of 
included studies is presented in Figure 4-1.  I deemed 1347 papers to be not relevant to 
the aims of this review: reasons included not reporting incidence of CAP/LRTI, not 
reporting incidence specifically among older adults, reporting incidence of hospital-
acquired illness, and reporting only hospitalisation rates or results for specific 
pathogens/subsets of LRTI.  I obtained the full text of 65 papers, of which 17 were found 
to meet the inclusion criteria.  Four papers reported different aspects of the same study; 
the results from the most recent of these publications are presented below, and the 
other three papers were excluded (after the additional information on the methods 
reported in these papers was extracted).[120]  One study known to the authors was not 
identified by the search due to the keywords for the paper not including a geographical 
region; this paper was also included, as were the data from the RCPG Weekly Returns 
Service annual reports.[34, 121] 
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Figure 4-1 Flow chart of study selection 
 
4.1.3.1 Included studies  
Incidence estimates for older adults were provided for CAP in 13 studies,[66, 120-131] 
and LRTI in six studies,[34, 35, 121, 131-133] (with two studies reporting both).  Results 
are presented in Table 4-1, Table 4-2 and Table 4-3.    
Community-acquired pneumonia  
Study populations: Studies reporting CAP incidence (n=13) were available across a wide 
geographical area, reporting results from eight countries from northern, central and 
southern Europe between 1981 and 2012 (Table 4-1).  Multiple studies took place in 
Spain (four), the UK (two) and the Netherlands (two).  Methods of case ascertainment 
varied; five studies which included primary care data only used pre-recorded pneumonia 
Records identified through Medline 
search  
(n=1432) 
Additional records identified  
(n=2, one additional paper, and 
RCGP Returns data) 
Records after duplicates removed  
(n=1414) 
Records screened  
(n=1414) 
Records excluded  
(n=1347) 
Full-text articles assessed 
for eligibility  
(n=50) 
Full-text articles excluded 
(n=30) 
Eligible studies  
(CAP: n=13, LRTI: n=6) 
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diagnoses from medical record review (including both UK studies,[66, 121, 128, 130, 
131] and five used patients’ primary and secondary care reports (one from health 
insurance reimbursement claims).[120, 123-125, 129]  Three studies collected patients’ 
data prospectively from both primary and secondary care.[122, 126, 127]  Only two 
studies were set specifically among older adults, one among those aged ≥50 years, and 
one among those aged ≥65 years.[122, 129]   
Case definitions: Seven studies identified pneumonia cases using a pre-specified code 
list.[66, 121, 123, 125, 128, 129, 131]  The codes used to define pneumonia were 
provided in the majority of studies (see Table 4-1); one UK study additionally included 
some non-specific LRTI codes such as “Acute Lower Respiratory Tract Infection”.[128]  
Five studies based pneumonia diagnoses on the presence of predefined clinical signs 
and symptoms, four of these required new radiological findings,[120, 122, 124, 126] and 
one included them as optional (Table 4-1).[127]  The Italian prospective study was based 
on GPs’ clinical opinion with no mention of a standardised case definition.[130]  One 
Spanish paper expanded their case definition for older patients to include investigation 
of those presenting with confusion and other non-specific symptoms.[126]  The criteria 
used to differentiate CAP from HAP were described in five papers, and a range of criteria 
were used; pneumonia developed >3 days after admission to hospital,[127] after 
admission at any time,[134] hospital discharge <7 days before symptom onset,[126] and 
discharge <14 days before pneumonia diagnosis.[122, 124]  Four of the remaining eight 
studies described the included pneumonias as CAP without supplying any exclusion 
criteria or definition,[120, 125, 129, 130] and four did not explicitly state that the 
pneumonias included in their analysis were community-acquired (but only cited and 
compared their results to other papers on CAP).[66, 123, 128, 131]  Despite HCAP not 
being a commonly adopted classification of pneumonia in Europe (see section 1.1.3), 
patients residing in nursing homes were excluded from two Spanish studies.[124, 126]   
Multiple events: Approaches to multiple CAP events were only outlined in three papers; 
one Dutch study using electronic health records excluded re-consultations within 90 
days,[66] and one Dutch and one Spanish study included only the first episode in the 
study period.[120, 131]  Repeat CAP events were not discussed by the other papers, 
with the exception of Myles et al who stated that 79% of cases had one pneumonia 
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diagnosis in the study period, but did not adjust for any clustering of episodes within 
patients in analyses.[128]   
Person-time at risk: A single study calculated incidence as a rate, including the time from 
patients entering the study to their first pneumonia or the study end.[120]  The 
remaining studies used population-based denominators, calculating risks per 1000 
population.[66, 121-131]  None of the CAP studies removed person-time not at risk (due 
to patients’ hospitalisations or the duration of their CAP) from the denominator.   
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Table 4-1 Studies reporting pneumonia incidence 
Country,  
Author [ref] 
Population  
(n if provided) 
Study 
period 
Case ascertainment Case definition Cases (n) Rate /1000 population 
(95%CI if provided) 
UK 
Myles [128] 
Patients from >300 
general practices  
1991-
2003 
Electronic health record 
review 
All recorded diagnoses (Read codes) of 
pneumonia , (including some non-
specific acute LRTI codes) 
All ages: 56,322 ≥65y 
60-69y:  
70-79y:  
≥80y: 
8 
3  
7 
16 
UK 
RCGP [121] 
Patients from ~100 
general practices  
2005-
2010 
Diagnoses/consultations for 
new illness/ exacerbations  
READ codes for pneumonia and 
pneumonitis mapped to ICD codes for 
analysis (ICD9 480-486) 
N/R Range among ≥65y: 0.9 to 3.6 
Full detail provided in Table 4-2 
Finland 
Jokinen 
[127] 
Individuals living in 
4 districts  
(n=46,979,  
≥60y:  n=8373) 
1981 –
1982 
All patients in study area 
with clinically suspected 
pneumonia, reported by 
health care units, university 
hospital & autopsy. 
Predefined clinical signs & symptoms 
or chest X-ray findings.  Diagnosis 
reviewed & confirmed at follow-up 
2/4w later.   
Excluded if onset >3d after admission 
to hospital 
               M     F 
60-74y: 64    34 
≥75y:     42    27 
Total:60-74y: 
≥75y: 
≥60y: 
M: 60-74y: 
≥75y: 
≥60y: 
F: 60-74y: 
≥75y: 
≥60y: 
15.4 (12.4-18.5)  
34.2 (26.2-42.1)  
19.9 (17.0-22.9)  
25.0 (18.9-31.0)  
65.2 (46.1-84.3)  
33.0 (26.9-39.2)  
9.0 (6.0-12.0)  
19.6 (12.3-27.0)  
11.8 (8.9-14.8) 
Netherlands 
Hak [131] 
Patients from 90 
general practices 
(n=358,008) 
2000-
2002 
Electronic health record 
review 
ICPC code R81 (pneumonia)  
Only first episode in study period used 
N/R 65-74y:  
≥75y:  
12.5 
21.6 
ICPC: International Primary Care Classification.  ICD: International Classification of Disease   
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Table 4-1 Studies reporting pneumonia incidence – continued 
Country,  
Author [ref] 
Population  
(n if provided) 
Study 
period 
Case ascertainment Case definition Cases (n) Rate /1000 population 
(95%CI if provided) 
Netherlands 
van 
Gageldonk-
Lafeber [66] 
Patients from ~85 
general practices 
(~350,000 patients) 
2001 – 
2007 
Electronic health record 
review 
GP consultations for pneumonia coded 
ICPC R81 
 
Excluded repeat consultations <90d after 
1st pneumonia consultation. 
N/R  
65-74y: 
≥75y: 
2001/2 
11. 3 
21.2 
2006/7 
17.5 
31.4 
Age/sex adjusted increase/year: 
65-74y:  13.6% (9.8-17.5)  
   ≥75y:   11.1% (6.9-15.5) 
Poland 
Patrzalek 
[123] 
Kielce population 
(n>200,000) 
2005,  
2007 – 
2010 
Inpatient & outpatient 
diagnoses registered by GPs 
& specialists in internal 
medicine   
ICD-10 codes for pneumonia (J18 and 
J15). 
≥65y: 
2005: 535 
2007: 581 
2008: 488 
2009: 309 
2010: 330 
≥65y: 
2005:  
2007:  
2008:  
2009:  
2010:  
 
19.4 
20.5 
16.9 
10.6 
11.0 
Hungary 
Tichopad 
[129] 
National population 
(of Hungary) 
≥65y: n=1,589,248 
2006-
2010  
Review of health insurance 
reimbursement claims 
Not reported ≥65y: 
22,470 inpatient 
56,813 outpatient 
(including primary care) 
≥65y: 
60-74y:  
75-84y:  
≥85y: 
35.8 
34.8 
35.5 
45.1 
Spain 
Almirall 
[126] 
Community-
dwelling residents 
aged >14y in one 
region (annual pop. 
74,368) 
1993 – 
1995 
Patients referred by GP or 
presenting to hospital: 
diagnosed by hospital 
specialists. 
Comprehensive list of symptoms/signs 
+ chest x-ray  (less specific 
symptoms/signs also investigated for 
older patients) 
Excluded: aspiration pneumonia, active 
pulmonary tuberculosis, hospital 
discharge <7d pre symptoms 
All ages: 241  
71 primary care 
170 inpatient 
≥65y (all): 
 
M ≥65y: 
F ≥65y: 
 
3.2 
 
5.2* 
1.9* 
 
*read off graph.  .  ICD: International Classification of Disease  
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Table 4-1 Studies reporting pneumonia incidence - continued 
Country,  
Author [ref] 
Population  
(n if provided) 
Study 
period 
Case ascertainment Case definition Cases (n) Rate /1000 population 
(95%CI if provided) 
Spain  
Vila-Corcoles 
2009 
[120, 135, 
136, 134] 
Community 
dwelling older 
adults (≥65 years) 
from 8 General 
Practices 
(n=11,240) 
 
2002 - 
2005 
Medical record review of 
hospital discharge 
summaries & primary care 
databases. 
Identified using ICD-9 code in discharge 
diagnosis/GP databases 
Case definition: Comprehensive list of 
symptoms/signs + chest x-ray. 
Excluded: re-hospitalisation <30d after 
in-patient CAP treatment & pneumonia 
post hospitalisation. First episode only  
Care setting ≥65y:  
65-74y:  
75-84y:  
≥85y: 
M≥65y:  
F ≥65y:   
14.0 (12.7-15.3)  
10.0 (8.6-11.4)  
16.9 (14.6-19.4)  
29.4 (23.5-36.2) 
19.2 (17.1-21.6) 
10.0 (8.6-11.5)  
 
≥65y 
65-74y 
75-84y 
≥85y   
1˚ 
355 
145 
50 
60 
2˚ 
118 
50 
43 
25 
Spain 
Capelastegui 
[124] 
Adult patients (≥18 
years) from one 
hospital & 150 GPs 
(n=254,523) 
2006 - 
2007  
GPs alerted study 
organisers to CAP cases.  
Hospital discharge 
diagnoses also checked  
New pulmonary infiltrate  on CXR + 
symptoms consistent with pneumonia  
Excluded: discharged from hospital/ 
palliative care in previous 14d, or 
acquired in hospital/nursing home 
All ages: 787 65-74y: 
≥75y: 
 
4.8* 
9.9 
 
Spain 
Sicras-Mainar 
[125] 
Adults from 6 
General Practices & 
2 hospitals 
(n=90315) 
2008 & 
2009 
Electronic health record 
review 
Codes for pneumonia (ICPC-2 codes 
R81, 480-487 & ICD-9-CM 481) 
Excluded: tuberculosis, lung cancer or 
‘from other sanitary areas' 
All ages: 581  
340 outpatients 
241 inpatients 
65-74y: 
≥75y: 
5.1 
8.1 
Italy 
Viegi [130] 
Patients from 287 
practices (around 
410,000 patients) 
1999 - 
2000 
GPs reported suspected 
CAPs & hospital 
discharges. 
Not reported ≥65y:  324 ≥65y: 
 
 3.34 
Crete 
Bertsias [122] 
Residents aged ≥50 
in rural area of one 
district (n=45,300) 
2011 - 
2012 
Cases identified at 6 
general practices, and 2 
pulmonary hospital clinics. 
Acute LRTI confirmed with lung 
infiltrate on chest X-ray.  Not 
hospitalised <14d pre diagnosis 
≥50y:  124 ≥50y: 27.35 
*read off graph.  ICPC: International Primary Care Classification.  .  ICD: International Classification of Disease 
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Table 4-2 Mean yearly pneumonia and LRTI data from RCGP Weekly Returns Service 
over time[121] 
 
Pneumonia  LRTI 
65-74 years ≥75 years 65-74 years ≥75 years 
Men Women Men Women Men Women Men Women 
2005 0.9 1.5 3.4 2.9 91.4 106.0 144.5 133.1 
2006 1.2 1.2 3.2 2.6 81.6 97.3 120.7 120.7 
2007 1.5 0.8 2.3 2.7 90.7 104.3 134.7 134.9 
2008 1.1 1.2 3.3 2.3 84.1 97.4 130.1 127.7 
2009 1.2 0.9 2.7 2.5 78.3 90.2 124.9 121.7 
2010 1.4 1.2 3.6 3.0 77.3 92.5 124.9 126.6 
 
Incidence: Within the UK, CAP incidence estimates ranged from 0.8/1000 among women 
aged 65-74 in 2007 to 16/1000 among both men and women aged ≥80 between 1991 
and 2003.[121, 128]  Estimates from the rest of Europe were generally higher, peaking 
at 45.1/1000 among those aged ≥85 in Hungary.[129]  Interestingly, rates also varied 
within countries (Table 4-1 and Table 4-2)  with the greatest variation demonstrated in 
Spain, where incidence rose more than threefold over a decade among patients aged 
≥65 in similar geographical regions.[120, 126] 
Older age was not finely classified: one broad category was used in four studies, two 
categories were used in five studies, and three groups in four studies (Table 4-1 and 
Table 4-2).  Of the seven studies (including both of those from the UK) which included 
two or more age groups within the older population, all showed rising incidence with 
rising age.[66, 120, 121, 124, 125, 127-129]  The age categorisation used varied between 
studies making direct comparison of age-specific estimates difficult.  Of the studies 
which stratified results within the older population by sex, five out of six found that men 
had higher incidence of CAP than women.[120, 124, 126-128]   This was also the case in 
most years for the ≥75 group from the RCGP (Table 4-2).[121]      
Incidence of CAP over time among the older population was reported by one UK, one 
Dutch and one Polish study with differing trends.   UK data from the RCGP fluctuated 
over time and showed no clear trend between 2005 and 2010.[121]  Over the same 
period, incidence in Poland was found to have decreased 43.5% among those aged ≥65 
years from 19.39/1000 CAP per population to 10.95/1000.[123]  Contrastingly, an earlier 
Dutch study reported an increase in CAP of 13.5% per year among those aged 65-74 and 
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11.1% among those aged ≥75 between 2001/2 and 2006/7 (adjusted for population 
changes in age and sex).[66]     
All Lower Respiratory Tract Infections 
Study populations: The six studies of LRTI incidence were equally distributed between 
the UK [34, 35, 121] and the Netherlands [131-133] in periods between 1990 and 2010 
(Table 4-3).  The UK studies included adults of all ages; two were small GP-based 
prospective cohort studies,[34, 35] and one used information provided by a large 
national general practice database.[121]  Two papers from the Netherlands utilised large 
general practice databases, one included all adults [131] while one was restricted to 
those aged ≥65 years.[132]  The third Dutch paper was a prospective cohort study of 85-
90 year olds in the Leiden region.[133]   
Case definitions: Specific case definitions for the diagnosis of LRTI were only supplied for 
two studies, both from the UK (Table 4-3).[34, 35]  The other studies used GP-diagnosed 
LRTI, in one case with the additional requirement of an antibiotic prescription or 
microbiological/radiological confirmation.[132]  The RCGP data were based on reports 
of new episodes of illness, with no further definition given. 
Multiple events: None of the UK studies provided information on their approach to 
including multiple events (e.g. creation of illness episodes, or use of first LRTI only), or 
the statistical methods used to account for multiple episodes per patient in analyses (if 
these were included).[34, 35, 121]  Among the Dutch studies, two restricted analyses to 
only the first episode of LRTI during the study period,[132, 133] while the other included 
multiple illnesses (again, with no discussion of adjustments made for clustering).[131]   
Person-time at risk: Only two (Dutch) studies used individual person-time at risk to 
estimate incidence rates,[132, 133] with other studies estimating risks,[34, 35] rates 
using the mid-year population as the denominator,[131] or providing no information on 
the denominator used.[121]  As with the CAP studies, no adjustment was made to the 
rates in any study to account for person-time not at risk of LRTI.    
Incidence: Overall LRTI rates ranged from 52/1000 among 65-74 year olds to 193.7/1000 
in ≥80 year olds.[131, 132]  Similar to the CAP studies, broad age categories were used 
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for in most analyses.  Rates of LRTI (as a whole) increased consistently with age, but 
varied considerably between studies, even among similar age groups.  For example, 
among those aged 65-74 years, incidence ranged from 52 to 106/1000 (Table 4-2 and 
Table 4-3).[121, 131]  Among older age groups, estimates of first LRTI ranged from 93.8 
to 193.7/1000.[132, 133]  Unlike CAP, there was no clear evidence of higher LRTI 
incidence rates among men, with higher incidence among women in the UK studies in 
at least some age groups (Table 4-2),[121, 34] and conflicting evidence of higher rates 
in men in the two Dutch studies (Table 4-3).[132, 131]   
Trends in incidence over time were solely available from the UK via the multiple yearly 
reports from the RCGP (Table 4-2).  These data showed an overall decrease in LRTI 
incidence between 2005 and 2010 with some yearly fluctuation.[121]   
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Table 4-3 Studies reporting LRTI incidence 
Country,  
Author [ref] 
Population  
(n if provided) 
Study period Case ascertainment Case definition Cases (n) Rate /1000 population 
(95%CI if provided) 
England 
Macfarlane 
[35] 
One Nottingham 
general practice 
(adult patients only) 
(60-69y n=1110  
70-79y n=783) 
1990 - 1991 Surgery consultations & 
home visits 
Provided comprehensive list of 
symptoms/signs  
+ antibiotics prescribed 
+ patient had not received antibiotics 
within the last 14 days 
All ages: 480 
60-69: 85 
70-79: 111 
60-69y:  
70-79y: 
66.2 
121.5 
England 
Macfarlane 
[34] 
Two Nottingham 
general practices 
(adult patients only) 
(n=14453, not 
further reported by 
age) 
1997 - 1998 Records of previously well 
adults consulting with LRTI  
Provided comprehensive list of 
symptoms/signs 
 + no consultation for LRTI in previous 
month 
All ages: 638 
(<25% of cases 
aged ≥60) 
All ≥60y:  
M  ≥60y: 
F  ≥60y:   
56 
45  
64  
UK 
RCGP [121] 
Patients from ~100 
general practices 
2005-2010 Diagnoses/consultations 
for new illness/ 
exacerbations 
READ codes for LRTI and pneumonia 
mapped to ICD codes for analysis 
N/R Range among ≥65y: 77.3 to 
144.5. 
Full detail provided in Table 
4-2 
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Table 4-3 Studies reporting LRTI incidence - continued 
Country,  
Author [ref] 
Population  
(n if provided) 
Study period Case ascertainment Case definition Cases (n) Rate /1000 population 
(95%CI if provided) 
Netherlands 
Voordouw 
[132] 
General Practice 
Research Database. 
Patients aged ≥65 + 
≥1 year recorded 
medical history 
(≈150 GPs, 
(n=26,701) 
1996 - 2002 Identified from medical 
chart of patient 
LRTI (pneumonia, acute bronchitis, or 
exacerbation of chronic bronchitis).   
+ antibiotics prescribed 
OR + X-ray/microbiological 
confirmation. 
First LRTI in study period only. 
65-69: 956 
70-79: 1478 
    ≥80: 978 
65-69y:  
70-79y:  
≥80y:  
  
91.1† 
140.5† 
193.7† 
Netherlands 
Sliedrecht 
[133] 
All consenting 
residents aged ≥85 
living in Leiden, 
Netherlands 
(n=587) 
Enrolled 1997- 
1999, 
followed for 
earlier of 5 
years or death  
Annual interviews of 
participating physicians, 
and deaths due to 
pneumonia (if no prior 
clinical diagnosis of LRTI) 
GP/nursing home physician diagnosis 
of LRTI, based on history taking, 
physical exam and clinical judgement. 
First LRTI in study period only. 
173 first LRTI 
 
85-89y: 93.8 (79.8-107.7) 
Netherlands 
Hak [131] 
Patients from 90 
computerised 
general practices 
throughout 
Netherlands 
(n=358,008) 
12 months 
within 2000 – 
2002 
Electronic health record 
review 
Codes for; acute bronchitis, influenza, 
pneumonia or asthma/COPD 
exacerbations 
Sensitivity analysis incl: dyspnoea, 
wheezing, other respiratory problems, 
coughing, abnormal sputum. 
N/R 65-74y:  
≥75y:  
52* 
70 
 
† calculated, not provided in paper, *read off graph.   
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4.1.4 Discussion 
This literature review highlights the paucity of information on incidence of CAP and LRTI 
as a whole among older adults in the UK, and describes considerable variation between 
estimates from the rest of Europe.     
Over a 35 year period, only two CAP and three LRTI studies were found which contained 
information on incidence among older adults in the UK.  These studies confirmed that 
incidence of CAP (and LRTI as a whole) increases markedly with age among the older 
population.  UK incidence trends over time were only available from the RCGP data, 
which suggested no clear trend for CAP rates between 2005 and 2010, but a slight 
decrease in LRTI rates.[121]   
In general, UK studies provided estimates which were either broadly comparable to or 
lower than those from other European countries.  This may have been in part due to the 
UK studies’ reliance on stand-alone GP records (thus underestimating overall incidence), 
whereas many other countries also included hospital admission records.   
In addition to the variation seen between countries, there was also a notable range of 
CAP and LRTI incidence estimates within countries.  Differing age structures (and a lack 
of consistency in age-stratification of rates) would undoubtedly account for some of the 
variation displayed.  Additionally, there may be regional differences in important risk 
factors such as co-morbidities and smoking status, or preventative measures such as 
pneumococcal and influenza vaccine programmes.   
A further contributing factor to the diverse estimates presented is the range of 
methodologies used by the different studies.  Methods of ascertaining cases of CAP (and 
of all LRTI) varied considerably between studies, as did the case definitions used.  Of the 
five CAP studies with specified case definitions, only one included a modified set of 
criteria to capture the sometimes complex or atypical presentation of CAP in older adults 
(such as weakness or confusion).[126]  Additionally, one prospective study included GP-
suspected CAP, which may have enabled capture of these patients.[130]  The exclusion 
of older patients with atypical CAP symptoms would likely have led to an 
underestimation of the disease burden among the older population.  The coded clinical 
diagnosis used by studies utilising electronic health records may have included atypical 
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presentations, and thus not been subject to this particular method of under 
ascertainment.   
Standalone GP records were used to calculate incidence in five of the CAP studies and 
all of those for LRTI as a whole.  Both of the UK CAP estimates solely used GP data; 
estimates from the RCGP were among the lowest presented,[121] possibly in part due 
to the under-diagnosis of pneumonia by GPs when chest radiograph confirmation was 
unavailable.[20]  Estimates from Myles et al were probably inflated due to the inclusion 
of non-specific codes for LRTI, some cases of which will not have been severe enough to 
be classed as pneumonia.[128]  In contrast, eight of the non-UK CAP studies included 
both primary and secondary care data, enabling capture of both patients who initially 
presented to their GP, and those who presented to A&E.  If GP recording of hospital 
discharge summaries was incomplete, this would have led to an underestimate of 
incidence in primary care data due to under-recording of these more severe cases.  
Conversely, both stand-alone and linked data are vulnerable to producing over-
estimates of incidence if repeat consultations are not managed appropriately, and such 
an approach was reported in only a single CAP study.[66]  This potential for both over- 
and underestimation when using stand-alone GP records without an episode structure 
makes the incidence estimates provided by studies using only primary care data difficult 
to interpret. 
One CAP,[131] and two LRTI papers [132, 133] limited inclusion to the first episode of 
illness.  Patients who have experienced a CAP/LRTI more broadly are known to be at 
higher risk of subsequent episodes of illness.  Therefore excluding these recurrent 
episodes will probably have led to an underestimate of the disease burden.  
Only five of the 13 CAP studies provided exclusion criteria for potential HAP, and these 
definitions varied from onset >3 days after admission to hospital to an apparently 
indefinite period after hospitalisation.[122, 124, 126, 127, 134]  Two of these studies 
excluded patients residing in nursing care, which is not in line with current European 
definitions of CAP, and will have led to the exclusion of older, frailer patients at higher 
risk of the infections under study.[126, 124]  In both studies, while patients in nursing 
facilities were excluded from the numerator if they had pneumonia, there is no mention 
that all nursing home residents were also excluded from the denominator.  This 
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reduction in cases and inflation of the population at risk will have both led to an 
underestimation of the incidence of CAP, in addition to making the results from these 
studies less generalisable to the older population as a whole. 
Overall, the number of studies which focussed on older adults was disappointing 
considering their high burden of disease, and none of the UK studies of either CAP or of 
all LRTI specialised in this population.  In two of the three UK LRTI studies, less than 25% 
of the study populations were aged ≥60 years, resulting in a small number of older 
participants.[34, 35]  Among all studies, the categorisation of age was fairly broad 
despite large study sizes.  The older population is a diverse group including a range of 
patients, from those who work full-time to those who require round the clock care.  This 
broad age categorisation offers little insight into the true burden among those most at 
risk.   
Information regarding incidence trends over time was also sparse, and was only 
presented by one UK and one non-UK source.  As the proportion of the European 
population aged ≥65 years continues to grow, it is crucial that we develop a more 
thorough knowledge of the incidence of LRTI and particularly CAP over time, including 
estimates finely stratified by age to enable accurate service planning and provision of 
resources.   
The CAP incidence results presented demonstrate a high degree of variability, even 
when examined by time, country, primary or secondary care setting or study design.   
Some of the disparity between study findings is likely to be attributable to the different 
sources of information used to make the CAP diagnosis.  As discussed in section 1.1.4, 
there is evidence that GPs tend to underdiagnose pneumonia in patients with acute 
cough when they do not have access to a chest radiograph,[20] while A&E clinicians tend 
to over-diagnose pneumonia compared to radiology reports.[21]  Thus, studies in which 
the diagnoses were made largely in primary care may have underestimated overall 
incidence, whereas inclusion of diagnoses from A&E (whether recorded in secondary 
care records or reported back to GPs and included in patients’ primary care notes) may 
have led to higher estimates of CAP incidence.  Even when chest radiographs were used 
to make diagnoses, the known inter-observer variability between radiologists across 
Europe in detecting infiltrates due to pneumonia on chest radiographs is also likely to 
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explain some of the differences in reported incidence between countries and over 
time.[20]  The availability of chest CT scans may have further contributed to between-
study differences; whether this would have led to increased estimates due to the ability 
to identify chest infiltrates too small to be seen on chest radiographs,[137] or decreased 
estimates due to better imaging and exclusion of some CAP previously diagnosed by 
radiographs, is difficult to ascertain.[138] 
The methods used to conduct the review also need consideration. While I conducted 
the literature search, assessment of eligibility and data extraction in a systematic 
manner, time and resource constraints necessitated restricting the search to the 
Medline database, and to papers reported in English. This may have resulted in some 
non-UK European studies being missed from this review.  Additionally, I selected studies 
and performed the data extraction single-handedly, without the benefit of a second 
reviewer.  This could have led to errors in the data extracted, and exclusion of some 
eligible studies, although I did seek advice on papers whenever I was unsure about their 
eligibility for inclusion in the review.   
4.1.5 Rationale for incidence study 
As detailed above, at the time of this study there was very little detailed information 
available on the burden of CAP (or of LRTI as a whole) within the older UK population.  
The UK studies identified in this review lagged behind those of other European countries 
due to their use of stand-alone GP data, rather than linked primary and secondary 
sources.  The UK studies were also small in size,[35, 34] included non-specific LRTI codes 
when calculating pneumonia incidence,[128] or did not provide results further stratified 
by age after 75 years.[121]  None of the UK studies differentiated between community- 
and hospital-acquired disease, and none excluded person-time not at risk from their 
denominators.  Accurate categorisation of person-time at risk is particularly important 
among the older population, who spend more time in hospital (and therefore not at risk 
of community-acquired infections) than the younger population.  The additional use of 
linked data to estimate the burden of these important infections would both enable 
more complete capture of pneumonia events, and allow better distinction between 
hospital- and community-acquired infections.  Furthermore, the UK studies did not 
clearly address the issue of multiple consultations for one episode of illness.  A clearly 
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defined episode structure to manage repeat recording of an ongoing illness would 
improve UK estimates of these common infections.   
4.2 Introduction to research paper 1 
A retrospective cohort study was used to estimate the burden of CAP, and of all 
community-acquired LRTI, among UK older adults.  The aim of this work was to use large 
general practice and (when available) linked hospital admissions data to provide better 
estimates of CAP and community-acquired LRTI in older adults in the UK.  As CAP is 
nested within LRTI, I present the incidence of LRTI first, followed by that of the CAP 
subset.  
I used the methods outlined in Chapter 2 to derive a cohort of patients using both the 
stand-alone CPRD and CPRD HES-linked data.  This enabled the inclusion of a large 
number of patients, and captured more events than if only the linked-data had been 
used.  Episodes of LRTI and of pneumonia were defined as explained in section 2.4.1 and 
community-acquired infections differentiated from those acquired in hospital as set out 
in section 2.4.2.  Patients’ person-time at risk was excluded from follow-up as discussed 
in section 2.5.2.   
In addition to the results presented graphically in the paper, tables of these results are 
included in Appendix D (supplied as online appendices to the article).   
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Introduction
Pneumonia and lower respiratory tract infections (LRTI) are
major causes of morbidity and mortality among those aged 65
years and over in the UK and other European countries [1–3].
The UK’s population is aging; recent estimates suggest that in
2035, 23% of the UK will be aged ≥65 years and 5% will be
≥85, compared to 17% and 2% respectively in 2010 [4]. The
‘oldest old’ (≥85 years) are at particularly high risk of infections
due to co-morbidities and waning immune function.
Community-acquired pneumonia (CAP) in older individuals is a
particular concern, as it can aggravate underlying co-
morbidities and have serious consequences [5]. Thus, the need
has been highlighted for new population-based studies of the
incidence of these infections among older adults in different
European locations [6].
There are few longitudinal studies on the burden of these
infections specifically amongst older adults in the UK. This is a
disparate group, including people working full-time and those
that require round-the-clock care. Available incidence
estimates vary, partly due to different age categorisations and
methods used [1,7,8], and community- and hospital-acquired
infections are rarely differentiated. Existing studies of regional
and socio-economic variations in incidence have not age-
stratified further after 65 years. Therefore there is a paucity of
information for this important and growing subsection of the
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population; it is essential that their LRTI burden is better
understood to enable planning and provision of health care.
The extent of antibiotic prescribing in general practice for both
LRTI and CAP among older adults also needs ongoing
assessment.
The aim of this study was to describe the incidence of
community-acquired LRTI and CAP among individuals aged
≥65 years between April 1997 and March 2011, using linked
electronic health records from primary and secondary care. We
describe how the incidence of these common infections varied
over time by age, sex, region and socioeconomic deprivation
and the extent of antibiotic prescribing in this group.
Methods
Data sources
The Clinical Practice Research Datalink (CPRD, formerly
known as GPRD) is a large UK-based electronic database of
primary care records which currently includes around 8% of the
UK population. The age, sex and regional distribution of
patients from contributing practices are representative of the
UK overall [9]. Anonymised patient-level information including
diagnoses (coded using Read codes), referrals to specialist
care, prescriptions, hospitalisations, demographic and lifestyle
details are included. Data from a practice are only used for
research after they have met a series of quality checks and
have been deemed ‘up to standard’ by CPRD.
Over 50% of English practices that contribute to CPRD
consent to linkage of their patients’ records to Hospital Episode
Statistics (HES) data. These contain information on all NHS
inpatient hospitalisations in England since 1997, with
diagnoses coded using ICD-10. Hospitalisations include one or
more ‘episodes’, each denoting a period of consultant care.
Study population and follow-up time
Patients aged ≥65 years between 1st April 1997 and 31st
March 2011 were eligible for inclusion. Follow-up began at the
latest of the study start date, patients’ 65th birthday, the date
CPRD deemed the practice ‘up to standard’ or 28 weeks after
patients’ registration (to exclude reports of historical illness that
are often recorded when a patient first joins a practice; the 28-
week period was chosen after analyses based on existing
methods) [10]. Follow-up ended at the earliest of the study end
date, death, transfer out of the CPRD or the practices’ last data
collection date. Patients who contributed at least one day of
follow-up were included in the study.
Codes used to define LRTI, hospitalisations and
antibiotics
Read and ICD-10 code lists for LRTI and within this list,
pneumonia were developed by three clinical epidemiologists,
including a consultant respiratory physician and a GP. An
estimated 50-70% of chronic obstructive pulmonary disease
(COPD) exacerbations are due to LRTI [11]; COPD
exacerbation codes that did not mention infection were also
identified for sensitivity analyses.
We examined evidence of hospitalisations to distinguish
between potentially hospital-acquired and community-acquired
infections. In the CPRD data, we identified hospitalisation
codes and relevant fields indicating hospitalisation in the
consultation, referral and clinical files (code lists available on
request).
Antibiotic therapy codes were identified and categorised by
their British National Formulary (BNF) subchapter, excluding
antituberculosis and antileprotic drugs [12–15].
LRTI/pneumonia illness-episode structure
Records containing LRTI or pneumonia codes were identified
in both CPRD and HES. In order to accommodate multiple
consultations for one illness, CPRD or primary HES LRTI/
pneumonia records within 28 days of each other were regarded
as part of the same illness-episode. The first record was
deemed the index date and the illness-episode finished 28
days after its last LRTI code. Within HES, only LRTI/
pneumonia codes recorded as the primary code of the first
episode of a hospitalisation (the condition the patient was
admitted for) were used when defining the index date, to avoid
including hospital-acquired infections.
As pneumonia formed a subset of LRTI, pneumonia illness-
episodes could start on the same date as an LRTI episode (if
the patient initially presented with pneumonia) or at some point
within an LRTI episode (if an LRTI had worsened).
Defining community-acquired illness
Incident cases of LRTI were regarded as hospital-acquired if
in the previous 14 days the patient had been discharged from
hospital (using HES records for any illness) or there was a
CPRD hospital code (using the unlinked data) [14,16–19].
Other variables
We used the ‘financial year’ definition of April–March to
ensure the winter peak of LRTI was not split across two years.
Age was grouped in five-year bands from 65 to 89 years, then
as ≥90 years. English regions were defined by Strategic Health
Authority (SHA). Index of Multiple Deprivation (IMD) quintile
(2007) was available at Office for National Statistics (ONS)
small area level (100 houses) for >50% of CPRD patients. The
IMD is calculated using seven domains: income, employment,
health deprivation and disability, education, skills and training,
barriers to housing and services, crime and living environment.
Analyses
At their simplest, incidence rates are calculated by dividing
the number of new episodes of illness by the person-time at
risk. Patients were considered not at risk of a community-
acquired LRTI during an LRTI illness-episode (whether
community or hospital-acquired), during a HES hospitalisation
or for the 14 days after any HES hospitalisation or CPRD
hospital code. This person-time was excluded from the
denominator when calculating incidence.
Incidence rates were calculated by year, sex, age, region of
England and IMD quintile. Poisson regression with random
effects was used to account for multiple illness-episodes per
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person. Incidence rates were directly age-standardised using
the ONS mid-year UK population estimates from 2004, and
95% confidence intervals (CI) were calculated.
We identified how many patients had been prescribed an
antibiotic on the illness index date, and the type of antibiotic
prescribed. Among those without a prescription on the index
date, we calculated the percentage that were hospitalised or
died as possible reasons for not having received a GP
prescription. For remaining patients, analyses were repeated
sequentially for the week after, and then two to four weeks after
the index date. Finally, records in the week before the index
date were examined to assess how many patients had
received an antibiotic prescription in this time.
Statistical analysis was conducted using Stata version 11.2
and Microsoft Excel.
Ethics information
All data were anonymised prior to receipt by the authors.
Ethics approval for the study was given by the Independent
Scientific and Advisory Committee (of CPRD), and the London
School of Hygiene and Tropical Medicine Ethics Committee.
Results
The study population comprised 1,534,443 patients from 625
practices across the UK (Table 1). Over half the participants
were aged 65-69 at the start of the study and 56% were
female. Median period of patient follow-up was 5.1 years
(interquartile range (IQR): 2.3-9.2). HES-linked information was
available for 59.7% of patients, whose characteristics were
largely similar to those of the whole cohort (Table 1).
Incidence by age and sex
Over the 14-year study period, 974,121 episodes of
community-acquired LRTI were identified in 448,469 patients
(median number of episodes=1, IQR:1-2). The median age at
diagnosis was 76 (IQR:70-82) years. Crude overall LRTI
incidence was 122.93 episodes/1000 person-years (IQR:
122.49-123.37/1000 person-years); incidence generally
increased over time with some fluctuations, from a low of
100.96 (1997) to a peak of 148.04/1000 person-years (2008),
and was similar in men and women (Figure 1a & Table S1).
After standardising for age the increase over time was less
marked, and a higher rate in men than women was revealed
(Figure 1a & Table S2).
The difference between the sexes was also apparent in the
age-stratified rates (Figure 2a,b), particularly in older age
groups. Incidence increased with age, doubling between the
65-69 and 85-89 age groups, and fluctuations over time were
more marked at older ages. Age-stratified results were not
presented graphically for those aged 90+, as the age structure
of this group varied over time, making the results difficult to
interpret (Table S1).
Inclusion of COPD exacerbation codes did not change the
overall pattern of LRTI incidence over time, but increased the
rates in both sexes by around 7% (Table S3 & Figure S1).
A total of 64,978 CAP episodes were identified in 58,772
patients. CAP patients were generally older than those with
LRTI (median age=81 years, IQR:75-87). Overall incidence of
CAP was 7.99/1000 person-years (IQR:7.92-8.07/1000 person-
years), was somewhat higher in men than women and
increased slightly over time (Figure 1b, Table S4). After
standardising for age, the increase was no longer apparent and
the higher rate in men than women was accentuated (Figure 1b
& Table S2). CAP rates increased with age with the rate in the
85-89 years group over seven times that of the 65-69 year olds
Table 1. Characteristics of the study population, for all
patients and for patients with HES-linked data.
 
Entire study
population  
HES-linked
patients
 n (%)  n (%)
Number of patients 1534443  916128 (59.7)
Median years follow-
up (IQR) 5.1 (IQR:2.3-9.2)  5.3 (IQR:2.3-9.6)
Sex    
Male 672858 (43.9)  402474 (43.9)
Female 861585 (56.1)  513654 (56.1)
Age at start of follow-
up    
65-69 819333 (53.4)  491205 (53.6)
70-74 237349 (15.5)  140743 (15.4)
75-79 197400 (12.9)  117298 (12.8)
80-84 142077 (9.3)  84533 (9.2)
85-89 89292 (5.8)  53559 (5.8)
90+ 48992 (3.2)  28790 (3.1)
Region practice is
baseda  
England only
%  
North East 29432 (1.9) 2.4 20615 (2.3)
North West 178011 (11.6) 14.5 145665 (15.9)
Yorkshire & The
Humber 71012 (4.6) 5.8 46482 (5.1)
East Midlands 60824 (4.0) 5.0 32744 (3.6)
West Midlands 130162 (8.5) 10.6 106627 (11.6)
East of England 150977 (9.8) 12.3 115749 (12.6)
South West 144749 (9.4) 11.8 128592 (14.0)
South Central 165094 (10.8) 13.5 110107 (12.0)
London 155219 (10.1) 12.7 106431 (11.6)
South East Coast 139681 (9.1) 11.4 103116 (11.3)
Northern Ireland 43633 (2.8)  N/A
Scotland 121428 (7.9)  N/A
Wales 144221 (9.4)  N/A
Index of Multiple
Deprivation (IMD)
quintiles relative to
country as a whole
   
Unavailable 712107 (46.4)  99150 (10.8)
0 (least deprived) 190874 (23.2)  189466 (23.2)
1 204589 (24.9)  203345 (24.9)
2 171462 (20.9)  170527 (20.9)
3 150185 (18.3)  149164 (18.3)
4 (most deprived) 105226 (12.8)  104476 (12.8)
a Hospital Episode Statistics (HES) data available for England only
doi: 10.1371/journal.pone.0075131.t001
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(Figure 2c,d). Women’s CAP incidence was comparable to that
of men aged five years younger.
Incidence by region and deprivation
Incidence of both LRTI and CAP varied markedly by English
region (Figure 3). Age-standardised incidence of LRTI was
higher among the North and Midland regions than the South,
and was highest in the North West. For CAP, high rates were
seen in the North East, but also in the South Central region.
For both conditions, the lowest rates were in London and the
South East Coast. Rates are only presented for England; rates
for Scotland, Northern Ireland and Wales were not comparable,
due to lack of linked HES data outside England.
Incidence of both LRTI and CAP increased with increasing
deprivation, with a marked difference between IMD quintiles
three and four (the most deprived, Figure 4). This pattern was
Figure 1.  Incidence of LRTI and CAP by sex over time.  Crude and age-standardised incidence of a) LRTI and b) CAP by sex
over time. Standardised to UK population, mid-year 2004.
doi: 10.1371/journal.pone.0075131.g001
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present for both men and women, and remained after
standardising for age.
Antibiotic treatment of LRTI and CAP
More than three-quarters of LRTI patients were prescribed
antibiotics by their GP on the day their illness-episode was
diagnosed; 7.8% did not receive antibiotics but were
hospitalised (Table 2). Over half of CAP patients were
hospitalised on the day of diagnosis without a GP-prescribed
antibiotic on that day (58.2%), with death on the index date
without antibiotics or hospitalisation (13.0%) more common
than antibiotic receipt (9.9%). A larger percentage of CAP
(12.7%) than LRTI episodes (11.0%) had no antibiotic or
hospitalisation records in the 29 days after the index date
(Table 2). Of these CAP episodes, only 10% had received
antibiotics in the previous week. Penicillins, macrolides and
cephalosporins were the most commonly prescribed antibiotics
on the day for both conditions (Table 3).
Figure 2.  Incidence of LRTI and CAP by age and sex over time.  Incidence by age of LRTI in a) men, b) women and CAP in c)
men, d) women over time.
doi: 10.1371/journal.pone.0075131.g002
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Discussion
This is the first study to provide detailed estimates of the
burden of community-acquired LRTI and CAP among older UK
individuals over a prolonged time period. We have shown that
the incidence of LRTI and CAP increases markedly with age
within this older population. Those aged 85-89 years had
double the rate of LRTI and seven times more CAP illness-
episodes than those aged 65-69 years, and rates were
predominantly higher in men than women of the same age
group. Incidence varied between regions of England, with rates
in the North generally higher than the South. We also found
striking differences by IMD quintile, with incidence in the most
deprived quintile around 70% higher than the lowest quintile for
both LRTI and CAP. There was an increase in incidence of
both diseases over the study period, although rates did
fluctuate somewhat. The increase was attenuated after age-
standardisation, indicating that the rise was largely due to
Figure 3.  Age-standardised incidence of LRTI and CAP by region and sex.  Age-standardised incidence of a) LRTI and b) CAP
by region and sex. Standardised to UK population, mid-year 2004.
doi: 10.1371/journal.pone.0075131.g003
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Figure 4.  Age-standardised incidence of LRTI and CAP by IMD quintile and sex.  Age-standardised incidence of a) LRTI and
b) CAP by index of multiple deprivation quintile and sex.
Standardised to UK population, mid-year 2004.
doi: 10.1371/journal.pone.0075131.g004
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population aging. LRTIs were most commonly treated by an
antibiotic prescription from a GP, whereas over half of CAP
patients did not receive a GP antibiotic prescription but were
hospitalised on the illness index date.
Up to now there has been relatively little detailed information
on the incidence of these infections among the UK’s older
population. Importantly, our exclusion of person-time not at
risk, and identification of potentially hospital-acquired illness
provides more accurate estimates of community-acquired
infection than previously presented for UK older adults [1,7].
Table 2. Timing of antibiotic prescriptions and other
outcomes around the index date of LRTI and CAP illness-
episodes.
  LRTI  CAP  
Timing of
treatment
Treatment
received (all
mutually
exclusive)
 
Antibiotics
prescribed
in 7 days
before
index date
 
Antibiotics
prescribed
in 7 days
before
index date
  Total(%) n (%)
Total
(%) n (%)
On index
date
Antibiotics
prescribed
738794
(75.9) 22541 (3.1)
6412
(9.9) 777 (12.1)
 
Patient
hospitalised (no
GP antibiotics)
75453
(7.8) 8013 (10.6)
37830
(58.2) 4980 (13.2)
 
Patient died (no
GP antibiotics/
hospitalisation)
8094
(0.8) 937 (11.6)
8476
(13.0) 1450 (17.1)
1-7 days
after index
date
Antibiotics
prescribed
16116
(1.7) 1776 (11.0)
788
(1.2) 157 (19.9)
 
Patient
hospitalised (no
GP antibiotics)
5461
(0.6) 671 (12.3)
961
(1.5) 168 (17.5)
 
Patient died (no
GP antibiotics/
hospitalisation)
722
(<0.1) 123 (17.0)
399
(0.6) 102 (25.6)
8-28 days
after index
date
Antibiotics
prescribed
17406
(1.8) 2198 (12.6)
1155
(1.8) 208 (18.0)
 
Patient
hospitalised (no
GP antibiotics)
4497
(0.5) 27 (9.3)
610
(0.9) 72 (11.8)
 
Patient died (no
GP antibiotics/
hospitalisation)
291
(<0.1) 423 (9.1) 89 (0.1) 21 (23.6)
No treatment
recorded on
index date or
subsequent
28 days
 107287(11.0) 7355 (6.9)
8258
(12.7) 855 (10.4)
Total  974121(100.0) 44064 (4.5)
64978
(100.0) 8790 (13.5)
doi: 10.1371/journal.pone.0075131.t002
The derivation of illness-episodes allowed us to combine
repeat consultations for one illness, giving a better measure of
new illness compared to studies which included all
consultations or restricted analyses to the first consultation in a
year [7,8]. The incidence of LRTI we present is up to double
that reported in previous UK studies [1,8]. A key factor in the
age-adjusted increase in incidence in our study is likely to be
the improved survival of patients with co-morbidities, resulting
in a higher prevalence of patients at increased risk of infection
over time. Our CAP incidence rates are almost 20% higher
than previously reported in a similar UK GP population during a
slightly earlier period, although with similar trends by sex and
IMD [7].
Comparison of our findings with those from elsewhere in
Europe are restricted by the paucity of large European studies
of either LRTI or CAP set specifically in an older population, by
methodological differences and limitations of some studies, and
by real variation in the underlying risk profile of the populations
studied. Among LRTI studies, incidence of first LRTI among
85-90 year olds in a municipality in the Netherlands during the
first half of our study period estimated a considerably lower rate
(93.8/1000 person years) than that we present [20]. This small
study only included patients’ first episode of LRTI in incidence
estimates and did not exclude person-time spent in hospital,
which may explain much of the difference. Estimates from the
Second Dutch National Survey of General Practice
(2000-2002) were also lower than ours (70/1000 person-years
among those ≥75); again, person-time not at risk was not
excluded, and a different coding system for LRTI was used
[21].
Table 3. Variety of antibiotic (by BNF sub-chapter)
prescribed on the LRTI/CAP index date.
Antibiotic variety Number of varieties prescribed
(by BNFa sub-chapter)   
 LRTI CAP
 n (%) n (%)
Penicillins 511253 (69.2) 3662 (57.1)
Cephalosporins 64609 (8.8) 610 (9.5)
Tetracyclines 36785 (5.0) 218 (3.4)
Aminoglycosides 18 (<0.1) 1 (<0.1)
Macrolides 125343 (17.0) 1665 (26.0)
Clindamycin 22 (<0.1) 3 (<0.1)
Others 130 (<0.1) 4 (<0.1)
Sulphonamides 10577 (1.4) 80 (1.3)
Metronidazole 542 (<0.1) 16 (0.3)
Quinolones 28812 (3.9) 522 (8.1)
Nitrofurantoin & Methenamine 692 (0.1) 21 (0.3)
Two or more antibiotics 25 (<0.1) 0 (0.0)
Total varieties of Antibiotic 778808 (105.4*) 6802 (106.0*)
Patients prescribed to 738794 6412
a British National Formulary
* Total is more than 100% as some patients were prescribed more than one variety
of antibiotic
doi: 10.1371/journal.pone.0075131.t003
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Rates of CAP among older adults in Europe in the last 30
years have varied widely, both between and within countries.
Some of these were small regional studies, and/or were
restricted to either hospital or primary care settings. For
example, a Spanish cohort study (2002-2005) of individuals
aged ≥65 years set in the Tarragona region which did include
both outpatient and hospitalised cases estimated CAP
incidence at 14/1000 person years, twice that reported in this
paper; higher incidence was largely among 65-74 year olds [6].
An active surveillance program for CAP was established before
the start of the Spanish study, with primary care physicians
encouraged to register all CAP cases confirmed
radiographically. This could have changed primary care
physicians’ diagnostic practices for CAP. In addition, a high
proportion of individuals sought care directly from hospital and
not from their general practitioner. This may have resulted in a
somewhat more frequent categorisation of LRTI cases as CAP
compared to our study population, in which some younger less
severe cases would have been diagnosed and treated in
primary care (where radiological investigations for suspected
CAP are uncommon). In contrast, our CAP rates are
considerably higher than those presented by another small
Spanish study set in the Barcelona region in a slightly earlier
study period, which estimated CAP incidence as 3.16/1000
among those aged ≥65 [22]. Neither Spanish study removed
person-time not at risk of CAP nor age-standardised their
overall rates. A large Italian study gave a lower CAP incidence
estimate of 4.8/1000 population among those aged ≥65 years,
but was restricted to hospitalised cases [23]. Interestingly, a
large German study that also included only hospitalised CAP
patients reported CAP incidence in those aged ≥60 of
7.65/1000 population, similar to our findings [24]. As with our
study, the German and Italian studies reported consistently
higher rates in men and sharply rising incidence with increasing
age. Incidence of CAP was higher still in a small Finnish study
of both hospitalised and non-hospitalised CAP in 1981/2 at
19.9/1000 population [25]. The difference between this finding
and ours may be due in part to an earlier study period and
climatic differences. Comparisons of our CAP incidence
findings with those from the USA are less meaningful, as in the
US patients in long-term residential care with pneumonia are
not included with CAP but classified separately as having
healthcare-associated pneumonia, which is not recommended
practice in Europe [26].
During our study period routine vaccination for all older
adults against seasonal influenza and pneumococcal disease
was introduced, in 2000 and 2003 respectively. Yearly uptake
of influenza vaccine has increased from 65% in 2000 and has
remained between 71% and 75% since 2003 [27,28]. Coverage
of pneumococcal vaccination (PPV23) has increased steadily
from 29% of ≥65 year olds in 2003 to an estimated 70.5% by
31 March 2011 [29,30]. Thus our findings show rising LRTI and
CAP incidence despite increasing levels of influenza and
pneumococcal vaccine coverage. This might be in part
because effectiveness of the PPV23 vaccine among older
individuals appears to be limited [31].
As lower respiratory tract infections are caused by a number
of pathogens whose circulation and severity of resulting
disease varies from year to year, it is no surprise that LRTI
incidence fluctuates somewhat over time. However, the peak
LRTI incidence shown here in 2008 has not been reported
elsewhere. National reported laboratory data for England and
Wales do not show peaks in isolates of Mycoplasma
pneumoniae, respiratory syncitial virus or influenza A or B in
2008 [32,33]. It should be noted that this peak is emphasised
by the decrease in 2009, which could have resulted from low
susceptibility among older individuals to the pandemic strain of
influenza circulating in the 2009/10 season [34].
A high proportion of individuals with LRTI were given an
antibiotic prescription on the index date, similar to a previous
report from 1995–2000 [13]. It has been shown that among
patients aged ≥65 presenting with an LRTI, 4% of those not
prescribed antibiotics on the index date were diagnosed with
pneumonia in the next month, compared to 1.5% of those
prescribed antibiotics [35]. Higher antibiotic prescribing rates in
older people may be to prevent worsening of LRTI or
deterioration of co-morbidities, in line with recently issued
guidance [36].
The increase in LRTI and CAP with age is unsurprising given
age-related immunosenescence, and the growing prevalence
of co-morbidities within older groups. The previously
unreported regional differences between the North and South
of England shown in this study may be due to interrelated
socioeconomic and other factors, such as smoking and
nutritional habits, as well as extent of co-morbidities and lower
winter temperatures. It is notable that the regions with the
highest age-standardised LRTI rates (North West, Yorkshire
and the Humber, West Midlands and females in the North East)
also have high reported prevalence of smoking [37]. The high
level of CAP (but not LRTI) found in the South Central region
was unexpected, and we cannot currently explain this; it does
not appear to be due to a higher proportion of ‘oldest old’. We
cannot exclude the possibility that some of the regional
variation in CAP is due to different diagnostic preferences
geographically in categorising LRTI as CAP. However, we think
it unlikely that this would explain all of the marked variation
seen.
Hospitalisation without a GP antibiotic prescription was the
primary intervention for 58% of CAP episodes in this study.
Previous reports estimated that a third of all pneumonia
patients are treated in hospital [38]; we would expect this to be
higher among our older population. Penicillins and macrolides
were the most prescribed antibiotics, in line with British
Thoracic Society guidelines issued at the time [39]. CAP cases
who died on the index date (13%) will have included some
death notifications received by the GP. However, 12.7% of
CAP cases had no record of treatment or death on the index
date or the following four weeks, and only 10% of these
patients had received antibiotics in the preceding week.
Reasons for this may include high-risk patients taking
previously prescribed prophylactic antibiotics, or prescription of
antibiotics during a home visit that were incompletely captured
in the electronic record.
Our study has many strengths, being a large, population-
based study of over 1.4 million patients’ primary care records,
with additional information on hospital admissions for 59% of
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patients. The addition of linked HES admission/discharge dates
allowed better differentiation between potentially hospital- and
community-acquired illness-episodes. It also enabled exclusion
of person-time not at risk from the incidence calculation. Older
adults spend more time in hospital than their younger
counterparts, making this an important consideration. HES
linkage was not available for the whole study population, and
so we could not remove person-time at risk from the
denominator of all patients. This may have led to a slight
underestimation of incidence. However, we did use
hospitalisation codes recorded in CPRD to exclude potentially
hospital-acquired infections from the CPRD-only subset of the
data.
In primary care settings in the UK, GPs often diagnose
pneumonia without an x-ray, which may have led to some CAP
cases being categorised as LRTI and vice-versa.
Misclassification between other conditions (e.g. chronic
respiratory disease) and LRTI may have occurred in a minority
of patients over time, but is not likely to have favoured one
condition over the other. Clinical guidelines for the diagnosis of
LRTI did not change substantially during the study period but
we cannot exclude the possibility that increased awareness
and variation in clinical practice could have contributed in part
to some of the upward trend observed. Thus our estimates
reflect those of GP clinical opinion, in line with previous studies
[1,7,35,40].
We used an episode structure for illnesses due to the high
consultation rate among our study population [41]. The 28-day
period free from LRTI consultations specified as necessary
before a new episode could begin was chosen to be similar to
previous UK studies, which excluded patients if they had an
LRTI diagnosis up to 28 days before the index date [8,40]. It is
possible that using this period excluded a few new illnesses
from the numerator of our rate, and also excluded some
person-time at risk. The 14-day exclusion period we placed
after any hospitalisation is commonly used [14,16–19], but
again may have excluded some new community-acquired
episodes.
Conclusions
Community-acquired LRTI and CAP are important causes of
morbidity and mortality in the aging UK population. Our new
estimates show that the summary incidence of LRTI and CAP
commonly presented for the ≥65 age group considerably
underestimates UK disease rates in the higher ages within this
group. It is important that variations in LRTI and CAP incidence
in older individuals by age, region and IMD are taken into
account in future health planning in the UK. Routine data such
as these are used in many countries to assess disease burden.
Given our findings, our methodology is likely to be highly
relevant to other countries with aging populations, so that they
can obtain more accurate incidence estimates of these
important infections.
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4.5 Further discussion around the use of combined stand-alone CPRD and HES-
linked CPRD data in one study 
These analyses utilised a combination of stand-alone CPRD records (40.3% of cohort) 
and HES-linked (59.7%) CPRD records.  Rather than limiting the analyses to using HES-
linked data only, it was decided to also include information from unlinked patients in 
order to provide a very large study population, enabling the calculation of detailed 
incidence estimates finely stratified by age group and sex over time.   
The two data sources contained a wealth of information, but neither were simple to use, 
as expected when using data whose primary purpose is for clinical rather than research 
use.  In addition to the data management considerations (outlined in sections 2.3.3 and 
2.4), the possible consequences of using the two data sources in a single analysis should 
not be overlooked.  Below I first outline the different strategies used, followed by how 
these could have affected the estimates I have presented. 
4.5.1 Different methods of capturing hospitalisation records 
The use of stand-alone CPRD data assumed accurate and timely recording by general 
practices of hospitalisations, thus enabling differentiation between HAP and CAP.  
Inspection of completeness and timeliness of recording of hospitalisations in CPRD data 
is being carried out as part of a separate ongoing investigation (Sara Thomas, personal 
communication).  Findings so far indicate that hospitalisations were recorded in CPRD 
on the HES date of admission, the HES date of discharge, the date the discharge 
summary was received by the practice, on another date or not at all.   
My analyses above also assumed that GP records included the reason patients were 
admitted to hospital (as notified via hospital discharge summaries), enabling 
hospitalisations due to pneumonia to be identified.  In contrast, all inpatient 
hospitalisations are recorded in HES, and cases of pneumonia are identifiable in HES data 
by looking at the reason for admission (which I assumed to be captured in the primary 
code of the first episode in a spell).    
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4.5.2 Different methods for calculating person-time at risk 
The methods used to define person-time at risk were applied slightly differently in the 
linked and unlinked data. As outlined in section 2.5.2, the inclusion of dates of hospital 
admission and discharge for HES-linked patients allowed the exclusion of the time these 
patients were in hospital, as well as the 14 days after discharge when patients were 
ineligible for a community-acquired infection.  The exclusion of time patients spent 
admitted to hospital was not possible in stand-alone CPRD data, as admission and 
discharge dates were not recorded.  Additionally, since the codes used to record 
hospitalisation in CPRD data and the recorded dates of these hospitalisations had not 
been validated at the time of the analyses, I decided not to exclude 14 days from the 
denominator after a CPRD hospitalisation code (as described in section 2.5.2.1).  My 
reasoning for this was if the codes for hospitalisation in stand-alone CPRD were incorrect 
or recorded on the wrong date, episodes of community-acquired illness would have 
been wrongly labelled as hospital-acquired and excluded, resulting in an underestimate 
of the incidence.  Excluding the 14 days after a CPRD hospital record from the person-
time included in the denominator would have decreased the size of the denominator, 
thus increasing the size of the estimate.  The resulting rates would have been difficult to 
interpret due to the contrasting direction of the effects of these mis-categorisations.  
Instead, I decided to be cautious and to exclude only the events but retain the person-
time, and produce conservative estimates of incidence. 
4.5.3 Potential implications of these differences between stand-alone and linked 
data 
The exclusion of person-time from linked data and extent of completeness of recording 
of hospitalisations by general practices are important when considering the impact of 
using both stand-alone and linked data in a single analysis.  The potential implications 
of these differences in the two data sources are summarised in Figure 4-2 below.   
In a best case scenario (box 1 in Figure 4-2), we assume that hospital admissions for CAP 
(when the patient presented directly to hospital, and had not initially consulted their 
GP) were fully recorded by the GP via information received in a hospital discharge 
summary.  In this scenario, CAP incidence estimates from linked and from stand-alone 
data would differ only by the amount of person-time that could be excluded during and 
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in the 14 days after a hospitalisation when using the linked data.  The inability to exclude 
this time when using the stand-alone data would have resulted in the denominator of 
the incidence calculation being too large, and thus a slight underestimation of incidence.   
Figure 4-2 Use of stand-alone CPRD data when calculating incidence estimates: effect 
of four scenarios 
 
 
In scenario 2, GPs recorded that patients had been admitted to hospital (allowing 
differentiation of community- and hospital-acquired illness) but did not record 
pneumonia as the reason for the hospitalisation.  This would have led to a reduction in 
the number of pneumonia episodes recorded in the stand-alone data (box 2 Figure 4-2), 
reducing the numerator in the incidence calculation.  This, in addition to the over-
inclusion of person-time at risk (in scenario 1) would result in further underestimation 
of CAP incidence. 
Thirdly, if a patient’s discharge summaries were not recorded in their GP records at all 
(scenario 3, box 3 Figure 4-2), it would also not be possible to tell whether GP-diagnosed 
pneumonias were community- or hospital-acquired.  This would result in the inclusion 
of some HAP episodes as CAP, inflating the rates previously underestimated due to lack 
of removal of person-time. 
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Finally, a single CAP episode could be recorded twice due to the patient consulting their 
GP, subsequently being hospitalised and the hospital admission (and CAP diagnosis) 
being recorded post-discharge in the patient’s general practice record more than 28 
days after the initial GP consultation.  This would also inflate the incidence rates 
produced (scenario 4, box 4 Figure 4-2). 
In reality the recording of hospitalisation and reasons for admission are likely to vary 
between general practices, resulting in a mix of scenarios one to four above.  It is 
probable that the exclusion of person-time and the more complete recording of events 
in the linked data would lead to the incidence rates calculated using these data being 
consistently higher than those produced using the stand-alone CPRD data.  
Consequently, although the characteristics of the HES-linked patients were similar to 
those of the cohort overall (Table 1 Paper 1), it does not follow that the incidence 
estimates produced by stand-alone and linked data would be equal.  The different 
method of excluding person-time not at risk and possible inaccuracies in recording of 
hospitalisations in GP data are likely to have affected CAP estimates more than those for 
all LRTI, as the majority of LRTIs are not severe enough to require hospitalisation and so 
are solely seen and recorded by a GP.  However, more than 58% of CAP episodes had a 
hospital admission record in either CPRD (stand-alone data) or HES (linked data) on the 
index date (Table 2 Paper 1).       
4.5.4 Further questions raised by the use of linked data 
It is unclear how much added value is gained by using linked primary and secondary care 
data compared to primary care data alone.  Do the incidence estimates from the linked 
data justify its use given the more complex and time consuming analysis required?  If 
the ratio of rates from the two data sources remained constant over time, would it be 
possible to approximate results from the linked-data using the stand-alone CPRD?   
I therefore devised an investigation to try to answer these questions, by comparing CAP 
incidence estimates from HES-linked and stand-alone CPRD data.  A full account of this 
is presented in the next Chapter.   
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Chapter 5 A comparison of CAP incidence estimates from stand-alone 
CPRD records versus CPRD HES-linked data in the same cohort of 
patients 
5.1 Background 
In the previous chapter I presented CAP incidence estimates which were estimated using 
records from CPRD HES-linked data for patients eligible for linkage, and from stand-
alone CPRD data for patients who were not.  I then discussed the possible ramifications 
of using both stand-alone and linked records in one analysis.  In this chapter I set out to 
answer some of the questions raised. 
While the value of linked over stand-alone data has been investigated for conditions 
such as cardiovascular events, asthma, diabetes, and upper gastrointestinal 
bleeding,[139-142] the benefits of using linked data to examine the burden of important 
infections such as pneumonia are less well known.  In order to investigate the disparity 
between estimates produced using primary care data and those from linked primary-
secondary records, I undertook a direct comparison of the incidence of CAP in a single 
group of patients using each of the two data sources in turn.  Using records for the same 
group of patients ensured that any differences in CAP incidence were due to the data 
type used, rather than underlying differences in the characteristics of the cohort. 
In this chapter I present the results of this comparison.  A version of this work which 
focuses more on the implications of the findings for future work on infections in older 
adults, rather than on the effect on CAP estimates has been submitted for publication 
to the Journal of Clinical Epidemiology (see Appendix E).  In the submitted version, 
population averaged models were used to adjust for the clustering of CAP episodes 
within patients.  Here, I use a random effects analysis to take account of the clustering, 
so that the methods were consistent with those in Chapter 4.  As discussed in section 
2.8, both methods are commonly used for these types of analyses, and the method of 
adjusting for clustering is the only change between the two analyses presented – the 
remaining methods, discussion and overall conclusions do not differ. 
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5.2 Methods 
5.2.1 Study populations and period of follow-up 
Both practices and patients joined CPRD throughout the study period, and thus analyses 
were performed on dynamic cohorts.  In order for the two data sources to be 
comparable, a near-identical group of patients were used in both analyses.  Patients 
included in the study were eligible for record linkage, were aged ≥65 years and 
contributed ≥1 day of follow-up.  Follow-up started at the latest of the study start date 
(1st April 1997), the patient’s 65th birthday, the UTS date or 28 weeks after patient 
registration.  Follow-up ended at the earliest of the study end date (31st March 2011), 
death, last collection date of information from CPRD or the date the patient left the 
practice. 
Total incidence of CAP included both GP-diagnosed and hospital-diagnosed cases (either 
identified in CPRD or HES).  I did not include a ‘HES only’ group, as that would examine 
the rate of hospitalised CAP rather than CAP incidence. 
5.2.2 Defining CAP episodes 
Pneumonia illness episodes, community-acquired infections and exclusion of person-
time were identified as outlined in section 2.4, and as used in the analyses in presented 
in Chapter 4.   
In both the analysis of the stand-alone CPRD data, and the analysis of the linked CPRD-
HES data, pneumonia episodes with no record of hospitalisation in the 14 days before 
the incident date were classed as community-acquired.  As with the incidence analyses 
in Chapter 4, episodes which started within 14 days of a hospitalisation were assumed 
to be hospital-acquired (HAP) and were not included as incident events.  The method 
for defining hospitalisation, and thus distinguishing between CAP and HAP, differed 
between the two analyses as outlined in section 2.4.2.  In the stand-alone data, records 
for hospitalisation were defined using Read codes and relevant fields in the consultation, 
referral and clinical GP files, and the date of these records were used as the start of the 
14 day period for categorising a pneumonia episode as HAP.  In the linked cohort the 14 
day period started at the discharge date of any hospital admission.     
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5.2.3 Defining person-time at risk 
Patients were not considered ‘at-risk’ of pneumonia during any pneumonia episode or 
for the 28 days after the last code in the episode, and this time was excluded from the 
denominator in both cohorts (see section 2.5.2).  As described in Chapter 4, a key 
difference in the analysis of the linked data was the capacity to also exclude the duration 
of any hospital admission and the subsequent 14 days from person-time at risk of a 
community-acquired infection, which is not replicated in the stand-alone data due to 
the absence of admission and discharge dates in these records. 
5.2.4 Statistical methods 
As in Chapter 4, Poisson models with random effects were used to calculate the 
incidence of CAP across clusters of CAP episodes per patient.   
Rates were calculated stratified by financial year, age group and sex.  The percentage 
increase in estimates when using the linked data was calculated using Equation 5-1. 
Equation 5-1 Percentage increase in CAP incidence estimates when using linked data: 
൬
ܥܣܲ ݅݊ܿ݅݀݁݊ܿ݁ ݎܽݐ݁ ݅݊ ݈݅݊݇݁݀ ݀ܽݐܽ
ܥܣܲ ݅݊ܿ݅݀݁݊ܿ݁ ݎܽݐ݁ ݅݊ ݏݐ݈ܽ݊݀ܽ݋݊݁ ݀ܽݐܽ 
× 100൰ − 100 
Within the linked data I was also able to attempt to examine pathways of care.  To do 
this, I examined whether patients had consulted with a GP (either face to face or by 
telephone) on the CAP incident date, using the ‘constype’ field in the CPRD consultation 
file.  I additionally checked whether there were any consultations for LRTI (excluding 
CAP) in the 28 days prior to the CAP incident date.   
5.3 Results 
5.3.1 Study population and number of CAP episodes identified in each dataset 
The study population included 917,852 patients in the stand-alone data from 351 
practices across England.  The linked analysis included 916,128 of these patients who 
had ≥1 day of follow-up after additionally excluding person-time in hospital (which 
resulted in exclusion of <0.2% of individuals from the linked analysis, Table 5-1).  In both 
analyses the majority of patients were aged 65-69 years at their start of study (53%) and 
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over half (56%) were female (Table 5-1).  When only GP records were used, 31,575 CAP 
episodes were identified between 1997 and 2010.  Using linked GP and hospital 
admission data identified 45,285 CAP episodes (Table 5-2).  The distribution of CAP 
episodes by age group and sex did not differ particularly between the two analyses.  
However, while the number of CAP episodes recorded increased over time in both data 
sources, the increase was considerably more pronounced in the linked data (Table 5-2). 
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Table 5-1 Characteristics of the study populations in each analysis 
 Number of patients (%) 
 CPRD only CPRD HES-linked 
Total 917852 916128 
Male 403191 (43.9) 402474 (43.9) 
Age group   
65-69 487509 (53.1) 487189 (53.2) 
70-74 141600 (15.4) 141398 (15.4) 
75-79 117973 (12.9) 117693 (12.8) 
80-84 85183 (9.3) 84828 (9.3) 
85-89 54853 (6.0) 54531 (6.0) 
≥90 30734 (3.3) 30489 (3.3) 
Number of CAP episodes   
1 26805 37040 
2 1848 3054 
3 253 479 
4 48 106 
5 11 32 
6 10 12 
7 0 4 
8 1 2 
 
Table 5-2 Number of CAP events recorded in each analysis 
 Number of CAP episodes (%) 
 CPRD only CPRD HES-linked 
Total 31575 45285 
Male 14551 (46.1) 21085 (46.6) 
Age group   
65-69 3250 (10.3) 4742 (10.5) 
70-74 4280 (13.6) 6216 (13.7) 
75-79 5677 (18.0) 8008 (17.7) 
80-84 6632 (21.0) 9468 (20.9) 
85-89 6159 (19.5) 9027 (19.9) 
≥90 5577 (17.7) 7824 (17.3) 
Year   
1997 1611 (5.1) 1801 (4.0) 
1998 1894 (6.1) 2174 (4.8) 
1999 2055 (6.5) 2422 (5.3) 
2000 1929 (6.1) 2330 (5.1) 
2001 2148 (6.8) 2760 (6.1) 
2002 2264 (7.2) 2908 (6.4) 
2003 2540 (8.0) 3272 (7.2) 
2004 2522 (8.0) 3431 (7.6) 
2005 2442 (7.7) 3421 (7.6) 
2006 2302 (7.3) 3578 (7.9) 
2007 2363 (7.5) 3860 (8.5) 
2008 2571 (8.1) 4536 (10.0) 
2009 2491 (7.9) 4351 (9.6) 
2010 2443 (7.7) 4441 (9.8) 
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5.3.2 Incidence estimates 
Incidence estimates using linked data were higher than those using stand-alone data 
(Figure 5-1).  Overall, the incidence was 48.9% higher using the linked-data, and the 
difference increased markedly over time from 13% higher in 1997, to 101% higher in 
2010. 
Figure 5-1 Incidence of CAP amongst older adults by data source over time 
 
 
While CAP rates rose with age in both data sources, the relative increase in CAP 
estimates using the linked compared to GP stand-alone data was comparable across age 
groups, therefore the disparity between the two data sources could not be attributed 
to a specific age group (Figure 5-2).  CAP incidence was higher in men than women in 
both analyses, but the divergence between estimates was observed at similar levels in 
both sexes (Figure 5-3).   
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Figure 5-2 Percentage increase in CAP estimates when using linked-data compared to 
stand-alone GP records, by age group 
 
Figure 5-3 Percentage increase in CAP estimates when using linked-data compared to 
stand-alone GP records, overall and by sex 
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Due to the dynamic nature of the cohort, the number of patients contributing to each 
analysis increased over the study period, increasing the person-time included.  However, 
while the increase in person-time within each analysis was similar (91% increase in 
linked vs. 93% in stand-alone), the increase in CAP episodes was substantially larger in 
the linked data (147% vs 52%, Table 5-2).   
Between 1997 and 2010, the percentage of patients who had consulted with their GP 
on the day of the CAP diagnosis decreased from 82% to 43%.  Over the same period, 
consultation with a GP for an LRTI in the 28 days prior to the CAP diagnosis also 
decreased, from 15% to 10% of CAP episodes. 
5.4 Discussion 
CAP incidence estimates from linked primary and secondary data were nearly 50% 
higher overall than those from primary care data alone.  The divergence between the 
estimates increased appreciably over the 14 year study period, and CAP incidence using 
linked data was double the estimate from stand-alone GP records by March 2011.   
As discussed in Chapter 4, the analysis using linked data permitted a different approach 
to defining person-time at risk of community-acquired infection, as I could discount the 
person-time patients were admitted to hospital.  This also led to the exclusion of 1724 
patients (<0.2%) whose HES records revealed that they were admitted to hospital or 
recently discharged from hospital (within the prior 14 days) for their entire period of 
follow-up, and so were not considered at risk of a community-acquired infection.  
However, from examining the change in crude number of CAP events and in the person-
time included in each analysis, it seems that the higher number of CAP episodes 
recorded in the linked data explains the divergence.  As previously discussed, all 
pneumonia events recorded in GP records are included in the linked data, but 
pneumonias from hospital admissions are only included in the stand-alone data if they 
are retrospectively recorded by the patient’s general practice.  It is apparent that not all 
CAP identified in hospital are then recorded using a Read code for pneumonia in GP 
records.  However, this under-recording of hospitalised CAP in primary care data could 
not explain the divergence shown on its own.  Additionally, hospital admissions due to 
pneumonia would have needed to increase over the study period (and be captured in 
the linked-data) in order to explain the divergence seen over time.   
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There may be more than one explanation for increasing hospital admissions for CAP in 
our study population.  For example, patients may be increasingly presenting directly to 
hospital rather than consulting their GP, due to changes in service provision or perceived 
severity of illness.  This is compatible with the decreasing trend in CAP episodes that had 
a GP consultation on the day of the CAP diagnosis.  Alternatively, the threshold for 
admission for older patients with CAP presenting to Accident and Emergency 
Departments may have decreased.  Both of these scenarios would be consistent with 
the larger increase in CAP episodes in the HES records.  Increasing CAP hospitalisations 
over the study period and the reasons behind this trend are the focus of the next 
Chapter, and are discussed further there.   
5.4.1 Study strengths 
The analyses used large, nationally representative datasets which contained ≥900,000 
patients.  Over 99.8% of patients were included in both analyses, thus virtually excluding 
any other factors from having an effect on the discrepancy reported, and enabling 
examination of the differences in estimates of CAP solely due to the type of data and 
methodology used. 
5.4.2 Potential limitations 
The two data sources use different coding systems, and coding practices may have 
varied over time within each data source.  Read codes (used in CPRD) include ‘tentative’ 
pneumonia codes such as ‘Influenza or pneumonia’, but equivalent codes do not exist 
in the ICD-10 coding system (used in HES).  The tentative pneumonia codes were not 
included as pneumonia in this study.  Patients who consulted their GP and were given 
this code, but were subsequently hospitalised with a CAP diagnosis would have been 
included as a CAP episode in the linked data analysis, but not in that of the stand-alone 
data.  However, to have contributed to the disparity, these tentative diagnoses would 
have needed to be increasingly used over time, whereas general consultations with a GP 
on the date of a CAP diagnosis, or for less serious LRTI within the previous 28 days both 
decreased over the study period.  Alternatively, if there was an increasing tendency over 
time for hospital physicians to diagnose and label older patients as having pneumonia 
(for example due to increasing use of CT scans), this would contribute to the divergent 
trends.  There is no direct evidence that this occurred, but a clear understanding of 
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trends in clinical and coding practices is essential for interpretation of findings from both 
stand-alone and linked data.   
5.4.3 Implications of the findings 
5.4.3.1 Implications for CAP incidence estimates presented in Chapter 4 
The CAP incidence estimates presented in Chapter 4 were produced using both stand-
alone CPRD records (40.3% of patients over the entire study period) and CPRD HES-
linked data, in order to get the best estimates from the whole CPRD population.  In 
section 4.5.4, I hypothesised that if the discrepancy between linked and stand-alone 
data remained constant over time, it may be possible to use stand-alone data and 
somehow adjust estimates for the increase that would be expected if linked data had 
been used.  The results presented here show that this is inadvisable, as the discrepancy 
between the record types varied so considerably over the study period.   
Comparison with the results from the mixed data sources (overall incidence presented 
in Appendix D) shows the rates from the mixed data were closer to the estimates from 
the HES-linked data than the stand-alone data in these analyses.  However, use of the 
results from this work to predict the level of underestimation reported in Chapter 4 is 
not straightforward.  CPRD-HES linkage is currently only available for English CPRD 
practices, thus CPRD practices from Scotland, Wales and Northern Ireland (who 
comprised 20% of the patients who contributed to the incidence analyses in Chapter 4) 
are automatically ineligible for HES-linkage.  These populations may have different age 
structures, underlying health problems and health behaviours (such as smoking status) 
to patients in England, and thus may differ slightly from the HES-linked patients included 
in this study population.  Additionally, devolution of the NHS has led to each country 
controlling its own service provision, which may affect generalisability between the 
nations. 
Secondly, the number of practices that consented to HES-linkage changed throughout 
the study period.  This may have resulted in a varying amount of possible 
underestimation due to the stand-alone data over time. 
Finally, even if results are limited to England, there is no clear gold standard between 
CPRD and HES without validation of diagnoses in both data sources.  While CAP may be 
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under-recorded in CPRD, it is also possible that CAP was increasingly ascertained in HES, 
or that there is an increasing trend in labelling patients as having CAP.  This will be 
discussed further in the next chapter.   
5.4.3.2 Implications of accounting for clustering using random-effects versus 
population-averaged model 
The analyses presented in this Chapter were repeated for publication using a 
population-averaged (PA) model (Appendix E).  It is important to consider the different 
interpretation of the two measures when thinking about the implications of their use on 
the results shown.  Random effects (RE) models produce subject-specific effects – the 
incidence estimates presented above are for the rate of CAP in the mean patient in the 
population under study.  The PA models represent the average rate of CAP across the 
patients in the population under study.  If there was no clustering of CAP at a patient 
level, the PA and RE models would produce the same estimates.  When clustering is 
present, PA models have been shown to produce consistently lower results than those 
from random effects RE models.[114]  However, the ratio between the parameter 
estimate and SE is similar in both models, and so p-values from the models are generally 
consistent.  Thus, while the estimates presented in Appendix E and the percentage 
increase in incidence when using linked compared to stand-alone data are slightly lower 
than those presented here, both sets are equally valid (as long as they are interpreted 
correctly), and show the same general trend. 
5.4.3.3 Implications for future research  
This study provides evidence that use of primary or secondary care data in isolation may 
not give accurate incidence estimates for some infections in older populations.  While 
the added value of using linked data has previously been shown for several non-
communicable conditions,[139-142] there has been a paucity of evidence regarding this 
topic when investigating infectious conditions.  In particular, illnesses for which patients 
may seek treatment in either a primary or secondary care setting are at risk of being 
underestimated.  In addition, incomplete recording of hospitalised pneumonia episodes 
in stand-alone GP data limits its use in studies of pneumonia in older adults.   
Neither the linked nor the stand-alone data were originally designed for research use, 
resulting in each having their own limitations.  Although considerably easier to use, 
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stand-alone CPRD data seem to under-record pneumonia events which occurred in 
hospital, leading to underestimates of the burden of disease.  HES-linked CPRD data 
require a very large amount of preparation before they can be analysed, but enable 
inclusion of both hospitalised and ambulatory events. 
For conditions that can be treated both in the community and in hospital, single data 
sources such as stand-alone CPRD are also likely to be susceptible to changes to health 
services, patient and clinician behaviour.  Using linked-data may protect against these 
external influences when attempting to accurately estimate the burden of disease over 
time, but they are still susceptible to changes to diagnostic thresholds and trends in 
coding practices.  Validation of the accuracy of pneumonia diagnosis and coding in both 
CPRD and HES over time would aid better understanding of the results I have presented.   
Further research is needed to establish whether the results shown are repeated in other 
infections, populations and settings.  It may be that due to the underlying health status 
of the older population and the severity of CAP in this group, the findings shown are 
more pronounced among those aged ≥65 years.   
5.4.3.4 Implications for the subsequent work in this thesis 
The second part of this thesis concerns severe outcomes after CAP episodes.  In order 
to fully capture CAP events, only patients eligible for CPRD HES-linked data are included 
in the analyses presented in later chapters.     
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Chapter 6 Risk factors for hospitalisation after CAP in older adults, and 
their contribution to increasing hospitalisation rates 
The second section of this thesis concentrates on CAP, which is both directly and 
indirectly responsible for a large number of hospitalisations and deaths among older 
adults.  Due to the disparities in recording of CAP in the linked and stand-alone data (as 
outlined in the previous chapter), all subsequent analyses in Chapter 6 (objective 2) and 
Chapter 7 (objective 3) only include patients who were eligible for CPRD HES-linked data 
(Figure 6-1). 
The focus of this chapter is on hospitalisations following CAP.  The main analysis aims to 
identify risk factors for hospitalisation after a CAP episode, and to assess the effect of 
these factors on trends in hospitalisation after CAP over time (objective 2).   
Firstly I provide a review of the literature on risk factors for hospitalisation after CAP.  
My main analyses for objective 2 are presented as a paper published in BMJ Open.  This 
is followed by additional detail of the methods I used to identify the variables included 
as potential risk factors for hospitalisation post-CAP.  Finally, a supplementary analysis 
is presented, which assesses the added benefit of using individual co-morbidities rather 
than the Charlson index when adjusting the regression model from Paper 2 for patients’ 
co-morbidities.   
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Figure 6-1 Records included in the analyses in this Chapter 
 
6.1 Background 
6.1.1 Trends in hospitalisation for CAP over time 
As highlighted in the Background (section 1.2.1), hospitalisations for pneumonia among 
older adults have risen in recent years both in the UK and other European countries.  In 
England, increasing hospitalisations for CAP have been reported by two studies for 
periods spanning April 1997 and March 2011.[61, 62]  Elsewhere in Europe, studies from 
Denmark,[64, 65] the Netherlands,[66] and Portugal,[67] have all shown rising 
admissions for pneumonia over the last 10 to 20 years.  The extent of the increase varied 
by study, but consistently increased with age.  However, as discussed in the Background, 
none of these studies were able to examine the observed trends in hospitalisation 
following pneumonia independent of underlying trends in pneumonia incidence.  
Additionally, only one English and one Dutch paper investigated the effect of increasing 
co-morbidity on hospitalisation trends over time.  In both cases this was achieved using 
the Charlson co-morbidity index and not by investigating the role of individual co-
morbidities.[61, 64]  The effect of medications, vaccinations and frailty factors was not 
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considered in any of the studies, despite these factors being prevalent among the older 
population who make up a large proportion of pneumonia hospitalisations.   
Could factors such as co-morbidities, increasing frailty and medication use lie behind the 
increasing levels of hospitalisation for pneumonia, and if so which of these factors might 
be driving the trend?  In order to identify potential risk factors for hospitalisation for 
CAP for further investigation, I performed a literature review on the topic, which is 
described below. 
6.2 Literature review of risk factors for hospitalisation for and after a CAP infection 
6.2.1 Aim 
The aim of this review was to identify factors among adults with CAP that have 
previously found to be associated with admission to hospital.  The factors of interest 
included those potentially recorded in patients’ electronic health records: co-
morbidities, frailty factors, medications and vaccinations, and lifestyle factors.  
6.2.2 Methods 
6.2.2.1 Search strategy 
A 2012 review paper which summarised risk factors among hospitalised CAP patients  
was taken as a starting point.[143]  I searched Medline for articles published since the 
review (from 2008 (to overlap with the end of the review), until May 2015).  The search 
strategy combined MeSH and free-text terms for community-acquired pneumonia, risk 
factors, hospitalisation and older adults (the full search strategy is provided in Appendix 
F).   
6.2.2.2 Inclusion criteria 
My primary interest was in the comparison between hospitalised and non-hospitalised 
CAP patients.  Due to the small number of papers expected to meet this criterion, I also 
identified papers of secondary interest, in which hospitalised CAP patients were 
compared to the background population.  These studies were considered separately due 
to their identifying risk factors for both developing CAP and being hospitalised for CAP.  
Studies comparing patients hospitalised for CAP to patients hospitalised for other 
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reasons were not included, as these were not thought to adequately identify risk factors 
for hospitalisation after CAP.   
In addition to using one of the comparison groups above, papers were included if they: 
reported original research, reported a multivariable model including measures of effect 
(rate-/risk-/odds ratio) for risk factors for CAP hospitalisation, were set in a high-income 
country, were written in English, and included older adults in their study population.  I 
did not specifically restrict the study population to older adults, as risk factors such as 
co-morbidities were considered likely to remain so across the adult age spectrum.   
Articles were excluded if they were set within a specific sub-population which may have 
affected the generalisability of the results to the older population.  This included those 
studying specific pathogens, CAP patients treated in ICU rather than all CAP 
hospitalisations (as these represent a specific more severe class of disease whose risk 
factors may not be generalisable to less severe hospitalised CAP), and CAP 
hospitalisations within a specific co-morbidity group (such as COPD) as risk factors within 
these groups may differ from those in the general population.  Additionally, studies of 
the effect of a particular treatment (for example a specific type of antibiotic), or studies 
on risk factors for aspiration pneumonia were excluded as these cases were not included 
in this study’s definition of CAP.   
6.2.2.3 Article screening 
I applied the inclusion criteria described in section 6.2.2.3 to the articles identified from 
the Welte review and from the Medline search.  For articles I considered to be 
potentially eligible, I obtained the full-text and further checked the article against the 
inclusion criteria.  I examined the reference lists of included articles in an attempt to 
identify additional papers of interest.  Whenever I was unsure of a study’s eligibility, I 
discussed it with my supervisor and a decision was reached by consensus.   
6.2.2.4 Data extraction 
I extracted relevant data into standardised data extraction forms in Excel.  Separate 
forms were used for the articles of primary interest (hospitalised vs non-hospitalised 
CAP patients) and for those of secondary interest (hospitalised CAP vs general 
population).  I extracted details of the study design and study population, the method 
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of ascertaining the outcome (hospitalisation after CAP), the hospitalisation rate, risk 
factors for hospitalisation that were identified including the ORs/RRs for these factors, 
and the statistical techniques used.   
Studies were summarised narratively. I noted aspects of the studies that were 
particularly good, weak or that were unclear, but formal quality assessments were not 
performed. 
6.2.3 Results 
The Medline search identified 367 papers.  Of these, only two compared CAP patients 
treated in a community setting to those hospitalised (the primary objective),[122, 125] 
and three compared hospitalised CAP patients to the background population (the 
secondary objective).[144-146]  The Welte review provided one further study for the 
primary objective and one for the secondary objective.[130, 147] 
6.2.3.1 Included studies 
Primary objective – CAP treated in the community as a comparison group 
The three studies which compared CAP patients treated in hospital with those treated 
in the community were all conducted in Southern Europe (40 provinces in Italy, the 
Barcelona region of Spain and a rural region of Crete, Greece, Table 6-1).[122, 125, 130]  
Two were prospective cohort studies in which data was collected from general 
practitioners,[130] and additionally pulmonary hospital clinics.[122]  The third was a 
retrospective cohort study which utilised electronic health records from both primary 
and secondary care.[125]  The studies were all relatively small, ranging from 124 to 699 
patients with CAP.  The Greek study was limited to older adults aged ≥50 years who had 
a hospitalisation rate of 32.3%.[130]  The other papers included patients of all ages with 
pneumonia (Italy) and all adults aged ≥18 years (Spain), and reported hospitalisation 
rates of 22% and 42% respectively.[122, 125]   
All three studies estimated effects using logistic regression and odds ratios.  Age was the 
only risk factor included in all three models; the odds of hospitalisation were found to 
increase by 10% per year of age in the Spanish study,[125] while Greek patients aged 
≥74 years had more than 7 times the odds of hospitalisation than those aged 50-73 years 
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(Table 6-1).[122]  The Italian paper reported adjusting their model for age, sex and 
smoking status but did not report the measures of effect for these variables.[130]   
Other factors reported by the three studies showed little overlap.  The Greek study 
found that the presence of two or more co-morbidities (included as a co-morbidity 
count), being obese (defined as ≥30kg/m2), and ≥40 pack years smoking were all 
associated with increased odds of hospitalisation (Table 6-1).  Pneumococcal vaccination 
(over an undefined time period of vaccine receipt) was shown to be protective.  Both of 
the other studies found associations between individual co-morbidities and odds of 
hospitalisation in multivariable analyses.  The Spanish paper reported that presence of; 
stroke, dementia, liver disease, COPD and diabetes were associated with increased odds 
of hospitalisation among CAP patients (Table 6-1).[125]  However, only odds ratios from 
the multivariable model with a p-value<0.002 were reported in the paper, indicating 
that other factors may also have been associated with hospitalisation.  The Italian 
multivariable model included heart disease, neurological disease, asthma, and cancer, 
as well as previous corticosteroid therapy (Table 6-1).[130]  All were shown to be 
associated with being hospitalised, however the results were only presented graphically 
and 95% confidence intervals for the last four factors appeared to cross one.   
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Table 6-1 Characteristics of studies comparing hospitalised and community treated 
CAP patients, and risk factors they identified  
Author [ref] Viegi [130]* Sicras-Mainar [125]† Bertsias [122] 
Study population 
Region, Country 40 provinces in Italy Barcelona, Spain Crete, Greece 
Study period 1999-2000 2008-2009 2011-2012 
Study design Prospective cohort Retrospective cohort Prospective cohort 
Study population 
Patients of all ages with 
‘suspected’ and ‘x-ray 
confirmed’ pneumonia 
episodes as reported by 
GPs from 287 randomly 
selected general practices 
 Electronic health records 
of inpatients & outpatients 
aged ≥18y in 6 primary 
care centres & 2 hospitals 
with ICPC-2 (outpatient) or 
ICD-9-CM (inpatient) codes 
for pneumonia, & diagnosis 
confirmed by X-ray 
  Patients aged ≥50y 
presenting to 6 general 
practices & 2 pulmonary 
hospital clinics (including 
access to A&E) with CAP, 
defined as patients 
presenting with acute LRTI 
confirmed with lung 
infiltrate on X-ray, who had 
not been hospitalised <14d 
pre diagnosis.   
Hospitalisation 
(case) 
ascertainment 
Separate forms 
completed by GP when 
notified of hospitalised 
patients 
ICD-9-CM code for 
pneumonia in 
hospitalisation records 
Not explicitly defined. 
Sample size 699 581 124 
Age (years) 
Mean (SD) 
1° care: 57.6 (19.2)  
2° care: 66.7 (18.7) 57.5 (19.1) 
Median 74  
(range 50-95) 
Male n (%) 328 (46.9) 323 (55.6) 64 (51.6) 
Hospitalised n (%) 151 (21.6) 241 (41.5) 40 (32.3) 
Risk factors identified: Odds Ratio (95% CI) 
Age  N/R Per yr increase: 1.1  
50-73 yrs: ref 
≥74yrs : 7.13 (2.23-22.79) 
Neurological 
disease 2.8 (1.5-5.5)~ Stroke: 3.6  
 
Dementia  3.5   
Liver disease  5.9   
Lung disease Asthma: 2.0 (1.0-3.6)~ COPD: 2.9   
Diabetes  1.9  
Heart disease 4.0 (2.5-6.0)~   
Cancer 3.5 (0.95-1.75)~   
Co-morbidity 
count  
 
Multi-morbidity  
(≥2 co-morbidities) 
5.77 (1.81-18.42) 
BMI   Obese : 3.36 (1.08-10.52) 
Smoking N/R  
0 pack years: ref 
1-39 pack yrs:  
0.32 (0.06-1.73) 
40+ pack yrs:  
3.82 (1.07-13.68) 
Pneumococcal 
vaccine  
 Vaccinated: 0.29 (0.09-0.95) 
Previous steroid use 2.1 (1.0-3.6)~   
Area of residence 1.5 (0.9-2.1)~   
*model also included sex and area of residence but results not reported.  †results only reported in paper if p<0.002, 
results reported to 1dp and no 95% CI provided.  N/R: included in model but results not presented in paper.   
~ORs estimated from Figure (no table provided) ICPC-2: International Primary Care Classification ICD-9-CM: 
International Classification of Diseases, ninth revision, Clinical Modification 
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Reporting of the statistical methods used was inadequate in all the studies.  No detail 
was provided on their model building strategies, or the other factors investigated but 
not included in the final multivariable models.   None of the studies were conducted for 
a sufficiently long period to assess the effect of the risk factors on hospitalisation rates 
over time.    
Secondary objective – using the background population as a comparison group  
Of the four papers that compared hospitalised CAP patients to the background 
population, three cohort studies were set in the USA,[144, 147, 146] and one case-
control study was from Canada.[145]  Hospitalisation rates for CAP in these study 
populations ranged from 6.2% to 45.2% (Table 6-2).  One American study pooled data 
from two prospective cohorts including adults aged ≥45 years,[146] while the other 
three papers only included older adults.  The second American paper used a subset of a 
larger cohort, restricting to patients with information on oral hygiene (who had fewer 
pneumonia outcomes than those who were excluded).[144]  The final American study 
also used data from a previous prospective cohort (the Cardiovascular Health 
Study).[147]  The Canadian case control study enrolled CAP cases at A&E, and recruited 
controls via random digit dialling.[145]     
A variety of factors were considered by these studies.  Age was consistently found to be 
associated with increased CAP hospitalisation,[144, 147, 146, 145] ranging from 7% 
increase per year of age[146] to a 28 fold increase in those aged 80-84 years compared 
to those aged <50 years.[147]  Two articles reported men having around twice the rate 
of CAP hospitalisation than women.[147, 144] 
The majority of co-morbidities were investigated by just two studies, with limited 
overlap between the factors they included in their multivariable models.[147, 145]  Co-
morbidities reported to increase the risk of CAP hospitalisation included diagnoses of 
COPD, congestive heart failure, coronary heart disease, diabetes, cerebrovascular 
accident, and renal disease (Table 6-2).  Previous pneumonia was reported as tripling 
the rate of CAP hospitalisation by one study,[144] but having no clear effect by 
another.[147] 
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Table 6-2 Characteristics of studies comparing hospitalised CAP cases to the 
background population, and risk factors they identified 
Author [ref] Loeb [145] Juthani-Mehta [144] Yende [146] O’Meara [147] 
Study population 
Region, Country Ontario & Alberta, Canada 
Memphis & 
Pittsburgh, USA Sites in six states, USA 
Sites in four 
states, USA 
Study period 2003 - 2005 1997-2008 1987-1990 1989 - 2001 
Study design Case-control Prospective cohort Prospective cohorts 
Prospective 
cohort 
Study population 
Cases: patients 
presenting to A&E. 
Controls: selected 
contemporaneously 
using random digit 
dialling from same 
catchment area. 
All aged ≥65y. 
Individuals aged 
70-79y 
participating in 
the Health, 
Ageing and 
Body 
Composition 
study -subset 
with dental 
examination 
assessment. 
Individuals aged ≥45y 
participating in the 
Cardiovascular Health 
Study or in the 
Atherosclerosis Risk 
in Communities 
study. 
. 
 
. Individuals 
aged ≥65y 
participating in 
the 
Cardiovascular 
Health Study. 
Hospitalised CAP (case) 
ascertainment 
Presented with ≥2 
specified 
signs/symptoms & 
new opacity on 
chest x-ray 
consistent with 
pneumonia. 
 
Adjudicated by 
a committee, 
using a 
combination of 
discharge 
summary, ICD-9 
diagnosis code, 
admission 
history, physical 
exam & x-ray 
reports.   
Hospitalisation for 
pneumonia within 
10yr period identified 
using combination of 
ICD-9 codes, with 
chart review and 
physician 
adjudication. 
Identified via 
patient self-
report, 
corroborated by 
ICD-9 codes for 
pneumonia as 
1st discharge 
diagnosis in 
Medicare data. 
Only included 
patient’s 1st CAP 
hospitalisation 
Sample Size 1584 1441 16260 5888 
Age (mean (SD)) Cases:79.1 (7.6)  Controls: 74.4 (6.7) 74.7 (2.9) 59.2 (10.1) N/R (all ≥65) 
Male n (%) Cases: 429 (60.4)†  
Controls: 273 (31.5) 
719 (49.9) 7172 (44.1) 2495 (42.4) 
Hospitalised n (%) 716 (45.2) 193 (13.4) 1000 (6.2) 582 (9.9) 
Risk Factors identified Hazard/Odds Ratio (95% CI) 
Age (years) OR: 1.93 (1.64-2.27) HR: 1.24 (0.93-1.65) 
HR: <50:Ref 
65: 4.84 (3.43-6.75) 
70: 9.93 (7.00-14.08) 
75: 14.72 (10.17-
21.31) 
80: 27.87 (18.67-
41.58) 
85: 16.13 (9.73-26.76) 
HR:1.07 (1.05-
1.09) 
Male gender  2.07 (1.51-2.83) 
 1.96 (1.59-2.42) 
Cerebrovascular 
accident 
   1.47 (1.06-2.05) 
COPD 13.53 (7.8-23.48)   1.49 (1.17-1.89) 
Diabetes    1.34 (1.05-1.70) 
Coronary heart disease    1.51 (1.22-1.87) 
Congestive heart 
failure 2.07 (1.22-3.49) 
  1.92 (1.38-2.77) 
Renal disease 4.06 (1.98-8.35)    
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Author [ref] Loeb [145] Juthani-Mehta [144] Yende [146] O’Meara [147] 
Previous CAP*  3.09 (1.86-5.14) 
 1.07 (0.88-1.30) 
Smoking* 
Lifetime >100 
cigarettes: 
2.01 (1.26-3.36) 
Pack years: 
1.01 
(1.00-1.01) 
past: 1.26 (1.07-1.49) 
current: 2.06 (1.70-
2.5) 
current:  
1.75 (1.35-2.26) 
Alcohol 
g/m prev yr (per 5g 
increase): 1.69 
(1.08-2.61) 
   
Pneumococcal vaccine    1.14 (0.92-1.42) 
Influenza vaccine in 
previous year 
   0.99 (0.81-1.21) 
Living alone 0.48 (0.30-0.76)    
Immunosuppressants 15.13 (4.74-48.29)    
Other factors related 
to frailty 
Dysphagia: 3.76 
(1.60-8.88) 
Nutritional score 
(per unit reduction): 
1.83 (1.19-2.80) 
Functional status 
(Barthel score 18+): 
7.94 (3.77-16.69) 
 
Incident 
mobility 
limitation 1.77 
(1.32-2.38) 
 
 
H/o 
claudication: 
2.11 (1.4-3.18) 
Time walk 15ft: 
1.02 (0.99-1.06) 
3MSE (cognitive 
exam): 0.99 
(0.97-1.01) 
3MSE: Modified Mini-Mental State Examination, H/o history of, ICD-9-CM: International Classification of Diseases, 
ninth revision, *=different categorisation used in different models, † Missing data on sex for 6 cases,  
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Patients’ smoking status was included in all four studies and consistently associated with 
increased CAP hospitalisation.[144-147]  In the Canadian study, alcohol consumption 
was found to increase the odds of hospitalisation by 69% with each 5g increase in 
alcohol.[145] 
Neither pneumococcal nor influenza vaccine were associated with decreased odds of 
hospitalisation in the only study which included vaccinations in its multivariable 
model.[147]  The only medication included in any of the final models was 
immunosuppressants, which in the Canadian study was shown to have one of largest 
effects of all factors studied (OR: 15.13 (4.74-48.29)).[145]  
Three of the four studies also investigated aspects of frailty.  Decreased functional status 
and decreasing nutritional score were both found to increase odds of CAP 
hospitalisation, while living alone was found to be protective (Table 6-2).[145]  The two 
American papers reported contrasting effects of limited mobility, one found it to be 
associated with increased CAP hospitalisation rates,[144] while the other found no 
effect.[147]  Cognitive impairment was also found to have no effect on the rate of CAP 
hospitalisation in the latter study.[147]  However, all three of these studies were 
restricted by exclusion criteria which would have omitted more frail patients from the 
study, thus limiting investigation of aspects of frailty.[144, 145, 147]     
In general, the reporting of statistical methods was more detailed than for the studies 
of primary interest, with two studies using backward stepwise selection of variables into 
their final models,[145, 147] and the third study using both forward and backward 
selection.[144]  The final study developed a prognostic model for risk of CAP 
hospitalisation over a 10-year period using a non-standard approach.[146]   
6.2.4 Comment 
In general, there is a paucity of information around risk factors for hospitalisation among 
older CAP patients, especially around frailty factors, medications and vaccinations.  Only 
three relatively small studies examined risk factors for hospitalisation specifically among 
CAP patients.  One of these studies was set within the older population, but used a co-
morbidity count rather than investigating the association between individual co-
morbidities and odds of hospitalisation.  In the other two studies, seven co-morbidities 
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were reported as increasing the odds of CAP hospitalisation, but different categorisation 
of neurological disease and lung disease resulted in none of the same conditions being 
identified in both studies.  In general, factors likely to influence decisions over site of 
care, such as frailty factors or place of residence (for example living alone or in 
residential accommodation) were not included in final multivariable models.  A larger 
variety of conditions were included in the four studies included in the secondary 
objective, which compared hospitalised CAP patients to the background population.  Six 
co-morbidities were shown to increase the risk of CAP hospitalisation in these studies, 
as was a history of CAP and a variety of frailty factors.  However, the usefulness of these 
results is limited by the inability to separate whether the conditions identified were risk 
factors for acquiring CAP or for CAP patients’ subsequent hospitalisation.     
None of the seven studies investigated the effect of the risk factors for hospitalisation 
on trends in CAP hospitalisation over time, and so the importance of these factors on 
increasing levels of CAP hospitalisation remains unquantified.  
Although my review highlights a lack of studies of risk factors for hospitalisation among 
CAP patients, some limitations need to be considered.  It is possible that by restricting 
my search strategy to papers identified in Medline and written in English (due to time 
and resource constraints), I may not have included all papers which addressed the topic.  
I did attempt to identify further studies by detailed examination of the reference lists of 
all included papers, although none were identified by this method.  The lack of a second 
reviewer to assess eligibility of studies and to extract data from selected studies may 
also have resulted in exclusion of eligible studies, as well as increasing the risk of errors 
in the reported results.   
6.3 Objective 2: identification of risk factors for hospitalisation after CAP in older 
adults 
6.3.1 Introduction 
In this study I aimed to identify risk factors for hospitalisation after a CAP diagnosis 
among older adults, and to assess the contribution of these factors to increasing levels 
of hospitalisation with CAP over time.  For this analysis I used all CAP episodes identified 
in the linked CPRD-HES data between 1st April 1998 and 31st March 2011. CAP records 
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from between 1st April 1997 and 31st March 1998 were not included, due to the 
unusually low numbers of CAP hospitalisations that were observed over this period (as 
reported in section 5.3.1).  I compared CAP episodes which resulted in hospitalisation 
within 28 days to those that solely received care from a GP.  All hospitalisations in the 
28 days after a CAP episode were included, not just those for which CAP was the primary 
code of the first episode, in order to capture events that CAP may have precipitated, 
such as a fall or MI. 
As discussed in section 2.8.2.2, when developing a causal model, the hierarchical 
relationship between the factors of interest and whether their effects are direct or 
mediated through other factors needs to be considered.[116]  Figure 6-2 shows a 
hierarchical framework for the groups of variables included in the analyses of 
hospitalisation in the 28 days after a CAP diagnosis. 
 
 
  
Figure 6-2 Hierarchical framework for hospitalisation after CAP 
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ABSTRACT
Objectives: To determine factors associated with
hospitalisation after community-acquired pneumonia
(CAP) among older adults in England, and to
investigate how these factors have contributed to
increasing hospitalisations over time.
Design: Cohort study.
Setting: Primary and secondary care in England.
Population: 39 211 individuals from the Clinical
Practice Research Datalink, who were eligible for
linkage to Hospital Episode Statistics and mortality
data, were aged ≥65 and had at least 1 CAP episode
between April 1998 and March 2011.
Main outcome measures: The association between
hospitalisation within 28 days of CAP diagnosis
(a ‘post-CAP’ hospitalisation) and a wide range of
comorbidities, frailty factors, medications and
vaccinations. We examined the role of these factors in
post-CAP hospitalisation trends. We also looked at
trends in post-CAP mortality and length of
hospitalisation over the study period.
Results: 14 comorbidities, 5 frailty factors and 4
medications/vaccinations were associated with
hospitalisation (of 18, 12 and 7 considered,
respectively). Factors such as chronic lung disease,
severe renal disease and diabetes were associated with
increased likelihood of hospitalisation, whereas factors
such as recent influenza vaccination and a recent
antibiotic prescription decreased the odds of
hospitalisation. Despite adjusting for these and other
factors, the average predicted probability of
hospitalisation after CAP rose markedly from 57%
(1998–2000) to 86% (2009–2010). Duration of
hospitalisation and 28-day mortality decreased over the
study period.
Conclusions: The risk factors we describe enable
identification of patients at increased likelihood of post-
CAP hospitalisation and thus in need of proactive case
management. Our analyses also provide evidence that
while comorbidities and frailty factors contributed to
increasing post-CAP hospitalisations in recent years,
the trend appears to be largely driven by changes in
service provision and patient behaviour.
INTRODUCTION
Hospitalisations for ambulatory care sensitive
conditions (ACSC, conditions which could
be treated outside of hospital) have
increased considerably over the past
decade.1 2 Pneumonia is one such condition,
with >56 000 more pneumonia admissions in
Strengths and limitations of this study
▪ Our novel use of large linked primary and sec-
ondary care data sets provided enriched patient
medical and therapeutic histories, and allowed
detailed identification of the determinants of hos-
pitalisation after community-acquired pneumonia
(CAP).
▪ The very large sample size, with more than
43 000 CAP episodes, enabled assessment of
multiple potential risk factors for hospitalisation
with precise estimation of relative risk.
▪ Using linked data also allowed us to distinguish
trends in the tendency to hospitalise patients
with CAP (the focus of this paper) from trends in
CAP hospitalisations due simply to increasing
CAP incidence.
▪ Our analyses suggested that frailty factors were
suboptimally recorded by general practitioners,
preventing full assessment of these factors and
highlighting the need for better capture of frailty
by practices.
▪ For similar reasons, analyses on the effect of
smoking were performed on a subset of the
data, due to previously described incomplete
recording of smoking status pre-2004.
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2010/2011 compared with 2001/2002.2 Most of this
increased burden is found among patients aged 65 years
and older who accounted for 70% of pneumonia admis-
sions in 2012/2013.3 In England, the recently intro-
duced Unplanned Admissions Enhanced Service
highlights the importance of proactive case management
in primary care of at-risk patients, many of whom are
expected to be older, to reduce ACSC hospitalisations.4 5
To date, risk factors for hospitalisation for
community-acquired pneumonia (CAP) have not been
quantiﬁed. Existing analyses based on stand-alone hospi-
talisation data are unable to compare hospitalised
patients with CAP to those who were treated in the com-
munity. They therefore cannot distinguish between
factors which affect a patient’s likelihood of hospitalisa-
tion after a CAP diagnosis from risk factors for develop-
ing CAP. Furthermore, hospitalisation data have
incomplete information on patients’ medical histories,
and contain little or no information on factors such as
alcohol and smoking habits, frailty, or medications pre-
scribed in the community. It is frequently hypothesised
that changes in comorbidities and frailty factors have
contributed to the increasing hospitalisation trends
for older individuals with CAP in the UK. Use of a
non-hospitalised comparison group would allow this
hypothesis to be tested, and to distinguish an increasing
tendency to hospitalise older patients with CAP from
increasing incidence of CAP among older adults.6
In this study, we used large linked general practice,
hospital admission and mortality data sets to assess a
variety of potential risk factors (comorbidities, medica-
tions and other factors) for hospitalisation after CAP
among older individuals in England. Use of the general
practice data enabled more complete capture of patient
histories than those derived from stand-alone hospital
records. We also investigated the risk over time of hospi-
talisation after a CAP diagnosis. The choice of a study
population who had been diagnosed with CAP allowed
us to examine speciﬁcally trends in hospitalisation after
CAP, independent of any trends in pneumonia inci-
dence. We assessed to what extent the patient factors
associated with hospitalisation explained these hospital-
isation trends. The linked mortality data enabled further
investigation into whether mortality rates in the 28 days
after CAP had changed over the same period, including
deaths occurring both in and outside hospital settings,
as a marker of CAP severity.
MATERIALS AND METHODS
Data sources
The Clinical Practice Research Datalink (CPRD, for-
merly GPRD) is a large database of UK general practice
records comprising a representative sample of around
8% of the UK population.7 8 Anonymised data in CPRD
include diagnoses (coded using Read codes), prescrip-
tions, referrals, tests and patient demographics. Over
50% of CPRD patients living in England have their
general practice records linked to Hospital Episode
Statistics (HES) which includes all inpatient National
Health Service (NHS) hospitalisations (coded using
International Classiﬁcation of Diseases (ICD)-10).9 Each
HES hospitalisation consists of one or more episode
denoting the time a patient is under the care of one
consultant. The data were also linked to Ofﬁce for
National Statistics (ONS) central mortality data to obtain
vital status and, if relevant, date of death.
Study population
We included patients who were registered with a CPRD
practice eligible for linkage to HES data, were aged
65 years or over between 1 April 1998 and 31 March 2011,
and who had a CAP episode recorded during that period.
Defining CAP episodes
The methods for deﬁning CAP illness episodes have
been described in detail elsewhere.6 In brief, lists of
Read (CPRD) and ICD-10 (HES) codes for pneumonia
and other lower respiratory tract infections (LRTIs) were
agreed by three clinical epidemiologists. Pneumonia
could be ﬁrst diagnosed either in general practice or
when presenting to hospital. In HES, in order to differ-
entiate between illness present at hospital admission and
subsequent hospital-acquired illness, only pneumonia
coded as the reason for admission (ie, the primary code
in the ﬁrst episode of a hospitalisation) was included in
the study. These HES pneumonia records were com-
bined with CPRD pneumonia records to determine
‘illness episodes’ whereby records within 28 days of each
other (or of an intermediate LRTI record) were deemed
part of the same infection.6 The earliest pneumonia
record in the ‘illness episode’ was the incident (diagno-
sis) date of pneumonia.
To be deﬁned as community-acquired, the CAP inci-
dent date needed to be ≥14 days after any HES inpatient
hospital discharge. All CAP episodes in eligible patients
during the study period were included in the study.
Defining hospitalisation after pneumonia
The outcome of interest was hospital admission
(deﬁned using HES) for any cause, on or up to 28 days
after the CAP diagnosis date. Thus, a CAP diagnosed
when a patient presented at hospital was automatically
assigned as having the outcome; a CAP diagnosed in
general practice had the outcome if the patient had a
hospital admission in the next 28 days. We chose all-
cause hospitalisation because we also wanted to capture
hospitalisations for events which pneumonia could have
precipitated in our older population, such as stroke,
myocardial infarctions and falls, or worsening of under-
lying comorbidities such as chronic obstructive pulmon-
ary disease or congestive heart failure.10
Other factors
Age was categorised in 5-year groups from 65 to 89 years,
and ≥90 years.
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Time period
Year of hospitalisation used a ﬁnancial year structure
(1 April to 31 March) to ensure respiratory pathogens
circulating throughout the winter were captured in the
same year. Year was then grouped as 1998–2000, 2001–
2003, 2004–2006, 2007–2008 and 2009–2010, to account
for health service changes such as the introduction of
payment-for-performance indicators in 2004 and
2009.11 12
Comorbidities and frailty factors
Code lists for the 19 comorbidities in the Charlson
Index and for additional cardiac, neurological and
immune disorders that could affect pneumonia disease
severity or a doctor’s decision to hospitalise were devised
by author SLT and at least one other clinical
epidemiologist.
Prevalidated frailty scores such as the frailty phenotype
or frailty index could not be utilised due to aspects of
each not being recorded in the electronic health
records used in this study (eg, grip strength and slow
gait speed from the phenotype and sucking problems
and poor muscle tone in neck from the index).13 14
Instead, a wide variety of factors identiﬁed in the frailty
index as associated with frailty, for which information
was potentially available in the databases, were consid-
ered. Authors ERCM and SLT devised Read and ICD-10
code lists and used other recording ﬁelds within the
data to capture health deﬁcits within the previous year
(eg, history of falls, inability to self-care) which were
likely to be recorded in patients’ health records, as well
as other factors that could increase the likelihood of
hospitalisation (eg, living alone).
The presence of chronic conditions (such as diabetes
or dementia) was determined using CPRD and HES
records from any point up to and including the CAP
incident date. For acute/potentially acute conditions
(myocardial infarction, stroke, congestive heart failure,
hemiplegia, falls, weight loss/undernutrition) which
could have occurred as a result of the CAP, records from
any point prior to but excluding the CAP incident date
itself were used as evidence of a pre-existing condition.
Terminal illness was deﬁned using Read and ICD-10
codes stating terminal illness, rather than speciﬁc condi-
tions. In addition, primary care information on referrals
to hospices was included.
Medications, vaccinations and health behaviours
Medications included oral steroids, inhaled steroids,
immunosuppressive drugs, statins and antibiotics. We
also considered inﬂuenza and pneumococcal vaccin-
ation status, and health behaviours such as smoking and
excessive alcohol consumption.
As is common when using routinely collected health
records, for all the factors aforementioned, the absence
of a code for a condition was assumed to represent
absence of the condition.
A full list of the factors considered, how they were
categorised and timescales used to determine if they
were present at CAP diagnosis, can be found in online
supplementary ﬁle A.
Main analyses
Some patients had more than one CAP event during the
study period. It is highly likely that decisions around
whether to hospitalise a patient after CAP were affected
by a previous history of CAP. Furthermore, decisions to
hospitalise may have been similar for patients within a
general practice, for example, due to local area service
provision. To account for this clustering at patient and
practice level, we used multilevel logistic regression
models for the binary hospitalisation outcome.15 The
model had three levels: CAP episodes nested within
patients who were nested within practices. The suitability
of the three-level model was assessed by comparing it to
simpler speciﬁcations (using likelihood ratio tests (lrt))
both before and after including explanatory factors in
the model.
First, minimally adjusted ORs of hospitalisation follow-
ing a CAP (adjusted for age, sex and year of CAP) were
produced for each of the factors of interest. The size of
these ORs and their 95% CIs were used to decide which
variables to include in later models. These variables
were grouped into (1) comorbidities; (2) frailty factors;
and (3) medications, vaccinations and health beha-
viours. We added the three groups of variables sequen-
tially to a model adjusted for age, sex and year of CAP,
according to each group’s hypothesised place on the
causal pathway to hospitalisation. This enabled examin-
ation of the independent effect of each comorbidity (in
the ‘comorbidity’ model), and how much of each
comorbidity’s effect was explained by resulting frailty
and/or medications (in subsequent models). A possible
interaction between age and sex on the odds of hospital-
isation was investigated in the ﬁnal (full) model, com-
paring full models with and without the interaction term
using an lrt.
To investigate the extent to which patient risk factors
for hospitalisation explained trends in the probability of
post-CAP hospitalisations, ORs for hospitalisation for
each temporal period relative to 2001–2003 were esti-
mated, controlling for changes in comorbidities and
other factors. Multilevel models produce cluster-speciﬁc
ORs of hospitalisation (ie, effects measured within each
cluster). When investigating the level of hospitalisation
after CAP over time, results at a population level were
deemed more useful. Thus, we used the predicted
cluster-level odds of hospitalisation derived from the
ﬁnal multilevel model to calculate the population
average of predicted percentages of CAPs hospitalised in
each year group.16
Further analyses
Records for smoking enable the recording of a negative
response (non-smoker), and so levels of missing data
Millett ERC, et al. BMJ Open 2015;5:e008737. doi:10.1136/bmjopen-2015-008737 3
Open Access
group.bmj.com on December 4, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
164
were able to be established for this variable. Smoking
status was more completely recorded over time, decreas-
ing from 26% missing data in 1998 to <1% by 2010 (see
online supplementary ﬁle B). Multiple imputation was
not considered appropriate as data were unlikely to be
missing at random, for example, with respect to
comorbidity status. Analyses including smoking as a cov-
ariate were therefore restricted to a subset of the data,
performing a complete case analysis of CAP episodes
with a recorded smoking status from 2007 onwards
(which included more than 97% of CAPs per year).
Trends in mortality in the 28 days after CAP were
assessed using the linked mortality data and multilevel
logistic regression modelling (as for hospitalisation).
Odds of mortality over time were adjusted for age and
sex, but not for comorbidities or other factors, to avoid
overadjustment of CAP severity resulting from under-
lying health deﬁcits.
Two other potential explanations for trends in hospi-
talisation were investigated. The length of hospital
admission for hospitalised patients over time (a further
potential proxy of severity of illness) was examined using
HES data. The pathway of care for each CAP episode
over time was assessed by examining method of admis-
sion data in HES, and whether there was a general prac-
tice consultation for CAP (or potential CAP) on the day
of diagnosis. We widened the deﬁnition of CAP in
general practice to any LRTI to allow for conservative
coding by general practitioners (GPs) in the absence of
radiographical conﬁrmation of pneumonia.17
All analyses were performed using Stata MP V.11.2.
RESULTS
Of 917 859 potentially eligible patients, 39 211 had at
least one recorded CAP and their 43 576 CAP illness
episodes were included in the study. The median age
at diagnosis was 81 years (lower-upper quartiles:
75–87 years) and 53% of CAPs were in females (table 1).
Most patients (91%) experienced one CAP, 7% of
patients had two episodes and 2% had 3–8 episodes.
The reason for admission was coded with an ICD-10
Chapter X code (Diseases of the respiratory system) for
95% of admissions throughout the study period, with
Chapter XVIII (Signs and symptoms not elsewhere clas-
siﬁed) and Chapter IX codes (Circulatory disease) each
contributing around 1% of admissions.
Risk factors for hospitalisation
After adjusting for age, sex and year, our study found
little evidence that hemiplegia, mild renal disease, self-
care problems, anxiety/depression, mobility issues, tired-
ness, history of falling or excessive alcohol consumption
were risk factors for hospitalisation, and these factors
were not included in subsequent analyses (see online
supplementary ﬁle C).
Results for the remaining 16 comorbidities, 6 frailty
factors and 7 medications/vaccinations are given in
ﬁgure 1 and in the online supplementary ﬁle C. The
ﬁgure reports the ﬁnal model in which ORs are mutu-
ally adjusted; the table reports minimally and then con-
secutively adjusted ORs in successive models.
Comorbidities
In the ﬁnal model, 12 comorbidities were associated with
increased odds of hospitalisation after CAP (ﬁgure 1).
Of the comorbidities common among this cohort,
chronic lung disease, ischaemic heart disease, congestive
heart failure, severe renal disease and diabetes (with and
without complications) were associated with a 25–82%
increased odds of hospitalisation. The greatest odds of
hospitalisation were found for less common conditions
such as metastatic cancer and other disorders of the
immune mechanism (adjusted ORs 2.46 and 2.49,
respectively). Only terminal illness and dementia
remained clearly associated with decreased odds of hos-
pitalisation. Comparison with earlier models indicated
that adjustment for frailty factors and medications made
little difference to effect estimates for individual
comorbidities except for those for connective tissue
disease (attenuated by medications) and dementia (atte-
nuated by frailty factors, online supplementary ﬁle C).
Frailty factors
Visual problems was the only frailty factor associated
with increased odds of hospitalisation in the ﬁnal
adjusted model, while the presence in the last year of
bedsores, low weight/poor nutrition or incontinence
had a negative effect on hospitalisation, as did residence
in a nursing home (ﬁgure 1).
Medications/vaccinations
Patients with a prescription for antibiotics in the previous
8–28 days were less likely to be hospitalised after CAP
than patients with no prescription in the previous
4 weeks, controlling for the other variables in the model.
Oral steroid use was associated with increased odds of
hospitalisation, but the strong effect of inhaled corticos-
teroids and other immunosuppressive medications
disappeared after adjusting for comorbidities (see online
supplementary ﬁle C). We did not observe a protective
effect of statin use against hospitalisation. Inﬂuenza
vaccination in the current inﬂuenza season lowered the
odds of hospitalisation after CAP in the ﬁnal adjusted
model by 25% compared with those who had never been
vaccinated. In contrast, receipt of pneumococcal vaccine
showed no protective effect, with evidence of slightly
increased odds among the group vaccinated ≥5 years
ago (compared with unvaccinated).
Age/sex
In the ﬁnal model, females remained at lower odds of
hospitalisation than males, and hospitalisation odds
increased with age up to 85–89 years. However, there was
evidence that the effect of age on hospitalisation varied
by sex (pinteraction<0.001). In contrast to men, women
4 Millett ERC, et al. BMJ Open 2015;5:e008737. doi:10.1136/bmjopen-2015-008737
Open Access
group.bmj.com on December 4, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
165
Table 1 Characteristics of the study population, factors of interest and hospitalisation within 28 days of CAP
Hospitalised within 28 days
n
Not hospitalised
n Total
All CAPs n (%) 33 321 (76.5) 10 255 (23.5) 43 576
Male n (%) 16 143 (79.5) 4151 (20.5) 20 294
Female n (%) 17 178 (73.8) 6104 (26.2) 23 282
Age (grouped) n (%)
65–69 3469 (75.9) 1099 (24.1) 4568
70–74 4703 (78.8) 1262 (21.2) 5965
75–79 6039 (78.4) 1663 (21.6) 7702
80–84 7227 (79.5) 1865 (20.5) 9092
85–89 6666 (76.6) 2038 (23.4) 8704
90+ 5217 (69.1) 2328 (30.9) 7545
Year of CAP (grouped) n (%)
1998–2000 4008 (57.7) 2944 (42.3) 6952
2001–2003 6266 (69.9) 2701 (30.1) 8967
2004–2006 8269 (79.2) 2173 (20.8) 10 442
2007–2008 7039 (83.7) 1372 (16.3) 8411
2009–2010 7739 (87.9) 1065 (12.1) 8804
Individual comorbidities n (%)
Ischaemic heart disease
Pre-MI 7261 (81.5) 1644 (18.5) 8905
Post-MI 4914 (83.2) 994 (16.8) 5908
Congestive heart failure 8289 (79.6) 2124 (20.4) 10 413
Peripheral vascular disease 4661 (82.7) 976 (17.3) 5637
Dementia 4526 (66.8) 2248 (33.2) 6774
Chronic lung disease 14 571 (83.4) 2905 (16.6) 17 476
Connective tissue disease 3347 (81.9) 740 (18.1) 4087
Peptic ulcer 3343 (81.1) 778 (18.9) 4121
Liver disease
Mild 241 (84.3) 45 (15.7) 286
Severe 165 (87.3) 24 (12.7) 189
Diabetes
Diabetes 4678 (81.3) 1076 (18.7) 5754
With complications 1633 (86.6) 253 (13.4) 1886
Hemiplegia 1243 (76.4) 384 (23.6) 1627
Cancer
Solid cancer 5208 (80) 1300 (20) 6508
Metastatic 1066 (83.9) 204 (16.1) 1270
Leukaemia/lymphoma 981 (85) 173 (15) 1154
Severe renal disease 7001 (88.6) 900 (11.4) 7901
Cerebrovascular disease 8338 (74.5) 2856 (25.5) 11 194
Neurological disease 2997 (73.1) 1103 (26.9) 4100
Disorders of the immune mechanism 243 (90) 27 (10) 270
Mild renal disease 401 (82.5) 85 (17.5) 486
Terminal illness 1190 (67.1) 584 (32.9) 1774
Frailty factors n (%)
Recent carer 1418 (79.6) 364 (20.4) 1782
Living arrangements
Not recorded 27 949 (77.6) 8070 (22.4) 36 019
Lives alone 1471 (81) 344 (19) 1815
Sheltered accommodation 477 (79) 127 (21) 604
Residential care 3424 (66.6) 1714 (33.4) 5138
Visual impairment 11 098 (78.8) 2984 (21.2) 14 082
Self-care 366 (79.7) 93 (20.3) 459
Anxious/depressed 2730 (76) 860 (24) 3590
Bedsore/ulcer 824 (59.7) 556 (40.3) 1380
Mobility issues 2072 (79) 552 (21) 2624
Tired 1957 (74.4) 672 (25.6) 2629
Low weight/poor nutrition 4460 (75.1) 1477 (24.9) 5937
Continued
Millett ERC, et al. BMJ Open 2015;5:e008737. doi:10.1136/bmjopen-2015-008737 5
Open Access
group.bmj.com on December 4, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
166
aged ≥90 years were not at increased odds of hospitalisa-
tion compared with women aged 65–69 years after
adjusting for comorbidities and other factors (table 2).
The three-level model remained the most appropriate
structure (compared with single or two-level) after the
addition of all other factors to the model (all p<0.001).
The effect of comorbidities on trends in post-CAP
hospitalisations
After adjusting for all factors and for clustering, a
marked increase in the percentage of CAP cases hospita-
lised over time remained, rising from 57% to 86% hospi-
talised over the study period. The wide range of
comorbidities and other factors identiﬁed as risk factors
for hospitalisation contributed very little to this increase
(table 3).
Smoking
In total, 17 008 CAP events between 2007 and 2010 were
included in the complete-case smoking analyses. After
adjusting for age and sex, smokers had nearly three times
the odds of being hospitalised than non-smokers
(OR=2.83, 95% CI 2.25 to 3.56) with ex-smokers at nearly
twice the odds (OR=1.88, 95% CI 1.59 to 2.23). After
adjusting for comorbidities, smokers had 96% higher
odds of hospitalisation than non-smokers, and ex-smokers
37% higher (see online supplementary ﬁle D).
Further analyses
The age-adjusted and sex-adjusted odds of dying in the
28 days post-CAP decreased progressively over the study
period, with patients in 2009–2010 having a 38% reduc-
tion in the odds of dying within 28 days of CAP com-
pared with those in 2001–2003 (table 4). Length of
hospital admission decreased slightly over the study
period, from 8 (IQR 4–16) days in 1998–2000 to 7 (IQR
3–13) days in 2009–2010 (table 4). The percentage of
short-term admissions (<2 days) increased over time
from 11.7% to 14.1%. The majority of admissions
(95.6%) occurred on the date of the CAP diagnosis.
Emergency admissions recorded as being via Accident
and Emergency (A&E) increased successively, from
50.6% of post-CAP admissions in 1998–2000 to 76.4% in
2009–2010. Conversely, emergency admissions coded as
arriving via a GP fell from 41.6% to 18.1%, and there
was a corresponding fall in the percentage of CAP
events with a CAP or potential CAP record in the GP
data, from 58% to 34%.
Table 1 Continued
Hospitalised within 28 days
n
Not hospitalised
n Total
Incontinence/catheter 3230 (71.7) 1274 (28.3) 4504
History of falling 4792 (76.4) 1484 (23.6) 6276
Excessive alcohol consumption
Any excess alcohol code 1720 (80.3) 423 (19.7) 2143
Medications n (%)
Immunosuppressants (other than steroids) in past 120 days 685 (85.3) 118 (14.7) 803
Inhaled corticosteroids
None pre-CAP 22 414 (73.6) 8023 (26.4) 30 437
Within 60 days 6864 (84.7) 1239 (15.3) 8103
Within 61–180 days 1620 (81.6) 366 (18.4) 1986
Within 181–365 days 597 (81.4) 136 (18.6) 733
More than 365 days ago 1826 (78.8) 491 (21.2) 2317
Antibiotics
None in previous 28 days 23 437 (77.2) 6926 (22.8) 30 363
In previous 1–7 days 5368 (76.9) 1610 (23.1) 6978
In previous 8–28 days 4516 (72.4) 1719 (27.6) 6235
Statins in previous 6 months 8829 (86.7) 1350 (13.3) 10 179
Oral steroids in previous 90 days 5242 (83) 1077 (17) 6319
Influenza vaccine receipt
No vaccine pre-CAP 4940 (69.7) 2143 (30.3) 7083
14–365 days pre-CAP 20 554 (76.2) 6420 (23.8) 26 974
Last season 5990 (75.5) 1949 (24.5) 7939
2–5 years pre-CAP 1846 (71.7) 728 (28.3) 2574
>5 years pre-CAP 656 (76.4) 203 (23.6) 859
Pneumococcal vaccine
No vaccine pre-CAP 13 126 (66.4) 6643 (33.6) 19 769
14–365 days pre-CAP 1872 (73.7) 669 (26.3) 2541
1–2 years pre-CAP 2095 (75.4) 682 (24.6) 2777
2–5 years pre-CAP 7260 (80.1) 1801 (19.9) 9061
>5 years pre-CAP 9633 (85.4) 1648 (14.6) 11 281
CAP, community-acquired pneumonia; MI, myocardial infarction.
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Figure 1 Mutually adjusted ORs (circles) with 95% CIs (lines) of hospitalisation in the 28 days after CAP for factors included in
the final model*. The model also contained year of CAP diagnosis, but the results for year are not presented. *Baseline
categories were age 65–69 years; condition or medication not present (for comorbidities, frailty factors, recent medications);
unvaccinated/no record of vaccination (for influenza and pneumococcal vaccination) (CAP, community-acquired pneumonia; MI,
myocardial infarction).
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DISCUSSION
This is the ﬁrst UK study to use large linked data sets to
explore the factors associated with hospitalisation
among CAP cases, and thus help identify high-risk
patients for proactive case management. The factors we
investigated had varying effects on hospitalisation. We
were able to identify a wide range of patient factors that
increased the odds of hospitalisation, including condi-
tions common in older populations such as chronic
lung disease, ischaemic heart disease, congestive heart
failure, severe renal disease and diabetes. Analysis of the
subset of data with near-complete recording of smoking
status illustrated that smoking is also a strong risk factor
for hospitalisation, independent of comorbidity status.
Factors associated with decreased likelihood of hospital-
isation included terminal illness, speciﬁc frailty factors
and receipt of residential care. Individuals who had
been recently vaccinated against inﬂuenza and those
with recent antibiotic treatment were also less likely be
hospitalised. An unexpected ﬁnding was that the oldest
women (but not men) in our study were not at
increased risk of hospitalisation compared with younger
women in adjusted analyses; one possible explanation
for this is a survivor effect among the oldest women.
Unlike previous studies that have reported pneumonia
hospitalisation trends, we were able to demonstrate that
hospitalisation after a CAP diagnosis is increasing inde-
pendently of any trends in CAP incidence.2 18 We add-
itionally found that this increase does not appear to be
driven by the underlying health and social issues of the
older population. The average predicted probability of
hospitalisation in the 28 days after CAP increased sub-
stantially in this population over the study period, from
57% to 86%, after extensive adjustment for changes in
the prevalence of patient factors. All-cause mortality in
the 28 days post-CAP and length of hospitalisation both
decreased over the study period, with an increasing pro-
portion of short-term (<2 day) admissions, suggesting
that the increase in hospitalisation was not linked to
increasing CAP severity. Owing to the lack of informa-
tion on illness severity in these data, we cannot ascertain
directly if less severely ill patients are being hospitalised
over time, or whether hospital treatment has helped
reduce mortality in the 28 days after admission.
We also found that over the study period progressively
lower proportions of patients arrived in A&E after refer-
ral from their GP or with evidence that the GP had seen
them for a LRTI on the day of CAP diagnosis, highlight-
ing changes in patients’ health-seeking behaviour.
Strengths
The use of large linked data sets meant that we could
distinguish between community and hospital-acquired
pneumonia and include non-hospitalised CAP episodes,
which enabled assessment of risk factors speciﬁcally for
hospitalisation. The very large linked data allowed thor-
ough investigation of individual comorbidities and other
variables, many of which are incompletely recorded or
unrecorded in hospital admission data. The advantage
of investigating individual comorbidities, compared with
using a summary comorbidity score such as the
Charlson score, is that we avoided masking of opposing
associations of individual comorbidities on hospitalisa-
tion. For example, a Charlson score of 1 is given to a
patient who has dementia, or to a patient with chronic
lung disease. According to our analysis, a patient with
dementia would have reduced odds of hospitalisation
after CAP, whereas a patient with chronic lung disease
would have increased odds. The linked data also allowed
assessment of trends in hospitalisation independent of
trends in CAP incidence, with detailed adjustment to
account for any changes in the prevalence of patient
Table 2 Results of the effect of age on post
community-acquired pneumonia hospitalisation, in males
and females
Age (years) Male OR (95% CI)* Female OR (95% CI)*
65–69 1 1
70–74 1.35 (1.13 to 1.61) 1.34 (1.10 to 1.61)
75–79 1.49 (1.26 to 1.76) 1.39 (1.16 to 1.66)
80–84 1.65 (1.40 to 1.96) 1.61 (1.35 to 1.93)
85–89 1.63 (1.36 to 1.94) 1.47 (1.23 to 1.75)
≥90 1.59 (1.31 to 1.94) 1.00 (0.84 to 1.19)
*Adjusted for: year, ischaemic heart disease, congestive heart
failure, peripheral vascular disease, dementia, chronic lung
disease, connective tissue disease, peptic ulcer, liver disease,
diabetes, cancer, leukaemia/lymphoma, severe renal disease,
cerebrovascular disease, neurological disease, disorders of the
immune mechanism, terminal illness, recent carer, place of
residence, vision problems, bed ulcer, underweight/nutritional
replacement, incontinence/catheter, immunosuppressants (other
than steroids), steroids, inhaled steroids, statins, antibiotics in
previous 28 days, influenza vaccine.
Table 3 Average predicted probability (%) of
hospitalisation within 28 days of community-acquired
pneumonia diagnosis, by year
Average predicted probability of
hospitalisation (%)
Year
No
adjustment
Adjusted for age,
sex and
comorbidities*
Full
model†
1998–2000 58 57 57
2001–2003 70 67 68
2004–2006 80 76 78
2007–2008 84 80 81
2009–2010 89 85 86
*Comorbidities: ischaemic heart disease, congestive heart failure,
peripheral vascular disease, dementia, chronic lung disease,
connective tissue disease, peptic ulcer, liver disease, diabetes,
cancer, leukaemia/lymphoma, severe renal disease,
cerebrovascular disease, neurological disease, disorders of the
immune mechanism, terminal illness.
†As for comorbidities, with addition of: recent carer, place of
residence, vision problems, bed ulcer, underweight/nutritional
replacement, incontinence/catheter, immunosuppressants (other
than steroids), steroids, inhaled steroids, statins, antibiotics in
previous 28 days, influenza vaccine.
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risk factors for hospitalisation over time. The linked
CPRD population is representative of the population of
England, making our ﬁndings generalisable to the popu-
lation at large, and the linked hospital data enabled us
to identify the outcome (hospitalisation) with minimal
misclassiﬁcation. Further linkage to central mortality
records allowed us to estimate mortality without restrict-
ing analyses to the subset of patients who died in hos-
pital, thus avoiding changes in mortality over time due
simply to changes in the relative proportions of patients
who died in and outside hospital.
In contrast to previous studies that used only the ﬁrst
CAP episode in a year, we included patients with
repeated episodes of CAP.18 19 The association between
speciﬁc comorbidities and hospitalisation could be par-
ticularly strong in this small but important subset of
patients, and inclusion of their multiple episodes
avoided potential underestimation of these associations.
Limitations
Validity of recorded diagnoses is generally high in
CPRD, and comorbidities and other risk factors that
were only recorded after the hospitalisation were not
included; thus, any misclassiﬁcation of these factors is
likely to be relatively small and non-differential with
respect to the outcome.20 The linked data enriched our
Table 4 Post-CAP mortality, length of hospital admission and consultation behaviour on the day of CAP diagnosis, over time
Year
1998–2000 2001–2003 2004–2006 2007–2008 2009–2010
OR for mortality within
28 days of CAP
diagnosis*
1.01 (0.93 to 1.10) 1 0.84 (0.78 to 0.91) 0.73 (0.67 to 0.79) 0.62 (0.57 to 0.68)
Length of hospital
admission median,
(lower-upper quartile),
days
8 (4–16) 8 (4–17) 8 (4–15) 7 (3–14) 7 (3–13)
0–2 468 (11.7) 660 (10.5) 981 (11.9) 999 (14.2) 1093 (14.1)
2–6 1138 (28.4) 1831 (29.2) 2595 (31.4) 2364 (33.6) 2731 (35.3)
7–13 1145 (28.6) 1737 (27.7) 2311 (27.9) 1827 (26) 1987 (25.7)
≥14 1256 (31.3) 2037 (32.5) 2383 (28.8) 1848 (26.3) 1930 (24.9)
Reason for admission, n (% of those hospitalised)
Emergency: via A&E 2027 (50.6) 3760 (60) 5559 (67.2) 5073 (72.1) 5914 (76.4)
Emergency: via GP 1666 (41.6) 2016 (32.2) 2231 (27) 1522 (21.6) 1402 (18.1)
Emergency: via bed
bureau
102 (2.5) 107 (1.7) 125 (1.5) 114 (1.6) 121 (1.6)
Emergency: via
consultant outpatient
clinic
26 (0.6) 42 (0.7) 43 (0.5) 41 (0.6) 42 (0.5)
Emergency: other
means (including A&E
from another place)
66 (1.6) 135 (2.2) 143 (1.7) 122 (1.7) 127 (1.6)
Transfer
(non-emergency),
elective, not known
120 (3) 205 (3.3) 169 (2) 166 (2.4) 135 (1.7)
Admitting diagnosis
ICD10 Chapter X—
diseases of the
respiratory system
3798 (94.8) 5979 (95.4) 7939 (96) 6743 (95.8) 7426 (95.9)
Hospitalisations on
CAP diagnosis date, n
(% of those
hospitalised)
3718 (92.8) 5893 (94.1) 7896 (95.5) 6804 (96.7) 7539 (97.4)
Relevant diagnosis on CAP date† (n, % all CAP)
CPRD only 3234 (46.5) 3074 (34.3) 2546 (24.4) 1607 (19.1) 1265 (14.4)
HES only 2909 (41.8) 4644 (51.8) 5990 (57.4) 5266 (62.6) 5787 (65.7)
CPRD and HES 809 (11.6) 1249 (13.9) 1906 (18.3) 1538 (18.3) 1752 (19.9)
*Adjusted for age and sex using three-level model.
†General practice records included LRTI records as ‘potential CAP’, to allow for potentially conservative coding by GPs in the absence of
radiographical confirmation of pneumonia (see Results section). HES records included any hospital admission record.
A&E, Accident and Emergency; CAP, community-acquired pneumonia; CPRD, Clinical Practice Research Datalink; GP, general practitioner;
HES, Hospital Episode Statistics; ICD, International Classification of Diseases; LRTI, lower respiratory tract infection.
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overall comorbidity coding, but smoking histories were
under-recorded in the earlier years of the study period.
The introduction of the Quality Outcomes Framework
(QOF) in 2004 has improved the recording of smoking
status in GP records, and analysis of the subset of data
with near-full recording of smoking indicated its import-
ance as a risk factor for hospitalisation after CAP.
Similarly, while the use of GP data enabled investigation
of some factors associated with frailty, these factors were
not frequently recorded by GPs which limited our ability
to assess fully their association with hospitalisation.
Owing to the frailty indicators included in the data, we
were unable to use an established measure of frailty
such as the frailty phenotype or frailty index.13 14
However, the frailty index includes several of the
comorbidities we included individually in our model,
such as diabetes, myocardial infarction and lung disease,
and so use of this score may have led to overadjustment
for these other important conditions. We examined a
wide variety of variables; thus, estimates in the ﬁnal
model with a 95% CI close to including the null value
should be interpreted with caution.
The HES pneumonia diagnoses used in this study
have not been validated. There have been small loca-
lised reports of overdiagnosis of pneumonia in English
hospitals, but trends over time at a national level have
not been reported.21–23 As such we cannot exclude that
overdiagnosis could have played a role in the increasing
level of hospitalisation after CAP identiﬁed in this study.
The forthcoming British Thoracic Society audit of CAP
diagnoses will help to clarify this issue. Nevertheless, it is
likely that the majority of these patients had a respira-
tory illness that was considered severe enough to merit
hospitalisation, and these are of public health
importance.
The data sources used in this analysis did not contain
direct measures of pneumonia severity, such as those in
the CURB score, and so severity of illness could not be
measured directly.24 However, our aim was to establish
patients’ pre-existing conditions which contributed to
the increase in hospitalisation over time, not the mech-
anism by which this occurred (either by altering severity
of CAP or by other means), and so we do not feel this
detracts from our study ﬁndings. Furthermore, a recent
systematic review highlighted suboptimal performance
of CURB scores for oldest patients, and stressed the
need to focus more on the presence of comorbidities
and frailty in these patients.25 Similarly, due to the
nature of the coding used in these data, we were not
able to examine the severity of many of the comorbid-
ities we investigated, and so could not directly assess
whether increasing severity of these comorbidities over
time could have explained some of the increase in hos-
pitalisations during the study period. However, where we
could distinguish categories of severity (eg, for diabetes,
liver disease, renal disease and ischaemic heart disease),
the likelihood of hospitalisation was very similar for
those with severe and milder manifestations of the
condition, and adjustment for these factors did not
materially affect increasing hospitalisations.
Findings in relation to other studies
We have previously shown that CAP incidence is rising
among older individuals in the UK.6 This study conﬁrms
that hospitalisation following a CAP diagnosis is also
increasing, with a growing percentage of cases hospita-
lised within 28 days of diagnosis. Our ﬁndings enhance
those from previous studies that used stand-alone hospi-
talisation data, which have shown increasing hospitalisa-
tions for pneumonia without distinguishing increasing
CAP incidence from an increasing tendency to hospital-
ise patients with CAP.2 18 In particular, our analyses of
hospitalisation trends update and extend those of a pre-
vious English study, which reported increasing pneumo-
nia hospitalisation rates between 1997 and 2004 after
less extensive adjustment for comorbidities, using the
Charlson Index.18 Other studies that have investigated
individual risk factors among older patients with CAP or
LRTI have mostly been small and included fewer factors;
some used hospitalisation or death as a composite
outcome, which will obscure the opposing effects of con-
ditions such as dementia or terminal care on these two
outcomes.19 26–29 Our ﬁnding that inﬂuenza vaccine
receipt is associated with protection against hospitalisa-
tion after CAP is also consistent with the direction of
effect shown in previous studies of inﬂuenza vaccine
effectiveness against hospitalised CAP,30 31 and studies
showing a relative lack of long-term protection of
pneumococcal vaccine, especially among those with
underlying health conditions.32 33 Our ﬁndings also add
to those from a recent systematic review, which high-
lighted between-study heterogeneity in the association
between statin use and outcomes of pneumonia.34 The
reduction in mortality seen over the study period echoes
that from the earlier English study which focused on
in-hospital mortality, as well as CAP mortality studies
from Europe and the USA.18 35 36
Meaning, explanations and implications for future
research
The risk factors identiﬁed in this study will be of
beneﬁt to clinicians managing patients in primary care
settings, by helping to identify patients at high risk of
unplanned admission to hospital who are in need of
proactive case management. Our ﬁndings will further
inform discussions with these patients about protecting
against infection risk and seeking early treatment for
symptoms.
Frailty is currently a health priority in the UK. The
requirement in the 2014 general practice contract for
increased identiﬁcation of vulnerable older members of
the practice population may result in better recording of
frailty in general practice data and enable more thor-
ough investigation of its effects on hospitalisation in
future research.37 The latter will be helped by a new
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primary care electronic Frailty Index, currently under
development in England.38
Despite their importance in identifying high-risk
patients, our adjusted analyses show that increasing
prevalence of comorbidities and frailty are not driving
the increase in hospitalisation rates. Declining mortality
and length of hospital stay indicate that this is not due
to increasing disease severity. What then explains the
increasing hospitalisation trend? The guidelines for
management of CAP issued by the British Thoracic
Society have not changed signiﬁcantly over the study
period.39 40 However, the diagnostic accuracy of pneu-
monia may have changed over time. An emergency
department-based US study found that the accuracy of
pneumonia diagnoses decreased after the change of a
core quality measure (time to ﬁrst antibiotic dose) from
8 to 4 h.41 In England, the introduction of the 4 h A&E
waiting time target in 2004 could have had a similar
effect.
In addition, changes to service provision and utilisa-
tion have been highlighted as playing a role in the
increase, with the change in out-of-hours access to GPs
during the study period.42 The effect of this is difﬁcult
to measure directly, but we found decreasing emergency
admissions over time arriving via a GP, and a decreasing
proportion of patients with a CAP or potential CAP
recorded by their general practice on their CAP diagno-
sis date. Studies have also shown that the increase in
emergency admissions among older individuals in
England is not restricted to pneumonia but are seen for
a range of other conditions, and that the percentage of
patients who attended A&E and were then admitted
rose by over a third between 2003 and 2012, with 75% of
this rise attributed to increasing emergency admissions
and 25% to an increase in A&E attendance.43 Thus, an
increasing tendency to hospitalise, coupled with an
increasing inclination of patients to present to A&E
rather than to their general practice, may be a main
driver of the growth in hospitalisation after CAP. It
would be interesting to compare our results with those
from equally detailed studies that use linked data to
investigate risk factors and hospitalisation trends for
other conditions, such as COPD or cellulitis. Results
from these studies would allow further interpretation of
whether increasing hospitalisation and decreasing
primary care consultation trends are not speciﬁc to CAP
among older adults.
Our study, based on very large numbers (minimising
random error) and with the ability to adjust hospitalisation
rates for many factors, supports the argument that focus-
ing on high-risk patients, while important for risk stratiﬁca-
tion, will not appreciably reduce emergency admissions.42
If the incidence of CAP among those aged ≥65 years also
continues to increase, these combined trends will place a
joint expanding burden on the health service.
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Supplementary files B-D can be found in Appendix G.  A more detailed version of the 
online supplementary file A from the paper is presented below. 
6.4 Supplementary Methods used to identify the presence of variables 
This section expands upon the supplementary methods referred to in Paper 2 (online 
material A), including a more detailed account of how co-morbidities, frailty factors, 
medications vaccinations and lifestyle factors were identified.  
6.4.1 Co-morbidities 
The large size of the data included in this study, and detailed medical history contained 
within patients’ linked records, enabled me to investigate the effects of individual co-
morbidities rather than using a summary score such as the Charlson index.[68]  I initially 
included all 19 co-morbidities in the Charlson index (as defined in the original 1987 
paper),[68] as well as additional conditions which were thought to potentially affect the 
probability of being hospitalised following CAP (neurological disease, disorders of the 
immune mechanism, and terminal illness).   
While it may be expected that GP records would contain the majority of a patient’s 
historical and current diagnoses, there is added detail and value in also utilising the HES 
data.[148]  Therefore, records for co-morbidities were sought from both CPRD and HES 
records in order to collect as complete a medical history for each patient as possible.   
To date, there is no real consensus on how far back to look through a patient’s medical 
records in order to identify the presence of underlying disease, and this will depend on 
the condition and the study question.  ‘Lookback’ periods used in other papers (when 
specified) range from a year[149] to all available records.[64]  If a patient has a long-
standing chronic condition, this may not be recorded repeatedly in medical records, 
necessitating longer lookback periods to identify it.  Additionally, when the outcome of 
interest can occur multiple times per patient (as with CAP), using a short lookback period 
could result in the patient fluctuating between disease states for different CAP episodes 
depending on when the last co-morbidity record occurred.  For example, if a patient was 
diagnosed with COPD and nine months later had an episode of CAP, the patient would 
have COPD listed as a co-morbidity using a one-year lookback.  If six months later the 
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patient had another CAP episode, but the COPD had not been re-recorded the patient 
would not be classified as having COPD during this illness.  In order to avoid this scenario 
and to allow me to gather as much information on the cohort of older patients as 
possible, I did not place time restrictions on how long ago co-morbidities could be 
recorded in order to be considered in these analyses.  Furthermore, I did not limit the 
records I used to those recorded after a certain time point (such as the date the practice 
was deemed ‘up to standard’ by CPRD), but included records for co-morbidities from 
any point in a patient’s records prior to the CAP episode.  This strategy was adopted as 
I was interested in whether the patient had ever experienced each disease rather than 
identifying incident cases, and so any recording of historical conditions potentially on 
the wrong date (pre-CAP) was not a concern.   
Read (CPRD) and ICD-10 (HES) code lists were defined for each co-morbidity of interest 
by one or more senior clinical epidemiologist at LSHTM, taking into account previous 
published code lists.[150]  These code lists were merged with the data, and the date of 
the earliest record recorded separately for CPRD and HES records.  If either of these 
earliest co-morbidity dates were prior to or on the CAP incident date, the patient was 
classified as having the condition.  For some conditions there were additional 
adaptations to this process, as described below. 
6.4.1.1 Differentiation between acute and chronic co-morbid events 
Conditions recorded for the first time on the same date as an incident CAP record were 
treated differently for acute and chronic illnesses.  For conditions such as MI, stroke, and 
falls which may have been precipitated by a CAP episode, records up to the day before 
the CAP incident date were used.[151, 152]  Records for chronic conditions (for example 
diabetes without complications), that were first recorded on the CAP incident date were 
included, as CAP is not known to lead to the onset of diabetes.      
6.4.1.2 Co-morbidities with more than one level of severity 
Specific co-morbidities were categorised with more than one level of severity, including 
ischaemic heart disease (categorised with no evidence or evidence of past MI), solid 
cancer (without/with metastases), liver disease (moderate and severe) and diabetes 
(without/with complications).  Data were time-updated such that patients were 
classified as having the less severe category of disease until the date of their first code 
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at the higher level, when they permanently changed to the higher level.  If patients only 
had codes for the higher level (e.g. metastatic cancer without a prior code for solid 
cancer) they were immediately categorised as having the higher level of disease. 
6.4.1.3 Additional, non-Charlson broad co-morbidity terms that included several 
diseases 
Neurological disease included Parkinsons disease and other extra-pyramidal/movement 
disorders, epilepsy, multiple sclerosis and other demyelinating diseases, systemic 
atrophies primarily affecting the central nervous system, hereditary and idiopathic 
neuropathy, cerebral palsy, Creutzfeldt-Jakob disease and atypical viral infections of the 
central nervous system. 
Disorders of the immune mechanism included aplastic anaemia, immunodeficiency with 
predominantly antibody defects, combined immunodeficiencies, immunodeficiency 
associated with other major defects, common variable immunodeficiency, functional 
disorders of polymorphonuclear neutrophils, chronic myeloproliferative disease, HIV 
infection, and unspecified immunodeficiency.  AIDS was also included when calculating 
the Charlson score (see section 6.5.2). 
Terminal illness was defined using Read and ICD-10 codes that stated terminal illness, 
rather than specific conditions.  In addition, GP information on referrals to hospices was 
included.   
6.4.2 Frailty factors 
Frailty is an important topic when considering the health of older adults.  As discussed 
in section 1.2.1.1, the definition and classification of frailty is complex and the cause of 
much discussion, and currently there are several working definitions of frailty and 
associated ways to measure it.  Two popular approaches (described in section 1.2.1.1) 
are the frailty phenotype, which recognises frailty from a set of five deficits, and the 
frailty index, which utilises a cumulative deficit approach (counting a number of factors 
for each patient across a range of systems, including co-morbidities, disabilities and 
clinical signs and symptoms).  
177 
 
It was not possible to categorise frailty using either the frailty index or frailty phenotype, 
as neither CPRD nor HES data include all the factors needed to calculate either score, 
such as grip strength, gait speed, or neck muscle strength.[73, 153]  Instead, I developed 
a series of variables based initially on those factors that are included in the frailty index 
which could possibly have been recorded in a patient’s records.[153]  Read, and when 
possible ICD-10 code lists were developed (by myself and Sara Thomas), incorporating 
information from additional recording fields within the data such as the entity type, and 
consultation type (when the type of consultation was recorded, e.g. residential home 
visit).   Unlike co-morbidities, only codes used within the previous year were counted as 
evidence of a frailty factor due to the ability of the frailty state to fluctuate.  The 
exception to this was visual impairment, for which more complex rules were developed 
as explained in detail later in this section.  The specific methodology used for each factor 
is laid out below. 
6.4.2.1 Frailty factors included if they were recorded in the year pre-CAP 
Anxiety/depression utilised Read and ICD-10 codes for anxiety and depression. 
Bedsores/ulcers included Read and ICD-10 codes for bedsores and pressure 
sores/ulcers. 
History of falls used information from both CPRD and HES to define whether a patient 
had fallen within the last year (excluding records on the CAP incident date).  Codes for 
hip fractures were also included in this category as it has been estimated that up to 95% 
of hip fractures are caused by falls.[154]  Codes for falls were included if the reason for 
the fall could have been due to a deficit in underlying health.  For example, codes 
pertaining to an accidental fall not associated with potential loss of function (such as 
falling from a bicycle) were not included.   
Incontinence included Read, ICD-10 and entity codes for bladder or bowel incontinence, 
and codes and prescriptions for catheters, leg bags and associated products. 
Mobility problems included Read codes and entity codes for problems with general 
mobility and with stairs, walking, being house- or chair-bound, immobile, in a 
wheelchair, as well as use of a zimmer/walking frame and difficulties getting in/out of 
bed.   
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Body mass index (BMI) was initially investigated, but the data were not included as a 
potential risk factor due to high levels of missing data and a lack of timeliness in the 
records available.  A quarter of patients included in the analysis had neither a recorded 
BMI value in their records nor information on their height and weight to enable BMI to 
be derived.  Furthermore, for those patients with a BMI record, timing of the record 
relative to the next CAP episode was suboptimal for much of the study period.  Less than 
40% of CAP episodes between 1997 and 2002 had a BMI value recorded in the previous 
two years, reaching 60-70% by the end of the study period.  This difficulty is not specific 
to this CAP cohort, as these values are similar to those presented over time for patients 
aged ≥65 years in a recent data resource profile of CPRD.[99]  In this older population 
with relatively high prevalence of co-morbidities, weight recorded several years prior to 
a CAP episode may not be accurate by the CAP incident date.  For example, patients may 
have gained weight due to mobility problems and inactivity, or have lost weight due to 
ill health or depression.  Thus, for weight records to accurately reflect a patient’s current 
BMI status they need to have been recorded relatively recently prior to the CAP episode.   
Previous studies have shown that compared to patients with a normal weight/BMI (and 
after taking other factors such as co-morbidity into account), patients who were 
overweight or obese were not at higher risk of developing CAP,[31, 155] and there is 
conflicting evidence whether higher BMI is a risk factors for being hospitalised for 
CAP.[122, 156]  However, there is stronger evidence that patients who were 
underweight were at increased risk of developing CAP,[31, 155] and being underweight 
is also an aspect of frailty.  Due to the high level of missing data and lack of timely 
recording for BMI, it was decided not to include BMI in this analysis.  Rather, I specifically 
looked at whether patients were recorded as underweight or needing nutritional 
supplementation, as described below.   
Low weight/poor nutrition included Read, ICD-10, prescription and entity type codes for 
weight loss, malnourishment, lack of appetite, anorexia, and prescriptions for nutritional 
supplementation.  As described above, due to the long period between BMI 
measurements and CAP episodes, low BMI values were not included.  
Recent support from a carer was defined in CPRD using Read codes and entity types in 
the year before the CAP episode.  Records were restricted to the prior year in order to 
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strike a balance between excluding historical records for patients who were no longer 
in receipt of care while including those for patients with long-term carers which may not 
be recorded frequently.    
It was hypothesized that a change in housing might result in modified use of a carer.  
Thus, patients could be classified as having a carer irrespective of which residence 
category they were in (defined below), but the carer variable was modified accordingly.  
Patients whose most recent residence code was within a year of the CAP index date 
were only classified as having a carer if the carer code was more recent than the 
residence code.  If there were no records relating to the patient’s place of residence or 
the residence code was recorded more than a year before the CAP index date, then the 
patient was coded as having a carer if it was coded in the year prior to the CAP. 
Self care problems included Read and entity codes for an inability to; wash/clean 
oneself, maintain personal hygiene, get dressed without assistance, use the toilet 
without assistance, perform housekeeping activities, buy and/or prepare food.   
Tiredness included Read codes regarding tiredness, fatigue, malaise, lethargy and 
chronic fatigue syndrome.   
6.4.2.2 Frailty factors included if recorded at any point pre-CAP 
Place of residence was defined using CPRD records only, as over 85% of records in HES 
were coded as admitted from ‘usual place of residence’ which could relate to 
independent housing or residential care.  Within CPRD the most recent record (using 
Read codes or the consultation type field) was used, as patients could move in and out 
of residential care, for example while recuperating after an illness or fall.  The categories 
living alone, sheltered accommodation and residential care were treated as being 
mutually exclusive, and when more than one category was used on a date the less 
independent place of residence was assigned.  The category residential care also 
included nursing homes – the Read codes used did not differentiate well between 
residential and nursing homes, so it was necessary to use a single category for both types 
of care.  
Visual impairment was defined using records from both CPRD and HES (using Read, ICD-
10 codes and entity codes).  To aid data management, visual codes were categorised as 
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long-term conditions (such as blindness), and those which were potentially treatable.  
The treatable conditions were further categorised as cataracts (diagnosis or surgery) and 
other eye conditions.  Within HES, codes within the primary code of the first episode 
(the main condition treated) were assumed to be admissions for cataract removal 
surgery.     
Patients with any long-term condition, other visual impairment at any point before CAP, 
or with a cataract diagnosis code but no cataract surgery code before the CAP, were 
coded as having a vision problem. 
6.4.2.3 How well did my approach really capture frailty? 
I chose not to use a cumulative deficit approach in my risk factors for hospitalisation 
analyses, as inclusion of both a frailty index and individual co-morbidities in the 
regression models may have led to over-adjustment of co-morbidities.  However, the 
use of the individual aspects of the frailty index to adjust for frailty (as I did) is not a 
validated approach, and may not have captured patients’ frailty status adequately.  The 
frailty index weights each included factor equally when estimating the cumulative 
deficit, resulting for example in patients with four different co-morbidities and two 
signs/symptoms having the same score as a patient with one co-morbidity and five 
signs/symptoms (both being classified as ‘mild’ frailty).  The model I built would not have 
had the same result, as the majority of co-morbidities were associated with increased 
odds of hospitalisation, whereas the other frailty factors I considered were not.  Thus, 
in my model the deficits would not have accumulated in a comparable way, and patients 
with a high number of non-co-morbidity frailty factors would most likely have been 
assigned lower odds of hospitalisation than patients with multiple morbidities but no 
other frailty factors.  While my approach allowed me to investigate a wide range of 
components of frailty, it did not enable me to explore any potentially cumulative effect 
these factors may have had, and thus may not have fully captured patients’ frailty status.    
6.4.2.4 A new approach - the Electronic Frailty Index 
Since I completed the work on this thesis, a study which developed and validated an 
electronic frailty index for use in English primary care records has been published.[157]  
Clegg et al developed and internally validated (using the split sample approach) their 
electronic frailty index (eFI) using a UK primary care data source (ResearchOne), and 
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then externally validated the index using a separate primary care data source (The 
Health Improvement Network, THIN).   
Patients aged 65-95 years who were registered with a practice contributing to either 
data source on 14 October 2008 were included, and these patients were followed-up for 
up to five years.  Thirty-six deficits were chosen for inclusion in the index across a range 
of categorises including disease states, signs/symptoms, and disabilities.  Using the 
cumulative deficit approach, each patient had their eFI calculated as the number of 
deficits present divided by 36 (the total number of possible deficits).  Four categories of 
frailty were defined, based on the quartiles of the frailty score: 1) Fit (those with scores 
of 0-0.12, i.e. 0 to 4 deficits present); 2) Mild frailty (scores of >0.12-0.24, 5 to 8 deficits); 
3) Moderate frailty (scores of >0.24-0.36, 9 to 12 deficits), and 4) Severe frailty (scores 
of >0.36, 13 or more deficits).  The derivation and internal validation cohorts assigned 
50% of patients as fit, 35% mildly frail, 12% moderately frail and 3% severely frail.  In the 
external validation THIN cohort, fewer patients were assigned as fit (43%), with slightly 
higher levels of moderately frail (16%) and similar levels of mildly frail (37%), and 
severely frail (4%). 
These four categories were then assessed against a range of outcomes; mortality, 
emergency hospitalisation and nursing home admission at one, three and five years.  
The authors described the discrimination of the model as good for the outcomes of 
mortality and nursing home admission (internal validation c-statistics ranged from 0.72 
at 1 year to 0.69 at 5 years for mortality) and ‘moderate’ for emergency hospitalisation 
(c-statistic 0.66 at 1 year to 0.63 at 5 years).  External validation showed improved 
discrimination for mortality (0.76 and 0.75) and emergency hospitalisation (0.71 and 
0.69) at one and five years, although the hospitalisation values in particular still have 
room for improvement. 
6.4.2.5 Limitations of assessing frailty using EHR 
The new eFI appears to have a moderate ability to identify older adults at risk of 
emergency hospitalisation within one year.  In general, frailty indices include a range of 
factors, as some of the physiological changes that bring about frailty do not result in 
specific diseases.  Consequently, an index which only includes co-morbidities (for 
example, the Charlson score) will not identify all frail patients.  Many of the factors 
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included in the eFI are co-morbidities, and thus the score relies on the completeness of 
coding of the other frailty factors in order to differentiate it from a simpler ‘co-morbidity 
count’ approach.     
As highlighted in the paper above and discussed in section 6.5.4, one potential 
disadvantage of using a score approach is that individual co-morbidities may have 
opposing effects on the risk of hospitalisation, and these opposing effects may not be 
identified when a score is used.   
No matter whether a frailty index (such as the eFI) or an individual factor approach (as 
in my analysis) is chosen, the most important limitation of assessing patients’ frailty 
using EHR is the lack of information on validity of the recording of non-disease factors.  
For example, when codes are used to denote that a patient has mobility problems (for 
example, an inability to climb stairs), these are likely to have been correctly applied to 
patients who have these signs/symptoms, and the codes are therefore likely have a high 
positive predictive value.  However, it is possible that not all patients with mobility 
problems are assigned such a code, either because they have not reported this issue to 
their GP, or because the GP has noted the issue (for example in a free text field) but not 
formally coded it.  This would result in the coding of these factors having low sensitivity 
and thus a patient’s frailty score would be underestimated.   
The increasing interest in frailty and its current priority status in the UK may result in 
more complete recording of the non-disease frailty factors in general practice 
records.[158]  Updates of the eFI in future years may benefit from this, resulting in an 
improved discriminative ability for emergency hospitalisation, and it will be interesting 
to see how the updated eFI changes over time.   
6.4.3 Medications 
Information for all medication variables was obtained from the therapy files in CPRD.  
Linked-HES data do not currently include information on medication prescribed during 
a patient’s hospital admission, and as a result drugs given during any hospital admission 
could not be included in the analysis.   
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Prescription recording in CPRD can include information on the date of prescription, drug 
name, quantity of tablets prescribed, the numeric daily dose and length of treatment.  
Unfortunately the information on daily dose and length of treatment are sometimes 
poorly recorded.  For medications such as oral steroids it can thus be difficult to work 
out whether some patients were prescribed a short high-dose course or a low long-term 
maintenance dose.  To work around this difficultly, I used both the time between the 
CAP incident date and the closest preceding prescription, as well as the length of a 
prescription (when recorded) in order to define exposure to the drug of interest, using 
different time windows depending on the medication.  
Inhaled corticosteroids: Timing of inhaled corticosteroids (ICS) prescribing was based 
upon recent work by Suissa et al.[33]  CAP episodes without an ICS prescription in the 
previous year were classed as ‘non-users’.  Those who did have a prescription were 
categorised by their most recent prescription pre- CAP; up to 60 days prior, 61-180 days 
prior, and 181-365 days prior to the CAP diagnosis. 
Immunosuppressants other than steroids: Patients were categorised as being 
recent/current immunosuppressant users if they had a prescription record within 120 
days of their CAP event date (assuming a 90 day prescription, and 30 day washout 
period). 
Oral steroids: As highlighted above, the categorisation of oral steroid use was 
challenging due to incomplete information in the numeric daily dose (36.9% missing) 
and length of treatment course (93.6% missing) fields.  This was a particular issue when 
patients had prescriptions for multiple tablet strengths (e.g. 1mg and 5mg) on the same 
day, and I was unable to differentiate regimens in which a patient was tapering their 
dose from those in which the patient was simply on a dose non-divisible by 5 (e.g. 8mg).  
To combat this problem, the timing of oral steroid use was based upon the strategy 
adopted by Dixon et al.[159]  This study explored several models for categorising 
exposure to oral steroids using routinely collected GP data, and the 90 day model had 
the best fit of the conventional ‘binary’ models presented.  Patients were categorised as 
being recent/current oral steroid users if there was evidence of a prescription for oral 
steroids within the 90 days pre-CAP, or if they had a prescription that would last into 
this period.  When prescriptions were issued up to 14 days pre-CAP (but not in the 15 to 
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90 days before the CAP), patients were not classified as being ‘on steroids’, as the 
treatment may have been given for an LRTI preceding the CAP (e.g. for an infection-
related COPD exacerbation), and because the immunosuppressive effects of the 
medication may not have taken effect before the CAP episode. 
Statin use was defined as a prescription within the previous six months (183 days).  A 
longer period was used than that for steroids or other immunosuppressants, as statins 
are prescribed as a long term therapy and not frequently used as an acute treatment.  
Antibiotic prescriptions were classified as given in the 1-7 or 8-28 days before the 
incident CAP diagnosis. 
6.4.4 Vaccines 
Vaccination status was determined using GP records alone.  I decided to prioritise 
records from the CPRD ‘immunisation’ and ‘therapy’ files (rather than the ‘clinical’ files), 
as these were thought more likely to record a current vaccination event rather than an 
historical one.  To account for the time taken for a vaccine to elicit an immune response, 
patients were considered ‘unvaccinated’ for the 14 days after the vaccination date.[53, 
48]  Timings were categorised in similar manner to Vindogrova et al, as outlined 
below.[160] 
Influenza vaccine status was categorised to reflect that influenza vaccine is offered to 
patients yearly.  The vaccination season was defined as 1st September to 31st August the 
next year.  
Individuals were classed as unvaccinated if they had no influenza vaccination record 
prior to their CAP diagnosis, or if they were first vaccinated less than 14 days pre-CAP.  
Those vaccinated ≥2 weeks prior to the CAP episode were classified according to their 
most recent vaccination date as being vaccinated in: the current season, the previous 
season, 2-5 years ago or >5 years ago. 
Pneumococcal vaccine status was categorised similarly to influenza vaccine, but without 
the use of a vaccination season; categories were unvaccinated, or vaccinated: this year, 
last year, 2-5 years and >5 years before the CAP diagnosis. 
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For both vaccines, patients with only a ‘history of vaccination’ code were classified 
conservatively as being vaccinated more than five years previously, as there was no way 
of identifying the correct date.   
6.4.5 Lifestyle/social factors 
Patients’ smoking status and excess alcohol consumption were considered as potential 
risk factors.  An episode of pneumonia may modify a patient’s behaviour, potentially 
making them more health conscious.  For this reason, only the most recent record for 
smoking and excess alcohol status prior to the CAP episode was used to classify a 
patient’s status for each CAP; records occurring after their CAP diagnosis were not used.   
Excess alcohol consumption: Previous studies have found a link between excessive 
alcohol consumption and risk of CAP.[31, 161]  I used markers for excess alcohol 
consumption in addition to specific measures of consumption as only 20% of CAP 
episodes had a record regarding alcohol consumption in the previous year (rising to 
31.3% in the previous two years).  Excess alcohol consumption was therefore identified 
using a Read/ICD code for high/excess alcohol consumption, for alcoholism, or a code 
specifying harm due to alcohol (for example, alcohol-induced hepatitis) recorded at any 
point before the CAP episode.  Patients with prescriptions for medications to treat 
alcohol dependency at any time before/on the date of the CAP episode, and those 
recorded as consuming ≥6 units of alcohol a day, or ≥42 units a week were also included. 
Smoking status was derived using Read/ICD-10 codes, prescriptions for nicotine 
replacement therapy and appropriate entity codes.  Patients with a code for ‘non-
smoker’ were amended to ‘ex-smoker’ if they had previous current or ex-smoker 
records.  Patients on nicotine replacement therapy were coded as current-smokers, as 
relapse rates are high.[162]   
Exclusion of socioeconomic status: I decided not to include a measure of socioeconomic 
status (i.e. IMD quintile) in this analysis, as IMD quintile was not available at the 
individual level for more than 4000 patients (>10% of patients included in this study 
population).  While practice-level deprivation quintiles were available for these patients, 
this should have been accounted for in part by the practice-level clustering included in 
the multilevel model.  Furthermore, SES is a distal determinant of hospitalisation, 
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mediated by the other variables of interest such as co-morbidities and lifestyle factors.  
Therefore the inclusion of these factors in the multivariable model will have at least 
partially accounted for the effect of SES.         
6.5 Additional analysis comparing co-morbidity adjustment using individual co-
morbidities versus the Charlson index 
6.5.1 Background 
The range of co-morbidities included in the preceding analysis was based upon those in 
the Charlson index, supplemented by additional potentially important disease groups.  
The diseases in the Charlson index were used as the starting point due to the index’s 
widespread use in epidemiological studies (the original paper has been cited >15,000 
times),[163] in particular its use in the analysis of CAP,[61, 148, 164, 165] and studies 
using electronic health records.[61, 148, 164, 165]  By supplementing the diseases 
included by Charlson with other cardiac, neurological and immune disorders it was felt 
that a wide and comprehensive range of potentially important co-morbidities was 
included. 
More specifically, the study of increasing hospitalisations for pneumonia in England by 
Trotter et al which originally inspired the analyses above found that using the Charlson 
co-morbidity index did not explain the increasing hospitalisation trend over time.[61]  
While my intention was never to use the Charlson index to adjust for co-morbidities in 
the main hospitalisation analysis, I thought it would be useful to compare its use to that 
of individual co-morbidities in investigating the underlying reasons for the 
hospitalisation trends.   
6.5.1.1 Potential issues with using the Charlson index to adjust for co-morbidity 
In the thirty years since the Charlson paper was originally published, the methods for 
developing prognostic models, and the prevalence and treatment of the diseases 
contained within the index, have changed considerably.  This has resulted in heightened 
awareness of the limitations in its use. 
Methodical limitations 
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Methodologically there are several problems with the approach used to develop the 
Charlson index.  The score was developed by assigning the rounded HRs for each 
predictor, rather than their Beta coefficients (the log HRs).  This is important, as the Beta 
coefficients are developed on an additive scale and therefore summing them to provide 
an overall score is appropriate, whereas the HRs are developed on a multiplicative scale 
and thus should not be summed but multiplied.  This incorrect method of totalling 
patients’ scores may decrease the calibration and predictive ability of the model.[166]  
Since the analyses for this thesis were completed, the effect of scoring Charlson co-
morbidities using HRs rather than the Beta coefficients has been investigated (in 
addition to several other methods) using CPRD records for older adults, to predict their 
one-year mortality.[167]  To compare the performance of these different scores, each 
was compared to a logistic regression model adjusted for age and sex only.  The score 
that used the individual factors’ Beta-coefficients was found to fit the data better than 
the original Charlson score.  When compared to the classification provided by the 
simpler model (adjusted only for age and sex), the Beta coefficient model was found to 
reclassify patients into the correct risk stratum a higher percentage of the time (9.43%) 
compared to the original Charlson score (6.95%).[167]   
Current advice is that use of Beta coefficients that have not been rounded to the nearest 
integer may produce models that better fit the data and have better performance.  This 
was also assessed by Mehta et al, and again the Beta coefficient model was a better fit 
to the data and correctly reclassified patients into the correct risk stratum to a greater 
extent (9.43%) than the Beta model that was rounded to the nearest integer 
(7.79%).[167]  This rounding can result in diseases that have very different associations 
with increased mortality being assigned the same score.  For example, when scored 
using HRs (as Charlson did), conditions assigned a score of two may have been 
associated with anywhere between 50% and 150% increased mortality.  Rounding of 
scores for individual conditions does make the index easier to use in a clinical setting, 
where time pressures may make scores with more complex sums inappropriate.  
However, in a research setting the inclusion of this extra detail should not be 
problematic.   
The exclusion of predictive factors below a certain threshold (in the case of Charlson, 
diseases with HRs<1.2 were not included) is also now considered poor practice.  In 
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addition to excluding diseases that have a comparatively small but positive association 
with the outcome, this threshold also removes all diseases that decrease the risk of the 
outcome (as these have a HR of less than 1.0).  In order to fully understand a patient’s 
risk, all factors that may positively or negatively influence their score should be included.   
Additional limitations 
An important consideration when using the Charlson score in epidemiological studies is 
the loss of information on the effects of individual diseases on the outcome of interest.  
In order to calculate the score, the presence of each co-morbidity must be established 
and therefore it would require little or no extra work to include these individual 
coefficients in the final adjusted model.  This would enable researchers and clinicians 
alike to assess the importance of each disease on a variety of outcomes, and discover in 
which scenarios certain co-morbidities were protective and others of no importance.  
While use of a co-morbidity score is simpler in that it only necessitates the inclusion of 
one categorical variable in a model rather than several additional variables, it also results 
in a potential wealth of information being lost. 
Treatments for the diseases that are included in the score and their survival probabilities 
will have changed over the last thirty years, and thus some of the HRs that informed the 
score (and their Beta-coefficients) may be out of date.  Therefore, the predictive 
performance of the model may have decreased over time.   
Furthermore, use of a summary index may not be appropriate when assessing trends 
over time.  As the co-morbidities included in the index may have opposing effects on the 
risk of the outcome, trends in the prevalence of individual conditions may affect the 
outcome rate in ways that are not identified when using a summary measure.   
Attempts have been made at updating the Charlson index, but as yet they have not been 
as popular or widely used as the original index.[168, 169]  Despite its limitations, the 
Charlson index is still frequently used to adjust for patients’ underlying co-morbidity 
status.  The following analysis assessed the added benefit of using individual co-
morbidities rather than the Charlson index to investigate the increasing trend in 
hospitalisation after CAP.   
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6.5.2 Methods 
Information on the 19 variables included in the Charlson index had already been 
gathered for use in the analyses presented in Paper 2.  The presence of co-morbidities 
was assessed as outlined in the paper and in section 6.4.1.  I also calculated Charlson 
scores for individuals at each CAP episode using the scores in Table 1-1 and then 
categorised as none (0), mild (1-2), moderate (3-4), severe (≥5).[68]  
The OR for hospitalisation in the 28 days after CAP by time period was then re-calculated 
using three-level unadjusted and minimally adjusted models (including age and sex), 
with the addition of the categorised Charlson score.   
6.5.3 Results 
Over 40% of patients were assigned a Charlson score of 1-2, and 27% a score of 3-4.  The 
unadjusted odds of hospitalisation after CAP increased steeply with increasing Charlson 
score, although this was somewhat attenuated when additionally adjusted for age, sex 
and year (Table 6-3).   
Table 6-3 Number of CAP episodes that resulted in hospitalisation within 28 days by 
Charlson score, and unadjusted and minimally adjusted ORs. 
Charlson 
score 
 
Hospitalised 
within 28 
days 
Not  
hospitalised 
Total 
Unadjusted OR 
(95% CI) 
Minimally 
adjusted OR 
(age, sex, year) 
0 (n (%)) 3980 (67.6) 1906 (32.4) 5886 1 1 
1-2 (n (%)) 13105 (73.1) 4830 (26.9) 17935 1.57 (1.42 - 1.73) 1.37 (1.25 - 1.5) 
3-4 (n (%)) 9380 (79.4) 2432 (20.6) 11812 2.61 (2.33 - 2.92) 1.9 (1.71 - 2.11) 
≥5 (n (%)) 6856 (86.3) 1087 (13.7) 7943 4.98 (4.32 - 5.73) 2.8 (2.46 - 3.18) 
 
Interestingly, adjusting the average predicted probability of hospitalisation after CAP 
over time using the Charlson score resulted in very similar results to those which were 
adjusted using individual co-morbidities (presented in Paper 2).  In the two earlier time 
periods use of the Charlson model resulted in probabilities 2% and 1% lower than the 
individual co-morbidity model, but from 2004 onwards both models provided the same 
estimates (Table 7.5). 
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Table 6-4 Average predicted probability (%) of hospitalisation within 28 days of CAP 
diagnosis, by time period, including adjustment for Charlson score 
Calendar 
period 
Average predicted probability of hospitalisation (%) 
No adjustment† Charlson score 
(categorised)* 
Individual  
co-morbidities 
included in final 
model† 
Full model† 
1998-2000 58 55 57 57 
2001-2003 70 66 67 68 
2004-2006 80 76 76 78 
2007-2008 84 80 80 81 
2009-2010 89 85 85 86 
†Originally presented in Table 3 of Paper 2, presented here for ease of comparison 
*Charlson score categorised as 0, 1-2, 3-4 and ≥5 
 
6.5.4 Discussion 
There was very little difference between the average predicted probability of 
hospitalisation after CAP when adjusted for co-morbidities using the Charlson score or 
when adjusted for individual conditions.  Multivariable analyses indicated that 
increasing prevalence of co-morbidities accounted for only 3-4% of the increase in 
hospitalisation post-CAP over the study period, irrespective of whether the co-
morbidities were included individually or as the Charlson score.  It may be that any 
difference between the two methods of adjustment was not noticeable when co-
morbidities appeared to account for such a small percentage of increasing levels of 
hospitalisation over time.    
Nevertheless, this analysis demonstrates that investigation of the effect of individual co-
morbidities (rather than use of a summary score) provided valuable information.  As 
outlined in Paper 2, the use of individual co-morbidities instead of a summary score in 
the models developed in this study showed that the diseases included in the Charlson 
score have contrasting directions of effect on the odds of hospitalisation.  For example, 
dementia and chronic lung disease both have a Charlson score of one, but dementia was 
found to decrease the odds of hospitalisation post-CAP while the presence of chronic 
lung disease increased the odds.  While both models provided similar population 
averaged results, the use of individual co-morbidities in this work has provided greater 
insight into the characteristics of patients who were hospitalised post-CAP than would 
have been possible if this work had been limited to using the Charlson score. 
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My intention in this analysis was to highlight the added value of investigating the effect 
of individual co-morbidities on the risk of hospitalisation after CAP, as opposed to using 
a summary co-morbidity index.  Had I been aiming for a more in-depth investigation of 
the utility of the Charlson index compared to the utility of models that included 
individual co-morbidities, additional analyses could have been attempted.  For example, 
I could update the index, following the suggestions of Quan et al and reassigning weights 
to each co-morbidity based on more recent mortality data,[169] or using the version by 
Mehta et al that corrects the erroneous use of HRs by deriving the score using the Beta 
coefficients.[167]  Addressing these limitations of the existing Charlson index could 
enable better assessment of the relative benefits of using a combined co-morbidity 
measure and individual co-morbidities. However, this would not deal with the 
differences in the direction of risk for hospitalisation and death for some of the co-
morbidities of interest.  Development of a new co-morbidity index for the risk of 
hospitalisation after infection, although outside the scope of the present work, could 
enable further examination of the combined effects of co-morbidities on hospitalisation.  
6.6 Implications of the work presented in this Chapter 
In this Chapter I have shown that hospitalisations after CAP among older adults have 
risen independently of any increase in CAP incidence, and that changes in CAP patients’ 
underlying health status does not appear to explain this trend.  Nevertheless, the risk 
factors I identified will help GPs identify patients at risk of unplanned hospital admission, 
should they become ill with CAP.  I have also highlighted the poor level of recording of 
frailty factors in primary care, which is particularly timely given the 2014 general practice 
contract requirement to identify older vulnerable members of the practice 
population.[158]  Further work is needed to better understand the real impact of 
changes in service provision and utilisation on hospitalisation trends over time. 
Increasing hospitalisations and decreasing mortality post-CAP over time have also 
resulted in a growing population of older adults with complex underlying health status 
who survive pneumonia hospitalisations.  These patients then return to the community, 
where they are cared for by their GP.  It seems that an increasing number of these 
patients present straight to hospital when ill, resulting in their GP being unaware of their 
illness until after the event.  As discussed in section 1.3.2.4, older adults hospitalised for 
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pneumonia have a higher mortality risk for at least a year post-discharge compared with 
patients hospitalised for other reasons.  In the next Chapter I present the final analyses 
of this thesis, which aimed to assist GP decision making by identifying patients at higher 
risk of dying in the post-discharge period.  
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Chapter 7 Development of prognostic models for long-term mortality 
risk for patients after CAP hospital discharge, in order to assist GP 
decision making 
In Chapter 6 I showed that hospitalisations within 28 days of a CAP diagnosis among 
older adults increased between 1998 and 2011, but over the same period mortality 
(either directly or indirectly due to CAP) in the 28 days after a CAP diagnosis declined.  
Thus there is a growing population of older patients who survive hospitalisation after 
CAP and are released back into their GPs’ care.  In this Chapter I examine predictors of 
subsequent mortality for these individuals, in order to try to aid GP decision making 
about plans for future care and support.  
I first provide a brief rationale for this study, and review the literature on risk factors 
associated with increased mortality after adults with CAP are discharged from hospital. 
This is followed by an outline of the methodology behind prognostic modelling, a 
statistical technique that enables the development of risk scores to aid and inform 
clinical decision making.  I then apply these methods to the patients in the linked CPRD-
HES cohort who were hospitalised for CAP and survived the hospitalisation.  The 
mortality rate and cause of death of these hospitalised CAP patients in the year after 
their discharge is examined, and I create a series of prognostic models to try to help GPs 
identify patients with a high predicted mortality risk over this period.  Finally, I discuss 
the limitations of my approach and alternative strategies which could be used to tackle 
this aim. 
7.1 Rationale – the need for prognostic models to predict mortality post-CAP in 
older adults 
7.1.1 Increasing GP interaction with older adults and those at high risk of hospital 
admission 
As outlined in section 1.3.2.4, patients hospitalised for CAP have a higher mortality risk 
for at least a year post-discharge compared with both the general population and with 
patients hospitalised for other conditions.[88, 92]  The combination of several trends 
has resulted in an increasing number of older adults belonging to this higher-risk group 
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of individuals who survive a CAP hospitalisation: an expanding older population, the 
rising incidence of CAP, the rising number of hospitalisations for CAP and decreasing in-
hospital mortality following CAP.   
These patients are returned to the care of their GP, who may learn about the CAP 
episode for the first time via a hospital discharge summary and who then need to decide 
what future care the patient requires.  This has recently become a particular focus for a 
specific group of patients, as changes to the GP contract (2014/15) in England have 
resulted in ‘at-risk’ patients being placed on the Enhanced Service (ES) register.  Patients 
placed on this list (a minimum of 2% of the practice list) have been identified as at risk 
of an unplanned admission to hospital, and their general practice is required to contact 
them within three days of discharge should admission occur.[170]  Given the increased 
mortality risk after a CAP hospitalisation, a prognostic model to assess a patient’s risk of 
death in the year after CAP hospital discharge would be useful for GPs at the time of this 
post-discharge contact, in order to inform decisions on the kind of support to be offered 
to the patient by the practice.  While not all patients on the ES register will be older 
adults, patients are chosen using a risk stratification tool or clinical judgement, making 
it highly likely that many will be aged ≥65 years.  Additional changes have resulted in all 
patients aged ≥75 years being assigned a named GP who is responsible for general 
oversight of their care.[171]  A simple to use prognostic model for mortality that requires 
minimal clinical input could also prove useful in health care planning for this group after 
a CAP hospitalisation.   
7.1.2 Limitations of currently available models 
Prognostic models are available to predict mortality risk post-CAP over short risk 
periods, however commonly used tools such as CURB-65 and the PSI were designed to 
be used at the point of CAP diagnosis, which may make them less suitable for use post-
discharge.[81, 80]  Patients who die during a CAP hospitalisation are likely to have 
different health profiles to those who survive, and therefore these populations need to 
be considered separately.  For example those with cardiovascular disease may have high 
in-hospital mortality (where it would thus be an important predictor of mortality), and 
so these patients would be less well represented in the post-discharge population 
(where it may be a less important predictor).  Fitting prognostic models to CAP survivors’ 
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characteristics would result in more accurate future risk predictions than those obtained 
from a model used at the point of hospital admission.  Additionally, models such as 
CURB-65 and PSI include clinical signs and symptoms present at the point of diagnosis 
such as respiratory rate, which are unlikely to be available in a primary care setting when 
the GP takes over a patient’s care post-discharge.   
As described in section 1.3.2.3, only three scores have been specifically developed for 
use in older patients in an outpatient or primary care setting.[85-87]  Unfortunately 
these three models were not limited to patients with pneumonia but also included 
patients with other LRTI, and all used a combined end point of hospitalisation or death.  
This combined outcome is problematical, as some of the risk factors for hospitalisation 
are likely to differ from those for death, or the direction of effect may not be the same.  
None of the previous primary care models were optimised for patients who survive a 
CAP hospitalisation, or to predict mortality over a period longer than 30 days after 
diagnosis.   
A wealth of information regarding patients’ medical histories, such as their co-morbidity 
profile, vaccination status and lifestyle factors is available to GPs.  A model including 
readily accessible factors such as these would therefore be appropriate in the CAP post-
discharge setting.   
7.1.3 Aim 
The objective of this study was to develop easy to use prognostic models to predict the 
risk of death in the year after a patient’s discharge from a CAP hospitalisation.  The 
results generated by the score could be used in addition to the GP’s own knowledge of 
the patient to aid in planning the patient’s future care.  An important feature of a good 
prognostic model is ease of use.  Some of the software used for clinical management by 
GPs already has clinical risk scores built in, such as QRISK, a score to assess 
cardiovascular risk.[172]  The prognostic models developed in this study were designed 
to similarly utilise patients pre-existing electronic health records, and so require minimal 
clinical input.   
Before discussing the methodology behind developing a prognostic model, I looked at 
the existing literature around risk factors for mortality post CAP-discharge, to see what 
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models were currently available, and to inform my choice of potential prognostic 
factors. 
7.2 Literature review of factors associated with long-term mortality after a CAP 
hospitalisation 
7.2.1 Aim 
The aim of this literature review was to identify studies of risk factors and prognostic 
models for mortality after a CAP hospitalisation in older adults.  Factors of interest were 
those which would be readily recorded in general practice records, or provided in a 
hospital discharge summary (for example co-morbidities, history of vaccinations and 
lifestyle factors).  Results from physical or laboratory examinations performed at point 
of hospital admission or during a hospitalisation (and therefore not immediately 
available to GPs) were not specifically of interest but were noted for completeness.     
7.2.2 Methods 
7.2.2.1 Search strategy 
A review of research about longer-term prognosis after an episode of community-
acquired pneumonia was published in 2013 by Restrepo et al.[93]  I updated this review 
by searching the Medline database for additional studies published since the review.  
The Medline search was performed using a combination of MeSH and free text terms 
for community-acquired pneumonia, mortality, older adults and risk factors/prognosis 
(see Appendix H).   
7.2.2.2 Inclusion criteria  
The Medline search was restricted to original research articles written in English and 
added to the database between 2011 (to overlap with the end of the Restrepo review) 
and May 2015.  Case series were excluded, as were animal studies.  In order to restrict 
included research to that broadly generalisable to my older English study population, 
only papers from high-income countries were included, and the study population had to 
include (but not necessarily be restricted to) patients aged 65 years and over.   
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As the interest of this work was in mortality after hospital discharge, studies which 
included in-hospital mortality (alone or in combination with post-discharge mortality) 
were excluded from the review, as predictors of death during admission are likely to 
differ from those post-discharge.  Additionally, studies which included patients treated 
for CAP as outpatients in addition to inpatients (and did not analyse the two groups 
separately) were excluded.  The rationale for this decision was that patients hospitalised 
for pneumonia will differ from those who are not hospitalised, either by severity of CAP 
or prevalence of severe co-morbidities including terminal illness (for which CAP may be 
an expected end of life event).  Thus patients who are not hospitalised are likely to have 
a different set of risk factors for mortality than hospitalised patients.  Similarly, studies 
set in an intensive care unit (ICU) were excluded, as ICU patients represent a more 
severe subset of CAP cases, and survivors of an ICU admission may differ from the 
general CAP hospitalisation cohort. 
Studies were also excluded if they; reassessed or compared established severity scores 
(such as PSI/CURB-65) without incorporating any new factors, focussed on CAP due to 
specific pathogens (e.g. Legionella pneumonia, as patients who have pathogens 
identified may differ from the wider older population), assessed specific treatments 
such as a type of antibiotic on patients’ mortality risk, focussed on aspiration pneumonia 
(as this was not included in my study definition of CAP), built models comparing 
mortality in CAP patients to that of those with HAP or HCAP, or used combined 
endpoints such as ICU admission/mortality.   
7.2.2.3 Article screening 
I initially screened all articles cited in the Restrepo review and those identified in the 
Medline search using their title and abstract, applying the inclusion/exclusion criteria 
outlined above.  For papers which appeared to meet the criteria, I obtained the full 
paper and again checked against the criteria above.  I also checked the reference lists of 
included articles for further possible papers of interest.  As in the previous reviews, if I 
was uncertain of a papers eligibility I discussed it with my supervisor and a decision was 
reached by consensus.   
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7.2.2.4 Data extraction 
I extracted data from the eligible papers into a standardised form in Excel.  Study 
characteristics of interest included the study population, year and duration of the study, 
method of ascertaining the outcome and mortality rate, demographics, and risk factors 
included in the final fully adjusted analyses.   
Study findings were summarised narratively. Aspects of the study that were considered 
good or poor were noted, but a formal quality assessment was not performed. 
7.2.3 Results  
The Medline search identified 276 papers, of which only two were eligible for inclusion 
in this review.  Of the 85 articles cited by Restrepo, three were found to be eligible for 
this review, providing a total of five included studies.  The key findings of these studies 
are discussed below, and summarised in Table 7-1. 
7.2.3.1 Included studies 
The post-hospitalisation mortality risk period investigated by the studies varied: two 
reported follow-up of one year,[173, 174] one ended after 18 months [175] and two 
lasted several years.[176, 92]  Four studies were analyses of risk factors for mortality, 
and one developed a new prognostic model.[175]  None of the papers were restricted 
to older adults (all included patients aged ≥18 years), but of those that summarised 
participants’ age, only one had a mean age <60 years (Waterer, mean age=58.1).[176] 
Further reporting of the factors found to be associated with longer-term mortality are 
discussed below, categorised by the length of follow-up used in the model. 
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Table 7-1 Characteristics of included studies, and the risk factors identified as 
associated with longer-term mortality among CAP patients post-discharge 
Length of follow-up 365 days >365 days 
Author  
Year (REF) 
Carriere  
2004 [173] 
Adamuz 
2014 [174] 
Guertler  
2011 [175] 
Waterer 
2004 [176] 
Bruns  
2011 [92] 
Region, Country 
Alberta, Canada Barcelona, 
Spain 
6 centres, 
Switzerland 
Memphis, 
USA 
Multiple 
centres, 
Netherlands 
Study period 1994-2000 2007-2011 2006-2008 1998-2001 2000-2003 
Study design Retrospective cohort 
Prospective 
cohort 
Prospective 
cohort 
Prospective 
cohort 
Prospective 
cohort 
Study population 
Patients (age ≥18y) 
in two 
administrative 
health databases for 
whom diagnosis of 
CAP was considered 
most responsible for 
hospital admission 
All adults 
with CAP 
admitted to 
hospital  
All CAP 
patients 
(age ≥18y) 
previously 
enrolled in 
multicentre 
trial 
(ProHOSP) 
who 
survived 
initial CAP 
hospitalisati
on. 
All CAP 
patients (age 
≥18y) 
admitted to 
Methodist 
Healthcare 
Memphis 
Hospitals for 
whom 
written 
consent 
could be 
obtained. 
Hospitalised 
patients 
(age ≥18y) 
from two, 
multicentre 
RCTs of 
antibiotic 
treatment 
strategies 
for CAP  
 Case ascertainment 
(mortality) 
Vital statistics 
declaration of death 
certificates merged 
with the Alberta 
Health Care 
Premium Registry 
databank  
Patient 
healthcare 
database of 
Catalan 
Health 
Service 
(routinely 
collects data 
on 
hospitalisatio
ns and in-
hospital or 
home 
mortality). 
Vital status 
ascertained 
in 
telephone 
interviews 
on days 30, 
180 & 540 
Relatives or 
treating 
primary 
care 
physician 
interviewed 
if patient 
could not 
be 
contacted 
Social 
security 
number-
linked death 
records, 
review of 
hospital and 
outpatient 
pharmacy 
records, 
contact with 
all known 
treating 
physicians, 
and postal 
contact at 
the last 
known home 
address. 
Ascertained 
post 
discharge 
using the 
Dutch 
Municipal 
Public 
Health 
Records 
Database 
Sample size 43642 1284 877 366 356 
Age (years) 
Median (IQR) age-
group: 
65-75y  
(45-64, 75-84) 
Age ≥65y: 
779 (60.7%) 
Median 73 
(59-82) 
Mean 58.1y 
(range,  
18–99) 
Mean 66y 
SD 16.1 
Male, n (%) NR 844 (65.7) 512 (58) 165 (45.1) 131 (6.8) 
Post CAP mortality rate 26% 7.2% 18 months: 
17.3% 
34%  
(mean 
follow-up 
1058 days) 
1 yr: 17% 
5 yrs: 43% 
7 yrs: 53% 
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Length of follow-up 365 days >365 days 
Author  
Year (REF) 
Carriere  
2004 [173] 
Adamuz 
2014 [174] 
Guertler  
2011 [175] 
Waterer 
2004 [176] 
Bruns  
2011 [92] 
FACTORS INVESTIGATED (ORs) (HRs) 
Age (years) 18-44: ref 
45-64: 2.54 
65-74: 3.05 
75-84: 3.90 
≥85: 6.18 
≥65: 1.59 <59: ref 
59-73: 1.5 
73-82: 2.0 
>82: 3.0 
 ≥65: 1.96 
Male gender 1.39 x 1.7   
Chronic respiratory 
disease/COPD* 
 1.76 1.5  1.72 (SS) 
Diabetes  2.13 x   
Chronic heart disease/ 
failure 
 1.71 0.8  1.72 (SS) 
Cardiovascular disease    1.72 1.72 (SS) 
Cancer*  2.62 2.5 x 2.07 
Renal disease*  1.33 1 x 1.72 (SS) 
Cerebrovascular disease*  1.01  2.52  
Dementia  3.86    
Liver disease    x 1.72 (SS) 
In nursing home 3.43 2.03   2.04 
Prognostic score: 
 
Co-morbidity 
count: 
1: 2.3 
2: 3.77 
>2: 4.79 
PSI 
>90: 1.35 
PSI x  PSI  
>90: 2.13 
Other factors investigated Readmitted  
<30d: 7.49 
Race Aboriginal: 
0.48 
Export from home 
region: 1.45 
Respiratory  
failure/arrest: 1.52 
Per capita hospital 
beds: 0.90 
Hypotension/ 
shock: 1.51 
Urban residence: x 
Rural hospitals: x 
Regional hospitals: x 
Steroids: 1.31 
Gastric acid 
suppressants: 
0.94 
Aspiration 
pneumonia: 
1.94 
Non-stable on 
discharge: 1.34 
Smoking: x 
Chronic liver 
disease x 
Previous CAP x 
Alcohol x 
Influenza 
vaccine x 
Pneumococcal 
vaccine x 
Statins x 
Chills: 0.6 
Temp:  
37-37.9: 0.8  
37.9-38.7:0.9  
>38.7: 0.4 
Procalcitonin 
x 
WBC x 
Albumin x 
ProADM & 
CRP x 
Altered mental 
state: 3.13 
Haemocrit 
<35%: 1.61 
Increasing 
blood glucose: 
x 
Other variables 
in PSI 
(individually): x 
 
*different categories used in different models, x = factor investigated but not selected into final model, SS= summary 
measure used for the presence of any of these variables.  RCT: randomised controlled trial, PSI: pneumonia severity 
index, WBC: white blood cell count, ProADM: ProAdrenomedullin,   
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Mortality within one year of hospital discharge 
Two studies examined risk factors for mortality within a year of CAP hospital discharge, 
using logistic regression.[173, 174]  One was a large retrospective cohort study using 
administrative data from Alberta, Canada which found a high one-year mortality of 
26.1% among patients who were discharged from hospital after an episode of CAP.[173]  
The second was a prospective cohort study which recruited all patients who were 
admitted to a hospital in Barcelona, Spain with CAP.  They reported a lower one-year 
mortality rate of 7.2%.[174]   
Both studies identified increasing age as a risk factor for mortality, although only the 
Canadian study was large enough to show this over several age groups among older 
adults (Table 7-1).  The study also showed that women had 28% lower odds of mortality 
than men after adjusting for all other factors in the model.[173]  The two papers 
reported different approaches to including co-morbidities in their models.  The Canadian 
study used a co-morbidity count, and showed increasing odds of mortality with 
increasing levels of multimorbidity (Table 8-1).[173]  In contrast the Spanish study 
investigated the effect of individual co-morbidities, and found that diagnoses of 
dementia, cancer and diabetes had the largest odds of mortality;  patients with COPD, 
chronic renal disease, chronic heart disease and cerebrovascular disease also had 
increased odds of death and were included in the final model (Table 8-1).[174]  
Surprisingly, a high PSI score (≥90) was included in the model in addition to many of the 
individual factors used to calculate this score, thus over-adjusting for these variables.  
Smoking status, alcohol use, influenza and pneumococcal vaccinations were 
investigated by the study but not included in the final model (Table 7-1).  Both studies 
found that patients in nursing homes had higher odds of death than patients who lived 
in the community (OR=3.43 and OR=2.03 respectively).   
Mortality in periods longer than a year after hospital discharge 
Three studies used prospectively collected data to examine risk factors for mortality 
over periods of more than one year post-CAP discharge, using Cox regression with one 
study developing a prognostic model (Table 7-1).  The studies were all smaller than those 
that examined the mortality up to a year post-discharge.  The Swiss study included 
patients previously hospitalised for CAP who had been enrolled in a multicentre trial and 
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had the shortest duration with follow-up of up to 18 months.[175]  The US study 
recruited CAP patients admitted to hospitals in Memphis, and followed patients for up 
to four years post-discharge.  Finally, a study in the Netherlands created a cohort of 
hospitalised CAP patients from two randomised placebo-controlled trials of antibiotic 
treatment strategies, and collected information on mortality for up to seven years.[176, 
92]  Mortality rates in these studies ranged from 17.3% at 18 months to 53% at seven 
years.[92, 175] 
All three studies included age in their final risk models for mortality.  In the Dutch study, 
those aged ≥65 years were found to have almost twice the mortality rate of those aged 
<65 years (Table 7-1).[92]  The Swiss study used smaller age groups and showed that 
mortality rates increased with rising age amongst the older population (Table 7-1).[175]  
The American study did not report the HRs for age from its final model.[176]  The effect 
of sex was only examined by the Swiss paper, which found that men had 70% higher 
mortality rates than women.[175] 
Again, the method of adjusting for co-morbidity varied by paper, with the Swiss and 
American studies investigating the effects of individual conditions,[175, 176] while the 
Dutch study combined several co-morbidities into one group.[92]  Cancer was the only 
co-morbidity investigated by all three studies and was included in the multivariable 
models of two, where it was shown to more than double the risk of death (Table 
7-1).[175, 92]  The Swiss final prognostic model also included COPD, chronic heart 
disease, and chronic renal disease, although the two latter factors both had wide 95% 
CIs which spanned the null.  A range of additional signs/symptoms and blood markers 
were also investigated, as was inclusion of the PSI, although this was not retained in the 
final prognostic score (Table 7-1).  In contrast, the American study did not include COPD, 
but did include cardiovascular disease, cerebrovascular disease, altered mental status 
and blood test values in its multivariable model (Table 7-1).  Liver and renal diseases 
were investigated but not included in the final model.[176]   
In the Dutch study, the combined co-morbidity variable (any of malignancy, COPD, 
congestive heart failure, cerebrovascular disease, liver disease, and renal disease) was 
associated with a 71% higher mortality rate over seven years (Table 7-1).[92]  However, 
in addition to malignancy being included in the co-morbidity variable, it was also 
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reported as having been included in a separate factor.  The final model also included PSI 
score>90, in addition to several constituent parts of the PSI score as individual factors 
(living in a nursing home, age and three co-morbidities).   
7.2.4 Discussion 
Only five studies were identified which examined risk factors for long-term mortality 
after discharge from a CAP hospitalisation.  None of the studies were set specifically 
among the older population, and none investigated risk factors for mortality in periods 
less than one year after hospital discharge.  Only one study developed a prognostic 
model.  The studies investigated a range of factors; increasing age, chronic respiratory 
disease, chronic heart disease, cancer, and living in a nursing home were found to be 
risk factors for increased longer-term mortality rates in at least three of the five studies, 
while male sex and cardiovascular disease were shown to increase mortality rates in two 
studies.  All of the studies included laboratory or physical examination findings (either 
individually, or via inclusion of the PSI) which might not be routinely available in a 
patient’s hospital discharge letter received by GPs.   
All five studies used robust methods to ascertain deaths.  However, the quality of the 
papers presented was highly variable with respect to the analysis.  For example, the 
double inclusion of malignancy in the multivariable model in the Dutch study made the 
findings difficult to decipher.[92]  Similarly, two studies included both the PSI in their 
final model and several of the constituent factors of PSI as individual covariates (age, 
cancer, liver disease, congestive heart failure, cerebrovascular disease and renal 
disease).[174, 92]  This will have resulted in an over-adjustment for these variables, and 
may have led to an underestimation of their individual associations with mortality in the 
final models.   
The American study did not present measures of effect for all co-variables included in 
the model and so the size and direction of their effects could not be discussed.[176]  The 
studies investigated many potential risk factors and some of the studies had small 
sample sizes, but only the Swiss prognostic model discussed the power of the sample 
size to investigate so many factors.[175]  
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The Swiss study was the only one to develop a new prognostic model to predict long-
term mortality risk, but the methods used to do so were incorrect.[175]  In prognostic 
models, the log HRs from the multivariable model should be used to calculate the scores 
for each factor, but the Swiss study used exponentiated (i.e. non-logged) HRs, rounded 
to the nearest integer values.  Also, the model was not validated either externally in a 
new dataset, or internally using boot-strapping or a split-sample approach.  As such, it 
is not possible to say whether the model would be appropriate for use in another 
population.  The methodological aspects of prognostic modelling are discussed in detail 
in section 7.3, below. 
The majority of the burden of CAP, hospitalisations for CAP and mortality directly or 
indirectly due to CAP is among those aged 65 years and older.  However, none of the 
studies identified were specifically set among this high risk group and the inclusion of 
younger patients who are likely to have differing underlying health and risk profiles will 
have made the studies’ results less valid for those aged ≥65.  There is currently a real 
need for specific models for use in the high-risk older population.   
My literature search did not identify any studies which had looked at increased risk of 
mortality for periods of less than a year after discharge from a CAP hospitalisation.  The 
cohort of patients who survive a CAP hospitalisation is likely to change over these longer 
time periods; in a similar manner to patients who die during hospitalisation differing 
from those who survive it, the risk factors and strength of effect of included factors may 
change over a period of a year post-discharge.  Thus it seems sensible to model several 
different time periods within a year, in order to capture these changes and produce 
models which better fit the underlying trends.   
Again, limitations of the review process itself need consideration.  As with other reviews 
I conducted for this thesis, a systematic approach was used for the search strategy, 
eligibility assessment and data extraction.  However, restriction of my search strategy 
to only one database (Medline) and the exclusion of papers not written in English could 
have resulted in some papers on the topic being excluded from the literature review.  I 
assessed eligibility of studies single-handedly (except when I was unsure about 
eligibility, when I consulted with my supervisor), and extracted the data from selected 
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studies myself, and this will have increased the possibility of excluding eligible studies 
and introducing errors in the data extraction.   
Despite the potential limitations of the review, it appears that there is a real paucity of 
information for GPs on their patients’ mortality risk post-discharge after an episode of 
CAP.  Currently, there are no simple models which utilise readily available data to aid 
clinical decision making post CAP-discharge.  The increasing number of patients 
hospitalised and subsequently discharged due to CAP, coupled with the new GP service 
requirements mean there is a need for such a tool to be developed.  In the next section 
I outline how these tools can be developed and assessed.   
7.3 Overview of the methods used to develop and validate a prognostic model 
Creating a prognostic model involves several stages. First the model itself must be 
developed.  Secondly its performance is assessed to check that it discriminates between 
patients with and without the outcome, and how well it works in a population different 
to the one it was developed in (model validation).  Finally its clinical impact is assessed.  
These stages are outlined below. 
7.3.1 Developing the model 
It is crucial that an appropriate dataset is used when developing the model - a key 
feature of the process is that the data used in model development should be 
representative of the population the model will be applied to.  If this is not the case, the 
model is unlikely to make accurate predictions and therefore not be clinically useful.  
Models can be built using a range of statistical techniques. As I use Cox regression in the 
analyses presented below, I will concentrate in this section on the methodology 
appropriate to Cox models. 
7.3.1.1 Candidate predictors 
The model itself must be defined from a set of candidate predictor factors.  To improve 
the generalisability of the model, these factors should be clearly defined, standardised 
and should be reproducible in the data the model will be applied to in a real world 
situation.[177]  Factors considered are typically demographic, clinical or other 
characteristics of a patient.  Factors known to be associated with or to be predictors of 
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the outcome under study should be included, as should those hypothesized to have an 
effect.[178]  While causal factors ought to be included as prognostic factors where 
possible, not all prognostic factors will cause the outcome.[177]  As with other modelling 
processes, predictors that are highly correlated with each other should either be 
combined (if both are important predictors), or only one should be included in the final 
model.[115] 
Caution has been advised when using medications as predictors in data from 
observational studies, as indications for their prescription may not be completely 
standardised across the study population.[177]  Prognostic models developed using 
clinical trial data frequently include medications as predictors, as the studies prescribe 
medications according to a strict protocol.  However for studies developing models using 
observational data, prescribing behaviour can vary between clinicians, and thus the 
inclusion of medications in the model would be modelling clinician behaviour rather 
than the true risk associated with the medication.    
In order for the study to have suitable power, it is commonly stated that the number of 
candidate predictors should not exceed one per ten outcomes in the study 
population.[179]  This calculation should include all candidate predictors assessed, not 
just those included in the final model. 
7.3.1.2 Model specification 
Commonly, development of a prognostic model uses a predictive modelling strategy 
(described in section 2.8.2.1).  Backward stepwise selection is frequently used to decide 
which variables should be included in the model.  For prognostic modelling, it is 
important that the criterion for inclusion is not too stringent, as use of a p-value<0.05 
may exclude strong but uncommon predictors.[115]       
7.3.1.3 Calculating scores and predicted risk 
A patient’s score is calculated by multiplying the regression coefficients for each factor 
in the multivariable model by the level of the factor that applies to the patient (for 
example the coefficient for cancer would be multiplied by 0 for no, 1 for yes), and 
summing these together.  When using Cox regression, it is also necessary to consider 
the risk over time in order to calculate the expected probability of the outcome (here, 
207 
 
mortality).  In order to obtain the predicted survival at time t, the total score is multiplied 
by the baseline survival at time t (as shown in Equation 7-1).[115] 
Equation 7-1 Predicted survival 
ܵ(ݐ|ܺ) = ܵ(ݐ)௘௫௣(ఉ௑) 
Where S(t|X) is the predicted survival at time t given a set of predictors X,  
S(t) is the baseline survival (the Kaplan-Meier estimate) at time t and 
βX is the linear predictor, i.e. the sum of the logHR for each factor present in a patient. 
Consequently, the predicted mortality at time t is: 
Equation 7-2 Predicted mortality at time t 
1 − ܵ(ݐ)௘௫௣(ఉ௑) 
After the model has been built and the prognostic scores and predicted risk calculated, 
the model’s performance must be assessed.    
7.3.1.4 Model performance 
The performance of the development model is assessed by looking at the discrimination 
and calibration of the model. 
Discrimination is the model’s ability to distinguish between patients who do and do not 
have the event of interest.  This is calculated using Harrell’s concordance-statistic (c-
statistic), which estimates the probability of concordance between predicted and 
observed responses.  A c-statistic of 0.5 represents no predictive discrimination, and a 
value of 1 represents perfect separation of patients with different outcomes.  The c-
statistic of prognostic models is usually found to be between 0.6-0.85.[178]   
Additionally, discrimination can be informally assessed graphically.  Patients’ scores are 
split into risk groups; if there are no clear clinical criteria on which to base these 
groupings, cut points can be chosen to give a good spread of risk.  Ideally, these groups 
should be of different sizes to enable identification of patients at very high or low risk, 
grouping together the other patients with similar prognoses.[180]  One method, 
developed by Cox, cuts the data into risk groups at the 16th, 50th and 84th centiles.  On a 
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normal scale, these points are roughly equivalent to 0 and ±1, i.e. the mean value ±1 
standard deviation, and they were specifically chosen to keep the loss of information 
(that can occur when data is split into groups) to a minimum.[180]  Kaplan-Meier curves 
are plotted of these risk groups over time; the better the separation between the curves, 
the better the discrimination of the model.[180]   
After discrimination, the model must be calibrated.  Calibration refers to the level of 
agreement between predicted and observed outcomes.  This can be assessed graphically 
by splitting the predicted mortality (calculated using Equation 8-2) into deciles, and 
plotting the mean proportion predicted and observed with the outcome for each decile 
group, with the aim that the predicted and observed risks for each decile will be similar.  
Greater spread between the observed deciles suggests a model with better 
discrimination.[181]   
7.3.2 Validation of the model 
The objective of model validation is to assess the model’s predictive performance in a 
different population to that in the development dataset.  While the model may describe 
the dataset it was developed in well, creation of the model can lead to it being too 
closely fitted to the data (called over-fitting), resulting in predictions that are not valid 
when the model is applied to a new population.  It is important that any optimism in the 
model’s performance is quantified and assessed.  Optimism is the difference between 
the model’s performance in a new population (its “true” performance), minus its 
performance in the development dataset (the “apparent” performance).   
Validation of the model can be performed in the re-sampled original data (internal 
validation), or using a new data source (external validation).  External validation is 
preferred as it truly tests the model by applying it to a completely new population, but 
is frequently not possible due to a lack of a second data source.  Other methods have 
therefore been developed to enable a model to be developed and validated in the same 
data.  The efficiency of the three common internal validation procedures (bootstrap 
validation, split-sample and cross-sample validation) have been compared using logistic 
regression models containing the same potential predictors on the same dataset to  
assess the best internal validation technique.[182]  This analysis found that bootstrap 
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validation provided more stable estimates with lower levels of bias than the other 
techniques.  Due its superiority, I used bootstrap validation in the analyses in this study. 
7.3.2.1 Bootstrap validation 
The steps involved in the bootstrap method are outlined below [115] (format adapted 
from Harrell et al [183]). 
1. Develop the prognostic model (for example, using a Cox model and backwards 
stepwise selection to identify predictors) using all subjects (n) available in the 
data.  Calculate the c-statistic for this model, Capparent 
2. Randomly generate a bootstrap sample of size n with replacement (meaning 
patients can be sampled multiple times) from the original dataset.   
3. Develop a new prognostic model, using the same technique as used in the 
brackets in step 1. 
4. Calculate the c-statistic for this new model, Cboot.  
5. Retain the model fitted in step 3, and fit it to the original dataset.  Calculate the 
c-statistic Corig 
6. Calculate the optimism of the c-statistic from the bootstrap sample, which is Cboot 
- Corig. 
7. Repeat steps 2 to 6, 200 times. 
8. Average the 200 optimism estimates calculated in step 6 to get O. 
9. Calculate the optimism-corrected c-statistic using Capparent minus O. 
This optimism-corrected c-statistic represents the model’s real ability to distinguish 
between patients who do and do not have the event of interest, (having taken into 
account the optimism of the prognostic model). 
The number of times each factor is selected into the bootstrap models can be used to 
assess the stability of the model.[183] 
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7.4 Methods used in this study to develop prognostic models for long-term 
mortality risk after CAP hospital discharge 
7.4.1 Time period of study 
The study period started at 1st April 2004, when financial incentives such as QOF resulted 
in GP recording becoming more standardised.  This resulted in more complete recording 
for important incentivised factors such as smoking status and diabetes.  While this 
decision led to a reduced study population, recording habits post-2004 are closer to 
those used currently, and so better represent the data the model will be applied to.[99]  
CAP events up to 31st March 2011 were included.   
7.4.2 Inclusion criteria and time ‘at risk’ 
Patients were included in the study if they met all of the following criteria (Figure 7-1);  
1) They contributed to CPRD and were eligible for hospital- and mortality-linked 
data at any time between 01/04/2004 and 31/03/2011.  
2) They were hospitalised for CAP (defined using HES) during this period.  
3) They did not die during the CAP hospital admission (or on the discharge date). 
4) They were aged ≥65 years at the point of CAP diagnosis.  
Patients must have survived until the day after hospital discharge in order to be included 
in the study, as it was not possible to distinguish patients who had died in hospital from 
those who died at home on the discharge date.   
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Figure 7-1 Data sources and population included in this study 
 
Only the first CAP episode that resulted in hospitalisation in a 365 day period was 
included in the study.  The patient was included as ‘at risk’ from the date of discharge 
until the earliest of 365 days post-discharge, death, the study end date (31st March 2011) 
or the date they stopped contributing to CPRD.     
Patients with no recorded smoking status prior to their CAP hospitalisation were 
excluded from the study, as there were very few such patients (<3%) and smoking status 
was considered an important potential predictor.[183]   As explained in Paper 2 (Chapter 
6) smoking status is unusual in CPRD as it is possible to code all three available states 
(non, ex, current smoker).  For all other factors considered, the absence of a code was 
assumed to be due to the absence of the factor in question. 
Patients with a terminal care code or with metastatic cancer were excluded as the death 
may not have been unexpected and these patients were not representative of the 
population the model would be applied to in future use.   
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7.4.3 Outcome definition 
The outcome of interest was death, defined using the date of death provided in the 
linked ONS data.  I additionally used the information on underlying and contributory 
causes of death from this data when investigating how causes of death changed over 
the year post-discharge. 
7.4.4 Eligibility of potential prognostic factors  
The model was designed to require very little manual input or calculation by clinical staff.  
Theoretically it could be built into the GP patient software and programmed to run 
automatically, checking through a patient’s electronic records to identify codes for the 
factors included in the model and then calculate a patient’s predicted risk of death in 
each time period.  In order to make this possible, the presence of co-morbidities and 
other factors of interest were only determined from CPRD data (the data available in the 
GP’s system), and while hospitalisations for CAP were defined using HES, the data used 
to develop the model did not utilise HES records.   
Variables included as potential prognostic factors were limited to those whose recording 
was considered generally standardised and reproducible in the data the model would 
be applied to (i.e. general practice records outside CPRD).  When there was evidence 
that factors were not well recorded (for example certain frailty measures such as 
‘immobile’), they were not considered for inclusion in the model.   
Similarly, medications were not included as potential prognostic factors as it was difficult 
to assess if they were prescribed in a uniform fashion (as outlined in section 7.3.1.1, 
above).  Additionally, it could not be known whether medications had been newly 
prescribed or altered during the hospitalisation (as this information is not provided in 
HES), which would have led to misclassification of medication status.  Pneumococcal and 
influenza vaccination status were included as both are offered uniformly to all older 
adults.   
7.4.5 Factors selected as ‘candidate predictors’ 
Sex and age were included in all models as a priori prognostic factors.  Age was 
categorised into five-year groups from 65 to 89 years, and then as ≥90 years.   
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7.4.6 Co-morbidities  
Co-morbidities were coded as present if there was a Read code for the condition in a 
patient’s CPRD record before the date of their hospital admission for CAP.  Factors 
investigated were based on those identified in the literature review in section 7.2 as well 
as those in the Charlson co-morbidity index and included; chronic heart failure, 
peripheral vascular disease, dementia, chronic lung disease, connective tissue disease, 
peptic ulcer, hemiplegia, leukaemia/lymphoma, other neurological disease, other 
immunological disease, cerebrovascular disease, solid cancer and previous/history of 
pneumonia.  These were binary variables, indicating presence of disease or no code for 
the disease.  Several other variables contained an additional level of disease severity.  
These were diabetes (without complications, with complications) liver disease 
(mild/moderate, severe), ischaemic heart disease (pre-MI, post-MI), and renal disease 
(mild/moderate, severe). 
Frailty and lifestyle factors included were: smoking status (non-smoker, ex-smoker, 
current smoker), living arrangements (lives alone, in sheltered housing, in residential 
care) underweight/poor nutrition, history of falls within the last year, recent use of a 
carer, and excessive alcohol consumption. 
Receipt of influenza and pneumococcal vaccinations were recorded from the most 
recent record of vaccination as: no record/not vaccinated, vaccinated in the current 
year, vaccinated in the previous year, vaccinated 2-5 years previously, vaccinated >5 
years previously. 
7.4.7 Cause of death 
Patients’ cause of death was investigated using the causes recorded in the ONS-linked 
data.  The number of deaths with pneumonia recorded as a) the underlying, or b) a 
contributory cause of death were calculated.  Other underlying causes of death were 
categorised in the same way as co-morbidities used in the analysis (for example, MI, 
solid cancer), and underlying causes which contributed ≥2.5% of deaths in each time 
period were plotted graphically.   
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7.4.8 Statistical analyses 
7.4.8.1 Models developed 
The primary aim of this study was to predict longer-term post-discharge mortality risk 
and to identify patients who may benefit from additional attention after a CAP 
hospitalisation.  However, the predictors of mortality are likely to vary in the immediate 
period post-discharge.  After discussion with the clinical members of my advisory panel 
I decided to build three models, for risk periods 1-7 days, 8-30 days and 31-365 days 
after hospital discharge.   
The one to seven day model covers the immediate period post-discharge, and will 
capture many of the subset of patients who have been discharged from hospital to 
enable them to die at home.   
The eight to thirty day model was decided upon to transition between the immediate 
post-discharge risk-period, and the longer period of follow-up.  GPs are likely to receive 
a patient’s discharge summary shortly after the date of discharge, and should then 
contact ES patients within three days.  This model would enable GPs to identify patients 
who may require attention relatively soon.  
The final model (the model of primary interest) was the 31-365 day model.  This 
identifies patients’ longer-term mortality risk, after the initial post-CAP period is over.  
The timing was limited to a year, as older adults’ health status may change considerably 
over any period longer than that, which would be likely to lead to inaccurate predictions.   
7.4.8.2 Model development 
All models were built using Cox regression with robust standard errors to account for 
clustering of CAP hospital discharges within patients.  The Cox model was deemed most 
appropriate as the risk of death was likely to vary over time within the three risk periods, 
and there was a degree of censoring in the data making a logistic model inappropriate.   
The total numbers of CAP episodes which resulted in hospital discharge included in each 
model and the number of events with the outcome (death) were calculated for each 
factor of interest.  Univariable and minimally adjusted (age and sex) Cox regression 
analyses were performed for each factor to enable assessment of the influence of other 
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factors when examining the full model (as recommended when reporting results of 
prognostic model research).[184]  Variables with more than two levels were included as 
a group of indicator variables, rather than a single factor variable in order for the 
bootstrapping command including robust standard errors to be able to run.  This did not 
affect the model, but did result in the logHR for each indicator variable being multiplied 
by one when the patients score was calculated (rather than increasing to 2, 3, 4 as the 
categories increased, as illustrated using smoking status in Table 7-2). 
Table 7-2 Different coding used for factor and indicator variables, using smoking status 
as an example 
 Factor 
variable 
Indicator variables values 
Smoking status Values Smoking_0 Smoking_1 Smoking_2 
Never 0 1 0 0 
Ex 1 0 1 0 
Current 2 0 0 1 
 
The complete set of variables was included in a backwards stepwise elimination process, 
with the cut-off for inclusion being a p-value<0.2 (defined using the Wald-test).[113]  
The p-value of 0.2 was chosen in an attempt to avoid over-fitting of the model to the 
data.[115]  Age and sex were forced into the model, and then each condition was 
considered in turn.  The condition with the highest p-value was removed from the model 
if p≥0.2.  The process was then repeated until all conditions had a p-value<0.2, resulting 
in the final model.   The c-statistic for the final model was calculated. 
7.4.8.3 Calculation of risk scores and predicted risks 
Risk scores and predicted risk of mortality for each subject were then calculated.  The 
predicted risk was spilt into deciles and plotted against the mean observed percentage 
that died in each group.   
The older patients included in the study population were very diverse in their underlying 
health status.  Rather than create pre-defined risk groups (such as low, medium, high 
etc.) which may not be clinically useful, I decided that GPs should be able to compare 
the mortality risk of their patient to the general (overall) mortality risk of a patient of 
the same sex and age group in the general population.   
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However, purely as a technical device to allow the separation of patients with different 
scores to be considered, the score was split into four groups (at the 16th, 50th and 84th 
centiles) as per the Cox method described in section 7.3.1.4.  Kaplan-Meier estimates 
for each model stratified by these risk groups were produced.   
As a comparison group, mortality rates for CPRD-ONS linked patients aged ≥65 years, 
who were active in CPRD between 1st April 2004 and 31st March 2011 were calculated 
by age group.  These rates were converted to a risk for each of the three time periods 
using Equation 7-3.[113]  Risk ratios of predicted risks of mortality to those of the linked 
CPRD population were calculated. 
Equation 7-3 Conversion of a rate to a risk 
ࡾ࢏࢙࢑ (࢛࢖ ࢚࢕ ࢚࢏࢓ࢋ ࢚) = ૚ − ࢋିࣅ࢚ 
Where λt= hazard (rate) at time t. 
7.4.8.4 Model validation 
Internal validation was assessed using bootstrap re-sampling with 200 repetitions.   As 
described in section 7.3.2.1, Cox regression models were developed in the same way as 
in the original data, c-statistics calculated and the model then applied to the original 
data, where the c-statistic was calculated again.  This process was repeated 200 times.  
The means of these two sets of c-statistics were calculated, and the difference between 
them provided the optimism of the model.[115] 
7.4.9 Presentation of risk scores to a clinical audience 
When used in a clinical setting, it is important that predicted risks are presented in a way 
that is easy to interpret as a population level statistic.  Ideally this would be done using 
text and/or a graphic explaining (for example) “Out of 1000 patients with this 
combination of health factors, on average we would expect 470 to die within the next 
year.  This level of risk is 4 times higher than the general population of the same age 
group and sex”.  This provides the clinician with the patient’s level of risk, as well as 
appropriate contextualisation.  I therefore developed tables to demonstrate this 
approach.   
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7.5 Results  
7.5.1 Study population and baseline characteristics 
There were 13,589 CAP hospital discharges recorded in 12,983 patients included in the 
study cohort; the derivation of the original discharge cohort, and the numbers included 
in each model are presented in Figure 7-2.  Characteristics of the population in each time 
period are shown in Table 7-3.  The median age of patients at CAP diagnosis was 80 
years, and 51% of episodes were in women.  The majority of episodes were among 
patients who had at least one existing co-morbidity of interest also recorded (the 
median number of co-morbidities in each model period was two (lower to upper 
quartiles, 1 to 3)).  The most common co-morbidity was chronic lung disease (41%) while 
in 30% of episodes the patients had a history of ischaemic heart disease and 20% had 
cerebrovascular disease.  In the first week after discharge, 313 (2.3%) patients in the 
initial cohort died.  Over 8-30 days 13,051 episodes were included of which 520 (4.0%) 
ended in death.  In the longer 31-365 day model, 12,204 episodes were included of 
which 2,415 (19.8%) resulted in the patient’s death.   
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15282 hospitalisations for CAP where the patient survived until at least the day after 
discharge 
EXCLUDED:  Hospitalisation within a year of a 
previous CAP discharge n=810 
EXCLUDED:   Terminally ill n=451 
Metastatic cancer n=78 
EXCLUDED:  Smoking status not recorded n=354 
1-7 days: 
13589 discharges 
(12983 patients) 
N=14472 
N=13943 
8-30 days: 
13051 discharges 
(12467 patients) 
31-365 days: 
12204 discharges 
(11667 patients) 
Follow-up: 
Median 334 days  
(IQR: 172-334) 
Died: 313, Censored: 225 
Died: 520, Censored: 327 
Died: 2415, Censored: 2419 
Figure 7-2 Flow chart for inclusion in the study 
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Table 7-3 Number of CAP hospital discharges and deaths per time period, and by 
potential prognostic factors 
Potential 
prognostic factor 
Value 
 
Model: 
1-7 days 8-30 days 31-365 days 
CAPs Died CAPs Died CAPs Died 
All CAP discharges 13589 313 13051 520 12204 2415 
Sex 
Male 6660 143 6411 258 6004 1274 
Female 6929 170 6640 262 6200 1141 
Age group  
(years) 
65-69 1765 24 1722 33 1658 195 
70-74 2169 24 2128 55 2038 308 
75-79 2595 38 2519 86 2392 401 
80-84 2926 68 2808 116 2612 555 
85-89 2481 77 2355 116 2164 546 
90+ 1653 82 1519 114 1340 410 
Number of co-
morbidities 
0 1685 31 1631 42 1554 181 
1 3468 64 3341 106 3143 560 
2 3436 98 3287 135 3066 613 
3 2585 58 2483 133 2295 499 
≥4 2415 62 2309 104 2146 562 
Congestive heart failure 2264 60 2159 80 2030 571 
Peripheral vascular disease 1423 43 1362 64 1268 301 
Dementia 1051 51 963 90 824 270 
Chronic lung disease 5658 115 5470 200 5150 1066 
Connective tissue disease 1341 23 1298 42 1228 265 
Peptic ulcer 1128 28 1084 50 1013 199 
Hemiplegia 117 1 115 8 105 30 
Solid Cancer 2059 63 1964 100 1816 433 
Leukaemia/Lymphoma 334 8 321 18 296 89 
Cerebrovascular disease 2835 94 2686 152 2472 597 
Other neurological disease 896 28 841 59 769 189 
Other immunological disease 52 0 52 1 51 13 
Diabetes 
Diabetes 1962 41 1893 66 1783 365 
+ complications 778 6 760 19 718 138 
Liver Disease 
Mild/moderate 61 1 59 2 56 10 
Severe 20 2 18 1 17 3 
Ischaemic heart 
disease  
pre-MI 2395 47 2313 108 2154 444 
post-MI 1760 39 1696 64 1591 349 
Renal Disease 
Mild/moderate 255 4 248 10 231 42 
Severe 2827 63 2694 120 2474 548 
Smoking status 
Non 2018 72 1915 114 1741 388 
Current 2637 47 2548 104 2380 478 
Ex 8934 194 8588 302 8083 1549 
Previous pneumonia 2060 41 1989 87 1864 447 
Excessive alcohol consumption 739 11 714 22 677 145 
Weight loss 960 51 893 93 776 287 
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Table 7-3 Number of CAP hospital discharges and deaths per time period, and by 
potential prognostic factors (continued) 
Potential 
prognostic factor 
Value 
 
Model: 
1-7 days 8-30 days 31-365 days 
CAPs Died CAPs Died CAPs Died 
Fall in previous year 1412 43 1324 72 1193 289 
Carer in previous year 478 12 456 17 420 92 
Living 
arrangements 
No records 11368 225 10969 356 10353 1872 
Lives alone 550 12 530 25 487 109 
Sheltered 
accommodation 160 6 151 6 139 35 
Residential Care 1511 70 1401 133 1225 399 
Influenza 
vaccination 
No records 1267 32 1218 46 1141 207 
14-365 days pre CAP 8991 189 8658 320 8125 1587 
Last season 2478 59 2371 121 2198 476 
2-5 years pre CAP 623 27 582 28 532 106 
>5 years pre CAP 230 6 222 5 208 39 
Pneumococcal 
vaccination 
 No records 3041 90 2898 126 2711 538 
14-365 days pre CAP 751 11 729 29 683 138 
1-2 years pre CAP 988 19 958 42 904 185 
2-5 years pre CAP 3525 75 3407 115 3242 642 
>5 years pre CAP 5284 118 5059 208 4664 912 
 
 
Kaplan-Meier survival curves for the complete year after discharge and for each model 
period are shown in Figure 7-3.  The mortality rate was highest in the week after 
discharge, then slowed and was approximately linear by day 150 post discharge (day 121 
in the third (31-365 day) model). 
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Figure 7-3 Kaplan Meier survival plots for the full year after discharge and each model period 
NOTE: differing scales on y-axis
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7.5.2 Cause of death  
Pneumonia was named as the underlying cause for 20% of deaths in the 1-7 day post-
discharge period, 13% in 8-30 days and 9% in 31-365 days (Figure 7-4).  The percentage 
of death certificates with pneumonia named as a contributory cause of death also 
decreased over the three time periods, and was named on 58%, 41% and 34% 
respectively (data not shown).  The percentage of deaths attributed to dementia 
decreased with increasing period after discharge, while those for cardiovascular 
conditions (in particular cerebrovascular disease and ischaemic heart disease (pre-MI)) 
made up an increasing percentage of deaths as time since discharge increased (Figure 
7-4).  The contribution of chronic lung disease did not differ substantially over the three 
time periods, and nor did that of solid cancers. 
7.5.3 Crude associations between potential predictors and mortality 
Unadjusted and minimally adjusted hazard ratios for each predictor in each time period 
are presented in Table 7-4.  In univariable analyses, age groups ≥80 years, a diagnosis of 
dementia, solid cancer, cerebrovascular disease, being underweight/requiring 
nutritional supplementation in the last year, having fallen in the last year and living in 
residential care were all associated with an increased mortality rate across all three time 
periods under study.  There were a larger number of factors associated with mortality 
in the 31-365 day period than either the 1-7 or 8-30 day periods.  These included 
relatively common conditions among older adults such as chronic lung disease and 
congestive heart failure. 
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Figure 7-4 Distribution of underlying causes of death by time period post-CAP hospital discharge 
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Table 7-4 Univariable & minimally adjusted mortality hazard ratios (HR) over each time period, for potential prognostic factors of interest (cont…) 
Potential 
prognostic factor Value 
1-7 days 8-30 days 31-365 days 
Unadjusted HR Minimally adjusted HR Unadjusted HR 
Minimally 
adjusted HR Unadjusted HR 
Minimally 
adjusted HR 
Sex Female 1.15 (0.92 - 1.43) 1.00 (0.80 - 1.24) 0.98 (0.83 - 1.17) 0.88 (0.74 - 1.05) 0.86 (0.79 - 0.93) 0.78 (0.72 - 0.84) 
Age 
70-74 0.81 (0.46 - 1.43) 0.81 (0.46 - 1.43) 1.35 (0.88 - 2.08) 1.36 (0.88 - 2.09) 1.30 (1.09 - 1.55) 1.30 (1.09 - 1.56) 
75-79 1.08 (0.65 - 1.79) 1.08 (0.65 - 1.79) 1.80 (1.20 - 2.68) 1.80 (1.21 - 2.69) 1.46 (1.23 - 1.73) 1.47 (1.24 - 1.74) 
80-84 1.72 (1.08 - 2.74) 1.72 (1.08 - 2.74) 2.20 (1.49 - 3.24) 2.21 (1.50 - 3.26) 1.94 (1.65 - 2.28) 1.98 (1.68 - 2.33) 
85-89 2.30 (1.46 - 3.64) 2.31 (1.46 - 3.64) 2.63 (1.79 - 3.88) 2.67 (1.81 - 3.94) 2.44 (2.08 - 2.88) 2.52 (2.14 - 2.97) 
90+ 3.73 (2.37 - 5.87) 3.73 (2.37 - 5.87) 4.11 (2.79 - 6.05) 4.22 (2.86 - 6.25) 3.15 (2.66 - 3.73) 3.33 (2.81 - 3.95) 
Congestive heart failure 1.19 (0.90 - 1.58) 1.03 (0.77 - 1.37) 0.92 (0.72 - 1.16) 0.80 (0.63 - 1.02) 1.65 (1.50 - 1.81) 1.45 (1.32 - 1.60) 
Peripheral vascular disease 1.37 (0.99 - 1.88) 1.41 (1.02 - 1.96) 1.21 (0.93 - 1.57) 1.19 (0.92 - 1.55) 1.26 (1.12 - 1.42) 1.22 (1.08 - 1.38) 
Dementia 2.36 (1.75 - 3.18) 1.88 (1.38 - 2.55) 2.75 (2.19 - 3.44) 2.30 (1.81 - 2.91) 1.98 (1.74 - 2.25) 1.65 (1.45 - 1.88) 
Chronic lung disease 0.81 (0.64 - 1.02) 0.96 (0.77 - 1.21) 0.86 (0.72 - 1.03) 0.97 (0.81 - 1.16) 1.09 (1.01 - 1.18) 1.21 (1.12 - 1.32) 
Connective tissue disease 0.72 (0.47 - 1.10) 0.72 (0.47 - 1.10) 0.79 (0.58 - 1.08) 0.80 (0.58 - 1.10) 1.12 (0.99 - 1.27) 1.16 (1.02 - 1.31) 
Peptic ulcer 1.08 (0.74 - 1.60) 1.12 (0.76 - 1.64) 1.18 (0.88 - 1.58) 1.17 (0.87 - 1.57) 1.00 (0.86 - 1.15) 0.97 (0.84 - 1.13) 
Solid Cancer 1.41 (1.07 - 1.86) 1.38 (1.04 - 1.83) 1.35 (1.09 - 1.68) 1.30 (1.04 - 1.62) 1.31 (1.18 - 1.45) 1.23 (1.10 - 1.36) 
Leukaemia/Lymphoma 1.04 (0.52 - 2.10) 1.16 (0.57 - 2.34) 1.43 (0.89 - 2.28) 1.54 (0.96 - 2.47) 1.62 (1.32 – 2.00) 1.72 (1.40 - 2.12) 
Cerebrovascular disease 1.64 (1.29 - 2.08) 1.48 (1.15 - 1.89) 1.61 (1.33 - 1.94) 1.45 (1.20 - 1.75) 1.35 (1.23 - 1.48) 1.21 (1.11 - 1.33) 
Other neurological disease 1.40 (0.95 - 2.07) 1.45 (0.99 - 2.14) 1.88 (1.43 - 2.46) 1.89 (1.44 - 2.48) 1.32 (1.14 - 1.53) 1.31 (1.13 - 1.52) 
Other immunological disease 0 (0 - 0) 0 (0 - 0) 0.47 (0.07 - 3.43) 0.59 (0.08 - 4.25) 1.41 (0.84 - 2.36) 1.71 (1.03 - 2.83) 
Diabetes 
Diabetes 0.85 (0.61 - 1.18) 0.92 (0.66 - 1.27) 0.83 (0.64 - 1.08) 0.87 (0.67 - 1.13) 1.05 (0.94 - 1.17) 1.08 (0.97 - 1.21) 
+complications 0.31 (0.14 - 0.70) 0.35 (0.16 - 0.80) 0.59 (0.38 - 0.94) 0.64 (0.40 - 1.01) 0.99 (0.84 - 1.18) 1.04 (0.88 - 1.23) 
Liver Disease 
Mild/moderate 0.71 (0.10 - 4.99) 0.90 (0.13 - 6.39) 0.84 (0.21 - 3.33) 1.00 (0.25 - 3.99) 0.94 (0.51 - 1.73) 1.12 (0.60 - 2.06) 
Severe 4.44 (1.12 - 17.51) 5.34 (1.28 - 22.23) 1.39 (0.19 - 10.02) 1.61 (0.22 - 11.93) 0.93 (0.30 - 2.82) 0.98 (0.31 - 3.12) 
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Potential 
prognostic factor Value 
1-7 days 8-30 days 31-365 days 
Unadjusted HR Minimally adjusted HR Unadjusted HR 
Minimally 
adjusted HR Unadjusted HR 
Minimally 
adjusted HR 
Ischaemic heart 
disease  
Pre-MI 0.81 (0.59 - 1.11) 0.79 (0.58 - 1.08) 1.22 (0.98 - 1.51) 1.17 (0.94 - 1.45) 1.07 (0.97 - 1.19) 1.02 (0.92 - 1.14) 
Post-MI 0.92 (0.65 - 1.29) 0.91 (0.65 - 1.29) 0.98 (0.75 - 1.27) 0.93 (0.71 - 1.22) 1.17 (1.04 - 1.31) 1.09 (0.97 - 1.22) 
Renal Disease 
Mild/moderate 0.67 (0.25 - 1.79) 0.72 (0.27 - 1.92) 1.04 (0.56 - 1.95) 1.10 (0.59 - 2.05) 0.98 (0.73 - 1.34) 1.02 (0.76 - 1.39) 
Severe 0.95 (0.72 - 1.26) 0.83 (0.62 - 1.09) 1.17 (0.95 - 1.44) 1.04 (0.85 - 1.28) 1.24 (1.12 - 1.36) 1.10 (1.00 - 1.22) 
Hemiplegia 0.36 (0.05 - 2.60) 0.39 (0.05 - 2.74) 1.79 (0.89 - 3.61) 1.87 (0.93 - 3.78) 1.46 (1.02 - 2.09) 1.44 (0.99 - 2.09) 
Weight loss 2.59 (1.93 - 3.49) 2.40 (1.78 - 3.23) 3.07 (2.45 - 3.83) 2.91 (2.33 - 3.65) 2.29 (2.03 - 2.59) 2.22 (1.97 - 2.50) 
Fall in last year 1.39 (1.01 - 1.91) 1.09 (0.78 - 1.50) 1.46 (1.14 - 1.87) 1.20 (0.93 - 1.55) 1.35 (1.19 - 1.53) 1.14 (1.01 - 1.30) 
Carer in last year 1.10 (0.62 - 1.95) 0.78 (0.44 - 1.40) 0.94 (0.58 - 1.53) 0.72 (0.44 - 1.17) 1.14 (0.93 - 1.40) 0.89 (0.72 - 1.09) 
Previous pneumonia 0.84 (0.61 - 1.17) 0.83 (0.60 - 1.15) 1.11 (0.88 - 1.40) 1.07 (0.85 - 1.35) 1.32 (1.19 - 1.46) 1.26 (1.13 - 1.39) 
Excessive alcohol consumption 0.63 (0.35 - 1.15) 0.85 (0.46 - 1.56) 0.76 (0.49 - 1.16) 0.94 (0.61 - 1.46) 1.11 (0.94 - 1.31) 1.30 (1.10 - 1.55) 
Smoking status 
Current 0.50 (0.34 - 0.72) 0.72 (0.50 - 1.05) 0.67 (0.52 - 0.88) 0.90 (0.68 - 1.19) 0.88 (0.77 – 1.00) 1.10 (0.96 - 1.27) 
Ex 0.61 (0.46 - 0.79) 0.71 (0.54 - 0.94) 0.58 (0.47 - 0.72) 0.64 (0.51 - 0.80) 0.83 (0.74 - 0.93) 0.88 (0.79 - 0.99) 
Living 
arrangements 
Lives alone 1.11 (0.62 - 1.98) 0.76 (0.42 - 1.37) 1.48 (0.99 - 2.22) 1.16 (0.76 - 1.76) 1.28 (1.06 - 1.56) 1.01 (0.82 - 1.23) 
Sheltered 
accommodation 1.89 (0.85 - 4.22) 1.28 (0.57 - 2.90) 1.23 (0.55 - 2.73) 0.94 (0.42 - 2.10) 1.45 (1.04 - 2.04) 1.14 (0.81 - 1.59) 
Residential Care 2.37 (1.82 - 3.1) 1.78 (1.34 - 2.36) 3.03 (2.49 - 3.70) 2.52 (2.04 - 3.11) 2.04 (1.83 - 2.28) 1.72 (1.53 - 1.92) 
Influenza 
vaccination  
(timing pre-CAP) 
14-365  0.40 (0.17 - 0.97) 0.53 (0.22 - 1.28) 0.82 (0.50 - 1.33) 0.98 (0.60 - 1.61) 1.14 (0.94 - 1.38) 1.29 (1.06 - 1.57) 
Previous season 1.26 (0.52 - 3.05) 1.85 (0.76 - 4.52) 0.46 (0.15 - 1.44) 0.64 (0.20 - 2.01) 1.13 (0.81 - 1.57) 1.49 (1.06 - 2.09) 
2-5 years  0.91 (0.13 - 6.38) 1.24 (0.19 - 8.15) 1.12 (0.28 - 4.45) 1.48 (0.37 - 5.93) 0.72 (0.32 - 1.61) 0.89 (0.40 - 2.01) 
>5 years  0.83 (0.57 - 1.21) 0.80 (0.55 - 1.17) 0.98 (0.72 - 1.33) 0.92 (0.67 - 1.25) 1.08 (0.94 - 1.25) 1.00 (0.86 - 1.15) 
Pneumococcal 
vaccination   
(timing pre-CAP) 
14-365  0.94 (0.61 - 1.45) 0.88 (0.57 - 1.35) 1.36 (0.97 - 1.90) 1.24 (0.88 - 1.74) 1.27 (1.08 - 1.49) 1.15 (0.98 - 1.35) 
1-2 years  1.74 (1.04 - 2.89) 1.61 (0.96 - 2.68) 1.29 (0.80 - 2.06) 1.18 (0.74 - 1.89) 1.21 (0.95 - 1.52) 1.11 (0.87 - 1.40) 
2-5 years  1.03 (0.43 - 2.46) 0.96 (0.40 - 2.30) 0.60 (0.24 - 1.50) 0.55 (0.22 - 1.39) 1.13 (0.81 - 1.57) 1.05 (0.75 - 1.46) 
>5 years  0.49 (0.26 - 0.92) 0.53 (0.28 - 0.99) 0.91 (0.61 - 1.37) 0.95 (0.63 - 1.41) 0.98 (0.82 - 1.19) 1.01 (0.84 - 1.22) 
226 
 
7.5.4 Model selection and performance 
When all the levels of the variables identified as candidate predictors were taken into 
account, the number of potential factors was 44.  The 31-365 day model had 54 
outcomes per potential factor, and the 8-30 day model had 11 outcomes per factor, but 
the 1-7 day model had only 7 outcomes per factor (and thus was under the ’10 events 
per potential prognostic factor’ rule).  Rather than fit a different list of factors to each 
model, I decided to use the same list and have slightly lower power for the 1-7 day 
mortality model, as there were no candidate predictors which were an obvious choice 
for omission. 
Backwards stepwise regression selected 12 factors (with 17 levels) into the 1-7 day 
model, 17 factors (with 23 levels) into the 8-30 day model and 17 predictive factors (with 
21 levels) into the 31-365 day model, in addition to the a priori factors age (5 levels) and 
sex (1 level).  Seven factors were selected into all three models (the ‘consistent’ factors: 
peripheral vascular disease, dementia, connective tissue disease, cerebrovascular 
disease, solid cancer, living arrangements and low weight), while five variables were not 
included in any of the final models (hemiplegia, peptic ulcer, renal disease, other 
immune mechanism disorders, and falls in the last year) (Table 7-5).   
Each of the sets of data was consistent with the proportional hazards assumption. 
7.5.5 1-7 day model 
The model for the shortest period included diabetes, influenza vaccination and liver 
disease, in addition to age, sex and the seven consistent factors.  These 12 predictors 
had the widest range of scores of any of the models, ranging from -1.11 for diabetes 
with complications (negative coefficients represent a decreased mortality risk) to 1.81 
for severe liver disease, although most scores were within the range -0.3 to 0.4 (Table 
7-5).  The uncorrected c-statistic was 0.699, suggesting the model was reasonably good 
at discriminating between patients who lived and died over the seven day period.  
The calibration was the weakest of the three models, with mortality over-predicted by 
the model in the lowest five deciles and observed mortality higher in decile six than in 
decile seven (Figure 7-5).  The Kaplan-Meier survival curves stratified by Cox-centile 
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showed little separation between the two lowest Cox-centile groups, but better 
separation between those at the two higher levels of risk (Figure 7-6).   
The optimism of the model was 0.031, and the corrected c-statistic 0.669.  The stability 
(in terms of repeated selection of factors into the model) was lower than the two longer-
duration models, with only low weight and peripheral vascular disease being selected 
into >70% of bootstraps (Table 7-6).   
7.5.6 8-30 day model 
The 8-31 day model contained 17 factors; diabetes and influenza vaccine were again 
selected as predictors, whereas liver disease was no longer a predictive factor.  Six 
additional factors were included when compared to the 1-7 day model; two were 
assigned negative coefficients (congestive heart failure and having a recent carer), three 
were found to be positive predictors (ischaemic heart disease, leukaemia/lymphoma 
and other neurological disease), and smoking status had a mixed effect depending on 
whether patients were current or ex-smokers.  Of the factors included in the model, low 
weight was assigned the largest score followed by residential care and the higher age 
groups (Table 7-5).  Among the factors assigned negative coefficients (and thus seen as 
‘protective’ against mortality) influenza vaccination >5 years ago and diabetes with 
complications had the largest negative effects, reducing patients’ scores by 0.49 and 
0.46 respectively.  Again, the model showed near-reasonable discrimination (unadjusted 
c-statistic=0.696) 
The 8-30 day model slightly over-predicted mortality risk in the first three risk deciles, 
and slightly under-predicted risk in deciles seven to nine (Figure 7-5).  The Kaplan-Meier 
survival curves stratified by Cox-centile showed reasonable separation between the 
groups, with good separation for the highest risk group (Figure 7-6). 
The optimism was the highest of all the models (0.038), thus the optimism corrected c-
statistic was sub-optimal at 0.658 (Table 7-5).  Living arrangements, low weight/poor 
nutrition, and dementia (kept in 200, 200, and 191 bootstraps respectively) showed high 
stability across the bootstrapping process (Table 7-6). 
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7.5.7 31-365 day model 
Of the 17 factors retained in the 31-365 day model, only leukaemia/lymphoma, other 
neurological disease, and smoking status remained from those selected into the 8-30 
day model.  Additionally, chronic lung disease, a history of pneumonia and excessive 
alcohol consumption were all predictors of mortality, and pneumococcal vaccination 
had a mixed effect depending on the timing of the vaccination.  Increasing age, low 
weight, leukaemia/lymphoma, residential care, dementia and congestive heart failure, 
were the strongest predictors of mortality (Table 7-5).  Being female, an ex-smoker and 
having received pneumococcal vaccine over a year ago each had negative score 
coefficients.  The discrimination of the model was lower than for the two shorter time 
periods (unadjusted c-statistic=0.647). 
The model showed fair calibration (Figure 7-5), with observed risk increasing as the 
predicted risk increased.  However, mortality risk was slightly over-predicted in the two 
lowest deciles compared to the observed risk (Figure 7-5).  The Kaplan-Meier curves 
stratified by Cox-centiles showed good separation between the groups (Figure 7-6).   
The model displayed relatively poor discrimination and little optimism (0.018) with an 
optimism-corrected c-statistic of 0.630 (Table 7-5).  The six strongest predictors also 
showed high stability, and were selected into ≥99% of bootstrap models (Table 7-6). 
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Table 7-5 Scores for variables included in each final model, and their C-statistics. 
 
Score for factor (logHR) Hazard Ratios 
Model period (days) Model period (days) 
1-7  8-30 31-365 1-7 8-30 31-365 
Sex Female 0.02 -0.15 -0.24 1.02 0.86 0.79 
Age 
70-74 -0.23 0.28 0.24 0.79 1.32 1.28 
75-79 0.01 0.53 0.36 1.01 1.70 1.44 
80-84 0.43 0.67 0.63 1.54 1.95 1.87 
85-89 0.67 0.79 0.84 1.95 2.21 2.32 
90+ 1.10 1.20 1.13 3.01 3.33 3.08 
Diabetes 
Diabetes -0.14 -0.15  0.87 1.13  
& complications -1.11 -0.46  0.33 0.86  
Peripheral vascular disease 0.40 0.23 0.16 1.49 0.63 1.18 
Dementia 0.42 0.45 0.37 1.52 1.56 1.44 
Living 
arrangements 
Lives alone -0.28 0.33 0.01 0.76 1.39 1.01 
Sheltered housing 0.24 0.04 0.07 1.27 1.04 1.07 
Residential Care 0.45 0.70 0.42 1.56 2.02 1.53 
Connective tissue disease -0.31 -0.21 0.14 0.73 0.81 1.15 
Influenza 
vaccination* 
14-365 days  -0.25 -0.11  0.78 0.90  
Previous season -0.21 0.14  0.81 1.16  
2-5 years  0.44 0.12  1.55 1.13  
>5 years  0.00 -0.49  1.00 0.61  
Solid cancer  0.35 0.28 0.19 1.42 1.33 1.21 
Liver Disease 
Mild/moderate -0.10   0.91   
Severe 1.81   6.11   
Low weight/poor nutrition 0.64 0.94 0.66 1.90 2.56 1.93 
Congestive heart failure  -0.19 0.36  0.83 1.44 
Cerebrovascular disease 0.29 0.18 0.09 1.34 1.20 1.09 
Recent carer  -0.36   0.69  
Ischaemic 
heart disease  
pre-MI  0.23   1.26  
post-MI  0.02   1.02  
Leukaemia/lymphoma  0.41 0.56  1.50 1.75 
Other neurological disease  0.42 0.19  1.52 1.21 
Smoking status 
Current  0.06 0.11  1.06 1.12 
Ex  -0.27 -0.10  0.76 0.91 
Chronic lung disease   0.20   1.23 
Previous pneumonia   0.14   1.16 
Excess alcohol consumption (Yes)   0.19   1.21 
Pneumococcal 
vaccination* 
14-365 days   0.01   1.01 
1-2 years   -0.08   0.92 
2-5 years   -0.12   0.89 
>5 years   -0.14   0.87 
Uncorrected C-stat 0.699 0.696 0.647    
Optimism  0.031 0.038 0.018    
Corrected C-stat 0.669 0.658 0.630    
Empty cells denote the factor not being selected into the model.  Scores are rounded to 2 
decimal places   *Timing of most recent vaccine pre-CAP 
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Table 7-6 Stability of the models: Number of times each variable was selected into 
each model made in the bootstrap samples of data (200 repetitions).   
Variable 1-7 day model 8-30 day model 31-365 day model 
Sex* 200 (100%) 200 (100%) 200 (100%) 
Age* 200 (100%) 200 (100%) 200 (100%) 
Chronic heart failure 29 (14.5%) 88 (44%) 200 (100%) 
Peripheral vascular disease 149 (74.5%) 80 (40%) 148 (74%) 
Dementia 137 (68.5%) 191 (95.5%) 200 (100%) 
Chronic lung disease 27 (13.5%) 25 (12.5%) 198 (99%) 
Connective tissue disease 66 (33%) 71 (35.5%) 115 (57.5%) 
Peptic ulcer 23 (11.5%) 48 (24%) 42 (21%) 
Hemiplegia 8 (4%) 62 (31%) 69 (34.5%) 
Leukaemia/lymphoma 16 (8%) 87 (43.5%) 198 (99%) 
Other neurological disease 49 (24.5%) 167 (83.5%) 144 (72%) 
Other immunological disease 7 (3.5%) 3 (1.5%) 56 (28%) 
Cerebrovascular disease 123 (61.5%) 101 (50.5%) 96 (48%) 
Previous pneumonia 55 (27.5%) 27 (13.5%) 156 (78%) 
Solid cancer 138 (69%) 152 (76%) 189 (94.5%) 
Smoking status 69 (34.5%) 167 (83.5%) 191 (95.5%) 
Diabetes 119 (59.5%) 87 (43.5%) 22 (11%) 
Liver Disease 134 (67%) 30 (15%) 10 (5%) 
Ischaemic heart disease  47 (23.5%) 79 (39.5%) 9 (4.5%) 
Renal disease 38 (19%) 30 (15%) 36 (18%) 
Living arrangements 123 (61.5%) 200 (100%) 200 (100%) 
Influenza vaccination (most recent) 124 (62%) 81 (40.5%) 68 (34%) 
Pneumococcal vaccination (most 
recent) 52 (26%) 43 (21.5%) 78 (39%) 
Low weight/poor nutrition 159 (79.5%) 200 (100%) 200 (100%) 
History of falling 18 (9%) 20 (10%) 25 (12.5%) 
Recent carer 30 (15%) 61 (30.5%) 48 (24%) 
Excessive alcohol consumption 36 (18%) 28 (14%) 127 (63.5%) 
Cells in green show variables included in the final model.   
*variables were forced into the model. 
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Figure 7-5 Calibration of the three models, split into deciles of predicted mortality 
  
NOTE: different y-axis scales used on each panel of the figure.  
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Figure 7-6 Kaplan-Meier curves stratified by Cox-centiles for each model 
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7.5.8 Predicted risks and risk ratios for (hypothetical) patients 
Predicted mortality risks for a range of hypothetical scenarios and the risk ratios 
comparing the predicted risk for each scenario to the risk in the CPRD-ONS linked 
population are shown separately for women and men in Table 7-7 and Table 7-8.   
Predicted risks (on the left side of Table 7-7 and Table 7-8) are presented as the number 
of patients per 1000 that would be expected to die in each risk period, given a specified 
combination of factors.  For example, out of 1000 women aged 80-84 with a previous 
cancer diagnosis and of low-weight, on average 343 would be expected to die within 31-
365 days post-CAP discharge (Table 7-7 – left-hand side); these women have 7.2 times 
the mortality risk of an 80-84 year old woman in the general CPRD-linked cohort (as 
shown in right-hand side of the table).  Similarly, of 1000 65-69 year-old men who were 
ex-smokers with COPD and who received an influenza vaccine this season, 126 would be 
expected to die within 31-365 days of a CAP discharge, which is 7.7 times the risk 
compared to men of the same age in the linked-CPRD population  (left and right sides of 
Table 7-8).  The ratios were calculated using mortality rates (converted to risks) for the 
CPRD-linked HES cohort, which can be found in Appendix I. 
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Table 7-7 Examples of predicted risk of mortality among women, and of risk ratios comparing predicted mortality of female patients post-CAP  
hospital discharge to the mortality risk of female patients in the general CPRD population for a range of factors in each model  
Factors included when 
calculating mortality risk 
among WOMEN 
Risk presented as number of patients per 1000 predicted 
to die in each time period given the set of factors stated 
Relative risk of dying post-CAP discharge compared to 
patients in the general CPRD population) given the set 
of factors stated 
  
 KEY 
(women) 
Age 65-69 70-74 75-79 80-84 85-89 90+ 65-69 70-74 75-79 80-84 85-89 90+  Risk/1000 
Age alone 
14 11 14 22 28 42 61.0 35.1 25.4 21.4 15.0 11.2  1-7 day 
17 23 29 33 38 56 23.4 22.4 16.3 10.4 6.5 4.8  8-30 
91 115 128 164 199 255 8.2 7.5 4.8 3.5 2.4 1.5  31-365 
Diabetes & 
Peripheral vascular 
disease  
19 15 19 28 36 55 79.1 45.6 33.0 27.8 19.4 14.4  RR 
19 24 31 36 41 61 25.2 24.1 17.6 11.2 7.0 5.1  1-7 day 
106 134 149 190 230 293 9.6 8.7 5.6 4.0 2.7 1.8  8-30 
Flu vaccine this season, 
COPD & 
Ex-smoker  
11 9 11 17 22 33 47.5 27.3 19.8 16.7 11.7 8.7  31-365 
12 16 20 23 26 39 16.1 15.4 11.3 7.2 4.5 3.3   
101 126 141 180 218 279 9.0 8.3 5.3 3.8 2.6 1.7   
Cancer & 
low weight  
38 30 39 58 73 110 162.4 93.7 67.7 56.8 39.4 29.1   
57 75 96 109 123 179 78.1 74.0 53.7 34.1 21.1 15.1   
201 249 275 343 406 499 18.1 16.2 10.3 7.2 4.8 3.0   
Dementia, 
Residential care  
34 27 34 51 65 98 143.6 82.9 59.9 50.3 34.9 25.8   
53 70 89 102 114 167 72.6 68.8 50.0 31.8 19.7 14.1   
190 236 261 326 387 477 17.1 15.4 9.7 6.9 4.6 2.9   
Pre-MI Ischaemic heart 
disease, Flu vaccine this 
season & PPV >5 years  
11 9 11 17 22 33 47.5 27.3 19.8 16.7 11.7 8.7   
20 26 33 38 43 64 26.5 25.3 18.5 11.8 7.3 5.4   
79 100 112 144 175 225 7.1 6.5 4.2 3.0 2.1 1.4   
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Table 7-8 Examples of predicted risk of mortality among men, and  of risk ratios comparing predicted mortality of male patients post-CAP hospital 
discharge to the mortality risk of male patients in the general CPRD population for a range of factors in each model  
Factors included when 
calculating mortality risk 
among MEN 
Risk presented as number of patients per 1000 predicted 
to die in each time period given the set of factors stated 
Relative risk of dying post-CAP discharge compared to 
patients in the general CPRD population) given the set 
of factors stated 
  
 KEY 
(men) 
Age 65-69 70-74 75-79 80-84 85-89 90+ 65-69 70-74 75-79 80-84 85-89 90+  Risk/1000 
Age alone 
14 11 14 22 27 42 40.7 22.1 17.0 14.7 11.2 9.8  1-7 day 
20 26 34 39 44 65 18.4 16.6 12.9 8.4 5.7 4.9  8-30 
114 143 160 203 245 311 7.0 6.0 4.1 3.0 2.2 1.7  31-365 
Diabetes & 
Peripheral vascular 
disease  
18 15 18 28 35 54 52.7 28.7 22.0 19.0 14.5 12.6  RR 
22 28 36 42 47 70 19.8 17.9 13.8 9.0 6.1 5.2  1-7 day 
133 166 185 234 282 355 8.1 7.0 4.7 3.5 2.6 1.9  8-30 
Flu vaccine this season, 
COPD & 
Ex-smoker  
11 9 11 17 21 33 31.7 17.2 13.2 11.4 8.7 7.6  31-365 
14 18 23 27 30 45 12.7 11.4 8.9 5.8 3.9 3.4   
126 157 175 223 268 339 7.7 6.6 4.5 3.3 2.4 1.8   
Cancer & 
low weight  
37 30 38 57 72 108 108.3 59.2 45.3 38.9 29.5 25.4   
66 87 110 126 141 204 61.1 54.7 42.0 27.3 18.4 15.3   
247 304 335 413 483 583 15.1 12.8 8.6 6.1 4.4 3.2   
Dementia, 
Residential care  
33 26 34 50 64 96 95.8 52.3 40.0 34.4 26.1 22.6   
62 81 103 117 131 191 56.8 50.9 39.1 25.4 17.2 14.3   
234 288 318 394 462 560 14.3 12.1 8.1 5.8 4.2 3.0   
Pre-MI Ischaemic heart 
disease, Flu vaccine this 
season & PPV >5 years  
11 9 11 17 21 33 31.7 17.2 13.2 11.4 8.7 7.6   
23 30 38 44 49 73 20.8 18.8 14.5 9.5 6.5 5.5   
99 125 140 178 216 276 6.1 5.3 3.6 2.6 2.0 1.5   
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7.6 Discussion 
In this study I have developed a series of risk scores to try to aid clinical decision-making 
around care in the year after a patient is discharged from hospital after a CAP episode.  
All three models have been designed to require minimal clinical input, and include 
important and common conditions such as cancer, cerebrovascular disease, ischaemic 
heart disease and dementia.  These scores would be usable by GPs whether or not the 
patient had consulted them for the CAP episode prior to their hospital admission, which 
is valuable given that GP consultations by patients prior to a CAP-related hospitalisation 
are decreasing (as described in Chapter 6).  Many existing prognostic models include 
signs and symptoms present at the point of diagnosis, which GPs are unlikely to have 
uniformly recorded, making these models unusable in a primary care setting. 
Seven predictors other than age and sex were included in all three models, predicting 
risk of death for varying lengths of time after patients with CAP are discharged from 
hospital.  These predictors were peripheral vascular disease, dementia, solid cancer, 
cerebrovascular disease, connective tissue disease, living arrangements and low 
weight/nutritional supplementation.  Of these, living alone (1-7 days) and connective 
tissue disease (1-7 and 8-30 days) had an initial protective effect which later became 
predictive of mortality in the longer-term models.  Six additional factors were present in 
two of the models, and seven were predictors in only one time period.   
In the main (31-365 day) model, 17 predictors were identified.  The model showed 
relatively poor ability to distinguish between patients who died and survived 
(discrimination) but good agreement between predicted and observed outcomes 
(calibration) in the mid-range of predicted risk, where it would be of most use to 
clinicians.    
It is important to consider the factors found to be predictive of mortality in this analysis 
in context of the study population.  Only patients who survived the initial hospitalisation 
for CAP were included in the study population, whereas those with the highest mortality 
risk after CAP were likely to have died in hospital. Thus several factors which one may 
expect to play a role in subsequent mortality may not be prominent risk factors for 
surviving patients.  A good example of such a situation is ischaemic heart disease, where 
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the ‘pre-MI’ (less severe) category had a higher score than ‘post-MI’ in the 8-30 day 
model (0.23 and 0.02 respectively).  Two possible reasons for this are; firstly, that 
patients with severe ischaemic heart disease are more likely to die in hospital, and thus 
not be included in the study population.  Secondly, those who survive the CAP episode 
may have been hospitalised for longer than patients without severe ischaemic heart 
disease to ensure they were sufficiently stable to be discharged.  Death in hospital, or a 
more cautious approach to discharge of specific CAP patients may also explain why 
chronic lung disease was a predictor of mortality only in the 31-365 day model, and why 
those with conditions associated with immune dysregulation and thus more severe 
infection (such as diabetes and connective tissue disorders), those with congestive heart 
failure and those living alone had a negative association with mortality in the 1-7 and/or 
8-30 day models.  Conversely, severe liver disease (with a coefficient of 1.81 in the 1-7 
day model) had the highest score of any factor in any model, including age.  This could 
be due to patients with severe liver disease being at higher risk of short-term death from 
conditions such as variceal bleeds or sudden unexplained death.[185] 
As previously stated, the exact mechanisms behind the increased mortality risk after a 
CAP hospital discharge are unclear, but the increased mortality is likely to be due to a 
combination of CAP being a marker for underlying ill-health and CAP having longer-term 
effects on the body (as outlined in sections 1.1.2 and 1.3.2.4).  For example, the 
increased association of dementia and solid cancer with death in all three models, and 
leukaemia/lymphoma and other neurological disease in the two longer periods may be 
more representative of CAP as a marker for underlying ill-health.  In all cases, the HRs 
remained high into the third period, with a minimum 21% increase.  Infections can also 
worsen existing comorbid conditions, most notably chronic lung disease.[186]  
As highlighted in section 1.3.2.4, changes to endothelial activity and platelet activation 
increase the risk of acute ischaemic events after systemic infection, which explains the 
inclusion of cerebrovascular disease in all three models, and pre-MI ischaemic heart 
disease in the 8-30 day model, as well as other co-morbidities such as diabetes that are 
associated with an increased cardiovascular risk after infection.[187]  The same 
mechanism could also explain the inclusion of peripheral vascular disease, although this 
was associated with increased mortality in the 1-7 and 31-365 models and decreased 
mortality in 8-30 days.  Similarly, myocardial injury and volume overload (due to the 
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mechanisms described in section 1.3.2.4), which lead to worsening heart failure, could 
explain its inclusion and increased risk of mortality in the longer model.  The decreased 
risk of congestive heart failure shown in the 8-30 day model is less obvious, but could 
perhaps be explained by heart failure being more acutely monitored in the month post-
CAP discharge.  
7.6.1 Findings in relation to other studies 
Direct comparison between the predictors identified in this study and the risk factors 
identified in the literature review is problematical, due to the many differences between 
those papers and this work.  Neither of the two papers which examined risk factors in 
up to one year post-CAP discharge separated their follow-up into more than one risk 
period.  This resulted in their capturing in a single model early as well as late post-
discharge deaths, which I have demonstrated have some differing prognostic 
factors.[174, 173]  However, as in my analyses, both papers found that mortality risk 
increased with increasing age, and that residence in a nursing home was associated with 
higher mortality.[174, 173]  To investigate the role of co-morbidities, the Canadian study 
used a simple count of the number of co-morbidities present,[173] while the Spanish 
paper adjusted for both co-morbidities and high PSI score.[174]  Several of the individual 
factors the Spanish study identified as risk factors were also included in my 31-365 day 
prognostic model (chronic lung disease, congestive heart failure, cancer, 
cerebrovascular disease and dementia), albeit with generally less pronounced measures 
of effect, possibly due to exclusion of earlier deaths from my model.[174]   
As well as providing the most accurate predictions possible, a prognostic model also 
needs to be fit for use in the appropriate setting.  Due to the intended use of this score 
by GPs, factors relating to the severity of the CAP and physical/laboratory findings such 
as those found in the PSI or hypotension/shock were not included in the model, despite 
being identified as risk factors for mortality in periods of a year or more after discharge 
in other studies.[92, 173-176]  Similarly, despite being identified by the Spanish paper 
as being associated with an increased mortality risk, re-hospitalisation was not included 
as a candidate predictor in this study.[174]  While it is possible to measure re-
hospitalisation in a retrospective cohort study, ‘future hospitalisation’ would not be 
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known at the point this score would be calculated (post-CAP hospital discharge), and so 
cannot be used to inform predictions.     
Two papers reported causes of death at one year of follow-up, with contrasting 
results;[174, 92] in general the results of this study sit between those presented by the 
two papers.  I found that over the full year of follow-up post-discharge, the majority of 
underlying causes of deaths were due to circulatory illnesses (28% ICD chapter I), 
followed by chronic lung disease and cancer with just under 20% each.  Pneumonia 
accounted for 10.7% of deaths.  The Spanish study found that 25.8% of 93 deaths were 
due to pneumonia, 22.6% to other infectious diseases, 20.4% to cardiovascular causes 
and 8.6% to cancer.[174]  In contrast, the Dutch paper depicted in graphical form that 
only approximately 3% of 198 deaths were due to pneumonia, 10% due to circulatory 
diseases, 27% to cancer and 7% to chronic lung disease.[92] 
The pattern of underlying causes found across the three model periods I present 
supports a theory by Mortensen et al that deaths within 45-days of a CAP diagnosis are 
CAP-related, and those after 45 days less likely to be so.[188]  I found that pneumonia 
was named either as the underlying or contributory cause of death in 57.8% of patients 
who died within 7 days of discharge, and was the underlying cause for 20.1%.  This is 
consistent with pneumonia being a part of the terminal care pathway, with some 
patients possibly being discharged from hospital to enable them to die at home.  These 
percentages of CAP-related deaths decreased with each model period, and were named 
in 34.4% of underlying or contributory causes and 8.9% of underlying causes of deaths 
in the 31-365 day model.   
7.6.2 Strengths and limitations  
This study included a sizable number of older patients who had been hospitalised with 
CAP and subsequently discharged.  A large number of potential prognostic factors were 
investigated, and these were used to develop models for three separate risk periods (for 
which patients had differing underlying causes of death and for which different 
prognostic factors for mortality were identified).  The models were designed to be used 
specifically in a primary care setting, and were developed to enable them to be 
incorporated into pre-existing software to require minimal input from staff.  Pre-existing 
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prognostic scores (such as CURB-65, PSI or Charlson) were not included as candidate 
predictors, and thus age and co-morbidities were not double-counted.   
The work I present here may also inform preventative approaches to CAP.  There has 
been considerable research around risk factors for developing CAP, and on risk factors 
for dying which can be identified at the point of CAP diagnosis.  This study adds to that 
body of work by identifying those at increased mortality risk in the year following CAP 
hospital discharge, thus further informing who might particularly benefit from strategies 
to prevent CAP (such as increased uptake of pneumococcal and influenza vaccines). 
I validated the models using bootstrapping, which is the recommended method of 
internal validation and has been shown to be robust.   
7.6.2.1 Use of stand-alone CPRD data in analyses 
A key decision was that, in order to create models that could be built into the GP patient 
software and programmed to run automatically, I only included co-morbidity diagnoses 
from within patients’ primary care records.  Recent work has shown that the addition of 
HES data may capture more co-morbidity diagnoses than stand-alone CPRD data,[148] 
but the inclusion of these HES data would have violated one of my primary aims – ease 
of use.  Thus, the models need to be interpreted taking into account that the included 
factors are only those known to and recorded by the practice in the patient’s electronic 
health record.  It seems likely that important pre-existing conditions a patient regularly 
receives treatment for are included in their general practice records, and validity of 
CPRD diagnoses has been shown to generally be high.[106]  However, the analyses 
excluded factors not recorded in the primary care record that were present at or arose 
during the CAP admission, and the potential limitations of this are discussed below.  
An important consideration is that the information made available to GPs about recent 
hospitalisations is different to hospitalisation information made available to 
researchers.  General practitioners now receive an electronic version of the hospital 
discharge summary soon after the patient is discharged.  However, much of the 
information from this summary is typically not coded into a patient’s electronic health 
record, and thus will not be in the anonymised CPRD data.  For example, if practice staff 
code only the CAP diagnosis and that the patient was recently hospitalised, then aspects 
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of the presenting features and the course of the CAP episode that are potential 
predictors of subsequent mortality (such as hypotension or high temperature at 
admission, or the patient being non-stable at discharge, Table 7.1), will be known to the 
GP from the discharge letter but will not be available in the primary care electronic 
record.   
Incorporation of HES data into the model is unlikely to have addressed this problem, as 
the coded information provided in HES is not the same as that contained in the discharge 
summary received by GPs.  Both sources of information are derived from the patient’s 
records during their hospitalisation, but the discharge summary is written by a member 
of clinical staff (primarily a doctor), usually at the point of discharge.  In contrast, HES 
records are derived from the information provided by a team of trained clinical coders, 
who extract information from the patient’s hospital records on the conditions present 
at admission or arising during hospitalisation, after the patient has been discharged.  
Presenting features of an illness and its clinical course are rarely captured in the ICD-
coded HES data, and thus I would not have been able to investigate these features in 
the prognostic models by using the HES data.  
It is also important to note that GPs do not receive HES data, and that hospital discharge 
letters may not include all information on the hospitalisation.  There are a limited 
number of studies which have evaluated the completeness of English discharge 
summaries, but reports suggest the information on co-morbid illnesses is not complete.  
An audit of discharge summaries received by a primary care trust in Eastern England 
between January and March 2011 found that only 50.3% of the summaries written by 
doctors contained complete information on patients’ co-morbidities, although 
information on the presenting diagnosis was well recorded (approximately 94% 
complete (data read from the figure provided in the report)).[177]  A separate 2009 
survey by the Care Quality Commission of 280 general practices across England found 
that 56% of the practices reported receiving inaccurate or incomplete discharge 
summaries over the last year ‘some of the time’, and 16% reported that this occurred 
‘most of the time’, compared to 27% reporting ‘not very often’ or ‘never’ receiving 
inaccurate/incomplete summaries.   
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Assuming the findings from these reports were broadly applicable to all discharge 
summaries over the time period of this study, then the information on diagnoses 
provided in HES might not be sufficiently similar to that provided to GPs in discharge 
summaries to be useful for developing prognostic models for use in primary care.  As 
previously mentioned (section 7.3.1), a key feature of the data used to develop a 
prognostic model is that these data are as similar as possible to the population the 
model will be applied to.  Inclusion of HES data could have increased the discriminative 
ability and internal calibration of the model.  However, if the model was then applied to 
an external sample of primary care data from practices for which HES records were not 
available (but instead potentially incomplete recording from discharge summaries), the 
calibration of the model would suffer due to the differences in recording, and the 
predictions made by the model would be less reliable (i.e. the external calibration would 
be poor).  The addition of HES information and its potential effect on the models is 
further discussed in section 7.6.4.1.   
A final potential limitation relates to the acceptability of the score to general 
practitioners. Although I discussed the development of the prognostic models with two 
general practitioners, I did not consult more widely with a sample of GPs to determine 
whether excluding information about a patient’s most recent hospitalisation would be 
clinically acceptable to them.  If this exclusion was not acceptable, GPs would be unlikely 
to use the score.   
7.6.2.2 Other considerations 
The low, non-uniform recording of frailty factors revealed in Chapter 6 resulted in the 
majority of the frailty factors included in that work being unsuitable for inclusion as 
potential predictors of mortality.  This was unfortunate, as such measures of underlying 
deficit may have strengthened the discrimination of these scores.  Recent attention on 
the effects and importance of frailty among older adults will hopefully lead to more 
complete recording of these factors over time, so they can be included in future, 
updated versions of these models.[158]     
Despite the absence of these frailty-specific factors in the models, it is possible that the 
models were simply identifying frail older patients.  In order to assess whether the 
models were identifying factors specific to mortality after a CAP hospitalisation, I would 
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have needed to apply the models to an alternative study population (such as patients 
hospitalised with an unrelated condition to CAP) and assess their calibration and 
predictive accuracy among this group.  I also did not compare my models to other more 
generic models such as Charlson, or the eFI (which was not published at the time of this 
work), and so cannot be certain that my models are better at identifying patients at 
higher mortality risk compared to those already available.   
Patients with a code for terminal illness or metastatic cancer were excluded from the 
analyses, as the aim of the study was to predict unexpected deaths.  Directives such as 
‘do not resuscitate’ orders or living wills are very poorly recorded in CPRD, and so 
patients who had expressed this wish (and thus would receive little/no active treatment 
for their CAP) but did not have terminal illness codes could not be excluded as ‘expected’ 
deaths.  This may have affected the shorter 1-7 and 8-30 day models, but should not 
have been such an issue for the primary (31-365 day) model.   
While more than one CAP hospital discharge per patient was included in the dataset, 
only the first discharge in one 365 day period was used.  This may mean that predictions 
from the model are less clinically useful for predicting mortality after a patient’s second 
or third CAP hospitalisation in a year.  Multiple CAP hospitalisations in such a period 
could be considered themselves a marker for underlying health deficit, and GPs could 
additionally use this as a marker of increased risk.   
The longer models (31-365 and 8-30 days) both had considerably more than 10 
outcomes per factor investigated, but the shortest (1-7 day) model had slightly too few 
outcomes per factor.  However, this model may be the least useful of the three, due to 
the timing of receipt of discharge summaries by GPs.   
While I validated the prognostic models using the well-regarded internal bootstrapping 
technique, I was unable to perform external validations.  Were these models to be 
considered for clinical use, future work would need to include validating the models 
developed in the CPRD data in other large, UK GP databases to assess the accuracy of 
their predictions in other settings.   
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7.6.3 Clinical relevance of the model 
Since this work was completed, GRADE guidelines have been published on the 
evaluation of tests used for clinical decision-making.[189]  The full framework has mainly 
been described in its role as an aid for panels who are making decisions and 
recommendations about tests and their usage, but it can also be applied to individual 
studies.  The GRADE guidelines include several items which have already been discussed 
in this thesis; consideration of whether the problem is a priority and the importance of 
the outcome are covered in section 7.1, the accuracy of the tests (in this case the models 
themselves) is covered in section 7.5.4.  Below, I discuss other aspects of the framework.   
7.6.3.1 Evidence of the suitability of an intervention to implement post risk 
stratification 
I developed these models with the aim of helping GPs to identify older patients at 
increased risk of mortality after a CAP hospitalisation.  However, as with any test, when 
developing a new prognostic model it is important not only to assess whether the model 
correctly identifies patients at increased risk of the outcome, but also to consider its 
clinical applicability, and whether any proposed intervention has any effect on the 
outcome.[189] 
Prognostic models are designed to be used in addition to (not instead of) clinical 
judgement.  As such, it’s unlikely that the scores developed in this study would be used 
to aid assessment of the most obviously high risk patients (for example those aged ≥90, 
residing in a nursing home and with dementia).  The aim is to aid GPs when they are not 
sure of the level of mortality risk, or when the risk is less obvious (i.e. in the mid older-
age groups, and the middle/upper centiles on the calibration graphs, which is where 
these models performed most reasonably).  While there is likely to be a greater level of 
uncertainty in the model among patients with a high number of conditions (as 
combining many coefficients’ standard errors will lead to wider confidence intervals), 
GPs will be aware of these patients due to their worse health.   
Unlike previously developed scores for other conditions, to the best of my knowledge 
there are currently no specific preventative interventions for patients at high-risk of 
mortality post-CAP (given the varied causes of death after CAP), and there is no 
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definitive evidence that identifying high-risk patients will affect mortality rates among 
this group.  The Swiss study identified in the earlier literature review (section 7.2.3) 
suggested that closer patient contact should be assessed in future prospective 
trials.[175]  My original idea when developing these models was that GPs could 
implement a form of case management, consisting of the assessment of patients with 
subsequent formulation of care plans specific to their pre-existing co-morbidities, and 
potentially their social care needs.[190]  Based on previous research, possible items for 
inclusion in the care management plans include a patient’s clinical history, current 
health status, medication review, ADL ability and needs, mobility and cognitive function, 
formal and informal care arrangements, physical and social care needs.[190]   
Studies have assessed the impact of case management in primary care on preventing 
adverse outcomes in a range of patient populations.  Within primary care, case 
management has most commonly been used to try to prevent emergency 
hospitalisations, but mortality has also been considered as an outcome.  A 2015 
systematic review of case management for ‘at risk’ patients in primary care found that 
the 12 studies which assessed short-term mortality (0-12 months), and the 13 studies 
that assessed longer-term mortality (13+ months), both showed heterogeneous results.  
None of these studies were in an older population recently discharged from hospital 
after CAP.  When results were pooled there was no evidence of an overall effect of case 
management on decreasing mortality.  However, subgroup analyses indicated that there 
might be small benefits of delivering case management via a multidisciplinary team and 
of including a social worker, and the authors suggested that these findings might be 
further explored in future studies.[191]    
7.6.3.2 Benefits and harms of the models 
Due to the nature of the models, there are no associated side-effects which could harm 
a patient.  As discussed above, there is currently little/no evidence that my proposed 
intervention of enhanced case management would lead to reduced mortality rates 
among the target population for the model, and as such the models may have no/limited 
benefits. 
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7.6.3.3 Balance between desirable and undesirable effects 
The unclear benefit of the case management approach also impacts on the balance 
between desirable and undesirable effects.  While the undesirable effects of using the 
model should be minimal, the predicted benefits of my proposed intervention could also 
be low. 
7.6.3.4 Acceptability of the score and intervention to patients and GPs 
Should the use of the score and case management be found to help reduce one-year 
mortality in older patients, then acceptability and adoptability of both the score and the 
intervention in the real world would need serious consideration.  The score was 
designed to be able to be inserted into software used by GPs, and thus to be easy to use.  
However, an ever-increasing number of prognostic scores are available in primary care 
and it is possible that GPs would not be willing or have time to adopt them all.  
Additionally (as outlined in section 7.6.2.1) it is not clear whether GPs would find it 
acceptable to adopt a score that did not incorporate the most recent patient data from 
the hospitalisation, and this would need to be assessed.  
From a patient perspective, the score itself would likely be acceptable as it requires no 
input or action.  After being identified as at increased risk, some patients may be reticent 
to spend more time with medical professionals after hospital discharge, and may not 
feel that case management is necessary.  The reasons for the case management 
approach would need to be carefully explained to this group in order to let them make 
a fully informed decision about how to proceed. 
7.6.3.5 Equity 
The integration of the score into GPs software would result in it running automatically if 
a patient had been coded as being hospitalised with CAP.  This automated approach 
should result in the score being applied to patients equitably.   
7.6.3.6 Feasibility and resource use 
Case management is resource intensive due to its potential multidisciplinary nature.  My 
intention was to aid GPs in identifying patients with increased risk of mortality but who 
might not otherwise have been identified (i.e. not the most frail patients, with whom  
247 
 
the GP would likely to already have frequent contact).  The relatively high cost of this 
intervention may preclude it from being used in a population not necessarily considered 
classically ‘high-risk’.  If effective, case management could prevent some decline in 
health and further hospital admissions, and thus avert the associated healthcare costs. 
However, without conducting a cost-effectiveness analysis, the viability of this approach 
is uncertain.   
7.6.3.7 Conclusion of GRADE assessment 
Due to population ageing and increasing hospitalisation for CAP, increased mortality 
after CAP hospitalisation should be considered a priority.  However, due to the lack of 
evidence that my proposed intervention would have an impact on patients’ mortality 
risk, the potentially high resource use and the moderate/weak predictive ability of the 
models I developed, they would not currently meet the GRADE criteria to be introduced 
into clinical practice.   
7.6.4 Reflection on my approach to aspects of this work 
Below I reflect further on the lessons learned from this work, discuss aspects that could 
have been carried out differently and the potential impact this would have had on the 
models and their performance. 
7.6.4.1 Exclusion of information regarding the most recent hospitalisation 
As discussed in section 7.6.2, I chose not to include information available in HES about 
patients’ CAP hospitalisation in the calculation of their risk score.  If the recording of co-
morbidities on discharge summaries becomes more consistent with that recorded in 
HES, the addition of co-morbidities recorded in the HES data during the CAP admission 
could enhance the predictive ability of my models by more accurately reflecting 
patients’ most recent health status.  This could better delineate those who are starting 
to decline from those who are generally well.  These co-morbidities could be included 
as separate ‘recent’ variables if not previously recorded in the patient’s primary care 
record, to signal their treatment during the hospitalisation.  Knowledge of the more 
recent occurrence of a co-morbidity may increase its prognostic score value, for example 
an MI occurring during a hospitalisation for CAP may have a stronger association with 
one-year mortality than an MI recorded five years ago.   
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Although HES data are suboptimal for recording factors that indicated the severity of 
CAP at presentation or during the hospitalisation, one factor I could have considered 
from the HES data (also included in hospital discharge summaries) is the patient’s length 
of stay in hospital.  This could have provided useful information in the severity of illness 
and been used as a proxy for the patient’s underlying health, as those who are frailer 
may have longer admissions than patients who are generally fit and well.  Were I to 
repeat these analyses, I could investigate length of stay as a potential predictor to 
ascertain whether it could improve the prognostic ability of the models.   
An alternative strategy would be to include patients’ self-reported details of their 
hospitalisation.  Information such as conditions arising in hospital could be ascertained, 
although information regarding any change in medications should strictly be excluded 
(due to the potential of modelling prescribing behaviour rather than the true risk 
associated with the medication, as described in section 7.3.1.1).  The accuracy of self-
report would need to be validated prior to its inclusion in the model, in particular among 
the older, more infirm patients who may recall these details less well than their younger 
or healthier counterparts.  
7.6.4.2 Assessing whether the inclusion of information from the most recent 
hospitalisation improves the prognostic ability of the models 
There are formal methods to investigate whether the addition of new candidate 
predictors (here, using predictors from the hospitalisation data), improve a model’s 
ability to classify patients into the correct outcome group, i.e. its sensitivity and 
specificity.  Net reclassification improvement (NRI), is a method of measuring whether 
patients with the outcome move up a classification category, while those without the 
outcome move down.  It is simplest to calculate and interpret when only one cut-point 
is being evaluated (i.e. the score only categorises patients into two groups).  In this case, 
the event NRI and non-event NRI are first obtained.  The event NRI is calculated among 
those with the outcome, as the proportion who moved up a category minus the 
proportion who moved down a category (the improvement in sensitivity).  The non-
event NRI is calculated among those without the outcome, as the proportion who 
moved down a category minus those who moved up a category (the improvement in 
specificity).[181, 192]  The overall NRI is then calculated as the sum of the event NRI and 
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non-event NRI.  Large overall NRI values may have been driven by an increase in correct 
reclassification of subjects either up or down (an increase in sensitivity or specificity), 
and thus without knowing the event and non-event NRI the direction of any 
improvement (and the new model’s clinical usefulness) cannot be ascertained.  The 
denominators for the event and non-event groups are likely to differ, resulting in the 
NRI being weighted by the event rate and thus complicating its interpretation.  
Therefore, several factors must be considered when using and interpreting the NRI.   
Most importantly for the models I present, NRI is only recommended for use where 
clinically meaningful cut points (or risk categories) can be chosen a priori, [192] and 
therefore the continuous NRI would be a better choice in this setting.  The continuous 
NRI considers the change in risk for all events and non-events without the need to create 
categories.  It is interpreted differently to the NRI, as not all changes in predicted risk 
would lead to a change in clinical management of a condition or implementation of an 
intervention, for example if a patient’s risk only changed minimally.  It has also been 
reported that the continuous NRI is often positive for weak markers, and that it can be 
strongly affected by miscalibration of the model.[192]  Correct calibration of models and 
ensuring that the two models to be compared were developed from the same data can 
minimise these issues.[192]   
Both NRI and continuous NRI are predominantly used to assess the addition of one or a 
small number of predictors to a pre-existing model.  When the classification abilities of 
two different models are to be compared and they are not well correlated, then both 
the discrimination and calibration of the models should be considered instead of the 
reclassification.[192]  This is due to the actual classification of patients being of greater 
interest than the movement of patients between groups.   
To assess whether the addition of discharge summary information improved the 
classification of the model, I would therefore need to first examine how well the two 
models were correlated.  Given the relatively small amount of additional data, I would 
expect to be able to use the continuous NRI.  In the case of the models I present, an 
increase in specificity (identifying more patients at a lower one-year mortality risk, and 
thus not assigning them to case management) would save clinicians time and health care 
resources, while not causing problems for the patient.  Increases in sensitivity (correctly 
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re-classifying patients at a higher mortality risk) would enable these patients to receive 
case management, and thus increases in sensitivity could be considered of higher 
importance than increases in specificity.   
7.6.4.3 Changing study population 
When developing these prognostic models, the study population comprised older 
patients who had been hospitalised with CAP between 2004 and 2011.  As shown in 
Chapter 6, hospitalisations with CAP increased over this period, but the increase did not 
appear to be explained by changes to the population’s co-morbidity profile, and short-
term mortality decreased.  The inclusion of data collected over a period during which 
there may have been an increasing tendency to hospitalise older patients with CAP could 
have created a cohort that had changing risks for longer-term mortality.  For example, 
the one-year mortality risk among those with specific co-morbidities may have 
decreased over time if those hospitalised with CAP more recently had less severe 
underlying disease compared to CAP patients hospitalised in 2004.  Had the prognostic 
models been calculated separately for each year, this scenario could have resulted in 
HRs for specific co-morbidities that were closer to null in later years than in 2004.     Had 
I restricted the study population to patients hospitalised with CAP in a later period, such 
as from 1st April 2008 (when CAP incidence first peaked in the linked data, as shown in 
Chapter 5) the cohort might have been less heterogeneous, and it is possible that the 
discrimination and calibration of the models could have been improved.  The Beta-
coefficients of the parameters in the model could then be updated annually (as happens 
with other prognostic scores such as QRisk,)[193] to take into account changes in disease 
severity in hospitalised patients that could result from changing health service patterns.  
A second consideration is that trends in disease ascertainment and recording are likely 
to have changed over the study period for some conditions, due to enhanced case 
finding and recording (for example, as a result of QOF).  This could have resulted in an 
already heterogeneous population becoming more diverse, and further diversified the 
group of patients categorised as having the specific co-morbidity in the prognostic 
models.  If disease severity was similar in those with ascertained and unascertained 
disease, the misclassification of disease status could have underestimated the effect of 
that co-morbidity on mortality risk in earlier years.  However, if (as seems more likely) 
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co-morbidities not ascertained until later in the study period were less severe that those 
ascertained earlier, the more recently diagnosed, less severely affected, patients could 
have had a lower one-year mortality risk than those diagnosed earlier.  Again, this may 
have resulted in the HRs associated with the co-morbidity over the entire study period 
being further from the null compared to those that would have been estimated had the 
study only included more recent data.   
For four of the co-morbidities of interest (diabetes, ischaemic heart disease, liver disease 
and renal disease) it was possible to broadly categorise patients into those with 
mild/moderate and severe disease, due to the codes used for these conditions.  For 
other illnesses such as chronic lung disease, it was difficult to differentiate between 
those with mild and severe disease.  For these latter groups in particular, the broad case-
mix is likely to have resulted in the assignment of a score for subsequent mortality that 
was too low for the more severely ill patients in the group, and too high for those with 
mild illness.  Similarly, the increased risk associated with specific age groups may not 
have captured the range of underlying health states, including frailty, within each age 
categorisation, and how this may have varied over the study period.  
7.6.4.4 Alternative models or strategies that could have been investigated 
It can seem attractive to create a single prognostic model for use in a wide range of 
patients; however, this may not always be the most appropriate approach.  If I were to 
repeat these analyses, one alternative could have been to use the now-available eFI to 
stratify the study population into those who were fit (0-4 frailty deficits), mildly frail (5-
8 deficits) or moderately/severely frail (≥9 deficits), and then develop separate 
prognostic models for each group.  The case-mix of patients included in each of these 
models may be less heterogeneous, which could increase the prognostic ability of the 
model.  In particular, the Beta-coefficients for variables such as age could be more 
appropriate for a larger proportion of the patients in each age group.  This approach 
would not tackle directly the lack of depth of coding for some co-morbidities.  However, 
in many cases, severe illness results in additional co-morbidity or increasing frailty and 
thus using the eFI to pre-stratify patients could also aid in creating more homogenous 
co-morbidity groups within each model.   
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Another potential approach would be to develop several disease-specific-models to 
assess predictors of mortality among patients with CVD or chronic lung disease.  
However, this approach could be complicated by patients with multi-morbidity 
potentially being assigned a different mortality risk in each disease-specific model, 
limiting its utility.  Due to this major limitation, the eFI stratification approach may be 
more appropriate.  
As highlighted above, restricting the study population to patients who were hospitalised 
with CAP from 2008 onwards could have been attempted to decrease heterogeneity in 
the case-mix over time. The drawback of developing models over a shorter time period, 
and possibly further stratifying by eFI to address differences in underlying frailty, is that 
the study populations would be considerably smaller than the one I used.  However, 
CPRD have recently gained access to anonymised GP data from practices that use EMIS 
general practice software, supplementing the existing data collected from practices that 
use Vision software.  Future provision of these EMIS data for research use will greatly 
increase the size of CPRD, and thus may help address sample size issues.  If the study 
populations of interest are still not large enough to meet the ten outcomes per potential 
predictor rule, then it may be necessary to attempt to limit the number of candidate 
predictors.   
7.7 Conclusions 
Information widely recorded in patients’ GP records has the potential to be used to 
inform GPs about patients’ one-year mortality risk after they have been discharged from 
hospital due to CAP.  The predictive value of the models was suboptimal, but could be 
increased in the future by using only recently collected data to develop the models, 
stratifying study populations by the extent of frailty, and including additional co-
morbidity information from the most recent hospitalisation (once recording on hospital 
discharge summaries is more consistent with that found in HES).  Before further models 
are developed and implemented, either the evidence for case management as an 
intervention would need to be strengthened, or an alternative intervention which could 
be implemented among higher-risk patients would need to be identified.  Then models 
such as those presented here could be useful for GPs who are contacting patients on the 
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ES register, and enable GPs to assess the level of post-hospital discharge support that 
older individuals may require in the longer-term after a CAP hospitalisation.   
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Chapter 8 Discussion 
The overall aim of this work was to use linked electronic health records to better 
understand the burden of community-acquired pneumonia among older adults in the 
UK, and to enable thorough assessment of risk factors for hospitalisation after CAP and 
for longer-term mortality after a CAP hospitalisation.  This chapter summarises the key 
findings of the main objectives, considers the strengths and limitations of using linked 
electronic health records for their investigation, and highlights the implications of the 
findings for research and clinical practice.  
8.1 Objective 1: Use of linked data to estimate the incidence of CAP and all LRTI 
8.1.1 What was known 
CAP and LRTI more broadly are common infections among older adults.  Given the 
increasing size of the UK’s older population, clarifying the burden of disease in this age 
group is important for health service planning.  However, there were relatively few 
studies of the incidence of CAP (or of LRTI in general) in the UK, and none specifically set 
among the older population.  Estimates of CAP incidence from the UK were generally 
lower than those from the rest of Europe.  This could be because the UK studies only 
utilised primary care data; CAP can be diagnosed and treated in either primary or 
secondary care, thus use of only one of these data sources may underestimate the total 
burden of infection.  Furthermore, there was a paucity of information about the burden 
of these infections in the UK over time, particularly age-specific estimates of incidence 
among those aged ≥65 years.      
8.1.2 What this study adds 
Novel methods were developed to identify episodes of pneumonia (and LRTI as a whole) 
from linked electronic health records (as described in Chapter 2), and to classify these 
as community- or hospital-acquired.  Within the primary care data, I identified an 
appropriate start of follow-up which excluded historical episodes of CAP reported when 
a patient registered with their general practice (Chapter 3).  The creation of illness-
episodes prevented repeat consultations for an ongoing infection from being counted 
as new events, whilst allowing the inclusion of subsequent incident episodes.  Use of 
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linked general practice and hospital data enabled capture of both moderate and severe 
cases of disease, more accurate identification (and subsequent exclusion) of hospital-
acquired infections, and more accurate estimation of person-time at risk of a 
community-acquired infection.   
The incidence analyses (Chapter 4) presented rates of CAP (and of all LRTI) among more 
than 1.5 million older patients over a 14 year period.  Crude incidence of CAP was 
estimated as 7.99 episodes/1000 person-years (and 122.9/1000 for all LRTI).  When 
stratified by age and sex, CAP estimates were almost 20% higher than those from a UK 
study using stand-alone primary care over a similar period.  The large study population 
permitted incidence estimates to be finely categorised by age, which revealed that 
between the ages of 65-69 years and 85-89 years, rates of CAP increased more than 
seven-fold and rates of LRTI as a whole doubled.  When examined over time, incidence 
of both CAP and of all LRTI generally increased (with fluctuations) between 1997/98 and 
2010/11; the increasing CAP trend was somewhat attenuated after adjusting for age, 
suggesting that the rising trend could be due to population ageing.   
Further assessment of the value of using linked data was performed by comparing CAP 
incidence using stand-alone CPRD data with that derived from linked CPRD and HES 
records in a single group of patients (Chapter 5).  This revealed increasing divergence 
between estimates from the two sources over time.  Rates derived from CPRD records 
did not increase over the study period, whereas those from the linked-data rose 
considerably.  Most of this increase was due to a higher number of CAP events recorded 
in the HES data over time.  Examination of CPRD records revealed that consultation with 
a GP on the day of the CAP diagnosis decreased over the study period from 82% to 43% 
of CAP episodes, and that consultation for any LRTI in the 28 days prior to the CAP 
diagnosis decreased from 15% to 10%.  This suggests that in addition to patients 
increasingly presenting to hospital when suffering from CAP, these hospitalised episodes 
are not completely recorded in primary care data.  This finding reinforces the value of 
using linked primary and secondary care data, and thus capturing both ambulatory and 
hospitalised episodes of disease.   
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8.2 Objective 2: Time trends and risk factors for hospitalisation after CAP  
8.2.1 What was known 
Hospitalisations for pneumonia in England have been shown to be increasing since 1997, 
and the majority of pneumonia hospitalisations are known to be among older adults.  
Use of secondary care data in isolation prevented these studies from distinguishing 
increasing pneumonia incidence from an increasing tendency to hospitalise older 
individuals with pneumonia.  Prior to this work, no UK studies had attempted to examine 
risk factors for hospital admission among patients with CAP, and thus estimate the 
contribution of factors such as individual co-morbidities, medication use or frailty to the 
increasing hospitalisation levels.    
8.2.2 What this study adds 
The cohort study of CAP patients in Chapter 6 showed that the population-averaged 
percentage of CAP episodes which resulted in hospital admission rose from 57% to 86% 
of episodes between 1998/2000 and 2009/10 after adjustment for a wide range of 
factors.  My use of linked primary and secondary care data revealed that hospitalisation 
post-CAP increased independently of any increases in CAP incidence over the study 
period.  The linked data also permitted thorough investigation of potential explanatory 
factors, some of which (such as vaccination status) were not routinely recorded in HES 
data. 
Fourteen co-morbidities, five frailty factors, and four medications/vaccinations were 
found to be associated with hospitalisation within 28 days of a CAP diagnosis.  Use of 
individual factors rather than a summary co-morbidity score identified very different 
associations between individual factors and odds of hospitalisation.  These ranged from 
terminal illness and dementia (which decreased patients’ odds of hospitalisation) to 
metastatic cancer, chronic lung disease and severe renal disease which all increased the 
odds of hospitalisation.  Replacing the individual co-morbidities included in the model 
with the Charlson co-morbidity index had almost no impact on the predicted probability 
of hospitalisation over time, but did conceal the direction and magnitude of individual 
risk factors’ association with hospitalisation. 
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This study also showed that over the study period, the odds of dying in the 28 days post-
CAP decreased progressively, and there was a slight decrease in length of hospital 
admission.  Together, these factors suggest that increasing CAP severity may not lie 
behind the rising trend in hospitalisation. 
While the factors identified explained little of the increase in hospitalisation post-CAP 
over the study period, investigation of other elements of the data provided possible 
explanation.  Emergency admissions coded as originating from A&E increased, while 
those arriving via a GP declined over the study period.  Records from primary care 
confirmed this trend; patients with a GP record of CAP (or LRTI more broadly) on the 
date of hospital admission also decreased over the study period.  This finding is in line 
with that from the data source comparison analysis (Chapter 5) which showed 
decreasing consultations with GPs on the date of CAP diagnosis over time.  Together, 
these analyses suggest an increasing tendency for older patients with CAP to present 
directly to hospital rather than via their GP. 
8.3 Objective 3: Prognostic models to predict longer-term mortality post-CAP 
hospitalisation  
8.3.1 What was known 
Older patients hospitalised for CAP have an increased mortality risk compared with both 
patients hospitalised for other reasons and the population at large.  Previous studies 
have shown that this risk persists after hospital discharge for periods ranging from one 
to more than ten years.  A tool to aid clinicians in identifying patients at increased risk 
of death after hospital discharge would enable GPs to monitor such patients’ underlying 
health conditions more closely, and potentially intervene to prevent some of these 
deaths.  Several prognostic scores are available to assist clinicians in decision making 
around whether to hospitalise a CAP patient at the point of diagnosis, based on 
predicted risk of death within 30 days.  However, studies of risk factors for longer-term 
mortality after discharge from a CAP hospitalisation are uncommon, and none have 
been undertaken specifically in the high-risk older population.  The risk factors identified 
in these papers were not restricted to those that are readily available to GPs, and thus 
would be of limited use after hospital discharge.  As described in the previous Chapter, 
only one existing study developed a prognostic model to be used post-hospital 
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discharge, but did so using incorrect methods and without validating the final model 
either internally or externally, and so its ability to perform in real-world settings is 
unknown.    
8.3.2 What this study adds 
Prognostic models for mortality post-CAP discharge were developed for three time 
periods: 1-7 days, 8-30 days and 31-365 days after hospital discharge, and each was 
internally validated using bootstrapping.  The prognostic scores were designed to need 
as little input from GPs as possible, making use of pre-existing information held within 
electronic general practice records.  In addition to the a priori variables age and sex, the 
candidate predictors included in the models varied by time period.  Of the 12 factors (1-
7 days), 17 factors (8-30 days) and 17 factors (31-365 days) included in each model, 
seven (peripheral vascular disease, dementia, connective tissue disease, 
cerebrovascular disease, solid cancer, living arrangements and low weight) were 
included in all three models.  The shorter scores showed reasonable discrimination, 
while the longest was sub-optimal.   All showed fair calibration.    
8.4 Strengths of the studies in this thesis 
Databases of electronic health records are increasingly commonly used in 
epidemiological research, due to their many strengths.  The linkage of these data to 
additional data sources is also becoming more common, providing researchers with a 
wealth of detailed data.  The use of linked data has resulted in the studies in this thesis 
having many strengths, as outlined below. 
8.4.1 Use of linked data 
Linkage of CPRD to HES and ONS death records provided an additional level of detail not 
available in stand-alone CPRD that benefitted the studies in a number of ways.   
8.4.1.1 Identification of CAP 
Linkage of CPRD to HES was important for many aspects of determining CAP and its 
incidence. Firstly, inclusion of hospital admissions for pneumonia enabled more 
complete capture of these events than would have been possible using CPRD alone, and 
resulted in a dataset of pneumonia episodes treated in hospital as well as episodes 
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managed in the community.  As shown in Chapters 4 and 5, this resulted in the reporting 
of more comprehensive and detailed CAP incidence estimates among older adults than 
had been achieved previously in the UK.   Secondly, use of the linked data informed the 
categorisation of pneumonia episodes into CAP or HAP (and thus the study populations 
of Chapter 6 and Chapter 7).  Although CPRD contains some information on patients’ 
hospitalisations such as the admission diagnosis, admission and discharge dates are not 
included.  Furthermore, the date a hospitalisation is recorded in CPRD may refer to the 
date of admission, date of discharge or the date the discharge summary was received 
by the general practice.  The accurate dates of admission and discharge provided by HES-
linkage were crucial to these analyses for several reasons, outlined below.     
8.4.1.2 Identifying episodes of infection, person-time at risk and CAP incidence over 
time 
Identification of all pneumonia (and other LRTI) records in both data sources enabled 
me to differentiate those that were related to an ongoing illness from those that were 
a new episode, by using a 28 day illness-episode structure.  I was then able to include 
the incident episodes experienced by each patient in my analyses, unlike many previous 
studies which have either included all consultations, or restricted analyses to the first 
diagnosis of CAP.    
The CAP illness-episode structure, together with hospital admission and discharge dates 
were used to define person-time not at risk of community-acquired infections in the 
incidence analyses presented in Chapter 4.  This improved the accuracy of the estimated 
incidence rates by only including person-time at risk of community-acquired infection.   
The linked data also facilitated better estimation of trends in CAP incidence.  Use of 
stand-alone primary or secondary care data may show a change in illness trends 
attributable simply to patients moving from one care setting to another over time.  This 
was illustrated in Chapter 5, in which CAP incidence estimated using stand-alone CPRD 
data suggested a slightly decreasing rate over time.  However, this was likely to have 
resulted (at least in part) from an increasing number of patients presenting and being 
first diagnosed with CAP in hospital, rather than a real decrease in disease incidence.  
Linkage of data sources provided protection against mis-characterisation of disease 
burden due to changing service provision or utilisation.   
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8.4.1.3 Better identification of risk factors for severe outcomes of CAP  
The date of CAP diagnosis and the hospital admission date provided by the linked data 
were used to define the outcome (hospitalised within 28 days of a CAP diagnosis) in the 
analysis of risk factors for hospitalisation.  Risk factors for hospitalisation post-CAP 
diagnosis are likely to differ from those for contracting CAP, but it is difficult to separate 
these using stand-alone data.  Use of linked data allowed restriction of the study 
population to those who had been diagnosed with CAP and thus examination of 
characteristics associated with their subsequent hospitalisation risk. 
The linked data were also essential for developing the prognostic models for mortality.  
Firstly, date of hospital discharge (from HES) provided an accurate start date for the 
mortality risk period.  The ONS-linked mortality data provided an accurate date of death, 
which was of utmost importance when examining time to death.  While CPRD records 
include a date of death, it is estimated from up to three dates that can be recorded 
within the general practice records, and so cannot be considered definitive.  When 
analysing short periods of follow-up (for example 1 to 7 or 8 to 31 days in the prognostic 
modelling work), errors in the date of death by even a few days may result in patients 
being included in the wrong mortality model, and inaccurate estimation of predictors of 
mortality.   
8.4.1.4 Identification of potential risk factors for severe outcomes  
The linked data provided more complete information on patients’ co-morbidity status.  
The CPRD data provided a record of patients’ longer-term medical history, while the use 
of HES records ensured that diagnoses made in hospital were fully captured.  Research 
comparing CPRD and/or HES to disease registries for MI and cancer show that linking 
CPRD to HES captures 23% and 33% more events respectively than use of stand-alone 
CPRD.[194, 139]  Additionally, each data source provided information not available in 
the other.  For example, CPRD provided detailed information on factors such as prior 
vaccination, therapies, smoking status and frailty, while admission diagnoses in HES 
enabled identification of hospitalisations for events such as cataract surgery.   
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8.4.2 Large sample size  
One of the primary strengths of both CPRD and HES is their considerable size, containing 
data collected over many years.  The study population for the incidence analyses in 
Chapter 4 contained over 1.5 million patients, over 900,000 of whom were eligible for 
HES linkage.  The large sample size enabled thorough examination of rates by age and 
sex over time, in a level of detail not previously reported in studies of CAP among older 
UK adults.[128, 121]  The >900,000 patients in the linked data provided more than 
45,000 CAP episodes in England over 13 years for the analysis of risk factors for 
hospitalisation.  Having a sizable study population facilitated the risk factor analysis, 
obtaining precise estimates of relative risk for a wide variety of individual co-morbidities 
and other factors which could influence hospitalisation decisions.  The availability of 
patient records over several years enabled me to then assess the contribution of these 
factors to increasing hospitalisation trends over time, which previous smaller studies 
comparing ambulatory and hospitalised CAP had not been able to do.[122, 125, 130]  In 
Chapter 7, patients’ CAP episodes were restricted to those that required hospitalisation 
and were discharged between 2004/5 and 2010/11, and >12,000 CAP episodes were 
eligible for inclusion in the development of prognostic models for long-term post-CAP 
mortality.  This provided a large population in which to investigate the contribution of 
the 44 candidate predictors of mortality, and (with the exception of the 1-7 day model) 
the analyses contained more than the recommended 10 outcomes per potential 
predictor.  The studies presented in this thesis would have been either impossible or 
severely limited in their scope if the data available had been smaller in size. 
8.4.3 Prospectively collected data  
Both CPRD and HES contain routinely recorded information, collected prospectively.  
CPRD captures all consultations between a patient and their GP (which are typically 
coded during the consultation), as well as patients’ medical history, prescriptions and 
vaccinations.  Diagnoses in HES capture the illnesses patients are treated for during a 
hospitalisation (including the main condition treated, any underlying conditions that 
require treatment and medical events that arise during the hospitalisation), and these 
diagnoses are translated into their equivalent codes at the end of the hospitalisation by 
specialised teams of medical coders.  The prospective nature of the recording of 
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exposures such as co-morbidities, vaccinations and medications eliminated the 
possibility of recall bias (in which patients’ reporting of their exposure status is 
influenced by their outcome status).  Observer bias (when knowledge of exposure status 
influences the classification of the outcome) should not have been an issue, as the 
outcomes were hospitalisation or death, defined using dates from the HES- and ONS-
linked data. 
8.4.4 Assessment of hospitalisation for any cause after CAP 
I did not restrict the analysis in Chapter 6 to hospitalisations specifically for CAP, but also 
included hospitalisations for any reason in the 28 days after CAP.  This will have captured 
the fuller effect of CAP via its role in worsening of patients’ co-morbidities, in addition 
to any acute events it may have precipitated such as MI, stroke or falls.  This will be of 
particular use when forecasting healthcare use among the older population. 
8.5 Potential limitations 
Despite their many strengths, it is important to remember that these records are 
primarily intended for clinical use, and the use of linked data thus provides some 
challenges and some limitations.  Those of specific studies were discussed in the relevant 
chapters; these are also summarised here along with overarching potential limitations. 
8.5.1 Misclassification   
8.5.1.1 Misclassification of CAP due to imperfect diagnostic validity 
As mentioned in previous chapters, pneumonia diagnoses have not yet been validated 
in either CPRD or HES, and thus there is no clear gold-standard.  As highlighted in section 
1.1.4, clinical diagnosis of pneumonia in adults has been shown to have low sensitivity 
compared to diagnoses made with chest radiographs and the diagnosis can be 
particularly difficult in older adults, who can present with fewer, non-specific 
symptoms.[18-20] 
A previous multi-centre European study of adults has indicated that clinical diagnoses of 
pneumonia in general practice had sensitivity as low as 29% when compared to 
subsequent chest x-ray in the week following diagnosis.[20]  It is possible that a similar 
level of under-diagnosis occurred in the CPRD data, although the older study population 
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included in these analyses may have been treated more cautiously by GPs than the 
somewhat younger patients that were included in the European paper.[20]  If GPs in the 
UK did regularly under-diagnose less severe cases of CAP (for example due to the less 
specific presentation of CAP among some older patients), this would have consequences 
for objectives 1 and 2 in this thesis.  In the incidence study CAP would have been under-
ascertained in primary care, and thus the incidence estimates presented in Chapter 4 
are likely to be underestimates.  Any under-ascertainment of ambulatory CAP episodes 
would have also affected the analysis of trends in post-CAP hospitalisation in Chapter 6, 
leading to an overestimate of the percentage of cases hospitalised.  As discussed in 
Chapter 5, the higher estimates of CAP incidence obtained from linked hospitalisation 
data compared to stand-alone general practice data are likely to be due to CAP 
diagnoses made in hospital that were either undiagnosed when seen earlier by GPs, or 
that were not seen by GPs (because patients presented directly to hospital), with the 
hospital diagnosis being incompletely recorded by general practices.  If the under-
ascertainment in general practice increased (i.e. sensitivity decreased) over time, while 
the sensitivity of pneumonia diagnoses in hospital remained stable or even increased 
(for example due to more frequent use of CT-scans), this would also have contributed 
to the greater increase over the study period in diagnoses of pneumonia in HES than 
CPRD reported in Chapter 5, as well as the growing hospitalisation trend shown in 
Chapter 6.         
When thinking about misclassification of disease status, it is important to consider not 
just the sensitivity and specificity, but also whether the recorded diagnoses are correct 
(their positive predictive value).  Again, the lack of access to chest x-rays in primary care 
may have resulted in pneumonia diagnoses in HES having a higher positive predictive 
value than those in CPRD.  In the multi-centre European study of adults with cough, 
clinical diagnoses of pneumonia by GPs had a PPV of 57%.[20]  However, prevalence of 
pneumonia in the European study was only 5%, and this limits generalisability of these 
PPV findings to older study populations with cough, who are likely to have higher 
prevalence of pneumonia.  On its own, imperfect positive predictive value of recorded 
pneumonia diagnoses would have resulted in an overestimation of CAP incidence.  
However, if the number of non-CAP cases incorrectly included was lower than the 
number of cases missed due to the imperfect sensitivity of the diagnoses, this would 
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have resulted in an overall underestimate of incidence.  In the hospitalisation risk factor 
analyses, inclusion of some ambulatory cases that were not CAP may also have affected 
effect estimates for some covariates.   
8.5.1.2 Misclassification of CAP due to diagnostic coding practices 
Over the period of study, the method by which hospitals were assigned funding 
changed, and this may have influenced the coding of diagnosis in the hospitalisation 
dataset used for this thesis.  Prior to 2003/4, hospitals were assigned funds according to 
a block grant based on their previous year’s costs and activity.[195]  Between 2003/4 
and 2007/8, a system called Payment by Results (PbR) was gradually introduced in 
England, which was developed to better link payment to the case-mix of patients 
treated.  The aims of PbR were to provide more transparent funding, reward efficiency, 
and encourage hospitals to work toward reducing waiting times.[196]  The system is 
similar to those used in the US, Canada, Australia and several European countries, 
whereby hospitals are paid for the services they have provided.  Within the English NHS, 
this payment is derived from the diagnoses made during a period of care, for example a 
hospital admission, and these diagnoses are translated post-discharge into ICD-10 codes 
by clinical coders.  The coded diagnoses are collected centrally, and these are the codes 
provided to researchers to be used in HES.  For the purposes of PbR, the codes are 
grouped into Healthcare Resource Groups, from which a payment for the care is 
assigned.[196]  National tariffs are published every year, along with adjustments which 
may be made for short/long stays, best practice and specialised care.[196] 
This type of payment system is susceptible to a practice called ‘upcoding’ or ‘gaming’, 
whereby patients are coded as having a condition that is more severe or more expensive 
to treat than the condition they actually have, thus increasing the income of the 
healthcare provider.  Instances of upcoding have been reported in the US and Europe, 
while preliminary studies of upcoding in England have provided conflicting 
evidence.[195]  A systematic review of discharge coding in the UK compared discharge 
coding accuracy before and after the introduction of PbR in 2004, and found no 
differences in coding accuracy overall (pre-PbR 77.0% (IQR: 66.2-89.0), vs. post-PbR 
86.1% (IQR: 73.1-96.1%)).  Accuracy of the primary diagnosis improved after PbRs 
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implementation (pre-PbR 73.8% (IQR: 59.3-92.1%), vs. post-PbR 96.0% (IQR: 89.3-
96.2%), p=0.020).[197]   
However, absence of evidence is not evidence of absence, and it is possible that 
upcoding occurs within the NHS.  There are several ways in which upcoding could have 
affected this work.  One is if LRTIs less severe than pneumonia were coded as pneumonia 
in order to attract a higher payment tariff.  This could explain at least some of the 
increase in hospitalisation after CAP over time that was described in Chapter 6, and 
would be compatible with the slight decrease in length of hospitalisation over that 
period.  Alternatively, some patients who had pneumonia, but who were admitted and 
treated primarily for a different condition that would have resulted in a lower tariff, 
could have been wrongly assigned a primary diagnostic code of pneumonia.  If these 
cases had pneumonia that was hospital-acquired, this would have resulted in over-
estimation of the incidence of CAP, and of hospitalisation after CAP over time.  It is 
possible that patients without pneumonia or any other LRTI were also assigned a 
pneumonia code, but given the increasing validity of HES diagnoses over time, there is 
little evidence to support this.    
8.5.1.3 Misclassification of CAP due to methods used to manage the data 
I categorised pneumonia episodes which started within 14 days of a hospitalisation as 
hospital-acquired.  As previously discussed, in stand-alone CPRD data hospitalisation 
was identified using information recorded by the practice from discharge summaries, 
which may have been recorded on one of several dates.  If the date of the record was 
before the real date of discharge, or if the hospitalisation was not recorded in CPRD, 
some pneumonia episodes would have been incorrectly categorised as CAP rather than 
HAP.  Conversely, if the recorded date was some time after the real discharge date, some 
episodes of CAP may have been incorrectly categorised as HAP.  More generally across 
both stand-alone and linked data, the use of a 14 day rule could have led to some 
misclassification between CAP and HAP.  There is no consistent choice across the 
literature of the timing of the exclusion window for HAP; previously used exclusion 
periods vary from between 7 to 30 days after hospital discharge.[81, 176, 19]  A two 
week exclusion period is commonly used,[80, 85, 198, 86] but as with any rule, 
exceptions are possible.  For example, a small number of CAP episodes may have been 
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excluded for patients who were infected soon after discharge from hospital.  
Misclassification of CAP and HAP may thus have occurred to some small extent due to 
incorrect recording of hospitalisation timing in stand-alone CPRD or to the use of the 14 
day hospitalisation rule.  Nevertheless, the analyses in this thesis approach the issue of 
separating hospital and community-acquired infections in a more detailed and thorough 
manner than has previously been attempted when examining CAP in the UK.   
Re-consultation for an ongoing LRTI within 28 days has been shown to be common (25% 
to 33% of patients),[35, 57-60] so I used a 28 day illness episode structure in order to 
combine multiple consultations for one illness into a single CAP illness episode.  It is 
possible, albeit very unlikely, that a small number of patients did experience two CAP 
episodes within 28 days, of which only one would have been included in the study.  Over-
recording of CAP was potentially more of an issue, although this too would have been 
at a low level due to the vast majority of patients only experiencing one CAP event over 
the study period.  Over-recording may have occurred if one episode of illness was 
recorded twice more than 28 days apart, either separately in CPRD and HES, or 
repeatedly in CPRD (for example once as the patient’s initial diagnosis and then 
subsequent recording of a hospital diagnosis).  Any over-counting of the number of 
episodes would have resulted in overestimation of CAP incidence.  If the recording 
occurred in both CPRD and HES, these single episodes would also have been included 
twice in the risk factors for hospitalisation analysis, and thus the importance of their 
underlying co-morbidities on odds of hospitalisation may have been slightly over-
estimated.  The restriction of the mortality prognostic models to the first CAP in a year 
will have prevented this from being an issue in these models.  Electronic discharge 
summaries were increasingly used across the study period, with the addition in 2008 of 
a 72-hour target for their receipt by GPs (decreasing further to 24 hours in 2010).[199]  
If very late recording did occur, it would have been in low and in decreasing numbers, 
and should not have significantly changed the results presented. 
As outlined in section 2.1.2, HES data can include up to 20 recorded diagnoses across an 
episode (a period of consultant care), along with the dates each episode began and 
ended.  Unfortunately, information which would have enriched this work, such as the 
specific date each diagnosis was made, the diagnosis at presentation to the hospital or 
the main reason the patient was admitted to hospital is not provided.  I used the primary 
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code of the first episode as a proxy for the reason for admission, as it seemed reasonable 
to assume that the majority of patients will have been admitted to hospital for the main 
condition that was subsequently treated or investigated over the episode of care.  This 
approach was also taken to minimise inclusion of episodes of pneumonia arising in 
hospital (HAP), assuming that HAP would usually be coded with a secondary diagnostic 
code.  However, there will have been occasions when patients admitted to hospital with 
CAP did not have pneumonia as the primary diagnostic code.   For example, if a patient 
with CAP was admitted for a more severe condition or one which required a larger 
amount of care than pneumonia (such as a myocardial infarction, or sepsis following 
pneumonia), then this condition would have been the primary code of the first episode, 
and the pneumonia recorded as a secondary code.  I would not have included these 
cases (unless they were also coded as pneumonia in CPRD on or before the day of 
admission, see section 2.4.3), thus underestimating the incidence of CAP and level of 
hospitalisation.   
Conversely, some of the hospitalisations in the 28 days following a pneumonia diagnosis 
made in the community, and some of the hospitalisations that had a pneumonia code 
as the primary diagnosis for the first episode, may not have been a result of CAP.  For 
example, if a patient developed a mild case of CAP in the month before a scheduled 
elective hospitalisation and the CAP was treated promptly, it is possible that the elective 
surgery subsequently went ahead.  However, it is unlikely that this would apply to many 
of the CAP episodes in the study, as most of the hospitalisations after a CAP diagnosis 
were on or very soon after the CAP diagnostic date.   Alternatively, if a patient was 
admitted with a less severe condition than pneumonia and subsequently acquired 
pneumonia in hospital during the first episode of care, it is possible that the pneumonia 
would have been chosen as the primary code of the first episode and a case of HAP 
incorrectly included in my analyses.  In retrospect, there were additional ways I could 
have utilised the data to further tease apart community- and hospital-acquired 
infections.   
One possibility would have been to limit pneumonia diagnoses to those classified as 
emergency admissions.  As shown in Table 4 of the hospitalisation paper (section 6.3.3), 
there were very few cases in which HES pneumonia codes were included and the 
admission type was recorded as ‘elective’ (defined as “when the decision to admit could 
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be separated in time from the actual admission”).[200]  These cases made up 2% of total 
CAP hospitalisations included in the analyses in Chapter 6, and this fluctuated a little by 
year (from 2.7% in 2001 to 1.5% in 2009).   While this was a small proportion of the CAP 
episodes included my analyses, I would exclude them if I was repeating this work, as 
they are more likely to have been HAP than CAP.  I would also exclude any elective 
admissions in the 28 days after a CAP diagnosis made in the community. 
I could also have examined the treatment speciality of the consultant to which the 
patient was assigned during the initial period of care.  This may have enabled me to 
identify cases with pneumonia who were treated on a surgical ward, and these cases 
could also have been excluded as probable HAP.  A more wide-reaching method would 
have been to flag all first episodes in HES which included both a primary code for 
pneumonia (i.e. when pneumonia was the main condition treated during the episode) 
and a code for any unrelated surgical procedure, as being potential HAP episodes.  This 
would have helped to identify patients who had surgery and subsequently developed 
HAP, which was then treated whilst under the care of the same consultant surgeon.  
Pneumonias diagnosed after surgery and treated by a medical rather than surgical team 
would have been recorded in a subsequent episode of the hospitalisation and thus not 
included in my analyses.  However, given the large number of surgical codes that this 
approach would have required to be considered, and the lower incidence of HAP than 
CAP, this would have been a labour intensive method to identify a small number of cases 
in addition to those I could have identified using the ‘elective’ admission type.       
8.5.1.4 Misclassification of other covariates of interest (co-morbidities, etc.) 
The positive predictive value of diagnoses in CPRD has generally been found to be high, 
and the accuracy of diagnoses in HES is improving.[106, 112]  When ascertaining the 
presence of co-morbidities in the analyses in Chapters 6 and 7, I included any diagnosis 
prior to the CAP incident date as evidence of a patient having the condition.  For some 
conditions such as cancer or stroke, a code may represent either an ongoing or a 
resolved event.  Utilising diagnoses from the complete patient record prior to the CAP 
considers ongoing and resolved comorbid events to have an equal strength of 
association with the outcome, which may not be the case.  However, the inclusion of all 
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prior diagnoses also ensures the inclusion of current co-morbidities such as chronic lung 
disease, that GPs may not repeatedly code (as they are not required to do so).   
Fewer validation studies have examined the sensitivity of diagnoses in these data.[106] 
In the analysis of risk factors for hospitalisation, the use of linked CPRD-HES data should 
have enhanced the recording (i.e. sensitivity) of co-morbidity status for patients who 
had been hospitalised for any reason prior to their CAP episode.  If these patients were 
also more likely to be hospitalised within 28 days of CAP this could have resulted in 
differential misclassification of exposure status, leading to possible over-estimation of 
effects of these co-morbidities on the odds of hospitalisation.  The vast majority of the 
older patients included in this analysis had hospital admission records at some point in 
time (94.4%), and so any bias is likely to have been very small.  Conversely, it is also 
possible that some factors, such as those pertaining to frailty, BMI, and smoking (in the 
earlier period of the study) were under recorded (had low sensitivity).  The effect of any 
bias from this misclassification would depend on whether these variables were better 
recorded in less well patients (who were more likely to be hospitalised or die) than in 
patients without the outcome of interest.  An important outcome of this thesis is that 
the low level of frailty recording in these data has now been highlighted. 
Non-acute co-morbidities which were recorded for the first time during a CAP 
hospitalisation, but only after the first episode of the hospitalisation, were not coded as 
‘present’ in my analyses in Chapter 6.  The rationale for this decision was to exclude 
conditions that had not yet occurred at the time patients with CAP were assessed by 
their GP or at hospital, as well as conditions that were present but only diagnosed after 
the patient was hospitalised.  For some of the longer-term conditions such as cancer or 
diabetes, new diagnoses may have been made later in the hospitalisation after the 
patient had presented with CAP.  Alternatively, it is possible that the diagnosis may have 
been known to the GP or admitting physician but not previously coded in the patient’s 
electronic health record.  Thus, exclusion of diagnoses recorded only after the first 
episode of the CAP hospitalisation could have resulted in some misclassification of co-
morbidity status.  In order for this to have substantially affected the ORs reported, a 
substantial number of newly recorded diagnoses would have needed to be made for 
patients hospitalised with CAP, during their second (or later) episode of care.  If I were 
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to repeat the analyses, it would be interesting to assess how much difference the 
addition of newly recorded chronic conditions would have made.     
The analyses to develop prognostic models for longer term mortality were limited to 
CPRD co-morbidity diagnoses only, to reflect the intended setting for these models.  The 
co-morbidity statuses used in these models thus reflect GPs’ recording practices rather 
than patients’ full underlying health status, and will have resulted in some under-
recording of patients’ medical history.  Again, the effect of any under-recording of co-
morbidity status on the results from this analysis depend on whether the under-
recording differed with respect to patients’ subsequent mortality.  Many of the 
conditions of interest require regular treatment and are thus likely to have been known 
to the GP.  Inclusion of HES diagnoses may have improved the sensitivity somewhat, but 
would have resulted in a model unsuited to automated use in primary care.  
8.5.2 Completeness of recording of pneumonia diagnoses across the data sources 
Over the time period covered by this study, there have been important changes to the 
provision of primary care, which had the potential to affect the recording of pneumonia 
diagnoses in both CPRD and HES.   
In 2004, GPs became able to opt-out of providing out-of-hours (OOH) care (broadly 
defined as care between 6.30pm and 8.00am, on weekends and bank holidays) which 
could instead be provided by a third party.  The majority of general practices have since 
opted out with only 10% of practices providing their own OOH care in 2013/14.  Over 
the same period, the number of cases being handled by OOH care declined from 8.6 
million in 2007-8 to 5.8 million in 2013-14.  The majority of this decrease was attributed 
to increased use of NHS Direct, a 24 hour telephone advice service staffed by nurses 
who provided basic health advice or directed patients with more serious illnesses to the 
appropriate part of the NHS, such as their GP or A&E.[201]    
Of the 5.8 million OOH cases in 2013-14, 3.3 million were face-to-face consultations 
including 800,000 GP home-visits.  The number of in-hours consultations provided by 
GPs that year was estimated at over 300 million.[202]  While the OOH consultations 
make up a small proportion of the total cared for in primary care, it is important that 
their information is still available in primary care records.  To ensure that GPs are aware 
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of OOH consultations, since 2005 OOH service providers have been required to meet a 
set of national quality requirements (NQR).  The second of these is that: 
“Providers must send details of all OOH consultations (including 
appropriate clinical information) to the practice where the patient is 
registered by 8.00 a.m. the next working day. Where more than one 
organisation is involved in the provision of OOH services, there must be 
clearly agreed responsibilities in respect of the transmission of patient 
data.”[202] 
Despite the requirement of the service provider to share the information of patients 
treated out-of-hours, some CAP diagnoses made during OOH consultations may not 
have been coded into patients’ GP records (and thus would not have been captured in 
CPRD).   
Over a longer time period, trends in A&E attendance rose considerably from 14.12 
million attendances in 1996/7 to 21.38 million in 2010/11.[203]  The majority of this 
increase happened from 2004 onwards (as OOH care changed providers), and was 
largely due to increasing visits to minor injury units and urgent care centres rather than 
major A&E departments.[204]  While A&E records were available for the HES-linked data 
from 2007 onwards, previous research has shown that the records were not complete 
until after 2010/11.[204, 205]  Additionally, the recorded diagnoses in the A&E data 
were lacking in detail and would not have provided sufficient depth of coding to have 
been useful in this work (for example, general headings such as ‘respiratory disease’ are 
widely used rather than ‘pneumonia’ or ‘COPD exacerbation’).[Rachel Williams, CPRD, 
personal communication]  Therefore the A&E data were not considered to be of high 
enough quality to include in my analyses.  The quality of this coding is now starting to 
improve, and it may be possible to include A&E diagnoses in future work. 
Within CPRD there is provision of a ‘constype’ field within the consultation file to record 
when and where the consultation (and the resulting diagnoses) occurred, such as a 
surgery consultation, night visit at home, A&E, or out-of-hours visit.  As the location of 
the consultation was not initially of interest, this was not something I investigated 
thoroughly.  In retrospect, an analysis of the ‘constype’ of CAP records in CPRD over time 
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could have provided useful detail when evaluating trends in recording of OOH and A&E 
care.  
As a result of the changes to OOH care and trends in A&E attendance, the analyses of 
incidence (Chapters 4 and 5) and of risk-factors for hospitalisation (Chapter 6) may not 
have fully captured patients who required out-of-hours treatment or presented to A&E 
with pneumonia, especially if these patients were not subsequently admitted to hospital 
or seen by their GP.  While it is not possible to know the extent of any underestimation 
in incidence, there are two reasons to believe it may not have been sufficiently large to 
change appreciably the results shown. 
Firstly, the NQR for providers of OOH care to send details of the OOH care to GPs may 
have reduced the potential for underascertainment of the relatively small proportion of 
consultations via this method, provided they were coded by the GP once reported.   
Secondly, while A&E and affiliated services such as minor injury units and urgent care 
centres accounted for a larger number of attendances than OOH care, an increasing 
percentage of hospitalisations for/after CAP were found to arise from A&E consultations 
(from 50.6% in 1998-2000, to 76.4% in 2009-10, see Chapter 6).  This suggests that many 
of the increased A&E consultations translated into admissions.   
Excluding some CAP events that were diagnosed in OOH services or in A&E may also 
have affected the hospitalisation risk factor analysis in Chapter 6.  It is possible that 
patients with CAP who were seen in these settings would have been more likely to have 
been captured in the CPRD or HES data (and thus included in the hospitalisation 
analyses) if they had specific characteristics.  For example, given the potential severity 
of CAP with increasing age and among those with co-morbid diseases, the oldest 
patients and those with co-morbidities could have had a higher probability of referral to 
their own GP for follow-up, or for hospitalisation after A&E assessment.  In contrast, 
relatively young patients and those with fewer co-morbidities could have been simply 
prescribed antibiotics by the clinician they consulted.  Exclusion of the latter patients 
from the ‘non-hospitalised’ group in the hospitalisation analyses may have resulted in 
an overestimation of the ORs for hospitalisation in younger age-groups, and an 
underestimation of the effects of some co-morbidities.  
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8.5.3 Accuracy of linkages to HES and to mortality data  
The analyses in this thesis assume that the linkages between CPRD, HES and ONS are 
accurate.  This is likely to be true for the majority of cases given the deterministic 
algorithm used by the trusted third party to link the datasets, which includes NHS 
number and other patient-identifiable data.  However, information regarding the 
accuracy of individual patient linkage between CPRD and HES is not readily available, 
and it is possible that linkage errors occurred at a low level.    
There are two types of linkage error which may have occurred.  False matches involve a 
patient’s CPRD records being incorrectly linked to a different patient’s HES records.  This 
would have resulted in an incorrect medical history being assigned to a CPRD patient via 
the HES records, in addition to incorrect dates of hospital admission and pneumonia 
diagnoses (if any occurred in the HES data).  Any false matched HES pneumonia 
diagnoses may have resulted in a small overestimation of CAP incidence and levels of 
hospitalisation post-CAP.  They may also have slightly biased the association between 
risk factors recorded in the patient’s CPRD record and hospitalisation post-CAP, or 
mortality post-CAP hospital discharge.  Should the CPRD patient have additionally been 
matched to the correct HES data, then their HES records will have included both correct 
and incorrect information (although this double-linkage seems extremely unlikely).     
Secondly, missed matches may have occurred where a patient’s CPRD records are not 
linked to their HES records.  This would result in their having missing data on hospital 
admissions (including the associated person-time not at risk, and any CAPs diagnosed in 
hospital) and thus potential under-ascertainment of the outcome in the hospitalisation 
analysis, and their exclusion from the mortality analysis. 
The lack of patient identifiers available to researchers makes recognition of these 
possible linkage errors between CPRD and HES extremely difficult.  A recent analysis 
attempted to identify possible false-matches for children and adolescent records within 
stand-alone HES data in the absence of patient-level identifiers, using simultaneous 
admission at multiple hospitals and readmission after death to identify false 
matches.[206]  Theoretically, this may also be possible to assess matching of CPRD to 
HES, although it is outside of the scope of this thesis.  However, readmission after death 
in HES data could equally be due to incorrect coding of death in the discharge 
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destination or discharge method.  A better understanding of the validity of these data 
fields may be advisable before using them as a gold standard to assess matching 
accuracy.   
Both of these types of linkage error may also have occurred when linking CPRD to ONS 
records.  However CPRD have recently started to provide information on this linkage 
including the strength of the match (as described in section 2.1.4) and the number of 
CPRD patients with more than one ONS date of death match.  Multiple matching 
occurred in an extremely small minority of patients in this study (87 of the >900,000 
eligible, <0.01%) and I was able to identify the most appropriate linked record in each of 
these cases.   
Considering the very small level of false-matching found between CPRD and ONS data, 
it seems likely that it occurred at a very low level between CPRD and HES, and thus any 
false matches should not have significantly affected the results I present.  While missed 
matches between the linked data sources may have occurred, again, it is unlikely this 
will have been at a high enough level to change my findings.   
8.5.4 Confounding 
If variables are misclassified, this can result in residual confounding.  In the majority of 
the analyses included in this work, covariates were included as factors of interest in their 
own right.  However, it was possible for variables to confound the effect of other factors 
in the model.  For example, the analyses in Chapter 6 showed that the strong effects 
shown in minimally adjusted models for some co-morbidities were diminished after the 
model was additionally adjusted for other co-morbidities.  It is therefore conceivable 
that in some cases in the analyses in Chapter 6 and Chapter 7, misclassification of 
covariates may have resulted in some low-level residual confounding.   
8.5.5 Multiple testing 
When large numbers of tests are carried out in one analysis, some of the associations 
which are revealed may have occurred by chance (a Type 1 error).  In these situations 
results should be interpreted cautiously.[113]  In this thesis this applies in particular to 
the risk factor analysis presented in Chapter 6, in which the final model included 
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fourteen co-morbidities, five frailty factors, and four medications/vaccinations in 
addition to age and sex.  P-values were intentionally excluded from the results presented 
in this paper, because even small differences are likely to have small p-values in analyses 
of very large data such as these.  The potential effect of multiple testing should be borne 
in mind when assessing the adjusted ORs for each factor in the model, and the size of 
effect estimates and examination of the 95% CIs were used instead to guide 
interpretation of the data.  Multiple testing also occurred during the development of the 
prognostic models in Chapter 7.  The p-value for selection of variables into the models 
was intentionally large (p<0.2) in order to include strong but uncommon predictors, as 
recommended when developing these scores.[115]  Unlike causal models, the inclusion 
of variables in prognostic models due to chance (known as ‘noise variables’) has been 
shown to have only a limited effect on their predictive ability, and is not thought to be 
a cause for concern.[115]   
8.5.6 Generalisability of the results  
Patients contributing to CPRD as a whole have been shown to be broadly similar to the 
UK population, most recently with regards to age and sex when compared to UK Census 
data from 2011.[99]  However, HES-linked data were only available for England, due to 
the different versions of HES used in Scotland, Wales and Northern Ireland.  The analyses 
of risk factors for hospitalisation and the prognostic models for mortality were thus both 
restricted to using English CPRD HES-linked data.  Linkage only occurs when practices 
consent to it, however patients with HES-linked data have been shown to be similar to 
those without these data.[104]  Differences in health policy since the devolution of UK 
health services in 1999 may have led to a lack of generalisability between the results 
presented here and for patients in the rest of the United Kingdom.  The results from the 
hospitalisation analysis in Chapter 7 may also have limited generalisability to older 
populations in other European nations, due to changes in service provision and usage 
which seem to have driven so much of the rising hospitalisation trend in England.   
When investigating CAP hospitalisation trends, I included all hospitalisations within 28 
days of a CAP diagnosis, rather than those specifically for CAP.  This enabled me to 
additionally capture hospitalisations for other conditions which were precipitated by 
CAP, but as a result the risk factors identified are not necessarily specific to 
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hospitalisation for CAP itself (although 95% of admitting diagnoses were coded as ICD-
10 Chapter X, diseases of the respiratory system).   
8.6 Implications of the study findings for clinical practice and future research  
8.6.1 Implications for clinical practice/health policy 
As the UK population ages and progresses through the older age groups, the overall 
incidence of CAP in the UK will increase, necessitating greater healthcare provision.  
Thus, CAP will continue to present an increasing burden to the health system.  Previous 
research on CAP from the UK has been among adults of all ages, and has lacked detailed 
stratification of the older population by age.  The incidence analyses I present show that 
older individuals comprise a highly heterogeneous population, with wide ranging 
disease burdens that are concealed by the summarised age grouping used in many 
studies.  These enhanced estimates of the burden of CAP in the older population provide 
important information for health planners as they prepare for the consequences of the 
ageing of the UK population.   
Rising numbers of CAP events will result in further increases in hospitalisations.  My 
thorough characterisation of the population of CAP patients at risk of hospitalisation, 
and the contribution of risk factors to hospitalisation trends will also help inform health 
provision in the future.   As a consequence of increasing hospitalisations, GPs will be 
responsible for ever larger numbers of older patients at increased risk of mortality.  The 
prognostic scores developed in Chapter 7 could assist GPs in identifying specific patients 
at heightened risk, and in future may enable targeted follow-up to ensure their co-
morbidities are well managed and their underlying health is not worsening.  Should 
external validation further confirm the scores to be an accurate clinical tool, it may be 
possible to build them directly into GP software systems.   
Frailty and older patients’ health are currently being highlighted as priority areas for 
primary care.  As discussed above, I have shown that the present level of frailty recording 
in CPRD precludes its use for extensive research on this topic, which is a missed 
opportunity.  Changes to the GP contract, including longer appointment times, may go 
some way toward supporting fuller recording of these aspects of patients’ lives.[158]  
The benefits and results of enhanced recording should also be fed back to the GP 
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community at large.  Time with patients will and should always take precedence over 
time spent coding, but without thorough and accurate coding the knowledge gained 
from these records is limited, and an opportunity lost. 
8.6.2 Implications for future research 
The findings presented in this thesis provide several areas for further research.  One of 
the most important of these is the validation of the pneumonia (and LRTI) codes used in 
this study.  A better understanding of the positive predictive value and sensitivity of 
these codes in both primary and secondary care data over time would allow more 
thorough interpretation of the results I have presented.  In particular it may inform the 
marked divergence in CAP rates estimated from stand-alone CPRD compared to linked 
CPRD-HES.  Currently, there is no ‘gold standard’ between HES and CPRD for pneumonia 
records, but validation of diagnoses in both data sources may help to identify one.   
Combining data from several sources can be complex and time consuming, and detailed, 
well-designed plans for merging the data must be made.  A thorough understanding of 
the individual data sources can result in their combined use greatly enhancing 
epidemiological analyses.  The methods I developed to use linked-data to identify 
episodes of disease, person-time at risk of infection and differentiate community- from 
hospital-acquired infection are transferable to many other infections across the wider 
population.  So far, my methods have been used in subsequent analyses of the incidence 
of community-acquired LRTI, urinary tract infections and sepsis among older adults with 
diabetes,[207] and LRTI, CAP and sepsis among older adults with chronic kidney disease 
and diabetes.[208, 209]  
My detailed analysis of the risk factors for hospitalisation post-CAP revealed that 
increasing hospitalisations cannot be attributed to changes to patients’ underlying 
health.  What then is the reason behind the considerable increase in hospitalisations 
after CAP, from 57% of cases in 1998-2000 to 87% in 2009-2011?  The forthcoming BTS 
audit of CAP diagnoses and a large ongoing validation study of CAP diagnosis in CPRD 
may provide some information on this topic.  A more comprehensive analysis of patterns 
of patient care within the older population may also be warranted in order to attempt 
to answer this question, and to stem the increasing tendency to treat CAP in hospital.   
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Information on frailty factors, and more detail on patients’ residential status (for 
example delineation between residential and nursing homes) is particularly lacking 
within CPRD.  Supplementary linkage to social care records would further enrich the 
CPRD data and facilitate more thorough investigation of the contribution of these 
factors to older patients’ health.  The ‘oldest old’ will make up 5% of the UK population 
by 2035,[44] and a better understanding of the effects of frailty by this point would 
greatly help in caring for this population. 
Further linkage to laboratory data would provide information on the causative pathogen 
behind these infections, enabling assessment of the role of specific pathogens in trends 
over time.  Additionally, the effectiveness of the pneumococcal vaccine and influenza 
vaccine against CAP among the older population could be estimated more accurately.  
It is widely agreed that prognostic models should be externally validated before being 
introduced into routine use.  There are several other primary care databases available, 
such as QResearch or ResearchOne which would be suitable for external validation of 
the models developed in Chapter 7.[210, 211]  If the risk scores were ever introduced 
into general use, future analyses would need to be undertaken to determine whether 
identification by GPs of high-risk patients after a CAP hospitalisation improved longer-
term patient mortality. 
8.7 Overall conclusions 
Use of linked primary, secondary and mortality records provided a large and detailed 
study population over a 14 year period, enabling a thorough investigation of the burden 
and outcomes of CAP among older individuals in the UK that was not previously possible.   
This thesis exploited linked data to meet several objectives.  CAP episodes from both 
primary and secondary care were combined to produce more complete incidence 
estimates than those currently available in the UK.  Increasing CAP hospitalisation was 
shown to be occurring separately to increasing CAP rates, and the linked-data enabled 
identification of a range of risk factors for hospitalisation, although patients’ worsening 
underlying health status was not found to explain the hospitalisation trends.  Finally, 
prognostic models to predict longer-term mortality post-CAP discharge were developed 
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to aid clinical decision making.  All of these analyses of this common and serious public 
health problem were made possible using data from multiple linked data sources.   
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Appendix A Read and ICD-10 codes for all LRTI and pneumonia 
LRTI and pneumonia Read codes used in CPRD 
Readcode Readterm Flag 
65VA.00 Notification of whooping cough 
 
A022200 Salmonella pneumonia pneumonia 
A203.00 Primary pneumonic plague pneumonia 
A205.00 Pneumonic plague, unspecified pneumonia 
A33..00 Whooping cough 
 
A330.00 Bordetella pertussis 
 
A331.00 Bordetella parapertussis 
 
A33y.00 Whooping cough - other specified organism 
 
A33yz00 Other whooping cough NOS 
 
A33z.00 Whooping cough NOS 
 
A3BXA00 Mycoplasma pneumoniae [PPLO] cause/dis classifd/oth chaptr 
 
A3By100 Eaton's agent infection 
 
A3By400 Pleuropneumonia-like organism (PPLO) infection 
 
A521.00 Varicella pneumonitis pneumonia 
A54x400 Herpes simplex pneumonia pneumonia 
A551.00 Postmeasles pneumonia pneumonia 
A730.00 Ornithosis with pneumonia pneumonia 
A785000 Cytomegaloviral pneumonitis pneumonia 
A789300 HIV disease resulting in Pneumocystis carinii pneumonia pneumonia 
AB24.11 Pneumonia - candidal pneumonia 
AB40500 Histoplasma capsulatum with pneumonia pneumonia 
AB40600 Acute pulmonary histoplasmosis capsulati 
 
AB41500 Histoplasma duboisii with pneumonia pneumonia 
AD04.00 Toxoplasma pneumonitis pneumonia 
AD63.00 Pneumocystosis pneumonia 
Ayu3A00 [X]Whooping cough, unspecified 
 
G520300 Acute myocarditis - influenzal 
 
H04..00 Acute laryngitis and tracheitis 
 
H041.00 Acute tracheitis 
 
H041000 Acute tracheitis without obstruction 
 
H041100 Acute tracheitis with obstruction 
 
H041z00 Acute tracheitis NOS 
 
H042.00 Acute laryngotracheitis 
 
H042000 Acute laryngotracheitis without obstruction 
 
H042100 Acute laryngotracheitis with obstruction 
 
H042z00 Acute laryngotracheitis NOS 
 
H04z.00 Acute laryngitis and tracheitis NOS 
 
H06..00 Acute bronchitis and bronchiolitis 
 
H060.00 Acute bronchitis 
 
H060.11 Acute wheezy bronchitis 
 
H060300 Acute purulent bronchitis 
 
H060400 Acute croupous bronchitis 
 
H060500 Acute tracheobronchitis 
 
H060600 Acute pneumococcal bronchitis 
 
H060700 Acute streptococcal bronchitis 
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H060800 Acute haemophilus influenzae bronchitis 
 
H060900 Acute neisseria catarrhalis bronchitis 
 
H060A00 Acute bronchitis due to mycoplasma pneumoniae 
 
H060B00 Acute bronchitis due to coxsackievirus 
 
H060C00 Acute bronchitis due to parainfluenza virus 
 
H060D00 Acute bronchitis due to respiratory syncytial virus 
 
H060E00 Acute bronchitis due to rhinovirus 
 
H060F00 Acute bronchitis due to echovirus 
 
H060w00 Acute viral bronchitis unspecified 
 
H060x00 Acute bacterial bronchitis unspecified 
 
H060z00 Acute bronchitis NOS 
 
H061.00 Acute bronchiolitis 
 
H061000 Acute capillary bronchiolitis 
 
H061200 Acute bronchiolitis with bronchospasm 
 
H061300 Acute exudative bronchiolitis 
 
H061500 Acute bronchiolitis due to respiratory syncytial virus 
 
H061600 Acute bronchiolitis due to other specified organisms 
 
H061z00 Acute bronchiolitis NOS 
 
H062.00 Acute lower respiratory tract infection 
 
H06z.00 Acute bronchitis or bronchiolitis NOS 
 
H06z000 Chest infection NOS 
 
H06z011 Chest infection 
 
H06z100 Lower resp tract infection 
 
H06z112 Acute lower respiratory tract infection 
 
H06z200 Recurrent chest infection 
 
H07..00 Chest cold 
 
H2...00 Pneumonia and influenza pneumonia 
H20..00 Viral pneumonia pneumonia 
H20..11 Chest infection - viral pneumonia pneumonia 
H200.00 Pneumonia due to adenovirus pneumonia 
H201.00 Pneumonia due to respiratory syncytial virus pneumonia 
H202.00 Pneumonia due to parainfluenza virus pneumonia 
H20y.00 Viral pneumonia NEC pneumonia 
H20y000 Severe acute respiratory syndrome pneumonia 
H20z.00 Viral pneumonia NOS pneumonia 
H21..00 Lobar (pneumococcal) pneumonia pneumonia 
H21..11 Chest infection - pneumococcal pneumonia pneumonia 
H22..00 Other bacterial pneumonia pneumonia 
H22..11 Chest infection - other bacterial pneumonia pneumonia 
H220.00 Pneumonia due to klebsiella pneumoniae pneumonia 
H221.00 Pneumonia due to pseudomonas pneumonia 
H222.00 Pneumonia due to haemophilus influenzae pneumonia 
H222.11 Pneumonia due to haemophilus influenzae pneumonia 
H223.00 Pneumonia due to streptococcus pneumonia 
H223000 Pneumonia due to streptococcus, group B pneumonia 
H224.00 Pneumonia due to staphylococcus pneumonia 
H22y.00 Pneumonia due to other specified bacteria pneumonia 
H22y000 Pneumonia due to escherichia coli pneumonia 
H22y011 E.coli pneumonia pneumonia 
H22y100 Pneumonia due to proteus pneumonia 
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H22y200 Pneumonia - Legionella pneumonia 
H22yX00 Pneumonia due to other aerobic gram-negative bacteria pneumonia 
H22yz00 Pneumonia due to bacteria NOS pneumonia 
H22z.00 Bacterial pneumonia NOS pneumonia 
H23..00 Pneumonia due to other specified organisms pneumonia 
H23..11 Chest infection - pneumonia organism OS pneumonia 
H230.00 Pneumonia due to Eaton's agent pneumonia 
H231.00 Pneumonia due to mycoplasma pneumoniae pneumonia 
H232.00 Pneumonia due to pleuropneumonia like organisms pneumonia 
H233.00 Chlamydial pneumonia pneumonia 
H23z.00 Pneumonia due to specified organism NOS pneumonia 
H24..00 Pneumonia with infectious diseases EC pneumonia 
H24..11 Chest infection with infectious disease EC 
 
H240.00 Pneumonia with measles pneumonia 
H241.00 Pneumonia with cytomegalic inclusion disease pneumonia 
H242.00 Pneumonia with ornithosis pneumonia 
H243.00 Pneumonia with whooping cough pneumonia 
H243.11 Pneumonia with pertussis pneumonia 
H246.00 Pneumonia with aspergillosis pneumonia 
H247000 Pneumonia with candidiasis pneumonia 
H247z00 Pneumonia with systemic mycosis NOS pneumonia 
H24y.00 Pneumonia with other infectious diseases EC pneumonia 
H24y000 Pneumonia with actinomycosis pneumonia 
H24y100 Pneumonia with nocardiasis pneumonia 
H24y200 Pneumonia with pneumocystis carinii pneumonia 
H24y300 Pneumonia with Q-fever pneumonia 
H24y400 Pneumonia with salmonellosis pneumonia 
H24y500 Pneumonia with toxoplasmosis pneumonia 
H24y600 Pneumonia with typhoid fever pneumonia 
H24y700 Pneumonia with varicella pneumonia 
H24yz00 Pneumonia with other infectious diseases EC NOS pneumonia 
H24z.00 Pneumonia with infectious diseases EC NOS pneumonia 
H25..00 Bronchopneumonia due to unspecified organism pneumonia 
H25..11 Chest infection - unspecified bronchopneumonia pneumonia 
H26..00 Pneumonia due to unspecified organism pneumonia 
H26..11 Chest infection - pnemonia due to unspecified organism pneumonia 
H260.00 Lobar pneumonia due to unspecified organism pneumonia 
H260000 Lung consolidation pneumonia 
H261.00 Basal pneumonia due to unspecified organism pneumonia 
H262.00 Postoperative pneumonia postoperative 
H27..00 Influenza 
 
H270.00 Influenza with pneumonia pneumonia 
H270.11 Chest infection - influenza with pneumonia pneumonia 
H270000 Influenza with bronchopneumonia pneumonia 
H270100 Influenza with pneumonia, influenza virus identified pneumonia 
H270z00 Influenza with pneumonia NOS pneumonia 
H271.00 Influenza with other respiratory manifestation 
 
H271z00 Influenza with respiratory manifestations NOS 
 
H27y.00 Influenza with other manifestations 
 
H27y000 Influenza with encephalopathy 
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H27y100 Influenza with gastrointestinal tract involvement 
 
H27yz00 Influenza with other manifestations NOS 
 
H27z.00 Influenza NOS 
 
H28..00 Atypical pneumonia pneumonia 
H29..00 Avian influenza 
 
H2A..00 Influenza due to Influenza A virus subtype H1N1 
 
H2A..11 Influenza A (H1N1) swine flu 
 
H2y..00 Other specified pneumonia or influenza 
 
H2z..00 Pneumonia or influenza NOS 
 
H30..11 Chest infection - unspecified bronchitis 
 
H3y0.00 Chronic obstruct pulmonary dis with acute lower resp infectn 
 
H510900 Pneumococcal pleurisy 
 
H510A00 Staphylococcal pleurisy 
 
H510B00 Streptococcal pleurisy 
 
H511.00 Bacterial pleurisy with effusion 
 
H511000 Pneumococcal pleurisy with effusion 
 
H511100 Staphylococcal pleurisy with effusion 
 
H511z00 Bacterial pleurisy with effusion NOS 
 
H530200 Gangrenous pneumonia pneumonia 
H530300 Abscess of lung with pneumonia pneumonia 
H540000 Hypostatic pneumonia pneumonia 
H540100 Hypostatic bronchopneumonia pneumonia 
H564.00 Bronchiolitis obliterans organising pneumonia pneumonia 
Hyu0400 [X]Flu+oth respiratory manifestations,'flu virus identified 
 
Hyu0500 [X]Influenza+other manifestations,influenza virus identified 
 
Hyu0600 [X]Influenza+oth respiratory manifestatns,virus not identifd 
 
Hyu0700 [X]Influenza+other manifestations, virus not identified 
 
Hyu0800 [X]Other viral pneumonia pneumonia 
Hyu0A00 [X]Other bacterial pneumonia pneumonia 
Hyu0B00 [X]Pneumonia due to other specified infectious organisms pneumonia 
Hyu0D00 [X]Pneumonia in viral diseases classified elsewhere pneumonia 
Hyu0H00 [X]Other pneumonia, organism unspecified pneumonia 
Hyu1.00 [X]Other acute lower respiratory infections 
 
Hyu1000 [X]Acute bronchitis due to other specified organisms 
 
Hyu1100 [X]Acute bronchiolitis due to other specified organisms 
 
16L..00 Influenza-like symptoms 
 
1J72.00 Suspected influenza A virus subtype H1N1 infection 
 
1J72.11 Suspected swine influenza 
 
1W0..00 Possible influenza A virus H1N1 subtype 
 
43jQ.00 Avian influenza virus nucleic acid detection 
 
43jx.00 Parainfluenza type 1 nucleic acid detection 
 
43jy.00 Parainfluenza type 2 nucleic acid detection 
 
43jz.00 Parainfluenza type 3 nucleic acid detection 
 
4J3L.00 Influenza A virus H1N1 subtype detected 
 
4JU0.00 Influenza H1 virus detected 
 
4JU2.00 Influenza H3 virus detected 
 
4JU3.00 Influenza H5 virus detected 
 
4JU4.00 Influenza A virus, other or untyped strain detected 
 
4JU5.00 Influenza B virus detected 
 
4JUF.00 Human parainfluenza virus detected 
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4JUK.00 Mycoplasma pneumoniae detected 
 
A39y000 Pulmonary nocardiosis 
 
AB42.00 Pulmonary histoplasmosis 
 
H042.11 Laryngotracheitis 
 
H052.00 Pharyngotracheitis 
 
H053.00 Tracheopharyngitis 
 
H060v00 Subacute bronchitis unspecified 
 
H271000 Influenza with laryngitis 
 
H271100 Influenza with pharyngitis 
 
H27z.11 Flu like illness 
 
H27z.12 Influenza like illness 
 
H50..00 Empyema 
 
H500.00 Empyema with fistula 
 
H500000 Empyema with bronchocutaneous fistula 
 
H500100 Empyema with bronchopleural fistula 
 
H500400 Empyema with pleural fistula NOS 
 
H501.00 Empyema with no fistula 
 
H501000 Pleural abscess 
 
H501200 Pleural empyema 
 
H501300 Lung empyema NOS 
 
H501400 Purulent pleurisy 
 
H501500 Pyopneumothorax 
 
H501600 Pyothorax 
 
H50z.00 Empyema NOS 
 
1419.00 H/O: pertussis History of 
1419.11 H/O: whooping cough History of 
14B2.00 H/O: pneumonia History of 
14B3.11 H/O: bronchitis History of 
H341.00 Post-infective bronchiectasis History of 
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LRTI and pneumonia ICD10 codes used in HES 
ICD10 code Diagnostic name Flag 
A37 Whooping cough  
A370 Whooping cough due to Bordetella pertussis  
A371 Whooping cough due to Bordetella parapertussis  
A378 Whooping cough due to other Bordetella species  
A379 Whooping cough, unspecified  
B012 Varicella pneumonia pneumonia 
B052 Measles complicated by pneumonia pneumonia 
B206 HIV disease resulting in Pneumocystis carinii pneumonia pneumonia 
B250 Cytomegaloviral pneumonitis pneumonia 
B960 Mycoplasma pneumoniae as cause dis class oth chaps  
J041 Acute tracheitis  
J042 Acute laryngotracheitis  
J09 Influenza due to other identified influenza virus  
J10 Influenza due to identified influenza virus  
J100 Influenza with pneumonia, influenza virus identified pneumonia 
J101 Influenza with oth resp manifest influenza virus identified  
J108 Influenza with other manifest influenza virus identified  
J11 Influenza, virus not identified  
J110 Influenza with pneumonia, virus not identified pneumonia 
J111 Influenza with oth resp manifestation virus not identified  
J118 Influenza with other manifestations, virus not identified  
J12 Viral pneumonia, not elsewhere classified pneumonia 
J120 Adenoviral pneumonia pneumonia 
J121 Respiratory syncytial virus pneumonia pneumonia 
J122 Parainfluenza virus pneumonia pneumonia 
J128 Other viral pneumonia pneumonia 
J129 Viral pneumonia, unspecified pneumonia 
J13 Pneumonia due to Streptococcus pneumoniae pneumonia 
J13X Pneumonia due to Streptococcus pneumoniae pneumonia 
J14 Pneumonia due to Haemophilus influenzae pneumonia 
J14X Pneumonia due to Haemophilus influenzae pneumonia 
J15 Bacterial pneumonia, not elsewhere classified pneumonia 
J150 Pneumonia due to Klebsiella pneumoniae pneumonia 
J151 Pneumonia due to Pseudomonas pneumonia 
J152 Pneumonia due to staphylococcus pneumonia 
J153 Pneumonia due to streptococcus, group B pneumonia 
J154 Pneumonia due to other streptococci pneumonia 
J155 Pneumonia due to Escherichia coli pneumonia 
J156 Pneumonia due to other aerobic Gram-negative bacteria pneumonia 
J157 Pneumonia due to Mycoplasma pneumoniae pneumonia 
J158 Other bacterial pneumonia pneumonia 
J159 Bacterial pneumonia, unspecified pneumonia 
J16 Pneumonia due to other infectious organisms NEC pneumonia 
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J160 Chlamydial pneumonia pneumonia 
J168 Pneumonia due to other specified infectious organisms pneumonia 
J17 Pneumonia in diseases classified elsewhere pneumonia 
J170 Pneumonia in bacterial diseases classified elsewhere pneumonia 
J171 Pneumonia in viral diseases classified elsewhere pneumonia 
J172 Pneumonia in mycoses pneumonia 
J173 Pneumonia in parasitic diseases pneumonia 
J178 Pneumonia in other diseases classified elsewhere pneumonia 
J18 Pneumonia, organism unspecified pneumonia 
J180 Bronchopneumonia, unspecified pneumonia 
J181 Lobar pneumonia, unspecified pneumonia 
J182 Hypostatic pneumonia, unspecified pneumonia 
J188 Other pneumonia, organism unspecified pneumonia 
J189 Pneumonia, unspecified pneumonia 
J20 Acute bronchitis  
J200 Acute bronchitis due to Mycoplasma pneumoniae  
J201 Acute bronchitis due to Haemophilus influenzae  
J202 Acute bronchitis due to streptococcus  
J203 Acute bronchitis due to coxsackievirus  
J204 Acute bronchitis due to parainfluenza virus  
J205 Acute bronchitis due to respiratory syncytial virus  
J206 Acute bronchitis due to rhinovirus  
J207 Acute bronchitis due to echovirus  
J208 Acute bronchitis due to other specified organisms  
J209 Acute bronchitis, unspecified  
J21 Acute bronchiolitis  
J210 Acute bronchiolitis due to respiratory syncytial virus  
J218 Acute bronchiolitis due to other specified organisms  
J219 Acute bronchiolitis, unspecified  
J22 Unspecified acute lower respiratory infection  
J22X Unspecified acute lower respiratory infection  
J440 Chronic obstructive pulmonary disease with acute lower respiratory infection  
J851 Abscess of lung with pneumonia pneumonia 
J86 Pyothorax  
J860 Pyothorax with fistula  
J869 Pyothorax without fistula  
U04 Severe acute respiratory syndrome [SARS] pneumonia 
U049 Severe acute respiratory syndrome, unspecified pneumonia 
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Appendix B Additional results for comparison of LRTI incidence in those 
who registered pre and post-UTS over the first three years of 
follow-up (Chapter 3) 
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Comparison of age-stratified LRTI incidence in those who registered pre and post-UTS over the 
first three years of follow-up 
 
Comparison of LRTI incidence stratified by year of start of follow-up in those who registered 
pre and post-UTS over the first three years of follow-up 
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Comparison of LRTI incidence over the first year of follow-up in the post-UTS group stratified 
by health check exclusion 
 
Comparison of LRTI incidence stratified by sex in those who registered pre and post-UTS over 
the first three years of follow-up 
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Appendix C Medline search strategy for the European incidence of CAP 
and all LRTI in literature review (Chapter 4) 
1 exp pneumonia/ 
2 (pneumonit* or pneumonia).ti,ab. 
3 bronchopneumonia.ti,ab. 
4 pleuropneumonia.ti,ab. 
5 ((lung or lobar or pulmonary) adj2 inflamm*).ti,ab. 
6 (lower respiratory adj3 (infection* or inflamm*)).ti,ab. 
7 LRTI.ti,ab. 
8 Bronchitis/ep, mo, sn [Epidemiology, Mortality, Statistics & Numerical Data] 
9 exp Bronchopneumonia/ep, mo [Epidemiology, Mortality] 
10 exp Bronchiolitis/ep, mo [Epidemiology, Mortality] 
11 exp Trachietis/ep, mo, sn 
12 
(bronchitis or bronchiolitis).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
13 
pneumonias.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
14 
(chest adj infection*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
15 
LRTI.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
16 or/1-15 
17 exp incidence/ 
18 exp Epidemiology/sn, td [Statistics & Numerical Data, Trends] 
19 exp Population Surveillance/ 
20 
inciden*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
21 
epidemiol*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
22 
surveillance.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
23 
occur*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
24 
frequency.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
25 or/17-24 
26 
exp Aged, 80/ and over.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
27 exp Aged/ 
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28 
((old adj age*) or elderly or (senior adj citizen)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
29 26 or 27 or 28 
30 exp Albania/ 
31 (Albania or Albanian or Albanians).ti,ab. 
32 exp Andorra/ 
33 (Andorra or Andorran or Andorrans).ti,ab. 
34 exp Armenia/ 
35 (Armenia or Armenian or Armenians).ti,ab. 
36 exp Austria/ 
37 (Austria or Austrian or Austrians).ti,ab. 
38 exp Azerbaijan/ 
39 Azerbaijan*.ti,ab. 
40 exp Belgium/ 
41 (Belgium or Belgian*).ti,ab. 
42 exp "Bosnia and Herzegovina"/ 
43 (Bosnia*-Her#egovin* or BOSNIA* or HER#EGOVIN*).ti,ab. 
44 exp Bulgaria/ 
45 (Bulgaria or Bulgarian or Bulgarians).ti,ab. 
46 exp Croatia/ 
47 (Croatia or Croatian or Croatians).ti,ab. 
48 exp Cyprus/ 
49 (Cyprus or Cypriot or Cypriots).ti,ab. 
50 exp Czechoslovakia/ 
51 exp Czech Republic/ 
52 (Czech Republic or Czechoslovakia or Czech or Czechs).ti,ab. 
53 exp Denmark/ 
54 (denmark or faeroe islands or Danish).ti,ab. 
55 exp Estonia/ 
56 (Estonia or Estonian or Estonians).ti,ab. 
57 exp Europe/ 
58 EUROPE*.ti,ab. 
59 exp Finland/ 
60 (Finland or Finnish).ti,ab. 
61 exp France/ 
62 (France or French).ti,ab. 
63 exp "Georgia (republic)"/ 
64 (Georgian or Georgians).ti,ab. 
65 exp Germany/ 
66 (Germany or German or Germans).ti,ab. 
67 exp United Kingdom/ 
68 
(great britain or GBR or united kingdom or UK or northern ireland or scotland or channel 
islands or (isle adj2 man) or British or Scottish or (wales not new south wales) or (england not 
new england)).ti,ab. 
69 exp Greece/ 
70 (Greece or Greek or Greeks).ti,ab. 
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71 exp Hungary/ 
72 (Hungary or Hungarian or Hungarians).ti,ab. 
73 exp Iceland/ 
74 (Iceland or Icelandic).ti,ab. 
75 exp Ireland/ 
76 (eire or ireland or Irish).ti,ab. 
77 exp Israel/ 
78 (Israel or Israeli or Israelis).ti,ab. 
79 exp Italy/ 
80 (Italy or Italian or Italians).ti,ab. 
81 exp Kazakhstan/ 
82 (kazakh or kazakhs or kazakhstan or kazakhstani).ti,ab. 
83 exp Kyrgyzstan/ 
84 (kirgizstan or kyrgyz or kirghizia or kirghiz or kyrgyzstan or Kyrgyzstani).ti,ab. 
85 exp Latvia/ 
86 (Latvia or Latvian or Latvians).ti,ab. 
87 exp Liechtenstein/ 
88 (liechtenstein or leichtenstein).ti,ab. 
89 exp Lithuania/ 
90 (Lithuania or Lithuanian or Lithuanians).ti,ab. 
91 exp Luxembourg/ 
92 (luxembourg* or luxemburg* or luxemborg).ti,ab. 
93 exp "Macedonia (republic)"/ 
94 (Macedonia or Macedonian or Macedonians).ti,ab. 
95 exp Malta/ 
96 (Malta or Maltese).ti,ab. 
97 exp Moldova/ 
98 (Moldavia or Moldavian or Moldova or Moldovan or Moldovans).ti,ab. 
99 exp Monaco/ 
100 (Monaco or Monegasque).ti,ab. 
101 (Montenegro or Montenegrin or Montenegrins).ti,ab. 
102 exp Netherlands/ 
103 (netherlands or holland or Dutch).ti,ab. 
104 exp Norway/ 
105 (Norway or Norwegian or Norwegians).ti,ab. 
106 exp Poland/ 
107 (Poland or (Polish adj3 (population or patient* or people))).ti,ab. 
108 exp Portugal/ 
109 (Portugal or Portuguese).ti,ab. 
110 exp Belarus/ 
111 (belarus or byelarus or belorussia or Belarusian or Belarusians).ti,ab. 
112 exp Romania/ 
113 (Romania or Romanian or Romanians).ti,ab. 
114 exp USSR/ 
115 (Russia or Russian or Russians).ti,ab. 
116 exp San Marino/ 
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117 exp Russia/ 
118 (San Marino or Sammarinese).ti,ab. 
119 exp Scandinavia/ 
120 (Scandinavia or Scandinavian).ti,ab. 
121 exp Serbia/ 
122 (Serbia or Serbian or Serbians).ti,ab. 
123 exp Slovakia/ 
124 (slovakia or slovak or Slovakian or Slovakians or Slovak or Slovaks).ti,ab. 
125 exp Slovenia/ 
126 (Slovenia or Slovenian or Slovenians).ti,ab. 
127 exp Spain/ 
128 (spain or balearic islands or canary islands or Spanish).ti,ab. 
129 exp Sweden/ 
130 (Sweden or Swedish).ti,ab. 
131 exp Switzerland/ 
132 (Switzerland or Swiss).ti,ab. 
133 exp Tajikistan/ 
134 (tadjikistan or tadzhik or tadzhikistan or tajikistan).ti,ab. 
135 exp Turkey/ 
136 (turkey or Turkish).ti,ab. 
137 exp Turkmenistan/ 
138 (turkmen or turkmenistan or Turkmens).ti,ab. 
139 exp Ukraine/ 
140 (Ukraine or Ukrainian or Ukrainians).ti,ab. 
141 exp Uzbekistan/ 
142 (uzbekistan or uzbek or Uzbeks).ti,ab. 
143 exp "Yugoslavia (pre-1992)"/ or exp Yugoslavia/ 
144 (Yugoslavia or Yugoslav or Yugoslavs or Yugoslavian or Yugoslavians).ti,ab. 
145 
30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 
46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 
62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 
78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 
94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 
108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 
121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 
134 or 135 or 136 or 137 or 138 or 139 or 140 or 141 or 142 or 143 or 144 
146 16 and 25 and 29 and 145 
147 exp Case Reports/ 
148 Animals/ 
149 Humans/ 
150 148 not (148 and 149) 
151 146 not 150 
152 151 not 147 
153 152 
154 limit 153 to yr="1980 -Current" 
155 154 
156 limit 155 to english language 
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Appendix D Supplementary material for Paper 1 (Chapter 4) 
Community-acquired LRTI incidence rates overall and over time by sex, age, region of England and IMD quintile   
Sex Age (years)   
Male Female 65-69 70-74 75-79 80-84 85-89 ≥90 
Overall 122.93 121.76 123.83 92.21 107.40 126.07 151.37 187.91 262.87 
95% CI 122.49-123.37 121.1-122.42 123.24-124.42 91.7-92.71 106.8-108 125.33-126.81 150.36-152.39 186.32-189.49 259.79-265.94 
1997 100.96 100.87 100.89 94.10 104.72 113.58 126.88 144.38 170.43  
99.91-102.01 99.27-102.48 99.51-102.28 92.01-96.19 102.38-107.06 110.91-116.26 123.37-130.38 139.49-149.27 163.18-177.69 
1998 104.37 101.35 106.54 93.24 102.54 117.40 133.64 158.26 177.00  
103.35-105.38 99.82-102.88 105.18-107.9 91.29-95.19 100.37-104.72 114.88-119.92 130.16-137.13 153.4-163.12 170.03-183.97 
1999 105.40 102.74 107.32 92.49 103.44 113.37 129.50 152.10 186.11  
104.44-106.36 101.3-104.19 106.04-108.61 90.7-94.29 101.42-105.46 111.1-115.65 126.32-132.69 147.72-156.47 179.44-192.79 
2000 102.13 100.69 103.14 86.91 98.31 108.03 121.03 144.89 173.51  
101.22-103.03 99.32-102.05 101.94-104.34 85.29-88.54 96.46-100.15 105.92-110.13 118.23-123.82 140.87-148.92 167.46-179.56 
2001 105.90 104.07 107.23 85.74 99.73 111.24 123.05 144.29 183.92  
105-106.81 102.7-105.44 106.03-108.44 84.18-87.3 97.92-101.54 109.14-113.34 120.37-125.72 140.38-148.2 177.86-189.98 
2002 112.22 110.64 113.39 91.00 101.98 115.03 128.12 148.88 185.77  
111.3-113.15 109.23-112.04 112.16-114.63 89.42-92.57 100.2-103.77 112.92-117.14 125.49-130.75 144.9-152.85 179.79-191.74 
2003 127.30 124.11 129.72 98.61 113.08 129.55 143.43 167.98 211.54  
126.3-128.3 122.61-125.61 128.38-131.05 96.99-100.23 111.19-114.97 127.29-131.8 140.69-146.18 163.65-172.32 205.14-217.94 
2004 131.97 130.66 133.00 99.20 113.45 131.45 146.52 172.24 223.38  
130.95-132.99 129.11-132.21 131.64-134.35 97.6-100.8 111.57-115.32 129.2-133.7 143.78-149.26 167.88-176.6 216.8-229.96 
2005 131.76 131.06 132.34 97.69 111.24 125.93 144.46 166.92 222.45  
130.74-132.78 129.51-132.62 130.99-133.69 96.12-99.26 109.4-113.08 123.76-128.1 141.74-147.19 162.84-171 215.89-229 
2006 134.09 134.70 133.72 97.57 111.26 126.59 145.70 162.82 223.53  
133.05-135.12 133.11-136.3 132.35-135.08 96-99.14 109.43-113.1 124.41-128.77 142.94-148.46 158.93-166.7 216.92-230.14 
2007 139.88 142.07 138.36 99.66 113.43 130.54 148.68 171.04 234.79  
138.81-140.95 140.42-143.73 136.96-139.77 98.08-101.25 111.58-115.28 128.32-132.76 145.86-151.49 167.11-174.97 227.84-241.73 
2008 148.04 149.65 147.02 101.86 117.61 134.62 158.30 183.45 267.05  
146.93-149.16 147.92-151.37 145.56-148.49 100.26-103.47 115.71-119.51 132.33-136.91 155.34-161.26 179.34-187.55 259.28-274.82 
2009 131.10 132.49 130.24 90.26 104.38 118.38 134.93 159.58 229.95  
130.06-132.14 130.88-134.1 128.87-131.61 88.77-91.74 102.6-106.16 116.24-120.52 132.23-137.63 155.8-163.35 222.78-237.11 
2010 137.30 135.46 138.90 93.95 107.69 119.46 140.93 167.30 240.21  
136.21-138.38 133.81-137.1 137.46-140.35 92.42-95.48 105.85-109.53 117.27-121.64 138.13-143.74 163.33-171.27 233.03-247.38 
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 Region  
North East North West Yorkshire  
& The Humber 
East Midlands West  
Midlands 
East of  
England 
South West South Central London South East 
Coast 
Overall 145.47 158.81 156.37 126.43 154.29 115.72 110.27 114.11 96.84 104.30 
95% CI 141.85-149.09 157.23-160.39 153.87-158.88 124.2-128.66 152.48-156.11 114.38-117.05 108.95-111.59 112.84-115.37 95.68-98 103.03-105.58 
1997 104.47 134.85 110.13 93.82 111.37 91.68 94.63 96.80 90.03 78.03  
97.94-111 131.47-138.23 105.65-114.61 89.45-98.18 107.77-114.96 88.69-94.68 91.15-98.1 93.12-100.47 86.8-93.26 74.85-81.21 
1998 112.42 125.24 124.57 108.18 130.84 101.35 94.42 94.97 93.54 79.21  
105.52-119.31 122.13-128.35 119.87-129.27 103.61-112.76 127.14-134.54 98.35-104.36 91.22-97.62 91.67-98.26 90.35-96.73 76.07-82.34 
1999 135.29 125.99 125.62 98.18 146.35 97.61 98.25 98.01 85.66 84.53  
127.49-143.09 122.97-129.01 120.96-130.28 94.05-102.31 142.49-150.21 94.8-100.41 95.28-101.22 95.04-100.98 82.8-88.51 81.52-87.53 
2000 122.24 127.19 131.39 106.53 125.68 94.40 86.60 93.83 91.12 81.63  
115.32-129.16 124.2-130.18 126.66-136.12 102.17-110.9 122.33-129.03 91.72-97.08 83.92-89.29 91.2-96.47 88.32-93.92 78.88-84.39 
2001 136.47 126.64 150.14 112.37 132.35 104.34 97.19 103.33 96.77 90.76  
128.95-143.99 123.73-129.55 145.08-155.19 107.93-116.8 128.89-135.81 101.52-107.15 94.31-100.08 100.63-106.04 93.95-99.59 87.89-93.64 
2002 152.07 142.05 160.25 116.39 146.89 111.47 102.17 102.96 91.00 95.52  
143.91-160.23 138.99-145.12 155.07-165.42 111.86-120.92 143.19-150.58 108.58-114.37 99.21-105.12 100.24-105.67 88.32-93.68 92.64-98.4 
2003 148.22 165.30 182.43 134.71 165.18 121.73 115.81 115.33 98.48 104.90  
140.12-156.33 161.91-168.69 176.7-188.16 129.73-139.69 161.21-169.14 118.66-124.8 112.64-118.99 112.43-118.23 95.65-101.31 101.9-107.9 
2004 177.09 173.26 178.00 139.49 168.54 126.02 116.06 121.68 100.24 106.26  
167.98-186.2 169.76-176.76 172.31-183.68 134.26-144.71 164.49-172.59 122.89-129.15 112.91-119.22 118.68-124.69 97.35-103.13 103.25-109.26 
2005 159.09 174.18 173.41 144.65 167.85 133.99 116.01 120.20 97.75 107.35  
150.54-167.64 170.66-177.7 167.79-179.02 139.26-150.05 163.76-171.93 130.71-137.26 112.87-119.16 117.2-123.2 94.92-100.59 104.34-110.37 
2006 152.34 176.98 175.66 156.95 168.53 125.31 118.64 124.05 98.54 114.06  
143.96-160.72 173.39-180.58 169.79-181.52 151.2-162.71 164.43-172.63 122.08-128.53 115.47-121.8 120.98-127.12 95.67-101.41 110.97-117.15 
2007 162.59 186.16 180.05 154.15 170.63 129.19 126.68 126.05 106.05 117.67  
154.12-171.06 182.4-189.91 173.95-186.16 148.31-160 166.43-174.83 125.79-132.58 123.38-129.99 123.03-129.07 103.09-109.01 114.53-120.8 
2008 176.49 193.87 192.55 162.69 181.75 138.13 132.73 137.58 108.18 130.18  
167.46-185.52 190-197.74 185.6-199.5 156.41-168.97 177.38-186.12 134.49-141.78 129.32-136.14 134.42-140.74 105.19-111.18 126.83-133.54 
2009 162.08 177.40 170.31 135.91 162.97 123.46 113.54 116.89 96.91 117.51  
153.38-170.79 173.71-181.09 163.04-177.57 129.98-141.85 158.89-167.06 119.99-126.94 110.44-116.64 114.04-119.74 94.13-99.7 114.4-120.62 
2010 165.09 192.69 169.65 136.60 175.98 133.71 121.80 125.60 99.86 123.34  
156.22-173.95 188.76-196.62 162.24-177.06 129.35-143.86 171.68-180.29 129.93-137.49 118.52-125.08 122.64-128.56 97.06-102.66 120.11-126.57 
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IMD Quintile  
0 (least deprived) 1 2 3 4 (most deprived) 
Overall 106.48 113.98 124.96 137.94 182.12 
95% CI 105.39-107.57 112.86-115.1 123.63-126.28 136.4-139.47 179.79-184.46 
1997 85.30 90.83 96.71 111.58 147.93  
82.48-88.13 88.11-93.55 93.65-99.77 108.14-115.02 143.27-152.6 
1998 92.70 97.59 103.73 113.91 141.04  
89.93-95.47 94.88-100.3 100.71-106.75 110.58-117.25 136.68-145.4 
1999 98.55 97.65 102.77 116.35 155.08  
95.93-101.18 95.09-100.21 99.95-105.59 113.12-119.57 150.58-159.58 
2000 89.87 94.66 101.23 114.68 150.27  
87.52-92.23 92.29-97.03 98.56-103.9 111.6-117.77 145.97-154.56 
2001 96.82 103.00 114.62 118.80 153.41  
94.39-99.24 100.56-105.45 111.8-117.45 115.73-121.87 149.12-157.71 
2002 97.81 107.35 116.83 129.44 175.75  
95.39-100.22 104.86-109.83 113.97-119.69 126.23-132.65 171.08-180.42 
2003 110.06 117.13 129.80 147.04 194.89  
107.48-112.64 114.52-119.74 126.75-132.85 143.55-150.53 189.86-199.92 
2004 111.16 122.91 136.51 149.93 201.40  
108.58-113.74 120.23-125.6 133.35-139.68 146.37-153.49 196.21-206.6 
2005 112.51 120.96 135.56 151.76 198.54  
109.91-115.1 118.31-123.61 132.38-138.73 148.14-155.38 193.34-203.75 
2006 114.92 125.28 139.07 151.50 195.91  
112.29-117.54 122.58-127.98 135.85-142.29 147.87-155.14 190.7-201.12 
2007 114.45 125.76 142.85 155.35 204.71  
111.86-117.04 123.06-128.46 139.59-146.1 151.66-159.05 199.34-210.08 
2008 125.74 135.11 151.18 167.15 217.22  
123.01-128.46 132.3-137.93 147.8-154.56 163.26-171.04 211.58-222.85 
2009 110.04 118.71 134.39 150.72 205.75  
107.55-112.53 116.12-121.29 131.25-137.53 147.04-154.4 200.2-211.31 
2010 114.76 126.32 140.00 155.29 219.00  
112.17-117.36 123.61-129.03 136.72-143.27 151.47-159.1 213.2-224.81 
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Age-standardised* incidence of LRTI and CAP by year, region of England and index of multiple deprivation quintile. 
 
LRTI Age-standardised* rate/1000 person years CAP Age-standardised* rate/1000 person years 
 
Men 95% CI Women  95% CI Men 95% CI Women 95% CI 
Year 
   
  
    
1997 122.40 120.31-124.5 107.72 106.18-109.27 10.27 9.68-10.87 6.82 6.48-7.17 
1998 121.34 119.38-121.34 112.11 110.62-113.6 9.91 9.36-10.46 7.51 7.17-7.85 
1999 120.24 118.44-122.05 110.64 109.27-112.01 9.89 9.39-10.4 6.79 6.49-7.1 
2000 114.01 112.38-115.64 103.87 102.63-105.11 8.31 7.88-8.74 5.56 5.3-5.81 
2001 115.00 113.42-116.59 105.80 104.59-107.02 8.99 8.56-9.41 5.77 5.52-6.02 
2002 118.49 116.92-120.07 110.16 108.94-111.37 8.78 8.37-9.19 5.83 5.58-6.08 
2003 129.80 128.16-131.44 123.90 122.6-125.19 9.76 9.32-10.19 6.54 6.28-6.8 
2004 133.16 131.52-134.81 124.75 123.47-126.03 9.47 9.05-9.89 6.62 6.36-6.88 
2005 129.94 128.34-131.55 122.30 121.04-123.56 9.04 8.64-9.44 6.43 6.18-6.69 
2006 130.10 128.5-131.69 122.13 120.87-123.39 9.36 8.96-9.76 6.43 6.17-6.68 
2007 134.88 133.25-136.51 124.82 123.54-126.1 9.74 9.33-10.15 6.53 6.27-6.79 
2008 140.55 138.85-142.25 131.36 130.04-132.69 11.09 10.65-11.53 7.65 7.37-7.93 
2009 122.79 121.22-124.36 115.42 114.18-116.65 10.82 10.39-11.26 7.17 6.89-7.44 
2010 124.18 122.6-125.77 121.24 119.95-122.52 11.00 10.57-11.44 7.64 7.36-7.92 
Region 
   
  
    
North East 138.39 133.56-143.21 143.34 139.49-147.2 13.10 11.95-14.24 8.73 8.05-9.4 
North West 162.52 160.3-164.74 153.74 152.06-155.42 11.67 11.23-12.1 7.91 7.65-8.17 
Yorkshire & 
The Humber 
160.95 157.44-164.47 146.74 144.12-149.36 11.02 10.34-11.69 7.23 6.83-7.63 
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East Midlands 129.12 126.01-132.23 121.78 119.37-124.18 10.41 9.73-11.08 6.58 6.18-6.97 
West 
Midlands 
157.17 154.67-159.68 145.14 143.26-147.02 10.87 10.39-11.35 7.43 7.14-7.72 
East of 
England 
120.29 118.41-122.17 108.10 106.7-109.5 10.20 9.78-10.63 6.65 6.39-6.9 
South West 111.64 109.85-113.43 102.41 101.02-103.81 9.92 9.5-10.33 7.01 6.74-7.27 
South Central 118.30 116.51-120.08 104.20 102.89-105.52 12.00 11.55-12.45 8.25 7.97-8.53 
London 97.38 95.76-98.99 94.41 93.11-95.71 9.23 8.82-9.63 6.31 6.06-6.56 
South East 
Coast 
107.87 106.08-109.67 96.57 95.22-97.91 8.44 8.05-8.83 5.85 5.61-6.09 
IMD Quintile 
   
  
    
0 (least 
deprived) 
116.31 114.75-117.86 99.67 98.51-100.83 9.51 9.15-9.86 6.35 6.13-6.56 
1 123.75 122.17-125.33 105.82 104.65-106.99 10.19 9.83-10.55 6.89 6.67-7.11 
2 134.28 132.43-136.13 116.33 114.95-117.71 11.85 11.42-12.29 8.13 7.86-8.39 
3 147.27 145.13-149.41 131.15 129.53-132.77 12.65 12.16-13.13 8.11 7.83-8.39 
4 (most 
deprived) 
188.05 184.91-191.19 177.79 175.26-180.31 15.35 14.68-16.02 10.77 10.36-11.19 
*Age-standardised-UK mid-year population estimates, 2004. 
LRTI: Lower respiratory tract infection 
CAP: community-acquired pneumonia 
IMD – index of multiple deprivation 
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Community-acquired LRTI incidence rates including COPD exacerbation codes overall and over time by sex, age, region of England and IMD quintile 
  
Sex 
 
Age (years 
     
 
Overall Male Female 65-69 70-74 75-79 80-84 85-89 ≥90 
Overall 132.06 132.25 131.90 96.98 115.93 138.56 167.02 205.94 283.39 
95% CI 131.57-132.54 131.52-132.99 131.25-132.54 96.45-97.51 115.29-116.57 137.75-139.37 165.9-168.14 204.19-207.69 280.01-286.77 
1997 102.99 103.13 102.67 97.44 108.89 117.79 131.31 147.66 172.24  
101.93-104.05 101.51-104.75 101.27-104.07 95.29-99.6 106.47-111.31 115.03-120.55 127.7-134.92 142.68-152.64 164.92-179.55 
1998 107.20 104.37 109.17 96.76 108.03 122.73 138.61 162.71 178.74  
106.17-108.24 102.82-105.92 107.79-110.55 94.75-98.77 105.77-110.3 120.12-125.35 135.02-142.2 157.73-167.68 171.71-185.77 
1999 108.66 106.25 110.33 96.58 108.78 118.80 134.70 156.84 187.88  
107.68-109.64 104.77-107.72 109.02-111.64 94.72-98.44 106.67-110.88 116.44-121.16 131.41-137.98 152.35-161.32 181.16-194.61 
2000 106.13 105.18 106.72 90.83 104.15 114.84 126.44 149.35 176.59  
105.2-107.05 103.78-106.59 105.48-107.95 89.15-92.52 102.22-106.08 112.63-117.05 123.54-129.33 145.22-153.48 170.45-182.72 
2001 110.88 109.64 111.72 90.17 106.02 118.29 130.46 149.88 187.60  
109.94-111.82 108.22-111.06 110.48-112.96 88.54-91.79 104.12-107.91 116.09-120.49 127.66-133.25 145.85-153.91 181.45-193.74 
2002 118.37 117.62 118.87 96.00 109.20 123.67 135.77 154.99 188.69  
117.41-119.33 116.15-119.09 117.59-120.14 94.35-97.64 107.32-111.09 121.43-125.9 133.01-138.52 150.88-159.1 182.64-194.74 
2003 135.09 133.35 136.38 104.36 121.73 139.58 152.51 175.13 216.31  
134.04-136.13 131.77-134.94 134.99-137.77 102.67-106.06 119.73-123.73 137.19-141.97 149.62-155.4 170.65-179.61 209.79-222.82 
2004 141.46 141.89 141.16 105.96 122.82 143.08 157.15 180.19 229.10  
140.38-142.54 140.23-143.54 139.75-142.58 104.28-107.65 120.83-124.81 140.68-145.49 154.25-160.04 175.67-184.71 222.39-235.81 
2005 142.54 143.99 141.54 104.71 121.01 138.39 156.13 176.86 228.82  
141.46-143.63 142.31-145.67 140.11-142.96 103.05-106.37 119.05-122.97 136.05-140.72 153.24-159.02 172.59-181.12 222.12-235.52 
2006 146.43 149.37 144.35 105.11 122.53 139.74 157.93 173.59 230.53  
145.31-147.54 147.64-151.11 142.9-145.81 103.45-106.78 120.56-124.51 137.39-142.09 155-160.87 169.5-177.67 223.75-237.31 
2007 153.88 159.00 150.26 107.82 125.19 145.17 162.54 182.49 243.09  
152.72-155.04 157.18-160.81 148.77-151.76 106.13-109.5 123.19-127.19 142.76-147.58 159.52-165.55 178.35-186.63 235.95-250.24 
2008 164.29 169.30 160.84 111.09 131.21 150.71 174.46 195.47 275.88  
163.08-165.51 167.38-171.21 159.26-162.42 109.37-112.81 129.14-133.29 148.2-153.21 171.26-177.65 191.14-199.79 267.89-283.87 
2009 147.23 151.77 144.13 99.12 117.72 134.10 150.20 172.31 238.24  
146.09-148.38 149.97-153.57 142.64-145.62 97.52-100.72 115.77-119.68 131.74-136.46 147.26-153.14 168.3-176.32 230.87-245.62 
2010 156.15 157.56 155.42 104.10 123.21 138.42 158.71 180.61 248.54  
154.95-157.36 155.7-159.43 153.84-157 102.44-105.76 121.17-125.25 135.97-140.87 155.63-161.79 176.39-184.84 241.15-255.93 
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Region 
         
 
North East North West Yorkshire & The 
Humber 
East Midlands West Midlands East of England South West South Central London South East 
Coast 
Overall 162.65 174.90 167.21 137.18 166.00 123.46 117.59 121.05 102.81 110.23 
95% CI 158.54-166.76 173.13-176.68 164.47-169.94 134.72-139.65 164.01-168 122.01-124.91 116.15-119.02 119.68-122.42 101.56-104.06 108.86-111.6 
1997 109.65 140.62 112.76 96.63 113.58 92.99 95.77 98.12 91.64 79.07  
102.93-116.38 137.14-144.09 108.22-117.3 92.18-101.07 109.95-117.22 89.97-96.01 92.28-99.25 94.42-101.82 88.38-94.9 75.86-82.28 
1998 118.58 133.60 128.21 111.55 133.46 104.20 96.52 96.31 95.02 80.62  
111.46-125.71 130.36-136.85 123.42-133 106.88-116.23 129.72-137.21 101.14-107.26 93.28-99.76 92.99-99.63 91.8-98.25 77.45-83.79 
1999 143.51 135.32 129.80 100.77 149.58 100.68 100.70 99.92 87.92 86.44  
135.39-151.62 132.15-138.49 125.04-134.57 96.56-104.97 145.66-153.49 97.82-103.54 97.69-103.72 96.91-102.92 85.02-90.82 83.39-89.49 
2000 130.13 135.65 138.19 111.04 131.86 97.90 90.03 95.86 93.92 83.63  
122.9-137.36 132.52-138.78 133.29-143.08 106.54-115.54 128.4-135.33 95.16-100.65 87.28-92.78 93.18-98.53 91.06-96.78 80.83-86.43 
2001 149.33 136.90 156.42 118.35 139.05 108.12 100.71 106.57 100.91 92.94  
141.3-157.37 133.83-139.98 151.21-161.64 113.73-122.97 135.46-142.63 105.23-111.01 97.75-103.67 103.8-109.34 98-103.82 90.01-95.86 
2002 167.10 155.44 168.93 123.41 155.76 115.93 106.64 106.84 95.61 98.32  
158.32-175.89 152.15-158.72 163.53-174.32 118.67-128.16 151.89-159.62 112.94-118.93 103.59-109.69 104.05-109.64 92.84-98.39 95.37-101.27 
2003 165.73 181.23 192.46 145.16 175.62 128.86 121.47 120.09 104.48 108.93  
156.9-174.56 177.58-184.89 186.47-198.46 139.87-150.46 171.46-179.78 125.65-132.07 118.18-124.76 117.09-123.08 101.52-107.43 105.84-112.01 
2004 195.80 190.95 191.22 151.80 182.43 135.40 122.06 128.23 106.87 111.97  
185.9-205.71 187.16-194.74 185.2-197.24 146.2-157.4 178.12-186.74 132.08-138.71 118.78-125.34 125.09-131.36 103.84-109.9 108.84-115.1 
2005 175.79 192.56 189.46 160.46 183.45 144.96 122.55 128.88 105.34 113.05  
166.5-185.09 188.73-196.39 183.43-195.48 154.6-166.33 179.07-187.83 141.47-148.45 119.27-125.83 125.71-132.04 102.35-108.33 109.91-116.18 
2006 173.20 197.78 192.41 174.70 185.01 135.87 127.37 134.38 106.81 121.85  
163.9-182.5 193.83-201.73 186.09-198.73 168.42-180.98 180.59-189.44 132.43-139.32 124.02-130.71 131.12-137.65 103.76-109.86 118.6-125.1 
2007 188.32 210.21 198.00 176.02 189.19 142.20 137.13 136.88 114.70 126.26  
178.73-197.9 206.04-214.37 191.39-204.61 169.53-182.52 184.62-193.75 138.54-145.86 133.6-140.65 133.65-140.1 111.55-117.84 122.94-129.59 
2008 206.01 221.58 215.92 185.92 202.87 152.24 145.86 149.19 116.67 141.00  
195.69-216.33 217.24-225.93 208.29-223.55 178.92-192.93 198.08-207.66 148.3-156.18 142.18-149.54 145.8-152.58 113.49-119.86 137.43-144.58 
2009 191.12 203.62 192.21 157.98 182.45 139.07 128.36 128.44 106.22 127.67 
 
181.11-201.14 199.47-207.77 184.23-200.19 151.3-164.66 177.96-186.93 135.25-142.88 124.95-131.77 125.37-131.52 103.23-109.2 124.34-131 
2010 217.42 224.76 191.29 164.59 200.78 150.10 138.89 139.18 109.42 136.14 
 
206.39-228.44 220.26-229.25 183.14-199.45 156.3-172.87 195.98-205.58 145.95-154.24 135.26-142.52 135.96-142.4 106.4-112.43 132.65-139.64 
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 IMD Quintile  
0 (least 
deprived) 
1 2 3 4 (most 
deprived) 
Overall 111.42 121.05 133.93 151.46 206.08 
95% CI 110.26-112.59 119.84-122.26 132.49-135.37 149.75-153.17 203.4-208.76 
1997 86.67 92.23 98.29 114.58 156.35  
83.82-89.52 89.49-94.96 95.21-101.38 111.09-118.07 151.51-161.19 
1998 94.28 100.39 105.80 119.08 151.99  
91.49-97.08 97.64-103.14 102.75-108.85 115.65-122.51 147.41-156.56 
1999 100.27 100.28 105.90 122.08 166.95  
97.62-102.92 97.68-102.88 103.03-108.78 118.75-125.41 162.21-171.7 
2000 92.40 97.73 105.28 121.50 161.79  
90-94.79 95.3-100.15 102.54-108.02 118.29-124.72 157.25-166.32 
2001 99.28 106.67 119.49 127.18 167.42  
96.81-101.75 104.16-109.18 116.57-122.41 123.95-130.41 162.83-172.01 
2002 100.73 112.34 122.96 139.18 196.06  
98.26-103.19 109.77-114.91 120-125.93 135.78-142.58 190.97-201.14 
2003 114.15 122.98 137.64 159.96 218.27  
111.49-116.81 120.27-125.69 134.45-140.83 156.22-163.69 212.76-223.78 
2004 115.90 129.77 146.40 165.13 228.02  
113.23-118.56 126.97-132.57 143.05-149.74 161.28-168.98 222.28-233.77 
2005 118.15 128.83 146.47 167.33 227.71  
115.45-120.84 126.05-131.61 143.1-149.85 163.41-171.25 221.89-233.52 
2006 120.76 134.16 151.23 170.58 228.84  
118.04-123.49 131.31-137.02 147.79-154.67 166.58-174.58 222.93-234.74 
2007 121.56 136.08 157.38 175.22 242.34  
118.84-124.28 133.2-138.95 153.86-160.9 171.14-179.3 236.17-248.51 
2008 133.98 147.48 167.09 191.22 257.30  
131.11-136.86 144.45-150.5 163.42-170.77 186.87-195.58 250.8-263.8 
2009 117.72 130.41 150.12 174.76 248.70  
115.09-120.34 127.62-133.2 146.68-153.56 170.6-178.91 242.21-255.2 
2010 123.33 140.50 158.68 184.22 272.37  
120.58-126.07 137.55-143.46 155.06-162.3 179.85-188.6 265.41-279.32 
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Community-acquired pneumonia incidence rates overall and over time by sex, age, region of England and IMD quintile 
 
Overall Sex Age (years) 
CAP 
 
Male Female 65-69 70-74 75-79 80-84 85-89 ≥90 
Overall 7.99 8.60 7.53 2.81 4.31 6.94 12.05 21.84 41.94 
95% CI 7.92-8.07 8.49-8.72 7.44-7.62 2.74-2.87 4.22-4.4 6.81-7.08 11.82-12.27 21.39-22.29 40.87-43.01 
1997 7.34 7.87 6.95 2.59 4.48 6.85 12.38 19.98 34.65  
7.07-7.61 7.44-8.3 6.61-7.3 2.27-2.9 4.04-4.91 6.25-7.44 11.38-13.38 18.32-21.65 31.57-37.74 
1998 7.69 7.67 7.71 2.88 4.30 7.31 12.98 20.98 35.54  
7.43-7.95 7.26-8.07 7.36-8.05 2.56-3.19 3.9-4.71 6.74-7.89 11.98-13.98 19.36-22.6 32.6-38.48 
1999 7.36 7.71 7.10 2.89 4.36 6.72 11.59 19.80 33.25  
7.12-7.6 7.33-8.08 6.79-7.41 2.6-3.18 3.98-4.74 6.21-7.23 10.71-12.48 18.35-21.26 30.64-35.87 
2000 6.30 6.70 6.00 2.16 3.40 6.11 9.37 17.70 27.31  
6.09-6.51 6.37-7.03 5.73-6.27 1.92-2.39 3.09-3.71 5.65-6.58 8.65-10.09 16.4-19 25.09-29.52 
2001 6.83 7.45 6.38 2.40 4.16 5.96 9.47 18.27 29.51  
6.62-7.05 7.11-7.79 6.1-6.65 2.16-2.64 3.83-4.5 5.51-6.4 8.79-10.15 16.99-19.55 27.3-31.73 
2002 6.92 7.48 6.50 2.43 3.88 6.43 9.90 17.48 27.95  
6.71-7.14 7.14-7.81 6.23-6.78 2.2-2.66 3.56-4.2 5.97-6.89 9.23-10.57 16.24-18.73 25.85-30.04 
2003 7.81 8.34 7.41 2.71 3.85 7.01 11.03 20.31 32.86  
7.59-8.04 7.98-8.69 7.12-7.71 2.47-2.96 3.53-4.16 6.53-7.48 10.34-11.72 18.94-21.68 30.61-35.12 
2004 7.93 8.33 7.62 2.68 4.23 7.05 11.10 18.42 33.16  
7.7-8.16 7.98-8.69 7.32-7.91 2.45-2.92 3.9-4.56 6.58-7.52 10.42-11.78 17.13-19.71 30.91-35.41 
2005 7.84 8.22 7.54 2.90 4.38 6.36 10.75 17.45 30.04  
7.61-8.06 7.87-8.57 7.24-7.83 2.65-3.14 4.05-4.71 5.92-6.81 10.08-11.42 16.27-18.64 27.93-32.16 
2006 8.16 8.75 7.70 2.87 4.38 6.73 11.35 16.57 30.57  
7.93-8.39 8.38-9.11 7.4-8 2.63-3.12 4.05-4.71 6.27-7.19 10.65-12.04 15.46-17.68 28.44-32.69 
2007 8.49 9.21 7.92 2.88 4.54 7.00 11.07 18.37 30.74  
8.26-8.73 8.84-9.59 7.62-8.23 2.64-3.12 4.21-4.87 6.54-7.47 10.38-11.75 17.22-19.52 28.59-32.89 
2008 9.91 10.66 9.30 3.57 5.03 7.77 13.41 20.92 36.12  
9.64-10.17 10.25-11.07 8.96-9.64 3.3-3.85 4.67-5.38 7.28-8.27 12.64-14.18 19.7-22.15 33.73-38.52 
2009 9.52 10.44 8.77 3.18 5.00 7.44 12.81 20.28 34.84  
9.26-9.78 10.03-10.84 8.44-9.1 2.93-3.44 4.64-5.35 6.95-7.92 12.05-13.57 19.08-21.48 32.48-37.19 
2010 10.06 10.82 9.44 3.61 4.87 7.84 13.37 21.49 34.97  
9.79-10.33 10.4-11.24 9.09-9.79 3.34-3.88 4.52-5.23 7.33-8.35 12.59-14.16 20.23-22.76 32.69-37.25 
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 Region 
CAP North East North West 
Yorkshire &  
The Humber 
East 
Midlands 
West 
Midlands 
East of 
England South West 
South 
Central London 
South East 
Coast 
Overall 10.21 9.11 8.73 7.93 8.71 8.25 8.77 10.27 7.76 7.18  
9.61-10.81 8.88-9.33 8.37-9.09 7.58-8.28 8.45-8.96 8.01-8.48 8.51-9.02 10.01-10.54 7.53-8 6.95-7.4 
1997 7.35 7.27 7.64 6.87 6.69 7.41 7.65 10.99 7.73 6.72  
5.8-8.9 6.55-7.99 6.53-8.74 5.73-8 5.87-7.5 6.6-8.22 6.7-8.6 9.79-12.18 6.83-8.64 5.83-7.62 
1998 7.38 7.50 7.69 7.31 7.78 8.90 7.57 9.79 7.75 7.57  
5.79-8.96 6.79-8.21 6.61-8.77 6.19-8.42 6.95-8.61 8.05-9.74 6.7-8.43 8.77-10.8 6.87-8.64 6.63-8.51 
1999 8.95 6.65 7.33 6.89 7.46 7.54 8.89 9.71 6.56 6.72  
7.18-10.72 6-7.29 6.29-8.38 5.87-7.9 6.67-8.24 6.81-8.28 8.05-9.73 8.82-10.6 5.81-7.31 5.91-7.54 
2000 8.15 6.21 6.81 5.72 6.98 6.59 5.98 7.77 7.29 4.61  
6.52-9.78 5.6-6.81 5.82-7.8 4.78-6.65 6.27-7.7 5.92-7.25 5.31-6.64 7.06-8.49 6.55-8.04 3.98-5.24 
2001 8.05 7.31 7.79 6.24 7.47 7.63 7.23 8.28 7.78 5.02  
6.4-9.7 6.67-7.95 6.74-8.83 5.28-7.19 6.72-8.21 6.93-8.34 6.49-7.96 7.57-8.99 7.03-8.53 4.38-5.66 
2002 8.68 8.24 7.63 6.93 8.09 6.94 7.13 8.68 6.78 5.07  
6.94-10.43 7.57-8.9 6.62-8.64 5.92-7.94 7.31-8.87 6.28-7.6 6.41-7.86 7.94-9.41 6.09-7.46 4.45-5.7 
2003 10.89 8.83 8.56 7.66 9.10 7.63 7.64 11.57 7.03 6.04  
8.89-12.88 8.13-9.52 7.46-9.67 6.59-8.73 8.27-9.93 6.94-8.33 6.9-8.38 10.71-12.44 6.32-7.74 5.37-6.71 
2004 9.81 9.59 9.55 8.59 9.25 7.17 8.56 10.52 7.79 5.93  
7.91-11.71 8.86-10.32 8.37-10.74 7.42-9.76 8.41-10.1 6.5-7.84 7.78-9.34 9.69-11.34 7.03-8.55 5.28-6.59 
2005 13.10 9.44 8.95 7.61 9.45 7.87 8.41 9.73 5.98 7.63  
10.87-15.34 8.71-10.16 7.79-10.1 6.5-8.72 8.58-10.32 7.16-8.58 7.64-9.18 8.94-10.53 5.33-6.64 6.88-8.38 
2006 12.13 9.76 8.87 8.81 8.74 8.03 8.84 10.88 6.68 7.75  
9.96-14.29 9-10.51 7.67-10.06 7.59-10.03 7.91-9.58 7.29-8.77 8.06-9.63 10.03-11.73 5.97-7.38 7-8.49 
2007 10.73 10.58 11.14 8.91 9.35 8.12 10.16 10.72 7.72 7.64  
8.74-12.72 9.78-11.37 9.73-12.54 7.64-10.17 8.47-10.23 7.35-8.9 9.31-11.01 9.9-11.54 6.97-8.47 6.89-8.38 
2008 14.17 12.12 11.19 10.36 11.18 10.29 11.23 13.36 9.39 10.18  
11.81-16.53 11.26-12.99 9.64-12.74 8.92-11.8 10.21-12.15 9.38-11.19 10.33-12.13 12.44-14.28 8.56-10.22 9.31-11.06 
2009 12.14 11.68 12.99 11.71 10.02 11.23 10.26 10.85 10.11 10.42  
9.93-14.35 10.82-12.53 11.11-14.86 10.1-13.33 9.1-10.94 10.26-12.2 9.4-11.11 10.03-11.67 9.25-10.97 9.54-11.3 
2010 14.53 12.84 12.88 12.74 10.94 12.26 11.00 11.46 10.06 10.68  
12.06-17 11.93-13.76 10.96-14.79 10.7-14.78 9.96-11.91 11.21-13.32 10.1-11.91 10.62-12.3 9.2-10.91 9.77-11.59 
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IMD Quintile 
CAP 0  
(least deprived) 
1 2 3 4  
(most deprived) 
Overall 7.58 8.35 9.93 10.08 12.78  
7.38-7.77 8.15-8.55 9.68-10.17 9.82-10.35 12.4-13.15 
1997 7.27 6.63 7.72 7.71 8.46  
6.47-8.06 5.93-7.33 6.9-8.54 6.86-8.56 7.45-9.47 
1998 6.89 7.49 8.80 8.54 10.47  
6.17-7.61 6.78-8.2 7.96-9.63 7.68-9.4 9.37-11.57 
1999 7.48 6.84 8.23 8.55 9.45  
6.8-8.17 6.2-7.48 7.48-8.98 7.74-9.37 8.45-10.46 
2000 5.61 6.10 7.32 7.53 8.87  
5.06-6.17 5.54-6.67 6.65-7.99 6.81-8.26 7.93-9.81 
2001 6.45 6.88 8.66 7.69 9.94  
5.86-7.04 6.3-7.47 7.94-9.38 6.98-8.4 8.96-10.92 
2002 6.61 7.15 8.28 8.43 10.82  
6.03-7.2 6.56-7.74 7.58-8.98 7.69-9.17 9.8-11.85 
2003 7.59 7.65 10.15 9.08 11.91  
6.96-8.22 7.05-8.26 9.37-10.94 8.31-9.86 10.82-13.01 
2004 7.71 8.41 10.63 8.92 12.79  
7.08-8.34 7.77-9.04 9.81-11.44 8.14-9.69 11.64-13.95 
2005 7.20 8.58 9.76 10.20 13.61  
6.59-7.81 7.94-9.23 8.98-10.54 9.36-11.04 12.39-14.84 
2006 7.99 8.48 10.14 10.81 13.50  
7.35-8.63 7.84-9.11 9.34-10.93 9.93-11.68 12.26-14.74 
2007 8.14 9.13 10.83 12.01 15.83  
7.49-8.78 8.46-9.79 10-11.65 11.08-12.94 14.47-17.2 
2008 9.65 10.62 13.28 14.35 17.82  
8.94-10.35 9.9-11.34 12.35-14.2 13.32-15.38 16.34-19.31 
2009 9.67 10.62 12.61 13.24 18.48  
8.97-10.37 9.91-11.34 11.71-13.51 12.24-14.24 16.92-20.04 
2010 9.29 11.33 13.31 14.11 20.35  
8.59-9.99 10.57-12.08 12.37-14.26 13.05-15.17 18.68-22.01 
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Appendix F Medline search strategy for the hospitalisation post-CAP 
literature review (Chapter 6) 
1 exp Community-Acquired Infections/ 
2 
(community adj1 acqui*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
3 exp Hospitalization/ 
4 hospitali$*.mp. 
5 
(hospital adj2 discharge).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
6 3 or 4 or 5 
7 exp Prognosis/ 
8 
(prognostic adj (score or rule or model)).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
9 
(predicti* adj (score or rule or model)).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
10 
(risk adj (score or rule or model)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
11 
(predictive adj1 factor).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
12 exp Risk Assessment/ 
13 
(decision adj (score or rule or model)).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
14 exp Decision Support Techniques/ 
15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
16 exp Risk Factors/ 
17 
(risk adj1 factor*).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
18 exp pneumonia/ 
19 (pneumonit* or pneumonia).ti,ab. 
20 bronchopneumonia.ti,ab. 
21 pleuropneumonia.ti,ab. 
22 exp Bronchopneumonia/ep, mo [Epidemiology, Mortality] 
23 
pneumonias.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
24 
exp Aged, 80/ and over.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
25 exp Aged/ 
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26 
((old adj age*) or elderly or (senior adj citizen)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier] 
27 community-acquired.mp. 
28 exp Case Reports/ 
29 Animals/ 
30 Humans/ 
31 determinant*.mp. 
32 16 or 17 or 31 
33 18 or 19 or 20 or 21 or 22 or 23 
34 1 or 2 or 27 
35 24 or 25 or 26 
36 33 and 34 
37 15 or 32 
38 35 and 36 and 37 
39 6 and 38 
40 29 not (29 and 30) 
41 39 not 40 
42 41 not 28 
43 limit 42 to english language 
44 limit 43 to yr="2008 -Current" 
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Appendix G Supplementary material from Paper 2 (Chapter 6). 
Supplementary File B. Completeness of recording of smoking status over time 
Year 
Smoking status n (%)  
Non smoker 
Current 
smoker Ex-smoker Missing Total 
1998 62 (2.8) 350 (16) 1194 (54.6) 582 (26.6) 2188 
1999 124 (5.1) 400 (16.4) 1319 (54.1) 595 (24.4) 2438 
2000 116 (5) 378 (16.3) 1228 (52.8) 604 (26) 2326 
2001 144 (5.2) 502 (18.1) 1499 (53.9) 634 (22.8) 2779 
2002 157 (5.4) 561 (19.3) 1591 (54.8) 592 (20.4) 2901 
2003 256 (7.8) 569 (17.3) 1887 (57.4) 575 (17.5) 3287 
2004 472 (13.7) 663 (19.3) 1902 (55.4) 396 (11.5) 3433 
2005 471 (13.7) 682 (19.9) 2044 (59.7) 229 (6.7) 3426 
2006 582 (16.2) 685 (19.1) 2152 (60.1) 164 (4.6) 3583 
2007 624 (16.2) 722 (18.7) 2435 (63.1) 80 (2.1) 3861 
2008 783 (17.2) 850 (18.7) 2853 (62.7) 64 (1.4) 4550 
2009 714 (16.4) 840 (19.3) 2757 (63.5) 31 (0.7) 4342 
2010 710 (15.9) 909 (20.4) 2811 (63) 32 (0.7) 4462 
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Supplementary File C Multivariable models adjusted for additional groups of explanatory factors (continued over four pages) 
    
 OR (95% CI) 
Adjusted for: (cumulative left to right)   
Age, sex, year & Individual  co-
morbidities 
& frailty factors † & medications/ 
vaccinations ¥ 
Male  1 1 1 1 
Female  0.71 (0.66 - 0.76) 0.8 (0.75 - 0.85) 0.81 (0.76 - 0.87) 0.82 (0.76 - 0.87) 
Age (grouped) 65-69 1 1 1 1 
  70-74 1.41 (1.24 - 1.61) 1.31 (1.16 - 1.49) 1.34 (1.17 - 1.52) 1.35 (1.18 - 1.53) 
  75-79 1.45 (1.28 - 1.65) 1.39 (1.23 - 1.57) 1.43 (1.26 - 1.62) 1.44 (1.27 - 1.63) 
  80-84 1.6 (1.41 - 1.81) 1.58 (1.39 - 1.78) 1.62 (1.43 - 1.84) 1.65 (1.45 - 1.87) 
  85-89 1.33 (1.18 - 1.51) 1.44 (1.28 - 1.63) 1.52 (1.34 - 1.73) 1.56 (1.37 - 1.77) 
  90+ 0.88 (0.78 - 1) 1.02 (0.9 - 1.16) 1.13 (0.99 - 1.28) 1.18 (1.03 - 1.34) 
Year of CAP (grouped) 1998-2000 0.52 (0.47 - 0.58) 0.56 (0.51 - 0.62) 0.55 (0.5 - 0.6) 0.54 (0.48 - 0.59) 
  2001-2003 1 1 1 1 
  2004-2006 1.91 (1.73 - 2.1) 1.81 (1.65 - 1.98) 1.99 (1.81 - 2.19) 1.94 (1.76 - 2.14) 
  2007-2008 2.77 (2.48 - 3.1) 2.34 (2.1 - 2.6) 2.64 (2.36 - 2.95) 2.51 (2.23 - 2.82) 
  2009-2010 4.38 (3.87 - 4.96) 3.63 (3.22 - 4.09) 4.16 (3.67 - 4.71) 3.86 (3.38 - 4.4) 
Individual  co-morbidities           
Ischaemic heart disease  pre-MI 1.64 (1.5 - 1.78) 1.38 (1.26 - 1.5) 1.35 (1.24 - 1.47) 1.34 (1.23 - 1.46) 
 post MI 1.73 (1.55 - 1.92) 1.37 (1.23 - 1.52) 1.35 (1.21 - 1.5) 1.31 (1.17 - 1.46) 
Congestive heart failure  1.68 (1.55 - 1.82) 1.22 (1.13 - 1.33) 1.25 (1.15 - 1.36) 1.25 (1.15 - 1.36) 
Peripheral vascular disease  1.59 (1.43 - 1.77) 1.26 (1.13 - 1.4) 1.27 (1.14 - 1.41) 1.27 (1.14 - 1.41) 
Dementia  0.45 (0.41 - 0.5) 0.56 (0.51 - 0.62) 0.69 (0.62 - 0.75) 0.71 (0.65 - 0.78) 
Chronic lung disease  1.85 (1.71 - 1.99) 1.62 (1.51 - 1.74) 1.59 (1.48 - 1.71) 1.62 (1.47 - 1.78) 
Connective tissue disease  1.53 (1.36 - 1.72) 1.34 (1.19 - 1.5) 1.35 (1.2 - 1.52) 1.21 (1.07 - 1.37) 
Peptic ulcer  1.32 (1.18 - 1.49) 1.17 (1.04 - 1.31) 1.17 (1.05 - 1.32) 1.17 (1.05 - 1.32) 
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 OR (95% CI) 
Adjusted for: (cumulative left to right)   
Age, sex, year & Individual  co-
morbidities 
& frailty factors † & medications/ 
vaccinations ¥ 
Liver disease Mild 1.92 (1.22 - 3.03) 1.68 (1.08 - 2.61) 1.7 (1.09 - 2.65) 1.71 (1.09 - 2.66) 
  Severe 2.12 (1.2 - 3.76) 1.81 (1.03 - 3.16) 1.78 (1.01 - 3.11) 1.8 (1.03 - 3.15) 
Diabetes Diabetes 1.4 (1.27 - 1.55) 1.26 (1.14 - 1.39) 1.28 (1.16 - 1.42) 1.27 (1.14 - 1.4) 
  With complications 1.81 (1.5 - 2.19) 1.41 (1.17 - 1.7) 1.34 (1.1 - 1.62) 1.31 (1.08 - 1.59) 
Cancer Solid cancer 1.24 (1.13 - 1.36) 1.24 (1.13 - 1.37) 1.26 (1.14 - 1.38) 1.26 (1.15 - 1.38) 
  Metastatic  1.6 (1.3 - 1.98) 2.55 (2.05 - 3.18) 2.55 (2.04 - 3.18) 2.46 (1.97 - 3.07) 
Leukaemia/lymphoma  1.93 (1.53 - 2.42) 1.95 (1.56 - 2.44) 1.91 (1.52 - 2.39) 1.94 (1.55 - 2.43) 
Severe renal disease  2.24 (2.01 - 2.49) 1.84 (1.66 - 2.05) 1.85 (1.66 - 2.05) 1.82 (1.64 - 2.03) 
Cerebrovascular disease  0.85 (0.79 - 0.92) 0.91 (0.84 - 0.98) 0.98 (0.91 - 1.06) 0.98 (0.91 - 1.06) 
Neurological disease  0.74 (0.66 - 0.83) 0.95 (0.85 - 1.05) 1.05 (0.95 - 1.18) 1.08 (0.97 - 1.21) 
Disorders of the immune mechanism 3.4 (2.01 - 5.74) 2.35 (1.41 - 3.92) 2.49 (1.49 - 4.15) 2.49 (1.49 - 4.15) 
Terminal illness  0.34 (0.29 - 0.4) 0.27 (0.23 - 0.32) 0.3 (0.25 - 0.36) 0.3 (0.25 - 0.35) 
Frailty factors           
Recent carer   1.37 (1.15 - 1.63)  1.18 (0.97 - 1.42) 1.17 (0.97 - 1.41) 
Living arrangements Not recorded 1  1 1 
  Lives alone 1.32 (1.11 - 1.58)  1.17 (0.97 - 1.41) 1.17 (0.97 - 1.4) 
  Sheltered accommodation 1.21 (0.91 - 1.61)  1.09 (0.82 - 1.45) 1.11 (0.83 - 1.48) 
  Residential Care 0.33 (0.3 - 0.37)  0.45 (0.4 - 0.5) 0.46 (0.41 - 0.51) 
Visual impairment   1.3 (1.21 - 1.4)  1.1 (1.02 - 1.18) 1.1 (1.02 - 1.18) 
Bedsore/ulcer   0.38 (0.32 - 0.45)  0.51 (0.43 - 0.6) 0.52 (0.44 - 0.61) 
Low weight/poor nutrition   0.72 (0.65 - 0.79)  0.84 (0.77 - 0.93) 0.84 (0.77 - 0.93) 
Incontinence/catheter   0.66 (0.59 - 0.73)  0.81 (0.73 - 0.9) 0.83 (0.75 - 0.92) 
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 OR (95% CI) 
Adjusted for: (cumulative left to right)   
Age, sex, year & Individual  co-
morbidities 
& frailty factors † & medications/ 
vaccinations ¥ 
Medications           
Immunosuppressants (other than steroids) in last 120 days 1.65 (1.26 - 2.17)   1.1 (0.84 - 1.45) 
Inhaled corticosteroids  None pre CAP 1   1 
  Within 60 days 1.73 (1.57 - 1.9)   0.99 (0.88 - 1.12) 
  Within 61-180 days 1.46 (1.24 - 1.71)   0.83 (0.69 - 0.98) 
  Within 181-365 days 1.56 (1.21 - 2.03)   0.93 (0.72 - 1.21) 
  More than 365 days ago 1.29 (1.12 - 1.5)   0.82 (0.7 - 0.95) 
Antibiotics None in previous 28 days 1   1 
  In previous 1-7 days 1.02 (0.93 - 1.11)   1.04 (0.95 - 1.14) 
  In previous 8-28 days 0.69 (0.63 - 0.76)   0.69 (0.63 - 0.76) 
Statins in previous 6 months  1.57 (1.43 - 1.72)   1.12 (1.01 - 1.23) 
Steroids in previous 90 days  1.8 (1.62 - 2)   1.42 (1.27 - 1.58) 
Influenza vaccine No vaccine pre CAP 1   1 
  Vaccinated 14-365 days pre CAP 0.87 (0.8 - 0.96)   0.75 (0.68 - 0.83) 
  Vaccinated last season 0.84 (0.75 - 0.94)   0.76 (0.67 - 0.85) 
  Vaccinated 2-5 years pre CAP 0.88 (0.75 - 1.03)   0.82 (0.71 - 0.96) 
  Vaccinated >5 years pre CAP 1.05 (0.81 - 1.34)   0.9 (0.7 - 1.15) 
Pneumococcal vaccine No vaccine pre CAP 1   1 
  Vaccinated 14-365 days pre CAP 1.01 (0.88 - 1.17)   1.02 (0.89 - 1.18) 
  Vaccinated 1-2 years pre CAP 1.07 (0.93 - 1.22)   1.02 (0.89 - 1.17) 
  Vaccinated 2-5 years pre CAP 1.24 (1.13 - 1.36)   1.07 (0.97 - 1.18) 
  Vaccinated >5 years pre CAP 1.57 (1.42 - 1.74)   1.16 (1.04 - 1.29) 
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 OR (95% CI) 
Adjusted for: (cumulative left to right)   
Age, sex, year & Individual  co-
morbidities 
& frailty factors † & medications/ 
vaccinations ¥ 
Factors not included in later models 
Hemiplegia  0.85 (0.72 - 1.01)    
Mild renal disease  0.97 (0.7 - 1.34)    
Self-care problems  0.79 (0.57 - 1.08)    
Anxious/depressed  1.07 (0.95 - 1.2)    
Mobility issues  1.00 (0.87 - 1.15)    
Tired  0.94 (0.83 - 1.07)    
History of falling  1.06 (0.97 - 1.16)    
Excessive alcohol 
consumption Any excess alcohol code 
1.10 (0.93 - 1.29)    
† frailty factors: recent carer, place of residence, vision problems, bed ulcer, underweight/nutritional replacement,  incontinence/catheter. 
¥ medication/vaccination: Immunosuppressants (not steroids), steroids, inhaled steroids, statins, antibiotics in previous 28 days, influenza vaccine 
All categorised as in (main text) Table 1. 
Supplementary File D.  Distribution of smoking status (where not missing) 2007-2010 and univariable, minimally adjusted, and adjusted ORs for hospitalisation.  
n=17008 
 
Hospitalised Not  hospitalised Total Unadjusted OR 
Minimally adjusted 
(age, sex, year) 
Adjusted  co-
morbidities 
 
n (%) n (%)     
Non smoker 2260 (79.8) 571 (20.2) 2831 1 1 1 
Current 
smoker 2969 (89.4) 352 (10.6) 3321 2.93 (2.34 - 3.67) 2.83 (2.25 - 3.56) 1.96 (1.58 - 2.44) 
Ex-smoker 9386 (86.5) 1470 (13.5) 10856 2.05 (1.74 - 2.43) 1.88 (1.59 - 2.23) 1.37 (1.17 - 1.61) 
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Appendix H Medline search strategy for the longer-term post-CAP 
mortality literature review (Chapter 7) 
1 exp Community-Acquired Infections/ 
2 
(community adj1 acqui*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
3 exp Mortality/ 
4 mortality.mp. 
5 death.mp. 
6 3 or 4 or 5 
7 exp Prognosis/ 
8 
(prognostic adj (score or rule or model)).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
9 
(predicti* adj (score or rule or model)).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
10 
(risk adj (score or rule or model)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
11 
(predictive adj1 factor).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
12 exp Risk Assessment/ 
13 
(decision adj (score or rule or model)).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
14 exp Decision Support Techniques/ 
15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
16 exp Risk Factors/ 
17 
(risk adj1 factor*).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
18 exp pneumonia/ 
19 (pneumonit* or pneumonia).ti,ab. 
20 bronchopneumonia.ti,ab. 
21 pleuropneumonia.ti,ab. 
22 exp Bronchopneumonia/ep, mo [Epidemiology, Mortality] 
23 
pneumonias.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] 
24 
exp Aged, 80/ and over.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
25 exp Aged/ 
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26 
((old adj age*) or elderly or (senior adj citizen)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier] 
27 community-acquired.mp. 
28 exp Case Reports/ 
29 Animals/ 
30 Humans/ 
31 determinant*.mp. 
32 16 or 17 or 31 
33 18 or 19 or 20 or 21 or 22 or 23 
34 1 or 2 or 27 
35 24 or 25 or 26 
36 33 and 34 
37 15 or 32 
38 35 and 36 and 37 
39 6 and 38 
40 29 not (29 and 30) 
41 39 not 40 
42 41 not 28 
43 limit 42 to english language 
44 limit 43 to yr="2011 -Current" 
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Appendix I Mortality rates (from 1st April 2004 to 31st March 2011) in patients aged ≥65 years who were eligible and 
contributed to CPRD-ONS linked data (Chapter 7) 
Age group 
Women Men 
Mortality rate/1000 
person-years 
Mortality risk in CPRD-ONS linked population 
over time period (%) 
Mortality 
rate/1000 person-
years 
Mortality risk in CPRD-ONS linked population 
over time period (%) 
1-7 days 8-30 days 31-365 days 1-7 days 8-30 days 31-365 days 
65-69 12.2 (11.7-12.8) 0.02 0.07 1.11 18 (17.3-18.8) 0.03 0.11 1.64 
70-74 16.9 (16.5-17.3) 0.03 0.10 1.53 26.3 (25.8-26.9) 0.05 0.16 2.38 
75-79 29.7 (29.1-30.2) 0.06 0.18 2.68 43.7 (42.9-44.5) 0.08 0.26 3.92 
80-84 53.2 (52.4-54.1) 0.10 0.32 4.75 76.5 (75.2-77.8) 0.15 0.46 6.76 
85-89 96.7 (95.3-98.2) 0.19 0.58 8.47 127.1 (124.8-129.4) 0.24 0.76 10.98 
90+ 197.9 (195.1-200.6) 0.38 1.19 16.56 222.9 (218-228) 0.43 1.33 18.45 
 
